

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 July 2003 (31.07.2003)

PCT

(10) International Publication Number
WO 03/062400 A2

- (51) International Patent Classification⁷: C12N Knolls Parkway, Ijamsville, MD 21754 (US). STEVEN-SON, Susan, C. [US/US]; 10974 Horseshoe Drive, Frederick, MD 21701 (US).
- (21) International Application Number: PCT/US03/02295
- (22) International Filing Date: 24 January 2003 (24.01.2003) (74) Agents: SEIDMAN, Stephanie, L. et al.; Heller Ehrman White & McAuliffe LLP, 7th Floor, 4350 La Jolla Village Drive, San Diego, CA 92122-1246 (US).
- (25) Filing Language: English
- (26) Publication Language: English (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (30) Priority Data:
60/350,388 24 January 2002 (24.01.2002) US
60/391,967 26 June 2002 (26.06.2002) US
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:
US 60/391,967 (CIP)
Filed on 26 June 2002 (26.06.2002)
US 60/350,388 (CIP)
Filed on 24 January 2002 (24.01.2002)
- (71) Applicants (*for all designated States except US*): THE SCRIPPS RESEARCH INSTITUTE [US/US]; 10550 North Torrey Pines Road, TPC-8, La Jolla, CA 92037 (US). NOVARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): KALEKO, Michael [US/US]; 8 Hearthstone Court, Rockville, MD 20854 (US). NEMEROW, Glen, R. [US/US]; 462 Cerro Street, Encinitas, CA 92024 (US). SMITH, Theodore [US/US]; 3346
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: FIBER SHAFT MODIFICATIONS FOR EFFICIENT TARGETING

(57) Abstract: Provided are adenoviral vectors and the production of such vectors. In particular, fiber shaft modifications for efficient targeting of adenoviral vectors are provided. The fiber shaft modifications can be combined with other modifications, such as fiber knob and/or penton modifications, to produce fully ablated (detargeted) adenoviral vectors. A scale-up method for the propagation of detargeted adenoviral vectors is also provided.

WO 03/062400 A2

-1-

FIBER SHAFT MODIFICATIONS FOR EFFICIENT TARGETING RELATED APPLICATIONS

Benefit of priority is claimed to U.S. provisional application Serial No. 60/350,388, filed 24 January 2002, entitled "FIBER SHAFT MODIFICATIONS
5 FOR EFFICIENT TARGETING," to Stevenson, Susan C., Kaleko, Michael, Smith, Theodore and Nemerow, Glen R., and to U.S. provisional application Serial No. 60/391,967, filed 26 June 2002, entitled "FIBER SHAFT MODIFICATIONS FOR EFFICIENT TARGETING," to Stevenson, Susan C., Kaleko, Michael, Smith, Theodore and Nemerow, Glen R. This application is also related to International
10 PCT application No. (attorney docket number 22908-1236), filed the same day herewith, entitled "FIBER SHAFT MODIFICATIONS FOR EFFICIENT TARGETING," to Stevenson, Susan C., Kaleko, Michael, Smith, Theodore and Nemerow, Glen R. Where permitted, the subject matter of each of these applications is incorporated by reference herein.

15 FIELD OF INVENTION

The present invention generally relates to the field of adenoviral vectors and the production of such vectors. In particular, detargeted adenoviral vectors are provided.

BACKGROUND

20 Most, if not all, adenoviral vector-mediated gene therapy strategies aim to transduce a specific tissue, such as a tumor or an organ. Systemic delivery will require ablation of the normal virus tropism as well as addition of new specificities. Multiple interactions between adenoviral particles and the host cell are required to promote efficient cell entry (Nemerow (2000) *Virology* 274:1-4).
25 An adenovirus entry pathway is believed to involve two separate cell surface events. First, a high affinity interaction between the adenoviral fiber knob and coxsackie-adenovirus receptor (CAR) mediates the attachment of the adenovirus particle to the cell surface. A subsequent association of penton with the cell surface integrins $\alpha_v\beta_3$ and $\alpha_v\beta_5$, which act as co-receptors, potentiates virus
30 internalization. There are a plurality of adenoviral fiber receptors, which interact with the group B (*e.g.*, Ad3) and group C (*e.g.*, Ad5) adenoviruses. Both of these groups of adenoviruses appear to require interaction with integrins for

-2-

internalization. CAR ablation, however, does not change biodistribution and toxicity of adenoviral vectors *in vivo* (Alemany *et al.* (2001) *Gene Therapy* 8:1347-1353; U.S. patent application No. 09/870,203, filed May 30, 2001, and published as U.S. Published application No. 20020137213). Thus, the role of

5 CAR interaction for *in vivo* gene transfer is not clear. Recently published studies have described conflicting results (Alemany *et al.* (2001) *Gene Therapy* 8:1347-1353; Leissner *et al.* (2001) *Gene Therapy* 8:49-57; Einfeld *et al.* (2001) *J. Virology* 75:11284-11291). For example, it has been shown that vectors

10 containing an S408E mutation in the Ad5 fiber AB loop yield efficient liver transduction in mice, despite having greatly reduced transduction efficiencies on cells in culture (see, Leissner *et al.* (2001) *Gene Therapy* 8:49-57). In contrast, vectors containing a more extensive fiber AB loop mutation showed a 10-fold reduction in liver gene expression (see, Einfeld *et al.* (2001) *J. Virology* 75:11284-11291).

15 A doubly ablated adenovirus has been prepared by modifying the CAR binding region in the fiber loop and the integrin binding region in the penton base (Einfeld *et al.* (2001) *J. Virology* 75:11284-11291). This doubly ablated adenovirus, lacking CAR and integrin interactions, was reported not only to lack *in vitro* transduction of various cell types but also to lack *in vivo* transduction of

20 liver cells. Specifically, the doubly ablated adenovirus was reported to have a 700 fold reduction in liver transduction when compared to the non-ablated adenovirus. These results, however, were not reproduced by others.

For many applications, the most clinically useful adenoviral vector would be deliverable systemically, such as into a peripheral vein, and would be targeted

25 to a desired location in the body, and would not have undesirable side effects resulting from targeting to other locations. *In vivo* adenoviral vector targeting is a major goal in gene therapy and a significant effort has been focused on developing strategies to achieve this goal. Successful targeting strategies would direct the entire vector dose to the appropriate site and would be likely to

30 improve the safety profile of the vector by permitting the use of lower, less toxic vector doses, which potentially also can be less immunogenic. Thus, there is a

-3-

need to develop adenoviruses which are fully detargeted *in vivo* for use as a base vector for producing redirected adenoviruses.

Therefore, among the objects herein, it is an object herein to provide fully detargeted adenoviral vectors, methods for preparation thereof, and uses thereof.

SUMMARY

Detargeted and fully detargeted adenoviral particles, adenovirus vectors from which such particles are produced, methods for preparation of the vectors and particles and uses of the vectors and particles are provided. Provided and described are capsid modifications, such as fiber shaft modifications, and the resulting proteins that, when expressed on adenoviral particles provide for detargeting of adenoviral vectors. The capsid modifications, such as the fiber shaft modifications, can be combined with other modifications, such as fiber knob and/or penton modifications, to produce fully ablated (detargeted) adenoviral particles. Thus, adenoviral vectors and adenoviral particles whose native tropisms are ablated through a modification or modifications of capsid proteins, particularly a fiber shaft region, are provided.

Thus, provided are capsid mutations, including fiber shaft modifications, that ablate binding to particular receptors, thereby permitting efficient targeting of adenoviral vectors that contain capsids with such modifications. For example, adenoviral vectors in which the fiber shaft's interaction with HSP is ablated (reduced or substantially eliminated), particularly *in vivo*, are provided. These fiber shaft modifications can be combined with other modifications, such as fiber knob and/or penton modifications, to produce fully ablated (detargeted) adenoviral vectors. Also provided are retargeted vectors and particles that include a ligand or ligands to provide for targeting of the detargeted vectors and particles to selected cells and/or tissues. Retargeting can be effected, for example, by manipulating the fiber protein to redirect the receptor specificity to a particular cell type.

Also provided are nucleic acids encoding the modified fiber proteins and also modified penton proteins. Also provided are nucleic acids encoding the modified fiber shaft protein that has ablated HSP binding and combinations

-4-

thereof with other modified fiber regions or other proteins, such as a modified fiber knob region and/or the modified penton protein. The nucleic acids also can contain heterologous nucleic acid sequences, such as promoters or nucleic acid sequences encoding polypeptides. The viral particles that express fibers
5 containing such shaft modifications and other modifications are also provided.

Also provided are methods for making and using the adenoviral particles that express the modified fibers and combinations of modified fibers and modified penton. With the fiber shaft modifications, particularly in combination with the fiber knob modifications and the penton modifications, the adenovirus
10 particles are ablated for binding to their natural cellular receptor(s), *i.e.*, they are detargeted. They can then be "retargeted" to a specific cell type through the addition of a ligand to the virus capsid, which causes the virus to bind to and infect such cell. The ligand can be added, for example, through genetic modification of a capsid protein gene.

Also provided is a method for reducing liver toxicity in adeno-
viral-mediated therapy. In contrast to the results of Einfeld *et al.* (Einfeld *et al.* (2001) *J. Virology* 75:11284-11291), it is shown herein that a doubly ablated adenovirus, lacking CAR and integrin interactions, is capable of *in vivo* liver transduction. It is shown herein that ablation of liver transduction requires
20 further and/or alternative modification(s). The method for reducing liver toxicity in adenoviral-mediated therapy includes modifying an adenoviral vector to ablate native tropism to liver cells *in vivo*. Such vector can be administered to a subject. The modifications include the modifications described herein.

25 The nucleic acids, proteins, adenoviral particles and adenoviral vectors have a variety of uses. These include *in vivo* and *in vitro* uses to target nucleic acid to particular cells and tissues, for therapeutic purposes, including gene therapy, and also for the identification and study of cell surface receptors and identification of modes of interaction of viruses with cells.

30 In particular, adenoviral fiber shaft modifications that ablate viral interaction with HSP (Heparin Sulfate Proteoglycans; also referred to as heparin sulfate glycosaminoglycans) are provided. These modifications include

-5-

mutations of individual amino acids in the fiber shaft that interact with HSP or mutations of amino acids in the fiber shaft that modify the ability of the HSP binding motif to interact with HSP. Adenoviral fiber shaft modifications also include replacements of fiber shafts using fiber shafts of adenoviruses, such as, for example, Ad3, Ad35 and Ad41 short fiber shaft, that do not contain HSP binding sites.

Also provided are adenoviral fiber shaft modifications that alter, particularly ablate viral interaction with HSP, as described above, in combination with fiber knob modifications that ablate viral interaction with CAR. The fiber knob modifications include: (a) mutations of individual amino acids in the fiber loop that interact with CAR, such as, for example, AB or CD loop modifications; (b) mutations of individual amino acids in the fiber loop that modify the ability of the CAR binding motif to interact with CAR; and (c) replacements of fiber knobs using adenoviruses that do not interact with CAR, such as, for example, Ad3 fiber knob, Ad41 short fiber knob, or Ad35 fiber knob.

Also provided are adenoviral fiber shaft modifications as described above in combination with penton modifications that ablate viral interaction with α_v integrins. The penton modifications include: (a) mutations of individual amino acids that interact with α_v integrins; (b) mutations of individual amino acids that modify the ability of the α_v integrin binding motif to interact with the α_v integrins; and (c) replacement of penton proteins using penton proteins from adenoviruses that do not interact with the α_v integrins.

Also provided are adenoviral fiber shaft modifications as described above in combination with fiber knob modifications as described above and penton modifications as described above.

Also provided is a scale-up method for the propagation of detargeted adenoviral vectors. The method uses polycations and/or bifunctional reagents, which when added to tissue culture medium results in entry of adenoviral particles into the producer cells.

-6-

Provided are recombinant viral particles that contain a modified capsid protein whereby binding to heparin sulfate proteoglycans (HSP) is reduced or eliminated compared to particles that contain unmodified capsid proteins. The modified capsid proteins include fiber proteins with modified shafts such that binding to HSP is reduced or eliminated.

Among the particular embodiments the following are provided. Provided are adenovirus capsid proteins that are modified to alter, typically reduce or eliminate, binding to or interaction with *in vivo* and/or *in vitro* to heparin sulfate proteoglycan (HSP). HSPs are expressed on various cells, including hepatocytes. It is shown herein that HSPs provide for or participate in transduction of cells, such as liver cells. Since it can be desirable to eliminate or reduce such transduction, the modifications of the capsid proteins, such as fiber proteins, permit detargeting of particles that express such proteins from such cells.

Thus provided are modified adenovirus fiber proteins that include a mutation, such as an insertion, deletion, change, replacement of amino acids or combinations thereof, whereby binding to or interaction with heparin sulfate proteoglycan (HSP) is altered. In particular, the binding of the modified fiber protein is eliminated or reduced compared to the unmodified protein. Exemplary of these mutations are mutations in the shaft of a fiber, where the shaft also can include the tail. The mutations can reduce or alter the affinity of the fiber protein for HSP is reduced at least by 2-fold, 5-fold, 10-fold, 100-fold or more, including substantially eliminating it.

As provided herein, fibers from adenoviruses that interact with HSP can include a motif, such as BBXB or BBBXB, where the B is a basic amino acid and X is any amino acid, particularly the consensus sequence KKTK in Ad5 and Ad2. Thus, provided are fibers in which the motif is altered to eliminate or reduce interaction with HSP.

Also provided are modified fiber protein of claim 1 that are chimeras in which the fiber shaft (or fiber shaft and tail) are derived from a fiber, such as Ad3, Ad35, Ad7, Ad11, Ad16, Ad21, Ad34, Ad40, Ad41 or Ad46 fiber, that does not interact with HSP and combined with fiber that does interact, such as

-7-

Ad5 or Ad2 fiber, to produce a complete fiber whose binding to HSP is reduced or eliminated.

All of the modified capsids proteins provided herein also can include one or more further modifications that reduce or eliminate interaction of the resulting
5 fiber with one or more cell surface proteins, such as but not limited to, CAR and α_v integrin or other receptor to which a particular native fiber binds, in addition to HSP. These modifications include, but are not limited to, modification to fiber that reduces or eliminates CAR binding and modification to penton that reduces or eliminate α_v integrin binding. The mutations can be in the fiber knob, shaft,
10 tail and shaft, and also in penton.

Any and all of the modified capsid proteins provided herein can further include a ligand that binds to a particular receptor thereby endowing a fiber (or other capsid protein) with binding specificity or the ability to interact with such receptor. The ligand can be inserted into any suitable site in a capsid protein,
15 such as an insertion or replacement. For example, fibers with ligands inserted into the knob region are exemplified. Any such ligand can be employed and a variety are exemplified herein.

A variety of modified capsid proteins are exemplified herein. These include, but are not limited to, fibers containing: the sequence of amino acids
20 set forth in any of SEQ ID Nos. 52, 54, 56, 58, 62, 66, 70 and 72; or a sequence of amino acids having 60%, 70%, 80%, 90%, 95% or greater sequence identity with a sequence of amino acids set forth in any of SEQ ID Nos. 52, 54, 56, 58, 62, 66, 70 and 72; or a sequence of amino acids encoded by a sequence of nucleotides that hybridizes under conditions of high stringency
25 along at least 70% of its length to a sequence of nucleotides that encodes a sequence of amino acids set forth in any of SEQ ID Nos. 52, 54, 56, 58, 62, 66, 70 and 72.

Nucleic acids encoding the capsid proteins, including the fibers are also provided. The nucleic acids can be provided as vectors, particularly as
30 adenovirus vectors. Many adenoviral vectors are known and can be modified as needed in accord with the description herein. Adenoviral vectors include, but are not limited to, early generation adenoviral vectors, such as E1-deleted

-8-

vectors, gutless adenoviral vectors and replication-conditional adenoviral vectors, such as oncolytic adenoviral vectors. The adenovirus vectors also can include heterologous nucleic acids that encode or provide products, such as therapeutic products. Any therapeutic product is contemplated and a variety are set forth
5 herein as exemplary. Heterologous nucleic acid can encode a polypeptide or comprise or encode a regulatory sequence, such as a promoter or an RNA, including RNAi, small RNAs, other double-stranded RNAs, antisense RNA, and ribozymes. Promoters include, for example, constitutive and regulated promoters and tissue specific promoter, including tumor specific promoters.
10 The promoter can be operably linked, for example, to a gene of an adenovirus essential for replication.

Cells containing the nucleic acid molecules and cells containing the vectors are also provided. Such cell include packaging cells. The cells can be prokaryotic or eukaryotic cells, including, mammalian cells, such a primate cells,
15 including human cells.

Also provided are adenoviral particles that contain the modified capsid proteins provided herein. The particles have altered interaction or binding with HSP compared to particles that do not contain the modified capsid proteins. In addition to altered binding to HSP, which is typically reduced or eliminated
20 binding, the particles can include further modifications, such as capsid proteins with altered interaction with other receptors as described above. In particular, the particles can have altered, typically reduced or eliminated, interaction with CAR, α_v integrin and/or other receptors. The mutation include mutations in the fiber knob, penton and hexon. Exemplary fiber know mutations are mutations in
25 the AB loop or CD loop, such as KO1 or KO12, which are described herein. In addition, the particles can include additional ligands for retargeting to selected receptors. The adenoviral particles can be from any serotype and subgroup.

Methods for expressing heterologous nucleic acids in a cell are provided. In these methods an adenoviral vector provided herein is transduced into a cell
30 to deliver the nucleic acid and/or encoded products. Transduction can be effected *in vivo* or *in vitro* or *ex vivo*, and can be for a variety of purposes including study of gene expression and genetic therapy. The cells can be

-9-

prokaryotic cells, but typically are eukaryotic cells, including mammalian cells, such as primate, including human, cells. The cells can be of a specific type, such as a tumor cell or a cell in a particular tissue. The vectors can be oncolytic vector to effect killing of tumor cells.

- 5 Since the modified capsid proteins herein have reduced or eliminated binding to HSP, viral particles containing such proteins exhibit ablated binding to HSP *in vitro* and *in vivo*. Thus provided is a method of reducing transduction of cells that express HSP, such as hepatocytes in the liver, by modifying a capsid protein, such as fiber to eliminate or reduce interaction with or binding to HSP.
- 10 Such reduction reduces or eliminates transduction of cells that express HSP, including liver cells.

- Also provided are scale-up methods for the propagation of detargeted adenoviral particle, such as those provided herein. The method includes the steps of infecting or transducing a cell capable of replicating, maturing and
- 15 packaging an adenoviral vector with a detargeted adenoviral vector in the presence of a reagent that results in entry of the adenoviral particle into the cell, such as a polycation and/or a bifunctional protein or other such reagent; and culturing the infected cell under conditions suitable for growth, spread and propagation of the adenoviral vector. The resulting adenoviral particles can be
- 20 recovered. Polycations include, but are not limited to, hexadimethrine bromide, polyethylenimine, protamine sulfate and poly-L-lysine. Bifunctional proteins, include, but are not limited to, an anti-fiber antibody ligand fusion, an anti-fiber-Fab-FGF conjugate, an anti-penton-antibody ligand fusion, an anti-hexon antibody ligand fusion and a polylysine-peptide fusion. The ligand is
- 25 selected to bind to a particular receptor.

- The viral particles that express a modified capsids provided herein can be produced by this method. The modification include, for example, one or more mutations selected from among mutations that reduce or eliminate interactions with one or more of α_v integrins, coxsackie-adenovirus receptors (CAR) and
- 30 heparin sulfate proteoglycans (HSP). Such mutations include, for example, PD1, KO1, KO12 and S*.

-10-

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a plasmid map for pSKO1.

Figure 2 is a plasmid map for pNDSQ3.1KO1.

Figures 3A-3C are plasmid maps of pAdmireRSVnBg.(Fig. 3A), pSQ1 Fig.
5 3B) and pSQ1KO12 (Fig. 3C)

Figure 4 is a plasmid map for pSQ1PD1.

Figures 5A-5B are plasmid maps of pSQ1FKO1PD1 (Fig. 5A) and
pSQ1KO12PD1 (Fig. 5B).

Figure 6 shows *in vitro* transduction efficiency of A549 cells using
10 adenoviral vectors containing fiber AB loop knob and/or penton, PD1 mutations.
The following adenoviral vectors were used in these studies: Av1nBg,
Av1nBgFKO1, referred to as FKO1, Av1nBgPD1, referred to as PD1, and
Av1nBgFKO1PD1 that is referred to as FKO1PD1.

Figure 7A-7B shows *in vivo* adenoviral-mediated liver gene expression
15 (Fig. 7A) and hexon DNA content (Fig. 7B) using adenoviral vectors containing
fiber AB loop knob and/or penton, PD1 mutations. The following adenoviral
vectors were used in these studies: Av1nBg, Av1nBgFKO1, referred to as
FKO1, Av1nBgPD1, referred to as PD1, Av1nBgFKO1PD1, referred to as
FKO1PD1, Av1nBgKO12, referred to as KO12, and Av1nBgKO12PD1 that is
20 referred to as KO12PD1.

Figure 8 is a plasmid map for pFBshuttle(EcoRI).

Figure 9 is a plasmid map for pSQ1HSP.

Figure 10 is a plasmid map for pSQ1HSPKO1.

Figure 11 is a plasmid map for pSQ1HSPPD1.

25 Figure 12 is a plasmid map for pSQ1HSPKO1PD1.

Figures 13A-13C show the transduction efficiency of A549 and HeLa
cells using adenoviral vectors containing fiber shaft, knob and/or penton
mutations. Fig. 13A shows the dose response for the transduction efficiency of
A549 cells. Fig. 13B shows the transduction efficiency of HeLa cells at 2000
30 ppc. Figure 13C shows the competition analysis of adenoviral vectors
containing fiber shaft mutations.

-11-

Figures 14A-14B shows the influence of fiber shaft mutations on *in vivo* adenoviral-mediated liver gene expression (Fig. 14A) and hexon DNA content (Fig. 14B).

Figures 15A-15B are plasmid maps of pSQ1HSPRGD (Fig. 15A) and
5 pSQ1HSPKO1RGD (Fig. 15B).

Figure 16 shows that insertion of a RGD targeting ligand can restore transduction of the vectors containing the HSP binding shaft S* mutation.

Figures 17A-17B are plasmid maps of pSQ1AD35Fiber (Fig. 17A) and pSQ1Ad35FcRGD (Fig. 17B).

10 Figures 18A-18B are maps of plasmids encoding 35F chimeric fibers. Fig. 18A is a plasmid map of pSQ135T5H, and Fig. 18B is a plasmid map of pSQ15T35H.

Figure 19 shows the results of an *in vitro* analysis of Ad5 vectors containing Ad35 fibers and derivatives thereof.

15 Figure 20 shows the results of an *in vivo* analysis of Ad5 vectors containing Ad35 fibers and derivatives thereof.

Figures 21A-21B are plasmid maps of pSQ1Ad41sF (Fig. 21A) and pSQ1Ad41sFRGD (Fig. 21B).

20 Figure 22 shows the results of an *in vivo* analysis of Ad5 vectors containing Ad41 short fiber.

Figure 23 shows the *in vitro* analysis of Ad5 based vectors containing the Ad41 short fiber which has been re-engineered to contain a cRGD ligand in the HI loop.

25 Figure 24 shows enhanced transduction of AE1-2a cells with the Av3nBgFKO1 detargeted adenoviral vector using hexadimethrine bromide (HB), protamine sulfate (PS) and poly-lysine-RGD (K14) or the anti-penton-TNF α bifunctional protein (α pen-TNF).

Figure 25 shows ablation of HSP interaction decreases adenoviral-mediated gene transfer to other organs

30 Figure 26 shows *in vivo* liver transduction with adenoviral vectors which encode for B-galactosidase and contain various mutations to the fiber and/or penton proteins. Results are plotted as percent transduction as compared to

-12-

wild type. Two different methods for determining the level of transduction are shown for each vector.

Figure 27 shows the adenoviral vector biodistribution to the liver and tumor for the vectors containing the S*, KO1S*, and 41sF fibers.

5 DETAILED DESCRIPTION

A. DEFINITIONS

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which the invention(s) belong. All patents, patent applications, published applications and publications, Genbank sequences, websites and other published materials referred to throughout the entire disclosure herein, unless noted otherwise, are incorporated by reference in their entirety. In the event that there are a plurality of definitions for terms herein, those in this section prevail. Where reference is made to a URL or other such identifier or address, it is understood that such identifiers can change and particular information on the internet can come and go, but equivalent information is known and can be readily accessed, such as by searching the internet and/or appropriate databases. Reference thereto evidences the availability and public dissemination of such information.

As used herein, the term "adenovirus" or "adenoviral particle" is used to include any and all viruses that can be categorized as an adenovirus, including any adenovirus that infects a human or an animal, including all groups, subgroups, and serotypes. Depending upon the context reference to "adenovirus" can include adenoviral vectors. There are at least 51 serotypes of Adenovirus that classified into several subgroups. For example, subgroup A includes adenovirus serotypes 12, 18, and 31. Subgroup C includes adenovirus serotypes 1, 2, 5, and 6. Subgroup D includes adenovirus serotype 8, 9, 10, 13, 15, 17, 19, 20, 22-30, 32, 33, 36-39, and 42-49. Subgroup E includes adenovirus serotype 4. Subgroup F includes adenovirus serotypes 40 and 41. These latter two serotypes have a long and a short fiber protein. Thus, as used herein an adenovirus or adenovirus particle is a packaged vector or genome.

-13-

As used herein, "virus," "viral particle," "vector particle," "viral vector particle," and "virion" are used interchangeably to refer to infectious viral particles that are formed when, such as when a vector containing all or a part of a viral genome, is transduced into an appropriate cell or cell line for the generation of such particles. The resulting viral particles have a variety of uses, including, but not limited to, transferring nucleic acids into cells either *in vitro* or *in vivo*. For purposes herein, the viruses are adenoviruses, including recombinant adenoviruses formed when an adenovirus vector, such as any provided herein, is encapsulated in an adenovirus capsid. Thus, a viral particle is a packaged viral genome. An adenovirus viral particle is the minimal structural or functional unit of a virus. A virus can refer to a single particle, a stock of particles or a viral genome. The adenovirus (Ad) particle is relatively complex and may be resolved into various substructures.

Included among adenoviruses and adenoviral particles are any and all viruses that can be categorized as an adenovirus, including any adenovirus that infects a human or an animal, including all groups, subgroups, and serotypes. Thus, as used herein, "adenovirus" and "adenovirus particle" refer to the virus itself and derivatives thereof and cover all serotypes and subtypes and naturally occurring and recombinant forms, except where indicated otherwise. Included are adenoviruses that infect human cells. Adenoviruses can be wildtype or can be modified in various ways known in the art or as disclosed herein. Such modifications include, but are not limited to, modifications to the adenovirus genome that is packaged in the particle in order to make an infectious virus. Exemplary modifications include deletions known in the art, such as deletions in one or more of the E1a, E1b, E2a, E2b, E3, or E4 coding regions. Other exemplary modifications include deletions of all of the coding regions of the adenoviral genome. Such adenoviruses are known as "gutless" adenoviruses. The terms also include replication-conditional adenoviruses, which are viruses that preferentially replicate in certain types of cells or tissues but to a lesser degree or not at all in other types. For example, among the adenoviral particles provided herein, are adenoviral particles that replicate in abnormally proliferating tissue, such as solid tumors and other neoplasms. These include the viruses

-14-

disclosed in U.S. Patent No. 5,998,205 and U.S. Patent No. 5,801,029. Such viruses are sometimes referred to as "cytolytic" or "cytopathic" viruses (or vectors), and, if they have such an effect on neoplastic cells, are referred to as "oncolytic" viruses (or vectors).

5 As used herein, the terms "vector," "polynucleotide vector," "polynucleotide vector construct," "nucleic acid vector construct," and "vector construct" are used interchangeably herein to mean any nucleic acid construct that can be used for gene transfer, as understood by those skilled in the art.

 As used herein, the term "viral vector" is used according to its
10 art-recognized meaning. It refers to a nucleic acid vector construct that includes at least one element of viral origin and can be packaged into a viral vector particle. The viral vector particles can be used for the purpose of transferring DNA, RNA or other nucleic acids into cells either in vitro or in vivo. Viral vectors include, but are not limited to, retroviral vectors, vaccinia vectors, lentiviral
15 vectors, herpes virus vectors (e.g., HSV), baculoviral vectors, cytomegalovirus (CMV) vectors, papillomavirus vectors, simian virus (SV40) vectors, Sindbis vectors, semliki forest virus vectors, phage vectors, adenoviral vectors, and adeno-associated viral (AAV) vectors. Suitable viral vectors are described, for example, in U.S. Patent Nos. 6,057,155, 5,543,328 and 5,756,086. The
20 vectors provided herein are adenoviral vectors.

 As used herein, "adenovirus vector" and "adenoviral vector" are used interchangeably and are well understood in the art to mean a polynucleotide containing all or a portion of an adenovirus genome. An adenoviral vector, refers to nucleic encoding a complete genome or a modified genome or one that can be
25 used to introduce heterologous nucleic acid when transferred into a cell, particularly when packaged as a particle. An adenoviral vector can be in any of several forms, including, but not limited to, naked DNA, DNA encapsulated in an adenovirus capsid, DNA packaged in another viral or viral-like form (such as herpes simplex, and AAV), DNA encapsulated in liposomes, DNA complexed
30 with polylysine, complexed with synthetic polycationic molecules, conjugated with transferrin, complexed with compounds such as PEG to immunologically

-15-

"mask" the molecule and/or increase half-life, or conjugated to a non-viral protein.

As used herein, oncolytic adenoviruses refer to adenoviruses that replicate selectively in tumor cells

5 As used herein, a variety of vectors with different requirements and purposes are described. For example, one vector is used to deliver particular nucleic acid molecules into a packaging cell line for stable integration into a chromosome. These types of vectors also are referred to as complementing plasmids. A further type of vector carries or delivers nucleic acid molecules in or
10 into a cell line (*e.g.*, a packaging cell line) for the purpose of propagating viral vectors; hence, these vectors also can be referred to herein as delivery plasmids. A third "type" of vector is the vector that is in the form of a virus particle encapsulating a viral nucleic acid and that is comprised of the capsid modified as provided herein. Such vectors also can contain heterologous nucleic acid
15 molecules encoding particular polypeptides, such as therapeutic polypeptides or regulatory proteins or regulatory sequences to specific cells or cell types in a subject in need of treatment.

As used herein, the term "motif" is used to refer to any set of amino acids forming part of a primary sequence of a protein, either contiguous or
20 capable of being aligned to certain positions that are invariant or conserved, that is associated with a particular function. The motif can occur, not only by virtue of the primary sequence, but also as a consequence of three-dimensional folding. For example, the motif GXGXXG is associated with nucleotide-binding sites. In this fiber is a trimer, hence the trimeric structure can contribute formation of a
25 motif. Alternatively, a motif can be considered as a domain of a protein, where domain is a region of a protein molecule delimited on the basis of function without knowledge of and relation to the molecular substructure, as, *e.g.*, the part of a protein molecule that binds to a receptor. As shown herein, the motif KKTK constitutes a consensus sequence for fiber shaft interaction with HSP.

30 As used herein, the term "bind" or "binding" is used to refer to the binding between a ligand and its receptor, such as the binding of an Ad5 shaft motif with HSP (Heparin Sulfate Proteoglycans), with a K_d in the range of 10-2

-16-

to 10⁻¹⁵ mole/l, generally, 10⁻⁶ to 10⁻¹⁵, 10⁻⁷ to 10⁻¹⁵ and typically 10⁻⁸ to 10⁻¹⁵ (and/or a K_a of 10⁵-10¹², 10⁷-10¹², 10⁸-10¹² l/mole).

As used herein, specific binding or selective binding means that a the binding of a particular ligand and one receptor interaction (k_a or K_{eq}) is at least 2-
5 fold, generally, 5, 10, 50, 100 or more-fold, greater than for another receptor. A statement that a particular viral vector is targeted to a cell or tissue means that its affinity for such cell or tissue in a host or *in vitro* is at least about 2-fold, generally, 5, 10, 50, 100 or more-fold, greater than for other cells and tissues in the host or under the *in vitro* conditions.

10 As used herein, the term "ablate" or "ablated" is used to refer to an adenovirus, adenoviral vector or adenoviral particle, in which the ability to bind to a particular cellular receptor is reduced or eliminated, generally substantially eliminated (*i.e.*, reduced more than 10-fold, 100-fold or more) when compared to a corresponding wild-type adenovirus. An ablated adenovirus, adenoviral vector
15 or adenoviral particle also is said to be detargeted, *i.e.*, the modified adenovirus, adenoviral vector or adenoviral particle does not possess the native tropism of the wild-type adenovirus. The reduction or elimination of the ability of the mutated adenovirus fiber protein and/or mutated adenovirus penton protein to bind a cellular receptor as compared to the corresponding wild-type fiber protein
20 and/or wild-type penton protein can be measured or assessed by comparing the transduction efficiency (gene transfer and expression of a marker gene) of an adenovirus particle containing the mutated fiber protein and/or mutated penton protein compared to an adenovirus particle containing the wild-type fiber protein and/or wild-type penton protein for cells having the cellular receptor.

25 As used herein, tropism with reference to an adenovirus refers to the selective infectivity or binding that is conferred on the particle by a capsid protein, such as the fiber protein and/or penton.

As used herein, "penton" or "penton complex" is used herein to designate a complex of penton base and fiber. The term "penton" can also be used to
30 indicate penton base, as well as penton complex. The meaning of the term "penton" alone should be clear from the context within which it is used.

-17-

As used herein, the term "substantially eliminated" refers to a transduction efficiency less than about 11% of the efficiency of the wild-type fiber containing virus on HeLa cells. The transduction efficiency on HeLa cells can be measured (see, *e.g.*, Example 1 of U.S. Patent Application Serial No. 09/870,203 filed on 30 May 2001, and published as U.S. Published application No. 20020137213, and of International Patent Application No. PCT/EP01/06286 filed 1 June 2001). Briefly, HeLa cells are infected with the adenoviral vectors containing mutated fiber proteins to evaluate the effects of fiber amino acid mutations on CAR interaction and subsequent gene expression. Monolayers of HeLa cells in 12 well dishes are infected with, for example, 1000 particles per cell for 2 hours at 37° C. in a total volume of, for example, 0.35 ml of the DMEM containing 2% FBS. The infection medium is then aspirated from the monolayers and 1 ml of complete DMEM containing 10% FBS was added per well. The cells are incubated for an sufficient time, generally about 24 hours, to allow for β -galactosidase expression, which is measured by a chemiluminescence reporter assay and by histochemical staining with a chromogenic substrate. The relative levels of β -galactosidase activity are determined using as suitable system, such as the Galacto-Light chemiluminescence reporter assay system (Tropix, Bedford, Mass.) Cell monolayers are washed with PBS and processed according to the manufacturer's protocol. The cell homogenate is transferred to a microfuge tube and centrifuged to remove cellular debris. Total protein concentration is determined, such as by using the bicinchoninic acid(BCA) protein assay (Pierce, Inc., Rockford, Ill.) with bovine serum albumin as the assay standard. An aliquot of each sample is then incubated with the Tropix β -galactosidase substrate for 45 minutes in a 96 well plate. A luminometer is used determine the relative light units (RLU) emitted per sample and then normalized for the amount of total protein in each sample (RLU/ μ g total protein). For the histochemical staining procedure, the cell monolayers are fixed with 0.5% glutaraldehyde in PBS, and then were incubated with a mixture of 1 mg of 5-bromo-4-chloro-3-indolyl- β -D-galactoside (X-gal) per ml, 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide and 2 mM MgCl_2 in 0.5 ml of PBS. The monolayers are washed with PBS and the blue cells are visualized by light

-18-

microscopy, such as with a Zeiss ID03 microscope. Generally, the efficiency is less than about 9%, and typically is less than about 8%.

As used herein, the phrase "reduce" or "reduction" refers to a change in the efficiency of transduction by the adenovirus containing the mutated fiber as compared to the adenovirus containing the wild-type fiber to a level of about 75% or less of the wild-type on HeLa cells. Generally, the change in efficiency is to a level of about 65% or less than wild-type. Typically it is about 55% or less. This system is able to rapidly analyze modified fiber proteins and/or modified penton proteins for desired tropism in the context of the viral particle.

As used herein, the term "mutate" or "mutation" or similar terms refers to the deletion, insertion or change of at least one amino acid in the part of the fiber shaft region interacting with HSP. The amino acid can be changed by substitution or by modification in a way that derivatizes the amino acid. Thus, for example a BBXB motif or BBBXXB motif, where B is a basic amino acid, in an adenovirus is mutated to ablate the viral interaction with HSP.

As used herein, the term "polynucleotide" means a nucleic acid molecule, such as DNA or RNA, that encodes a polynucleotide. The molecule can include regulatory sequences, and is generally DNA. Such polynucleotides are prepared or obtained by techniques known by those skilled in the art in combination with the teachings contained therein.

As used herein, adenoviral genome is intended to include any adenoviral vector or any nucleic acid sequence comprising a modified fiber protein. All adenovirus serotypes are contemplated for use in the vectors and methods herein.

As used herein, the term "viral vector" is used according to its art-recognized meaning. It refers to a nucleic acid vector construct that includes at least one element of viral origin and can be packaged into a viral vector particle. The viral vector particles can be used, for example, for transferring DNA into cells either *in vitro* or *in vivo*.

As used herein, a packaging cell line is a cell line that is able to package adenoviral genomes or modified genomes to produce viral particles. It can provide a missing gene product or its equivalent. Thus, packaging cells can

-19-

provide complementing functions for the genes deleted in an adenoviral genome (e.g., the nucleic acids encoding modified fiber proteins) and are able to package the adenoviral genomes into the adenovirus particle. The production of such particles require that the genome be replicated and that those proteins necessary
5 for assembling an infectious virus are produced. The particles also can require certain proteins necessary for the maturation of the viral particle. Such proteins can be provided by the vector or by the packaging cell.

As used herein, detargeted adenoviral particles have ablated (reduced or eliminated) interaction with receptors with which native particles. Fully
10 detargeted particles have two or more specificities altered. It is understood that *in vivo* no particles are fully ablated such that they do not interact with any cells. Degareted and fully degareted have reduced, typically substantiall reduced, or eliminated interaction with native receptors. For purposes herein, detargeted particles have reduced (2-fold, 5-fold, 10-fold, 100-fold or more) binding or
15 virtually no binding to HSP receptors; fully degareted vectors include further capsid modifications to eliminate interactions with other receptors, such as CAR and integrins or other receptors. The particles still bind to cells, but the types of cells and interactions are reduced.

As used herein, pseudotyping describes the production of adenoviral
20 vectors having modified capsid protein or capsid proteins from a different serotype than the serotype of the vector itself. One example, is the production of an adenovirus 5 vector particle containing an Ad37 or Ad35 fiber protein. This can be accomplished by producing the adenoviral vector in packaging cell lines expressing different fiber proteins. As provided herein, detargeting of an
25 adenovirus 5 particle or other serotype group C adenovirus or other adenovirus that binds to HSP to reduce or eliminate binding to HSPs can be effected by replacing all or a portion that includes the shaft or at least the HSP consensus binding sequence of the Ad5 fiber with an adenovirus fiber or portion thereof that does not bind to HSP. Adenoviruses having fiber shafts that do not interact
30 with HSP include (a) adenoviruses of subgroup B, e.g., Ad3, Ad35, Ad7, Ad11, Ad16, Ad21, Ad34 which do not have interaction with HSP, (b) adenoviruses of

-20-

subgroup F, e.g., Ad40 and Ad41, specifically the short fiber, and (c) adenoviruses of subgroup D, e.g., Ad46.

As used herein, receptor refers to a biologically active molecule that specifically or selectively binds to (or with) other molecules. The term "receptor protein" can be used to more specifically indicate the proteinaceous nature of a
5 specific receptor.

As used herein, the term "cyclic RGD" (or cRGD) refers to any amino acid that binds to α_v integrins on the surface of cells and contains the sequence RGD (Arg-Gly-Asp).
10

As used herein, the term "heterologous polynucleotide" means a polynucleotide derived from a biological source other than an adenovirus or from an adenovirus of a different strain or can be a polynucleotide that is in a different locus from wild-type virus. The heterologous polynucleotide can encode a polypeptide, such as a toxin or a therapeutic protein. The heterologous
15 polynucleotide can contain regulatory regions, such as a promoter regions, such as a promoter active in specific cells or tissue, for example, tumor tissue as found in oncolytic adenoviruses. Alternatively, the heterologous polynucleotide can encode a polypeptide and further contain a promoter region operably linked to the coding region.

As used herein, reference to an amino acid in an adenovirus protein or to a nucleotide in an adenovirus genome is with reference to Ad5, unless specified otherwise. Corresponding amino acids and nucleotides in other adenovirus strains and modified strains and in vectors can be identified by those of skill in the art. Thus recitation of a mutation is intended to encompass all adenovirus
20 strains that process a corresponding locus.

As used herein, the KO mutations refer to mutations in fiber that knock out binding to CAR. For example, a KO1 mutation refers to a mutation in the Ad5 fiber and corresponding mutations in other fiber proteins. In Ad5, this mutation results in a substitution of fiber amino acids 408 and 409, changing
30 them from serine and proline to glutamic acid and alanine, respectively. As used herein, a KO12 mutation refers to a mutation in the Ad5 fiber and corresponding mutations in other fiber proteins. In Ad5, this mutation is a four amino acid

-21-

substitution as follows: R512S, A515G, E516G, and K517G. Other KO mutations can be identified empirically or are known to those of skill in the art.

As used herein, PD mutations refer to mutations in the penton gene that ablate binding by the encoded to α_v integrin by replacing the RGD tripeptide.

- 5 The PD1 mutation exemplified herein results in a substitution of amino acids 337 through 344 of the Ad5 penton protein, HAIRGDTF (SEQ ID No. 9), with amino acids SRGYPYDVPDYAGTS (SEQ ID No. 10), thereby replacing the RGD tripeptide.

- 10 As used herein, treatment means any manner in which the symptoms of a condition, disorder or disease are ameliorated or otherwise beneficially altered.

As used herein, a therapeutically effective product is a product that is encoded by heterologous DNA that, upon introduction of the DNA into a host, a product is expressed that effectively ameliorates or eliminates the symptoms, manifestations of an inherited or acquired disease or that cures said disease.

- 15 As used herein, a subject is an animal, such as a mammal, typically a human, including patients.

- As used herein, genetic therapy involves the transfer of heterologous DNA to the certain cells, target cells, of a mammal, particularly a human, with a disorder or conditions for which such therapy is sought. The DNA is introduced
20 into the selected target cells in a manner such that the heterologous DNA is expressed and a therapeutic product encoded thereby is produced.

- Alternatively, the heterologous DNA may in some manner mediate expression of DNA that encodes the therapeutic product, it may encode a product, such as a peptide or RNA that in some manner mediates, directly or indirectly, expression
25 of a therapeutic product. Genetic therapy may also be used to deliver nucleic acid encoding a gene product to replace a defective gene or supplement a gene product produced by the mammal or the cell in which it is introduced. The introduced nucleic acid may encode a therapeutic compound, such as a growth factor inhibitor thereof, or a tumor necrosis factor or inhibitor thereof, such as a
30 receptor therefor, that is not normally produced in the mammalian host or that is not produced in therapeutically effective amounts or at a therapeutically useful time. The heterologous DNA encoding the therapeutic product may be modified

-22-

prior to introduction into the cells of the afflicted host in order to enhance or otherwise alter the product or expression thereof.

As used herein, a therapeutic nucleic acid is a nucleic acid that encodes a therapeutic product. The product can be nucleic acid, such as a regulatory
5 sequence or gene, or can encode a protein that has a therapeutic activity or effect. For example, therapeutic nucleic acid can be a ribozyme, antisense, double-stranded RNA, a nucleic acid encoding a protein and others.

As used herein, "homologous" means about greater than 25% nucleic acid sequence identity, such as 25%, 40%, 60%, 70%, 80%, 90% or 95%. If
10 necessary the percentage homology will be specified. The terms "homology" and "identity" are often used interchangeably. In general, sequences are aligned so that the highest order match is obtained (see, e.g.: *Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic
15 Press, New York, 1993; *Computer Analysis of Sequence Data, Part I*, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; Carillo *et al.* (1988) *SIAM J Applied Math* 48:1073).
20 By sequence identity, the number of conserved amino acids are determined by standard alignment algorithms programs, and are used with default gap penalties established by each supplier. Substantially homologous nucleic acid molecules would hybridize typically at moderate stringency or at high stringency all along the length of the nucleic acid or along at least about 70%, 80% or 90% of the
25 full-length nucleic acid molecule of interest. Also contemplated are nucleic acid molecules that contain degenerate codons in place of codons in the hybridizing nucleic acid molecule.

Whether any two nucleic acid molecules have nucleotide sequences that are at least, for example, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%
30 "identical" can be determined using known computer algorithms such as the "FAST A" program, using for example, the default parameters as in Pearson *et al.* (1988) *Proc. Natl. Acad. Sci. USA* 85:2444 (other programs include the GCG

-23-

program package (Devereux, J., *et al.*, *Nucleic Acids Research* 12(II):387 (1984)), BLASTP, BLASTN, FASTA (Atschul, S.F., *et al.*, *J Molec Biol* 215:403 (1990); Guide to Huge Computers, Martin J. Bishop, ed., Academic Press, San Diego, 1994, and Carillo *et al.* (1988) *SIAM J Applied Math* 48:1073). For

5 example, the BLAST function of the National Center for Biotechnology Information database can be used to determine identity. Other commercially or publicly available programs include, DNASTar "MegAlign" program (Madison, WI) and the University of Wisconsin Genetics Computer Group (UWG) "Gap" program (Madison WI)). Percent homology or identity of proteins and/or nucleic

10 acid molecules can be determined, for example, by comparing sequence information using a GAP computer program (*e.g.*, Needleman *et al.* (1970) *J. Mol. Biol.* 48:443, as revised by Smith and Waterman ((1981) *Adv. Appl. Math.* 2:482). Briefly, the GAP program defines similarity as the number of aligned symbols (*i.e.*, nucleotides or amino acids) which are similar, divided by the total

15 number of symbols in the shorter of the two sequences. Default parameters for the GAP program can include: (1) a unary comparison matrix (containing a value of 1 for identities and 0 for non-identities) and the weighted comparison matrix of Gribskov *et al.* (1986) *Nucl. Acids Res.* 14:6745, as described by Schwartz and Dayhoff, eds., *ATLAS OF PROTEIN SEQUENCE AND STRUCTURE*, National

20 Biomedical Research Foundation, pp. 353-358 (1979); (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each gap; and (3) no penalty for end gaps. Therefore, as used herein, the term "identity" represents a comparison between a test and a reference polypeptide or polynucleotide.

As used herein, the term "at least 90% identical to" refers to percent

25 identities from 90 to 99.99 relative to the reference polypeptides. Identity at a level of 90% or more is indicative of the fact that, assuming for exemplification purposes a test and reference polynucleotide length of 100 amino acids are compared, no more than 10% (*i.e.*, 10 out of 100) of amino acids in the test polypeptide differs from that of the reference polypeptides. Similar comparisons

30 can be made between a test and reference polynucleotides. Such differences can be represented as point mutations randomly distributed over the entire length of an amino acid sequence or they can be clustered in one or more

-24-

locations of varying length up to the maximum allowable, e.g. 10/100 amino acid difference (approximately 90% identity). Differences are defined as nucleic acid or amino acid substitutions, or deletions. At the level of homologies or identities above about 85-90%, the result should be independent of the program and gap parameters set; such high levels of identity can be assessed readily, often without relying on software.

As used herein: stringency of hybridization in determining percentage mismatch is as follows:

- 1) high stringency: 0.1 x SSPE, 0.1% SDS, 65°C
- 2) medium stringency: 0.2 x SSPE, 0.1% SDS, 50°C
- 3) low stringency: 1.0 x SSPE, 0.1% SDS, 50°C

Those of skill in this art know that the washing step selects for stable hybrids and also know the ingredients of SSPE (see, e.g., Sambrook, E.F. Fritsch, T. Maniatis, in: *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory Press (1989), vol. 3, p. B.13, see, also, numerous catalogs that describe commonly used laboratory solutions). SSPE is pH 7.4 phosphate-buffered 0.18 M NaCl. Further, those of skill in the art recognize that the stability of hybrids is determined by T_m , which is a function of the sodium ion concentration and temperature ($T_m = 81.5^\circ \text{C} - 16.6(\log_{10}[\text{Na}^+]) + 0.41(\% \text{G} + \text{C}) - 600/l$), so that the only parameters in the wash conditions critical to hybrid stability are sodium ion concentration in the SSPE (or SSC) and temperature.

It is understood that equivalent stringencies can be achieved using alternative buffers, salts and temperatures. By way of example and not limitation, procedures using conditions of low stringency are as follows (see also Shilo and Weinberg, *Proc. Natl. Acad. Sci. USA* 78:6789-6792 (1981)): Filters containing DNA are pretreated for 6 hours at 40°C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500 µg/ml denatured salmon sperm DNA (10X SSC is 1.5 M sodium chloride, and 0.15 M sodium citrate, adjusted to a pH of 7).

Hybridizations are carried out in the same solution with the following modifications: 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 µg/ml salmon sperm DNA, 10% (wt/vol) dextran sulfate, and 5-20 X 10⁶ cpm ³²P-labeled probe is

-25-

used. Filters are incubated in hybridization mixture for 18-20 hours at 40°C, and then washed for 1.5 hours at 55°C in a solution containing 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS. The wash solution is replaced with fresh solution and incubated an additional 1.5 hours at 60°C. Filters are
5 blotted dry and exposed for autoradiography. If necessary, filters are washed for a third time at 65-68°C and reexposed to film. Other conditions of low stringency which can be used are well known in the art (*e.g.*, as employed for cross-species hybridizations).

By way of example and not way of limitation, procedures using
10 conditions of moderate stringency include, for example, but are not limited to, procedures using such conditions of moderate stringency are as follows: Filters containing DNA are pretreated for 6 hours at 55°C in a solution containing 6X SSC, 5X Denhart's solution, 0.5% SDS and 100 µg/ml denatured salmon sperm DNA. Hybridizations are carried out in the same solution and 5-20 X 10⁶ cpm
15 ³²P-labeled probe is used. Filters are incubated in hybridization mixture for 18-20 hours at 55°C, and then washed twice for 30 minutes at 60°C in a solution containing 1X SSC and 0.1% SDS. Filters are blotted dry and exposed for autoradiography. Other conditions of moderate stringency which can be used are well-known in the art. Washing of filters is done at 37°C for 1 hour in a
20 solution containing 2X SSC, 0.1% SDS.

By way of example and not way of limitation, procedures using conditions of high stringency are as follows: Prehybridization of filters containing DNA is carried out for 8 hours to overnight at 65°C in buffer composed of 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA,
25 and 500 µg/ml denatured salmon sperm DNA. Filters are hybridized for 48 hours at 65°C in prehybridization mixture containing 100 µg/ml denatured salmon sperm DNA and 5-20 X 10⁶ cpm of ³²P-labeled probe. Washing of filters is done at 37°C for 1 hour in a solution containing 2X SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA. This is followed by a wash in 0.1X SSC at 50°C for 45
30 minutes before autoradiography. Other conditions of high stringency which can be used are well known in the art.

-26-

The term substantially identical or substantially homologous or similar varies with the context as understood by those skilled in the relevant art and generally means at least 60% or 70%, preferably means at least 80%, 85% or more preferably at least 90%, and most preferably at least 95% identity.

5 As used herein, substantially identical to a product means sufficiently similar so that the property of interest is sufficiently unchanged so that the substantially identical product can be used in place of the product.

As used herein, substantially pure means sufficiently homogeneous to appear free of readily detectable impurities as determined by standard methods
10 of analysis, such as thin layer chromatography (TLC), gel electrophoresis and high performance liquid chromatography (HPLC), used by those of skill in the art to assess such purity, or sufficiently pure such that further purification would not detectably alter the physical and chemical properties, such as enzymatic and biological activities, of the substance. Methods for purification of the
15 compounds to produce substantially chemically pure compounds are known to those of skill in the art. A substantially chemically pure compound can, however, be a mixture of stereoisomers or isomers. In such instances, further purification might increase the specific activity of the compound.

The methods and preparation of products provided herein, unless
20 otherwise indicated, employ conventional techniques of chemistry, molecular biology, microbiology, recombinant DNA, genetics, immunology, cell biology, cell culture and transgenic biology, which are within the skill of the art (see, *e.g.*, Maniatis *et al.* (1982) *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY); Sambrook *et al.* (1989)
25 *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Ausubel *et al.* (1992) *Current Protocols in Molecular Biology*, Wiley and Sons, New York; Glover (1985) *DNA Cloning I and II*, Oxford Press; Anand (1992) *Techniques for the Analysis of Complex Genomes* (Academic Press); Guthrie and Fink (1991) *Guide to Yeast Genetics and*
30 *Molecular Biology*, Academic Press; Harlow and Lane (1988) *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY; Jakoby and Pastan, eds. (1979) *Cell Culture. Methods in Enzymology* 58,

-27-

Academic Press, Inc., Harcourt Brace Jovanovich, NY; *Nucleic Acid Hybridization* (B. D. Hames & S. J. Higgins eds. 1984); *Culture Of Animal Cells* (R. I. Freshney, Alan R. Liss, Inc., 1987); *Immobilized Cells And Enzymes* (IRL Press, 1986); B. Perbal (1984), *A Practical Guide To Molecular Cloning*; *Gene Transfer Vectors For Mammalian Cells* (J. H. Miller and M. P. Calos eds., 1987, Cold Spring Harbor Laboratory); *Methods In Enzymology*, Vols. 154 and 155 (Wu et al. eds.); *Immunochemical Methods In Cell And Molecular Biology* (Mayer and Walker, eds., Academic Press, London, 1987); *Handbook Of Experimental Immunology*, Volumes I-IV (D. M. Weir and C. C. Blackwell, eds., 1986); Hogan et al. (1986) *Manipulating the Mouse Embryo*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.

B. Capsid modifications

Provided herein are modifications of the viral capsid that ablate the interaction of an adenovirus with its natural receptors. In particular, fiber modifications that result in ablation of the interaction of an adenovirus with HSP are provided. These fiber modifications can be combined with other capsid protein modifications, such as other fiber modifications and/or penton and/or hexon modifications, to fully ablate viral interactions with natural receptors, when expressed on a viral particle. The modification should not disrupt trimer formation or transport of fiber into the nucleus.

1. Fiber genes and proteins

The fiber protein extends from the capsid and mediates viral binding to the cell surface by binding to specific cell receptors (Philipson et al. (1968) *J. Virol.* 2:1064-1075). The fiber is a trimeric protein that includes an N-terminal tail domain that interacts with the adenovirus penton base, a central shaft domain of varying length, and a C-terminal knob domain that contains the cell receptor binding site (Chroboczek et al. (1995) *Curr.Top.Microbiol.Immunol.* 199:163-200; Riurok et al. (1990) *J.Mol.Biol.* 215:589-596; Stevenson et al. (1995) *J. Virol.* 69:2850-2857). The sequences of the fiber gene from a variety of serotypes including adenovirus serotypes 2 (Ad2), Ad5, Ad3, Ad35, Ad12, Ad40, and Ad41 are known. There are at least 21 different fiber genes in Genbank.

-28-

As noted, the fiber protein can be divided into three domains (see, *e.g.*, Green *et al.* (1983) *EMBO J.* 2:1357-1365). The conserved N-terminus contains the sequences responsible for association with the penton base as well as a nuclear localization signal. A rod-like shaft of variable length contains repeats of a 15 amino acid beta structure, with the number of repeats ranging from 6 in Ad3 to 22 in Ad5. A conserved stretch of amino acids which includes the sequence TLWT (SEQ ID No. 36) marks the boundary between the repeating units of beta structure in the shaft and the globular head domain. The C-terminal head domain ranges in size from 157 amino acid residues for the short fiber of Ad41 to 193 residues for Ad11 and Ad34. The fiber spike is a homotrimer and it is thought that the C-terminus is responsible for trimerization of the fiber homotrimer and there are 12 spikes per virion which are attached via association with the penton base complex.

2. Modification of HSP interaction

The adenovirus fiber protein is a major determinant of adenovirus tropism (Gall *et al.* (1996) *J. Virol.* 70:2116-2123; Stevenson *et al.* (1995) *J. Virol.* 69:2850-2857). Dogma in the field has been that adenoviral entry occurs via binding to CAR and integrins. This is underscored by published data (Einfeld *et al.* (2001) *J. Virology* 75:11284-11291). It is shown herein, however, these published entry pathways are not the predominant ones that act *in vivo*. Moreover, as shown herein, the dominant entry pathway for hepatocytes *in vivo* involves a mechanism mediated by the fiber shaft, such as Ad5 shaft, through heparin sulfate proteoglycans binding.

It is shown herein that elimination of this binding eliminates entry vis HSP binding, such as in hepatocytes. Adenoviral fiber shaft modifications that ablate viral interaction with HSP are provided. Thus, as provided herein, efficient detargeting of adenovirus *in vivo* can be achieved with appropriately designed fiber proteins. Suitable modifications, such as described herein, can be made with respect to any adenovirus in which the wild-type interacts with HSP.

As provided herein, the ability of an adenoviral vector to interact with HSP is modified. In particular, the ability to interact is reduced or eliminated. Modifications include insertions, deletions, individual amino acid mutations and

-29-

other mutations that alter the structure of the fiber shaft such that the HSP binding of the modified fiber protein is ablated when compared to the HSP binding of the wild-type fiber protein.

In a first aspect of this embodiment, an adenoviral fiber protein is modified by mutating one or more of the amino acids that interact with HSP. For example, the HSP binding motif of the modified fiber protein is no longer able to interact with HSP on the cell surface, thus ablating the viral interaction with HSP. For example, the adenoviral fiber is from a subgroup C adenovirus. Binding to HSP can be eliminated or reduced by mutating the fiber shaft in order to modify the ability of the HSP binding motif, which is, for example, KKTK sequence (SEQ ID No. 1) located between amino acid residues 91 to 94 in the Ad 5 fiber, to interact with HSP. The fiber proteins are modified by chemical and biological techniques known to those skilled in the art, such as site directed mutagenesis of nucleic acid encoding the fiber or other techniques as illustrated herein.

In another aspect of this embodiment, the ability of a fiber to interact with HSP is modified by replacing the wild-type fiber shaft with a fiber shaft, or portion thereof, of an adenovirus that does not interact with HSP to produce chimeric fiber proteins. The portion is sufficient to reduce or eliminate interaction with HSP. Examples of adenoviruses having fiber shafts that do not interact with HSP include (a) adenoviruses of subgroup B, such as, but are not limited to, Ad3, Ad35, Ad7, Ad11, Ad16, Ad21, Ad34, which do not have interaction with HSP, (b) adenoviruses of subgroup F, such as, but are not limited to, Ad40 and Ad41, specifically the short fiber, and (c) adenoviruses of subgroup D, such as but are not limited to, Ad46. In another embodiment, adenoviral fiber shaft modifications that ablate viral interaction with HSP in combination with adenoviral fiber knob modifications that ablate viral interactions with CAR are provided. Suitable adenoviral fiber modifications include the fiber knob modifications are known to those of skill in the art and are exemplified herein (see, also, US. Patent Application Serial No. 09/870,203, filed on 30 May 2001, and published as U.S. Published application No. 20020137213, in International Patent Application No. PCT/EP01/06286 filed on 1 June 2001).

-30-

Modifications of the fiber include mutations of at least one amino acid in the CD loop of a wild-type fiber protein of an adenovirus from subgroup C, D, or E, or the long wild-type fiber of an adenovirus from subgroup F, whereby the ability of a fiber protein to bind to CAR is reduced or substantially eliminated. The fiber proteins with ablated CAR interaction are modified by chemical and biological techniques known to those skilled in the art, as illustrated herein and as described in the above patent application.

Alternatively, adenoviral fiber modifications are made by replacing the wild-type fiber knob with a fiber knob of an adenovirus that does not interact with CAR. The fiber protein also will be selected so that it does not interact with HSP. Examples of adenoviruses having fiber knobs that do not interact with CAR include (a) adenoviruses of subgroup B, e.g., Ad3, Ad35, Ad7, Ad11, Ad16, Ad21, Ad34, (b) adenoviruses of subgroup F, e.g., Ad40 and Ad41, specifically the short fiber.

In another embodiment, adenoviral fiber shaft modifications that ablate viral interaction with HSP in combination with penton modifications that ablate viral interactions with α_v integrins are provided. Suitable adenoviral penton modifications include the penton modifications, which are well known to those of skill in the art (see, e.g., U.S. Patent No. 5,731,190; see, also Einfeld *et al.* (2001) *J. Virology* 75:11284-11291; and Bai *et al.* (1993) *J. Virology* 67:5198-5205).

For example, penton interaction with α_v integrins can be ablated (reduced or eliminated) by substitution of the RGD tripeptide motif, required for α_v interaction, in penton with a different tripeptide that does not interact with an α_v integrin. The penton proteins with ablated α_v integrin interactions are modified by chemical and biological techniques known to those skilled in the art (see, e.g., described U.S. Patent No. 6,731,190 and as illustrated herein). Generally, the adenovirus is a subgroup B or C adenovirus.

Also provided are adenoviral fiber shaft modifications that ablate viral interaction with HSP in combination with adenoviral fiber knob modifications that ablate viral interactions with CAR and with penton modifications that ablate viral interactions with α_v integrins. These modifications are described above and

-31-

prepared using chemical and biological techniques known to those skilled in the art and as illustrated herein. Generally the adenovirus is a subgroup B or subgroup C adenovirus.

Preparation of fibers modified to eliminate or reduce HSP interactions and
5 fibers modified to alter interactions with other receptors and cell surface proteins, such as CAR and/or α_v integrin, is also described in the Examples below. The nucleic acid and/or amino acid sequences of exemplary modified fibers, whose construction are described below) are set forth as SEQ ID Nos. 45-72 as follows:

10 SEQ ID Nos. 45 and 46 set forth the encoding nucleotide sequence and amino acid sequence of the modified fiber designated 5FKO1, where 5F refers to Adenovirus 5 fiber, KO1 is an exemplary mutation of the CAR interaction site described herein;

SEQ ID Nos. 47 and 48 set forth the encoding nucleotide sequence and
15 amino acid sequence of the modified ber designated 5FKO1RGD, which further includes an RGD ligand to demonstrate retargeting;

SEQ ID Nos. 49 and 50 set forth the encoding nucleotide sequence and amino acid sequence of the modified fiber designated 5FKO12, where 5F refers to Adenovirus 5 fiber, KO12 is another exemplary mutation of the CAR
20 interaction site described herein;

SEQ ID Nos. 51 and 52 set forth the encoding nucleotide sequence and amino acid sequence of the modified fiber designated 5F S* nuc, where 5F refers to Adenovirus 5 fiber, S* is an exemplary mutation of the shaft that alters binding to HSP;

25 SEQ ID Nos. 53 and 54 set forth the encoding nucleotide sequence and amino acid sequence of the modified fiber designated 5F S*RGD nuc, which further includes an RGD ligand;

SEQ ID Nos. 55 and 56 set forth the encoding nucleotide sequence and amino acid sequence of the modified ber designated 5FKO1S*, which contain
30 the KO1 and S* mutations;

-32-

SEQ ID Nos. 57 and 58 set forth the encoding nucleotide sequence and amino acid sequence of the modified fiber designated 5FKO1S*RGD, which further includes an RGD ligand;

5 SEQ ID Nos. 59 and 60 set forth the encoding nucleotide sequence and amino acid sequence of a Ad35 fiber;

SEQ ID Nos. 61 and 62 set forth the encoding nucleotide sequence and amino acid sequence of the modified fiber designated 35FRGD, which is 35F fiber with an RGD ligand;

10 SEQ ID Nos. 63 and 64 set forth the encoding nucleotide sequence and amino acid sequence of a Ad41 short fiber;

SEQ ID Nos. 65 and 66 set forth the encoding nucleotide sequence and amino acid sequence of the modified fiber designated 41sFRGD, which is 41F short fiber with an RGD ligand;

15 SEQ ID Nos. 67 and 68 set forth the encoding nucleotide sequence and amino acid sequence of Ad5 penton;

20 SEQ ID Nos. 69 and 70 set forth the encoding nucleotide sequence and amino acid sequence of the modified fiber designated 5TS35H, which is a chimeric fiber in which an Ad5 fiber tail and shaft regions (5TS; amino acids 1 to 403) are connected to an Ad35 fiber head region (35H; amino acids 137 to 323) to form the 5TS35H chimera; and

25 SEQ ID Nos. 71 and 72 set forth the encoding nucleotide sequence and amino acid sequence of the modified fiber designated 35TS5H, which is a chimeric fiber in which an Ad35 fiber tail and shaft regions (35TS; amino acids 1 to 136) are connected to an Ad5 fiber head region (5H; amino acids 404 to 581) to form the 35TS5H chimera.

30 SEQ ID No. 1 sets forth the nucleotide sequence of Ad fiber; SEQ ID Nos. 2 and 3 also set forth the coding nucleic acid sequences for fibers with modified fiber knobs for ablated CAR interaction (see, SEQ ID No. 2 for KO1 and SEQ ID No. 3 for KO12); SEQ ID No. 4 also sets for the encoding nucleic acid sequence of a modified penton for ablated α_v integrins (SEQ ID No. 4).

The modified fibers are displayed on virus particles by modifying the fiber protein and optionally additional proteins. This can be achieved by preparing

-33-

adenoviral vectors that express the modified capsid proteins and produce particles with modified fibers, or by packaging adenoviral vectors, particularly those that do not encode one or more capsid proteins in appropriate packaging lines. Hence, as discussed in detail below, adenoviral vectors and viral particles
5 with modified fibers that do not bind to HSP are provided.

C. Nucleic acids, Adenoviral vectors and cells containing the nucleic acids and cells containing the vectors

Also provided are polynucleotides that encode modified capsid proteins and that encode vectors for preparation of adenovirus that express modified
10 capsid proteins provided herein. The sequences of the wild-type adenovirus proteins are well known in the art and are modified as described herein. Nucleic acid molecules, such as cDNA that encode an exemplary modified fiber knob for ablated CAR interaction (see, SEQ ID No. 2 for KO1 and SEQ ID No. 3 for KO12) and for a modified penton for ablated α_v integrins (SEQ ID No. 4) are provided.
15 As discussed above, modified capsid proteins with altered tropism for CAR and α_v integrins are known and described in the patents, applications and literature cited herein and known to those of skill in the art (see, *e.g.*, U.S. Patent No. 5,731,190, U.S. application Serial No. 09/870,203, published as U.S. Published application No. 20020137213; and Bai *et al.* (1993) *J. Virology*
20 67:5198-5208).

Also provided are vectors including the polynucleotides provided herein. Such vectors include partial or complete adenoviral genomes and plasmids. Such vectors are constructed by techniques known to those skilled in the art and as illustrated herein. Also provided are adenoviral vectors modified by replacing
25 whole fiber protein, or portions thereof, with the fiber proteins, or appropriate portions thereof, of an adenovirus that does not interact with HSP.

Adenoviruses that do not interact with HSP can be identified by using the methods described herein which detect binding or non-binding of fiber proteins and adenoviruses with HSP. Among the adenoviral vectors provided herein are
30 those of subgroup C, which include Ad2 and Ad5, in which the nucleic acid encoding the fiber shaft or a portion including the HSP-binding portion is

-34-

replaced with nucleic acid encoding fiber or an appropriate portion thereof from a serotype, such as Ad35.

Adenoviral fiber modifications, thus, can be made in viral particles by replacing the entire fiber protein with the fiber protein of an adenovirus that does not interact with CAR and/or replacing the HSP binding portion with a portion that does not bind. Generally the adenovirus is a subgroup B or subgroup C adenovirus, and also an adenovirus of subgroup D, such as Ad46. Adenoviral vectors of subgroup C, such as Ad2 and Ad5, having a replaced fiber knob are prepared using techniques well known in the art and as illustrated herein.

1. Preparation of viral particles

The packaging cells used to produce the viruses provided herein contain the nucleic acid encoding the capsid protein, including the mutated fiber protein provided herein. Such nucleic acid can be transfected into the cell, generally part of as part of plasmid, or it can be infected into the cell with a viral vector. It can be stably incorporated into the genome of the cell, thus providing for a stable cell line. Alternatively, nucleic acid encoding the mutated capsid protein can be removed from the genome, in which case a transient complementing cell is employed.

The adenovirus genome to be packaged is transferred into the complementing cell by techniques known to those skilled in the art. These techniques include transfection or infection with the adenovirus. The nucleic acid encoding the mutated fiber protein can be in this genome instead of in the packaging cell.

In certain cases, when the nucleic acid encoding the mutated fiber is in the genome to be packaged, it can be desirable for the packaging cell to also encode a fiber protein. Such protein can assist in the maturation and packaging of an infectious particle. Such protein can be a wild-type fiber protein or one modified such that it is unable to attach to the penton base protein and is for use, for example, in producer cells where the fiber is included to provide the packaging function and the vector encodes a full-length fiber.

The packaging cells are cultured under conditions that permit the production of the desired viral particle. The viral particles are recovered by

-35-

standard techniques. An exemplary method for producing adenoviral particles provided herein is as follows. The nucleic acid encoding the mutated fiber protein is made using standard techniques in an adenoviral shuttle plasmid. This plasmid contains the right end of the virus, in particular from the end of the E3
5 region through the right ITR. This plasmid is co-transfected into competent cells of an *E. coli* strain, such as the well known *E. coli* strain BJ5183 (see, *e.g.*, Degryse (1996) *Gene* 170:45-50) along with a plasmid, which contains the remaining portion of the adenovirus genome, except for the E1 region and sometimes also the E2a region and also contains a corresponding region of
10 homology. Homologous recombination between the two plasmids generates a full-length plasmid encoding the entire adenoviral vector genome.

This full-length adenoviral vector genome plasmid is then transfected into a complementing cell line. The transfection can be performed in the presence of a reagent that directs adenoviral particle entry into producer cells. Such
15 reagents include, but are not limited to, polycations and bifunctional reagents, such as those described herein. A complementing cell is, for example, is a cell of the PER.C6 cell line, which contains the adenoviral E1 gene (PER.C6 is available, for example, from Crucell, The Netherlands; deposited under ECACC accession no. 96022940; see, also Fallaux *et al.* (1998) *Hum. Gene Ther.*
20 9:1909-1907; see, also, U.S. Patent No. 5,994,128) or an AE1-2a cell (see, Gorziglia *et al.* (1996) *J. Virology* 70:4173-4178; and and Von Seggern *et al.* (1998) *J. Gen. Virol.* 79:1461-1468)).

AE1-2a cells are derivatives of the A549 lung carcinoma line (ATCC # CCL 185) with chromosomal insertions of the plasmids pGRE5-2.E1 (also
25 referred to as GRE5-E1-SV40-Hygro construct and listed in SEQ ID No. 41) and pMNeoE2a-3.1 (also referred to as MMTV-E2a-SV40-Neo construct and listed in SEQ ID No. 42); which provide complementation of the adenoviral E1 and E2a functions, respectively.

The 633 cell line (see, von Seggern *et al.* (2000) *J. Virology*
30 74:354-362), which stably expresses the adenovirus serotype 5 wild-type fiber protein, and was derived from the AE1-2a cell line, is another an example of complementing cells. When the cell line is 633 cells, the final passage of

-36-

adenoviral vector is performed on another complementing cell line (*e.g.*, Per.C6), which does not express wild-type Ad5 fiber.

The transfected complementing cells are maintained under standard cell culture conditions. The adenoviral plasmids recombine to form the adenoviral genome that is packaged. The particles are infectious, but replication deficient because their genome is missing at least the E1 genes. When performed in the 633 cells the particles contain wild-type and mutated fiber proteins. They are recovered from the crude viral lysate, amplified, and are purified by standard techniques.

10 The recovered particles can be used to infect PER.C6 or AE1-2a cells. This permits the recovery of particles whose capsids contain only the desired mutated fiber. This two-step procedure provides high titer batches of the adenoviral particles provided herein. The adenoviral particles can be replication competent or replication incompetent.

15 In one embodiment, the particles selectively replicate in certain predetermined target tissue but are replication incompetent in other cells and tissues. In a particular embodiment, the adenoviral particles replicate in abnormally proliferating tissue, such as solid tumors and other neoplasms. In replication conditional adenoviruses, a gene essential for replication is placed
20 under control of a heterologous promoter which is cell or tissue specific. For example, the E1a gene is placed under control of a promoter which is active in a tumor cell to produce an oncolytic adenovirus or oncolytic adenoviral vector. Administration of oncolytic adenoviral vectors to tumor cells kills the tumor cells. Such replication conditional adenoviral particles and vectors can be produced by
25 techniques known to those skilled in the art, such as those disclosed in the above-referenced U.S. Patent Nos. 5,998,205 and 5,801,029. These particles and vectors can be produced in adenoviral packaging cells as disclosed above. Generally packaging cells are those that have been designed to limit homologous recombination that could lead to wild-type adenoviral particles. Such cells are
30 well known and include the packaging cell known as PER.C6 (see, *e.g.*, U.S. Patent Nos. 5,994,128 and 6,033,908; deposited under ECACC accession no. 96022940). Since oncolytic vectors are replication competent in certain cell

-37-

types, they can be amplified in cell lines derived from said cell type without provision of Ad complementary genes.

2. Adenoviral vectors and particles

The adenovirus as used herein for production of the adenoviral vectors
5 and particles can be of any serotype. Adenoviral stocks that can be employed as a source of adenovirus or adenoviral coat protein, such as fiber and/or penton base, can be amplified from the adenoviral serotypes 1 through 47, which are currently available from the American Type Culture Collection (ATCC, Rockville, Md.), or from any other serotype of adenovirus available from any other source.
10 For instance, an adenovirus can be of subgroup A (e.g., serotypes 12, 18, 31), subgroup B (e.g., serotypes 3, 7, 11, 14, 16, 21, 34, 35), subgroup C (e.g., serotypes 1, 2, 5, 6), subgroup D (e.g., serotypes 8, 9, 10, 13, 15, 17, 19, 20, 22-30, 32, 33, 36-39, 42-47), subgroup E (serotype 4), subgroup F (serotype 40, 41), or any other adenoviral serotype.
15 In certain embodiments, the adenovirus is a subgroup B or a subgroup C adenovirus. Subgroup C adenoviruses which are modified in as described herein, include, but are not limited to, Ad2 and Ad5. For Ad5, the mutation is made in the KKTK sequence (SEQ ID No. 1) located between amino acid residues 91 to 94. The fiber proteins can be modified by chemical and biological techniques
20 known to those skilled in the art. These methods include, but are not limited to, site directed mutagenesis and techniques as illustrated herein.

The adenoviral particle generally includes a targeting ligand as described above. The presence of the targeting ligand permits the delivery of a gene to a desired cell type which is different from the cell type that wild-type adenovirus
25 particles infect or the same as that a wild-type particle infects, but allowing the infection in a selective manner, *i.e.*, non-target cell types are not significantly infected.

The adenoviral vectors provided herein can be used to study cell transduction and gene expression *in vitro* or in various animal models. The latter
30 case includes *ex vivo* techniques, in which cells are transduced *in vitro* and then administered to the animal. They also can be used to conduct gene therapy on humans or other animals. Such gene therapy can be *ex vivo* or *in vivo*. For *in*

-38-

vivo gene therapy, the adenoviral particles in a pharmaceutically-acceptable carrier are delivered to a human in a therapeutically effective amount in order to prevent, treat, or ameliorate a disease or other medical condition in the human through the introduction of a heterologous gene that encodes a therapeutic protein into cells in such human. The adenoviruses are delivered at a dose ranging from approximately 1 particle per kilogram of body weight to approximately 10^{14} particles per kilogram of body weight. Generally, they are delivered at a dose of approximately 10^6 particles per kilogram of body weight to approximately 10^{13} particles per kilogram of body weight, and typically the dose ranges from approximately 10^8 particles per kilogram of body weight to approximately 10^{12} particles per kilogram of body weight.

Any vectors known to those of skill in the art can be employed and used to produce viral particles that include fibers modified to ablate (including reduce) binding to HSP. Some exemplary vectors are as follows.

a. Gutless vectors

Gutted adenovirus vectors are those from which most or all viral genes have been deleted. They are grown by co-infection of the producing cells with a "helper" virus (such as using an E1-deleted Ad vector), where the packaging cells expresses the E1 gene products. The helper virus trans-complements the missing Ad functions, including production of the viral structural proteins needed for particle assembly. To incorporate the capsid modifications into a gutted adenoviral vector capsid, the changes must be made to the helper virus as described herein. All the necessary Ad proteins including the modified capsid protein are provided by the modified helper virus, and the gutted adenovirus particles are equipped with the particular modified capsid expressed by the host cells. The E1a, E1b, E2a, E2b and E4 are generally required for viral replication and packaging. If these genes are deleted, then the packaging cell must provide these genes or functional equivalents.

A helper adenovirus vector genome and a gutless adenoviral vector genome are delivered to packaging cells. The cells are maintained under standard cell maintenance or growth conditions, whereby the helper vector genome and the packaging cell together provide the complementing proteins for

-39-

the packaging of the adenoviral vector particle. Such gutless adenoviral vector particles are recovered by standard techniques. The helper vector genome can be delivered in the form of a plasmid or similar construct by standard transfection techniques, or it can be delivered through infection by a viral particle containing the genome. Such viral particle is commonly called a helper virus. Similarly, the gutless adenoviral vector genome can be delivered to the cell by transfection or viral infection.

The helper virus genome can be the modified adenovirus vector genome as disclosed herein. Such genome also can be prepared or designed so that it lacks the genes encoding the adenovirus E1A and E1B proteins. In addition, the genome can further lack the adenovirus genes encoding the adenovirus E3 proteins. Alternatively, the genes encoding such proteins can be present but mutated so that they do not encode functional E1A, E1B and E3 proteins. Furthermore, such vector genome can not encode other functional early proteins, such as E2A, E2B3, and E4 proteins. Alternatively, the genes encoding such other early proteins can be present but mutated so that they do not encode functional proteins.

In producing the gutless vectors, the helper virus genome is also packaged, thereby producing helper virus. In order to minimize the amount of helper virus produced and maximize the amount of gutless vector particles produced, the packaging sequence in the helper virus genome can be deleted or otherwise modified so that packaging of the helper virus genome is prevented or limited. Since the gutless vector genome will have an unmodified packaging sequence, it will be preferentially packaged.

One way to do this is to mutate the packaging sequence by deleting one or more of the nucleotides comprising the sequence or otherwise mutating the sequence to inactivate or hamper the packaging function. One exemplary approach is to engineer the helper genome so that recombinase target sites flank the packaging sequence and to provide a recombinase in the packaging cell. The action of recombinase on such sites results in the removal of the packaging sequence from the helper virus genome. The recombinase can be provided by a nucleotide sequence in the packaging cell that encodes the recombinase. Such

-40-

sequence can be stably integrated into the genome of the packaging cell. Various kinds of recombinase are known by those skilled in the art, and include, but are not limited to, Cre recombinase, which operates on so-called lox sites, which are engineered on either side of the packaging sequence as discussed
5 above (see, *e.g.*, U.S. Patent Nos. 5,919, 676, 6,080,569 and 5,919,676; see, also, *e.g.*, Morsy and Caskey, *Molecular Medicine Today*, Jan. 1999, pgs. 18-24).

An example of a gutless vector is pAdARSVDys (Haecker *et al.* (1996) *Hum Gene Ther.* 7:1907-1914)). This plasmid contains a full-length human
10 dystrophin cDNA driven by the RSV promoter and flanked by Ad inverted terminal repeats and packaging signals. 293 cells are infected with a first-generation Ad, which serves as a helper virus, and then transfected with purified pAdARSVDys DNA. The helper Ad genome and the pAdARSVDys DNA are replicated as Ad chromosomes, and packaged into particles using the viral
15 proteins produced by the helper virus. Particles are isolated and the pAdARSVDys-containing particles separated from the helper by virtue of their smaller genome size and therefore different density on CsCl gradients. Other examples of gutless adenoviral vectors are known (see, *e.g.*, Sandig *et al.* (2000) *Proc. Natl. Acad. Sci. U.S.A.* 97(3):1002-7).

20 b. Oncolytic vectors

Briefly, oncolytic adenoviruses, which are viruses that replicate selectively in tumor cells, are designed to amplify the input virus dose due to viral replication in the tumor, leading to spread of the virus throughout the tumor mass. *In situ* replication of adenoviruses leads to cell lysis. This *in situ* replication
25 permits relatively low, non-toxic doses to be highly effective in the selective elimination of tumor cells. One approach to achieving selectivity is to introduce loss-of-function mutations in viral genes that are essential for growth in non-target cells but not in tumor cells. (See, *e.g.*, U.S. Patent No. 5,801,029.) This strategy is exemplified by the use of Addl1520, which has a deletion in the
30 E1b-55KD gene. In normal cells, the adenoviral E1b-55KD protein is needed to bind to p53 to prevent apoptosis. In p53-deficient tumor cells, E1b-55K binding

-41-

to p53 is unnecessary. Thus, deletion of E1b-55KD should restrict vector replication to p53-deficient tumor cells.

Another approach is to use tumor-selective promoters to control the expression of early viral genes required for replication (see, *e.g.*, International PCT application Nos. WO 96/17053 and WO 99/25860). Thus, in this approach the adenoviruses selectively replicate and lyse tumor cells if the gene that is essential for replication is under the control of a promoter or other transcriptional regulatory element that is tumor-selective.

For example oncolytic adenoviral vectors that contain a cancer selective regulatory region operatively linked to an adenoviral gene essential for adenoviral replication are known (see, *e.g.*, U.S. Patent No. 5,998,205). Adenoviral genes essential for replication include, but are not limited to, E1a, E1b, E2a, E2b and E4. For example, an exemplary oncolytic adenoviral vector has a cancer selective regulatory region operatively linked to the E1a gene. In other embodiments, the oncolytic adenoviral vector has a cancer selective regulatory region of the present invention operatively linked to the E1a gene and a second cancer selective regulatory region operatively linked to the E4 gene. The vectors also can include at least one therapeutic transgene, such as, but not limited to, a polynucleotide encoding a cytokine such as GM-CSF that can stimulate a systemic immune response against tumor cells.

Other exemplary oncolytic adenoviral vectors include those in which expression of an adenoviral gene, which is essential for replication, is controlled by E2F-responsive promoters, which are selectively transactivated in cancer cells. Thus, vectors that contains an adenoviral nucleic acid backbone that contains in sequential order: A left ITR, an adenoviral packaging signal, a termination signal sequence, an E2F responsive promoter which is operably linked to a first gene, such as E1a, essential for replication of the recombinant viral vector and a right ITR (see, published International PCT application No. WO02/06786, and U.S. Patent No. 5,998,205).

In other embodiments, the oncolytic adenoviral vector has a cancer selective regulatory region operatively linked to the E1a gene and a second cancer selective regulatory region operatively linked to the E4 gene. The vectors

-42-

can also carry at least one therapeutic transgene, such as, but not limited to, a polynucleotide encoding a cytokine such as GM-CSF that can stimulate a systemic immune response against tumor cells.

3. Packaging

5 The viral particles provided herein can be made by any method known to those of skill in the art. Generally they are prepared by growing the adenovirus vector that contains nucleic acid that encodes the modified fiber protein in a standard adenovirus packaging cells to produce particles that express the modified fibers. Alternatively, the vectors do not encode fibers. Such vectors
10 are packaged in producer cells to produce particles that express the modified fiber proteins.

As discussed, recombinant adenoviral vectors generally have at least a deletion in the first viral early gene region, referred to as E1, which includes the E1a and E1b regions. Deletion of the viral E1 region renders the recombinant
15 adenovirus defective for replication and incapable of producing infectious viral particles in subsequently-infected target cells. Thus, to generate E1-deleted adenovirus genome replication and to produce virus particles requires a system of complementation which provides the missing E1 gene product. E1 complementation is typically provided by a cell line expressing E1, such as the
20 human embryonic kidney packaging cell line, i.e. an epithelial cell line, called 293. Cell line 293 contains the E1 region of adenovirus, which provides E1 gene region products to "support" the growth of E1-deleted virus in the cell line (see, *e.g.*, Graham *et al.*, *J. Gen. Virol.* 36: 59-71, 1977). Additionally, cell lines that may be usable for production of defective adenovirus having a portion of
25 the adenovirus E4 region have been reported (WO 96/22378). Multiply deficient adenoviral vectors and complementing cell lines have also been described (WO 95/34671, U.S. Patent No. 5,994,106).

For example, copending U.S. application Serial No. 09/482,682 (also filed as International PCT application No. PCT/EPO0/00265, filed January 14,
30 200, published as International PCT application No. WO/0042208) provides packaging cell lines that support viral vectors with deletions of major portions of the viral genome, without the need for helper viruses and also provides cell lines

-43-

and helper viruses for use with helper-dependent vectors. The packaging cell line has heterologous DNA stably integrated into the chromosomes of the cellular genome. The heterologous DNA sequence encodes one or more adenovirus regulatory and/or structural polypeptides that complement the genes deleted or

5 mutated in the adenovirus vector genome to be replicated and packaged.

Packaging cell lines express, for example, one or more adenovirus structural proteins, polypeptides, or fragments thereof, such as penton base, hexon, fiber, polypeptide IIIa, polypeptide V, polypeptide VI, polypeptide VII, polypeptide VIII, and biologically active fragments thereof. The expression can be constitutive or

10 under the control of a regulatable promoter. These cell lines are particularly designed for expression of recombinant adenoviruses intended for delivery of therapeutic products. For use herein, such packaging cell lines can express the modified capsid proteins, such as the fiber proteins who binding to HSP is reduced or eliminated, and/or the modified penton and hexon proteins.

15 Particular packaging cell lines complement viral vectors having a deletion or mutation of a DNA sequence encoding an adenovirus structural protein, regulatory polypeptides E1A and E1B, and/or one or more of the following regulatory proteins or polypeptides: E2A, E2B, E3, E4, L4, or fragments thereof.

The packaging cell lines are produced by introducing each DNA molecule
20 into the cells and then into the genome via a separate complementing plasmid or plurality of DNA molecules encoding the complementing proteins can be introduced via a single complementing plasmid. Of interest herein, is a variation in which the complementing plasmid includes DNA encoding adenovirus fiber protein (or a chimeric or modified variant thereof), from Ad virus of subgroup D,
25 such as Ad 37, polypeptide or fragment thereof.

For applications, such as therapeutic applications, the delivery plasmid further can include a nucleotide sequence encoding a heterologous polypeptide. Exemplary delivery plasmids include, but are not limited to, pDV44, p Δ E1B β -gal and p Δ E1sp1B. In a similar or analogous manner, therapeutic nucleic acids,
30 such as nucleic acids that encode therapeutic genes, can be introduced.

-44-

The cell further includes a complementing plasmid encoding a fiber as contemplated herein; the plasmid or portion thereof is integrated into a chromosome(s) of the cellular genome of the cell.

Typically, the packaging cell lines will contain nucleic acid encoding the
5 fiber protein or modified protein stably integrated into a chromosome or
chromosomes in the cellular genome. The packaging cell line can be derived from
a procaryotic cell line or from a eukaryotic cell line. While various embodiments
suggest the use of mammalian cells, and more particularly, epithelial cell lines, a
variety of other, non-epithelial cell lines are used in various embodiments. Thus,
10 while various embodiments disclose the use of a cell line selected from among
the 293, A549, W162, HeLa, Vero, 211, and 211A cell lines, and any other cell
lines suitable for such use are likewise contemplated herein.

D. Addition of a targeting ligand

The viral particles that are detargeted as described herein, can be
15 retargeted to selected cells and/or tissues by inclusion of an appropriate
targeting ligand in the capsid. The ligand can be included in any of the capsid
proteins, such as fiber, hexon and penton. Loci for inclusion of nucleic acid
encoding a is known to those of skill in the art for a variety of adenovirus
serotypes; if necessary appropriate loci and other parameters can be empirically
20 determined.

The ligand can be produced as a fusion by inclusion of the coding
sequences in the nucleic acid encoding a capsid protein, or chemically
conjugated, such as via ionic, covalent or other interactions, to the capsid or
bound to the capsid (*e.g.*, by Ab-ligand fusion, where Ab binds capsid protein; or
25 by disulfide bonding or other crosslinking moieties or chemistries).

Thus, for example, a modified fiber nucleic acid also can include
sequences of nucleotides that encode a targeting ligand to produce viral particles
that include a targeting ligand in the capsid. Targeting ligand and methods for
including such ligands in viral capsids are well known. For example, inclusion of
30 targeting ligands in fiber proteins is described in U.S. Patent Nos. 5,543,328 and
5,756,086 and in U.S. Patent Application Serial No. 09/870,203, published as
U.S. Published application No. 20020137213, and International Patent

-45-

Application No. PCT/EP01/06286. For different serotypes and strains of adenoviruses, loci for insertion of targeting ligands can be empirically determined. For different serotypes and strains, such loci can vary.

Because the adenovirus fiber has a trimeric structure, the ligand can be
5 selected or designed to have a trimeric structure so that up to three molecules of the ligand are present for each mature fiber. Such ligands can be incorporated into the fiber protein using methods known in the art (see, *e.g.*, U.S. Patent No. 5,756,086). Instead of the fiber, the targeting ligand can be included in the penton or hexon proteins. Inclusion of targeting ligands in penton (see for
10 example, in U.S. Patent Nos. 5,731,190 and 5,965,431) and in hexon (see for example, in U.S. Patent No. 5,965,541) is known.

In one exemplary embodiment, the ligand is included in a fiber protein, which is a fiber protein mutated as described herein. As shown herein, the targeting ligand can be included, for example, within the HI loop of the fiber
15 protein. Any ligand that can fit in the HI loop and still provide a functional virus is contemplated herein. Such ligands can be as long as or longer than 80-100 amino acids (see, *e.g.*, Belousova *et al.* (2002) *J. Virol.* 76:8621-8631). Such ligands are added by techniques known in the art (see, *e.g.*, published International Patent Application publication No. WO99/39734 and U.S. Patent
20 Application number 09/482,682). Other ligands can be discovered through techniques known to those skilled in the art. Some non-limiting examples of these techniques include phage display libraries or by screening other types of libraries.

Targeting ligands include any chemical moiety that preferentially directs
25 an adenoviral particle to a desired cell type and/or tissue. The categories of such ligands include, but are not limited to, peptides, polypeptides, single chain antibodies, and multimeric proteins. Specific ligands include the TNF superfamily of ligands which include tumor necrosis factors (or TNF's) such as, for example, TNF α and TNF β , lymphotoxins (LT), such as LT- α and LT- β , Fas ligand which
30 binds to Fas antigen; CD40 ligand, which binds to the CD40 receptor of B-lymphocytes; CD30 ligand, which binds to the CD30 receptor of neoplastic cells of Hodgkin's lymphoma; CD27 ligand, NGF ligand, and OX-40 ligand;

-46-

transferrin, which binds to the transferrin receptor located on tumor cells, activated T -cells, and neural tissue cells; ApoB, which binds to the LDL receptor of liver cells; alpha-2-macroglobulin, which binds to the LRP receptor of liver cells; alpha-I acid glycoprotein, which binds to the asialoglycoprotein receptor of liver; mannose-containing peptides, which bind to the mannose receptor of macrophages; sialyl-Lewis-X antigen-containing peptides, which bind to the ELAM-I receptor of activated endothelial cells; CD34 ligand, which binds to the CD34 receptor of hematopoietic progenitor cells; ICAM-I, which binds to the LFA-I (CD11b/CD18) receptor of lymphocytes, or to the Mac-I (CD11a/CD18) receptor of macrophages; M-CSF, which binds to the c-fms receptor of spleen and bone marrow macrophages; circumsporozoite protein, which binds to hepatic Plasmodium falciparum receptor of liver cells; VLA-4, which binds to the VCAM-I receptor of activated endothelial cells; HIV gp120 and Class II MHC antigen, which bind to the CD4 receptor of T -helper cells; the LDL receptor binding region of the apolipoprotein E (ApoE) molecule; colony stimulating factor, or CSF, which binds to the CSF receptor; insulin-like growth factors, such as IGF-I and IGF-II, which bind to the IGF-I and IGF-II receptors, respectively; Interleukins 1 through 14, which bind to the Interleukin 1 through 14 receptors, respectively; the Fv antigen-binding domain of an immunoglobulin; gelatinase (MMP) inhibitor; bombesin, gastrin-releasing peptide; substance P; somatostatin; luteinizing hormone releasing hormone (LHRH); vasoactive peptide (VIP); gastrin; melanocyte stimulating hormone (MSH); cyclic RGD peptide and any other ligand or cell surface protein-binding (or targeting) molecule.

E. Heterologous polynucleotides and Therapeutic Nucleic Acids

The packaged adenoviral genome also can contain a heterologous polynucleotide that encodes a product of interest, such as a therapeutic protein. Adenoviral genomes containing heterologous polynucleotides are well known (see, *e.g.*, U.S. Patent Nos. 5,998,205, 6,156,497, 5,935,935, and 5,801,029). These can be used for *in vitro* and *in vivo* delivery of the products of heterologous polynucleotides or the heterologous polynucleotides.

Thus, the adenoviral particles provided herein can be used to engineer a cell to express a protein that it otherwise does not express or does not express

-47-

in sufficient quantities. This genetic engineering is accomplished by infecting the desired cell with an adenoviral particle whose genome includes a desired heterologous polynucleotide. The heterologous polynucleotide is then expressed in the genetically engineered cells. For use herein the cell is generally a

5 mammalian cell, and is typically a primate cell, including a human cell. The cell can be inside the body of the animal (*in vivo*) or outside the body (*in vitro*). Heterologous polynucleotides (also referred to as heterologous nucleic acid sequences) are included in the adenoviral genome within the particle and are added to that genome by techniques known in the art. Any heterologous

10 polynucleotide of interest can be added, such as those disclosed in U.S. Patent No. 5,998,205, incorporated herein by reference. Polynucleotides that are introduced into an Ad genome or vector can be any that encode a protein of interest or that are regulatory sequences. Proteins include, but are not limited to, therapeutic proteins, such as an immunostimulating protein, such as an

15 interleukin, interferon, or colony stimulating factor, such as granulocyte macrophage colony stimulating factor (GM-CSF; see, *e.g.*, 5,908,763F. Generally, such GM-CSF is a primate GM-CSF, including human GM-CSF. Other immunostimulatory genes include, but are not limited to, genes that encode cytokines IL1, IL2, IL4, IL5, IFN, IFN, TNF, IL12, IL18, and flt3), proteins that

20 stimulate interactions with immune cells (B7, CD28, MHC class I, MHC class II, TAPs), tumor-associated antigens (immunogenic sequences from MART-1, gp100(pmel-17), tyrosinase, tyrosinase-related protein 1, tyrosinase-related protein 2, melanocyte-stimulating hormone receptor, MAGE1, MAGE2, MAGE3, MAGE12, BAGE, GAGE, NY-ESO-1, -catenin, MUM-1, CDK-4, caspase 8, KIA

25 0205, HLA-A2R1701, -fetoprotein, telomerase catalytic protein, G-250, MUC-1, carcinoembryonic protein, p53, Her2/neu, triosephosphate isomerase, CDC-27, LDLR-FUT, telomerase reverse transcriptase, and PSMA), cDNAs of antibodies that block inhibitory signals (CTLA4 blockade), chemokines (MIP1, MIP3, CCR7 ligand, and calreticulin), and other proteins.

30 Other polynucleotides, including therapeutic nucleic acids, such as therapeutic genes, of interest include, but are not limited to, anti-angiogenic, and suicide genes. Anti-angiogenic genes include, but are not limited to, genes that

-48-

encode METH-1, METH -2, TrpRS fragments, proliferin-related protein, prolactin fragment, PEDF, vasostatin, various fragments of extracellular matrix proteins and growth factor/cytokine inhibitors. Various fragments of extracellular matrix proteins include, but are not limited to, angiostatin, endostatin, kininostatin, fibrinogen-E fragment, thrombospondin, tumstatin, canstatin, and restin. Growth factor/cytokine inhibitors include, but are not limited to, VEGF/VEGFR antagonist, sFlt-1, sFlk, sNRP1, angiopoietin/tie antagonist, sTie-2, chemokines (IP-10, PF-4, Gro-beta, IFN-gamma (Mig), IFN, FGF/FGFR antagonist (sFGFR), Ephrin/Eph antagonist (sEphB4 and sephrinB2), PDGF, TGF and IGF-1.

10 A "suicide gene" encodes a protein that can lead to cell death, as with expression of diphtheria toxin A, or the expression of the protein can render cells selectively sensitive to certain drugs, e.g., expression of the Herpes simplex thymidine kinase gene (HSV-TK) renders cells sensitive to antiviral compounds, such as acyclovir, gancyclovir and FIAU (1-(2-deoxy-2-fluoro--beta.-

15 D-arabinofuranosil)-5-iodouracil). Other suicide genes include, but are not limited to, genes that encode carboxypeptidase G2 (CPG2), carboxylesterase (CA), cytosine deaminase (CD), cytochrome P450 (cyt-450), deoxycytidine kinase (dCK), nitroreductase (NR), purine nucleoside phosphorylase (PNP), thymidine phosphorylase (TP), varicella zoster virus thymidine kinase (VZV-TK), and

20 xanthine-guanine phosphoribosyl transferase (XGPRT). Alternatively, a therapeutic nucleic acid can exert its effect at the level of RNA, for instance, by encoding an antisense message or ribozyme, a protein that affects splicing or 3' processing (e.g., polyadenylation), or a protein that affects the level of expression of another gene within the cell, e.g. by mediating an altered rate of

25 mRNA accumulation, an alteration of mRNA transport, and/or a change in post-transcriptional regulation. The addition of a therapeutic nucleic acid to a virus results in a virus with an additional antitumor mechanism of action. Thus, a single entity (i.e., the virus carrying a therapeutic transgene) is capable of inducing multiple antitumor mechanisms. Other encoded proteins, include, but

30 are not limited to, herpes simplex virus thymidine kinase (HSV-TK), which is useful as a safety switch (see, U.S. Patent Application No. 08/974,391, filed

-49-

November 19, 1997, which published as PCT Publication No. WO/9925860), Nos, FasL, and sFasR (soluble Fas receptor).

Also contemplated are combinations of two or more transgenes with synergistic, complementary and/or nonoverlapping toxicities and methods of
5 action. The resulting adenovirus can retain the viral oncolytic functions and, for example, additionally are endowed with the ability to induce immune and anti-angiogenic responses and other responses as desired.

Therapeutic polynucleotides and heterologous polynucleotides also include those that exert an effect at the level of RNA or protein. These include
10 include a factor capable of initiating apoptosis, RNA, such as RNAi and other double-stranded RNA, antisense and ribozymes, which among other capabilities can be directed to mRNAs encoding proteins essential for proliferation, such as structural proteins, transcription factors, polymerases, genes encoding cytotoxic proteins, genes that encode an engineered cytoplasmic variant of a nuclease
15 (e.g. RNase A) or protease (e.g. trypsin, papain, proteinase K and carboxy-peptidase). Other polynucleotides include a cell or tissue specific promoters, such as those used in oncolytic adenoviruses (see, *e.g.*, U.S. Patent No. 5,998,205).

The heterologous polynucleotide encoding a polypeptide also can contain
20 a promoter operably linked to the coding region. Generally the promoter is a regulated promoter and transcription factor expression system, such as the published tetracycline-regulated systems, or other regulatable systems (WO 01/30843), to allow regulated expression of the encoded polypeptide. Exemplary of other promoters, are tissue-selective promoters, such as those
25 described in U.S. Patent No. 5,998,205. An exemplary regulatable promoter system is the Tet-On(and Tet-Off(systems currently available from Clontech (Palo Alto, CA). This promoter system allows the regulated expression of the transgene controlled by tetracycline or tetracycline derivatives, such as doxycycline. This system can be used to control the expression of the encoded
30 polypeptide in the viral particles and nucleic acids provided herein. Other regulatable promoter systems are known (see, *e.g.*, published U.S. No. 20020168714, entitled "Regulation of Gene Expression Using Single-Chain,

-50-

Monomeric, Ligand Dependent Polypeptide Switches," which describes gene switches that contain ligand binding domains and transcriptional regulating domains, such as those from hormone receptors). Other suitable promoters that can be employed include, but are not limited to, adenoviral promoters, such as the adenoviral major late promoter and/or the E3 promoter; or heterologous promoters, such as the cytomegalovirus (CMV) promoter; the Rous Sarcoma Virus (RSV) promoter; inducible promoters, such as the MMT promoter, the metallothionein promoter; heat shock promoters; the albumin promoter; and the ApoA1 promoter.

10 Therapeutic transgenes can be included in the viral constructs and resulting particles. Among these are those that result in an "armed" virus. For example, rather than delete E3 region as in some embodiments described herein, all or a part of the E3 region can be preserved or re-inserted in an oncolytic adenoviral vector (discussed above). The presence of all or a part of the E3
15 region can decrease the immunogenicity of the adenoviral vector. It also increases cytopathic effect in tumor cells and decreases toxicity to normal cells. Typically such vector expresses more than half of the E3 proteins.

Adenoviruses for therapy, including those for human therapy, are known. Such known viruses can be modified as provided herein to reduce or eliminate
20 interaction with HSPs and optionally additional receptors. The adenoviral vectors that are used to produce the viral particles can include other modifications. Modifications include modifications to the adenovirus genome that is packaged in the particle in order to make an adenoviral vector. As discussed above, adenovirus vectors and particles with a variety of modifications are available.
25 Modifications to adenoviral vectors include deletions known in the art, such as deletions in one or more of the E1, E2a, E2b, E3, or E4 coding regions. These adenoviruses are sometimes referred to as early generation adenoviruses. include those with deletions of all of the coding regions of the adenoviral genome ("gutless" adenoviruses, discussed above) and also include replication-conditional adenoviruses, which are viruses that replicate in certain types of cells or
30 tissues but not in other types as a result of placing adenoviral genes essential for replication under control of a heterologous promoter (discussed above; see, also

-51-

U.S. Patent No. 5,998,205, U.S. Patent No. 5,801,029; U.S. patent application 60/348,670 and corresponding published International PCT application No. WO02/06786). These include the cytolytic, cytopathic viruses (or vectors), including the oncolytic viruses discussed above.

5 Alternatively, as discussed above, the vector can include a mutation or deletion in the E1b gene. Typically such mutation or deletion in the E1b gene is such that the E1b-19kD protein becomes non-functional. This modification of the E1b region can be combined with vectors where all or a part of the E3 region is present.

10 The oncolytic adenoviral vector can further include at least one heterologous coding sequence, such as one that encodes a therapeutic product. The heterologous coding sequence, such as therapeutic gene, is generally, although not necessarily, in the form of cDNA, and can be inserted at any locus that does not adversely affect the infectivity or replication of the vector. For
15 example, it can be inserted in an E3 region in place of at least one of the polynucleotide sequences that encode an E3 protein, such as, for example, the 19kD or 14.7 kD E3 gene.

F. Propagation and Scale-up

 Since doubly ablated adenoviral vectors containing mutations in the fiber
20 and/or penton capsid proteins result in inefficient cell binding and entry via the CAR/ α v integrin entry pathway, scaled up technologies improve the growth and propagation of such vectors to produce high titers of the adenoviral vectors for clinical use. Thus, also provided is a method for scaling up the production of detargeted adenoviral vectors. The detargeted adenoviral vectors comprise an
25 adenoviral vector modified to ablate the interaction of said vector with at least one host cell receptor compared with a wild-type adenoviral vector. The detargeted adenoviral vectors can comprise an adenoviral vector modified to ablate the interaction of said vector with one, two, three or more host cell receptors. Thus, the method is suitable for producing the detargeted adenoviral
30 vectors disclosed herein.

 As noted, growth and propagation of doubly and fully ablated adenoviral vectors is enhanced by new scale up technologies. Doubly ablated vectors

-52-

contain mutations in the fiber and penton capsid proteins that result in inefficient cell binding and entry via the normal cellular entry pathway using CAR and integrins. These vectors are fully detargeted *in vitro* and, thus, alternative cellular entry strategies allow for the efficient growth and generation of high titer preparations.

Two strategies have been envisioned to scale up vectors that are detargeted via fiber and/or penton modifications. These include: (a) the use of pseudoreceptor cell lines engineered to express a surface receptor that binds a ligand displayed on the vector (see, *e.g.*, International PCT application No. WO 98/54346) and (b) complementing cell lines that are engineered to express native fiber and that can be engineered to express native fiber and penton (see, *e.g.*, International PCT application No. WO 00/42208). Although these systems have shown promise for scaling up ablated adenoviral vectors, there is a need to develop a system for the simple, efficient production of the fully detargeted adenoviral vector for therapeutic uses.

Provided herein is a scale-up method for the propagation of detargeted adenoviral vectors. The method uses polycations and/or bifunctional reagents, which when added to tissue culture medium, bind adenoviral particles and direct their entry into the producer cells.

Reagents (also called medium additives) also can be included in the tissue culture medium containing producer cells to be infected with the detargeted adenoviral vectors. Alternatively the reagents can be pre-mixed with the virus, which mixture is then added to the tissue producer cells. The reagents can be added to tissue culture medium containing producer cells, or producer cells can be added to tissue culture medium containing the reagents. Any suitable producer cell known to the skilled artisan can be used in the present methods. The reagents can be added at the same time that the producer cells are infected with detargeted adenoviral vectors. Generally the reagents are present in the tissue culture medium prior to infection by the detargeted adenoviral vectors. The medium additives are maintained in the tissue culture medium during vector growth, spread and propagation. High titer yields of adenoviral vectors are obtained by this method.

-53-

Reagents which are useful in this method are those that are capable of directing adenoviral particle entry into the producer cells. Such reagents include, but are not limited to, polycations and bifunctional reagents. Suitable polycations include, but are not limited to, polythetylenimine; protamine sulfate; 5 poly-L-lysine hydrobromide; poly(dimethyl diallyl ammonium) chloride (Merquat(r)-100, Merquat(r)280, Merquat(r)550); poly-L-arginine hydrochloride; poly-L-histidine; poly(4-vinylpyridine), poly(4-vinylpyridine) hydrochloride; poly(4-vinylpyridine)cross-linked, methylchloride quaternary salt; poly(4-vinylpyridine-co-styrene); poly(4-vinylpyridinium poly(hydrogen fluoride)); poly(4-vinylpyridinium-P-toluene sulfonate); poly(4-vinylpyridinium-tribromide); poly(4-vinylpyrrolidone-co-2-dimethylamino-ethyl methacrylate); polyvinylpyrrolidone, 10 cross-linked; poly vinylpyrrolidone, poly(melamine-co-formaldehyde); partially methylated; hexadimethrine bromide; poly(Glu, Lys) 1:4 hydrobromide; poly(Lys, Ala) 3:1 hydrobromide; poly(Lys, Ala) 2:1 hydrobromide; poly-L-lysine succinylated; poly(Lys, Ala) 1:1 hydrobromide; and poly(Lys, Trp) 1:4 15 hydrobromide.

Suitable bifunctional reagents include, but are not limited to, antibodies or peptides that bind to the adenoviral capsid and that also contain a ligand that allows interaction with specific cell surface receptors of the producer cells. 20 Examples of bifunctional reagents include: (a) anti-fiber antibody ligand fusions, (b) anti-fiber-Fab-FGF conjugate, (c) anti-penton-antibody ligand fusions, (d) anti-hexon antibody ligand fusions and (e) polylysine-peptide fusions. The ligand is any ligand that will bind to any cell surface receptor found on the producer cells.

25

The following examples are included for illustrative purposes only and are not intended to limit the scope of the invention.

-54-

EXAMPLE 1**Construction of Ad5 Vectors Containing the Fiber AB Loop, KO1 and Penton, PD1 Mutations and Derivatives Thereof**

Three recombinant adenoviral vectors were prepared that contain the KO1 fiber or PD1 penton base mutations either alone or in combination, these vectors are designated Av3nBgFKO1, Av1nBgPD1, and Av1nBgFKO1PD1. Construction of these vectors is described below and a general description of each vector is set forth in Table 1.

TABLE 1
Description Of Detargeted
Recombinant Adenoviral Vectors Used For Scale-up
Vector

Vector	Description
Av3nBg	An E1, E2a, E3-deleted adenoviral vector encoding a nuclear localizing β -galactosidase
Av1nBg	An E1 and E3-deleted adenoviral vector encoding a nuclear localizing β -galactosidase
Av3nBgFKO1	The same as Av3nBg but containing the KO1 mutation in the fiber gene
Av1nBgPD1	The same as Av1nBg but containing the PD1 mutation in the penton gene
Av1nBgFKO1PD1	The same as Av1nBg but containing the fiber KO1 and penton PD1 mutations

20 Av1nBg

This is a well-known vector, its sequence is set forth in SEQ ID No. 43.

Av3nBg

This is a well-known vector, its sequence is set forth in SEQ ID No. 44.

Av3nBgFKO1**25 Genetic incorporation of the KO1 fiber mutation to generate Av3nBgFKO1**

The adenoviral vector Av3nBgFKO1 was generated in an E1-, E2a-, E3-deleted backbone based on the adenovirus serotype 5 genome. It contains a RSV promoted nuclear-localizing β -galactosidase gene in place of the E1 region. In addition, the fiber gene carries the KO1 mutation. This mutation results in a

-55-

substitution of fiber amino acids 408 and 409, changing them from serine and proline to glutamic acid and alanine, respectively.

The vector was constructed as follows. First, the plasmid pSKO1 (Figure 1) was digested with the restriction enzymes SphI and MunI. The resulting DNA fragments were separated by electrophoresis on an agarose gel. The 1601 bp fragment containing all but the 5' end of the fiber gene was excised from the agarose gel and the DNA was isolated and purified. The fragment was then ligated with the 9236 bp fragment of p5FloxHRFRGD, which had been digested with SphI and MunI. The resulting plasmid, p5FloxHRFKO1, was digested with SpeI and PacI and the 6867 bp fragment containing the fiber gene was isolated. The fragment was ligated with the 24,630 bp SpeI-PacI fragment of pNDSQ3.1. The resulting plasmid, pNDSQ3.1KO1 (Figure 2), was used together with pAdmireRSVnBg (Figure 3A) to generate a plasmid which encodes the full-length adenoviral vector genome. It, however, was necessary to remove the PacI site from pNDSQ3.1KO1 (Figure 2) prior to recombination with pAdmireRSVnBg (Figure 3A) so that the final plasmid contains a unique PacI site adjacent to the 5' ITR. The PacI site in pNDSQ3.1KO1 was removed by digestion with PacI followed by blunting with T4 DNA Polymerase and religation. The resulting plasmid was called pNDSQ3.1KO1(Pac).

To generate a full-length plasmid containing the entire adenoviral genome, pAdmireRSVnBg (Figure 3A) was digested with SalI and co-transfected into competent cells of the *E. coli* strain BJ5183 along with pNDSQ3.1KO1ΔPac, which had been digested with BstBI. Homologous recombination between the two plasmids generated a full-length plasmid encoding the entire adenoviral vector genome, which was called pFLAv3nBgFKO1.

The plasmid pFLAv3nBgFKO1 was linearized with PacI and transfected into 633 cells. In the fiber complementing 633 cell line, the resulting viral DNA containing the KO1 mutation is capable of being packaged into infectious viral particles containing a mixture of wildtype fiber and mutant fiber proteins. After five rounds of amplification in 633 cells, a cytopathic effect was observed. Three more rounds of amplification in 633 cells were performed followed by purification of the virus by standard CsCl centrifugation procedures. This viral

-56-

preparation was used to infect AE1-2a cells, which do not express fiber. The resulting virus contained only the mutant fiber protein on its capsid. Virus particles were purified by standard CsCl centrifugation procedures.

Av1nBgFKO1

- 5 The vector Av1nBgFKO1 is made in a similar manner to Av3nBgFKO1 described above.

Av1nBgKO12

- An additional fiber AB loop mutation (described by Einfeld *et al.* (2001) *J. Virology* 75:11284-11291) was incorporated into the genome of Av1nBg. This
- 10 AB loop mutation is a four amino acid substitution, R512S, A515G, E516G, and K517G, and is referred to as KO12. The KO12 mutation was incorporated into the fiber gene by PCR gene overlap extension using the plasmid pSQ1 (Figure 3B) as template. The pSQ1 plasmid contains most of the Ad5 genome, extending from base pair 3329 through the right ITR, in a pBR322 backbone.
- 15 First, a segment of the Ad5 genome extending from within the E3 region into the fiber gene was amplified by PCR using the plasmid pSQ1 as a template with the following primers termed 5FF, 5'-GAA CAG GAG GTG AGC TTA GA-3' SEQ ID No. 4), and 5FR, 5'-TCC GCC TCC ATT TAG TGA ACA GTT AGG AGA TGG AGC TGG TGT G-3' (SEQ ID No. 6). The primer 5FR contains an 18 base
- 20 5'-extension that encodes the modified fiber AB loop amino acids from 512 through 517. A second PCR using pSQ1 as a template amplified the region immediately 3' of the AB loop substitution and extending past the MunI site located 40 base pairs 3' of the fiber gene stop codon. The two primers used for this reaction were 3FF: 5'-TCA CTA AAT GGA GGC GGA GAT GCT AAA CTC
- 25 ACT TTG GTC TTA AC-3' (SEQ ID No. 7), and 3FR: 5'-GTG GCA GGT TGA ATA CTA GG-3' (SEQ ID No.8). The primer 3FR contains an 18 base 5'-extension that encodes the modified fiber AB loop amino acids 512 through 517. Amplified products of the expected size were obtained and used in a second PCR with the end primers 5FF and 3FR to join the fragments together.
- 30 The KO12 PCR fragment was digested with XbaI and MunI cloned directly into the fiber shuttle plasmid, pFBshuttle(EcoRI) to generate the plasmid pFBSEKO12 which contains the 8.8kB EcoRI fragment of pSQ1. The pFBSEKO12 plasmid

-57-

was digested with XbaI and EcoRI and cloned into pSQ1 using a three-way ligation to generate pSQ1KO12 (Figure 3C). The KO12 cDNA was incorporated into the genome of Av1nBg, an adenovirus vector with E1 and E3 deleted encoding β -galactosidase, by homologous recombination between ClaI-linearized

5 pSQ1KO12 and pAdmireRSVnBg digested with Sall and PacI to generate Av1nBgKO12. The KO12 vector was transfected in 633 cells, scaled-up on non-fiber expressing cells and purified, as described above for KO1.

Av1nBgPD1

10 Genetic incorporation of the PD1 penton mutation to generate Av1nBgPD1

The adenoviral vector Av1nBgPD1 is an E1-, E3-deleted vector based on the adenovirus serotype 5 genome. It contains a RSV promoted nuclear-localizing β -galactosidase gene in the E1 region and also contains the PD1 mutation in the penton gene. The PD1 mutation results in a substitution of

15 amino acids 337 through 344 of the penton protein, HAIRGDTF (SEQ ID No. 9), with amino acids SRGYPDVDPYAGTS (SEQ ID No. 10), thus replacing the RGD tripeptide (see, Einfeld *et al.* (2001) *J. Virology* 75:11284-11291). The mutation in the penton gene was generated in the plasmid pGEMpen5, which contains the Adenovirus serotype 5 penton gene. To generate the mutation,

20 four oligonucleotides were synthesized. The sequences of the oligonucleotides were as follows: penton 1: 5' CGC GGA AGA GAA CTC CAA CGC GGC AGC CGC GGC AAT GCA GCC GGT GGA GGA CAT GAA 3' (SEQ ID No. 11); penton 2: 5' TAT CGT TCA TGT CCT CCA CCG GCT GCA TTG CCG CGG CTG CCG CGT TGG AGT TCT CTT CC 3' (SEQ ID No. 12); penton 3: 5' CGA TAG CCG

25 CGG CTA CCC CTA CGA CGT GCC CGA CTA CGC GGG CAC CAG CGC CAC ACG GGC TGA GGA GAA GCG CGC 3' (SEQ ID No. 13); penton 4: 5' TCA GCG CGC TTC TCC TCA GCC CGT GTG GCG CTG GTG CCC GCG TAG TCG GGC ACG TCG TAG GGG TAG CCG CGG C 3' (SEQ ID No. 14). The complementary oligonucleotides penton 1 and penton 2 were annealed to each other as were

30 penton 3 and penton 4. The duplex generated by annealing penton 3 and penton 4 encoded the substitution of amino acids 337 through 344 described above. The duplex generated by annealing penton 1 and penton 2 possessed a 5 base

-58-

5' overhang which was compatible to a 5 base 5' overhang on the duplex generated by annealing penton 3 and penton 4. The opposite end of the duplex generated by annealing penton 1 and penton 2 contained an Earl compatible overhang. The opposite end of the duplex generated by annealing penton 3 and penton 4 contained a BbvCI compatible overhang. The two duplexes were ligated to each other and ligated back into the pGEMpen5 backbone as follows. First, pGEMpen5 was digested with BbvCI and PstI and the resulting DNA fragments were separated by electrophoresis on an agarose gel. The 3360 bp fragment was excised from the gel and purified. The plasmid pGEMpen5 was also digested with PstI and Earl and the resulting fragments were separated by electrophoresis on an agarose gel. The 955 bp fragment was excised from the gel and purified. These two fragments from the pGEMpen5 plasmid were ligated with the two pairs of annealed oligonucleotides to generate the plasmid pGEMpen5PD1.

15 The mutated penton gene was transferred from pGEMpen5PD1 to pSQ1 using a 5-way ligation as follows. First, the region of the penton gene containing the PD1 mutation was excised from pGEMpen5PD1 by digestion with PvuI and AscI. The 974 bp fragment containing the PD1 mutation was purified. Four DNA fragments were prepared from the pSQ1 plasmid (Figure 3B) as follows. The plasmid was digested with Csp45I and FseI and the 9465 bp fragment was purified. In addition pSQ1 was digested with FseI and PvuI and the 2126 bp fragment was purified. The plasmid pSQ1 was digested with AscI and BamHI and the 5891 bp fragment was purified. Finally, pSQ1 was digested with BamHI and Csp45I and the 14610 bp fragment was purified. The 5 purified DNA fragments were ligated to each other to form the plasmid pSQ1PD1 (Figure 4).

To generate adenoviral vector, pSQ1PD1 was linearized by digestion with ClaI and co-transfected into PerC6 cells with pAdmireRSVnBg (Figure 3A) which had been digested with SalI and PacI. hexadimethrine bromide was maintained in the medium at 4 μ g/ml. When a cytopathic effect was observed, a crude viral lysate was further expanded on PerC6 cells. The virus was purified by standard CsCl centrifugation procedures.

-59-

Av1nBgFKO1PD1

Genetic incorporation of the fiber KO1 or KO12 mutation in combination with the penton PD1 mutation to generate Av1nBgFKO1PD1

The adenoviral vectors Av1nBgFKO1PD1 and Av1nBgKO12PD1 were generated in an E1-, E3-deleted adenovirus serotype 5 genome. Both vectors contains a RSV promoted nuclear-localizing β -galactosidase gene in the E1 region and also contains either the KO1 or KO12 mutation in the fiber gene as well as the PD1 mutation in the penton gene. The vectors were constructed as follows. First, the plasmid pSQ1PD1 was digested with Csp45I and SpeI and the 23976 bp fragment containing the PD1 mutated penton gene was purified. In addition, the plasmids pSQ1KO1 or pSQ1KO12 (Figure 3B) were digested with Csp45I and SpeI and the 9090 bp fragment containing the KO1 or KO12 mutated fiber gene were purified. The appropriate purified fragments were ligated to each other to form the plasmid pSQ1FKO1PD1 (Figure 5A) or pSQ1KO12PD1 (Figure 5B) that contains the KO1 (or KO12) mutated fiber gene and the PD1 mutated penton gene. To generate virus, pSQ1FKO1PD1 or pSQ1KO12PD1 was linearized with ClaI and co-transfected into 633 cells with pAdmireRSVnBg (Figure 3A) which had been digested with Sall and PacI. After three rounds of amplification in 633 cells a cytopathic effect was observed and the crude viral lysate was then amplified on PerC6 cells. Hexadimethrine bromide was maintained in the medium at 4 μ g/ml. Each virus was purified by standard CsCl centrifugation procedures.

EXAMPLE 2***In Vitro* Evaluation of Adenoviral Vectors Containing the KO1 and PD1 Mutations**

Several recombinant adenoviral vectors were used in these studies to demonstrate the function of the KO1 fiber mutation and included Av1nBg, Av1nBgFKO1, Av1nBgPD1, and Av1nBgFKO1PD1, described above. The transduction efficiencies of adenoviral vectors containing the KO1 and/or PD1 mutations were evaluated on cells of the alveolar epithelial cell line A549. The transduction efficiencies were compared to that of Av1nBg, an adenoviral vector containing wild type fiber and penton.

-60-

The day prior to infection, cells were seeded into 24-well plates at a density of approximately 1×10^5 cells per well. Immediately prior to infection, the exact number of cells per well was determined by counting a representative well of cells. Each of the vectors, Av1nBg, Av1nBgFKO1, and Av1nBgFKO1PD1 were used to transduce A549 cells at each of the following particle per cell (PPC) ratios: 100, 500, 1000, 2500, 5000, 10,000. The cell monolayers were stained with X-gal 24 hours after infection and the percentage of cells expressing β -galactosidase was determined by microscopic observation and counting of cells. Transductions were done in triplicate and three random fields in each well were counted, for a total of nine fields per vector.

The results at the 500 PPC ratio are shown in Figure 6 and show a significantly reduced transduction efficiency on A549 cells using vectors containing the KO1 mutation alone or when combined with PD1 compared to Av1nBg. The vectors containing the PD1 mutation alone had no effect on adenoviral transduction of A549 cells *in vitro*.

EXAMPLE 3

In Vivo Analysis of Adenoviral Vectors Containing the FKO1 and PD1 Mutations

This Example provides experiments that evaluate the *in vivo* biodistribution of adenoviral vectors containing the KO1 and PD1 mutations and their influence on adenoviral-mediated liver transduction. The results show that ablating the viral interaction with CAR and/or integrins is not sufficient to fully detarget adenoviral vectors from the liver *in vivo*.

A positive control cohort received Av1nBg and a negative control group received HBSS. Additionally, the Av1nBgFKO12 and Av1nBgFKO12PD1 vectors were analyzed *in vivo*. These vectors each contain a fiber protein with the four amino acid substitution in the AB loop. Additionally, Av1nBgFKO12PD1 contains a mutation in the penton base. Both of these mutations were known (see, Einfeld *et al.* (2001) *J. Virology* 75:11284-11291), and were alleged to decrease liver transduction 10 to 700 fold, respectively. Cohorts of five C57BL/6 mice received each vector via tail vein injection at a dose of 1×10^{13} particles per kg. The animals were sacrificed approximately 72 hours after vector administration by carbon dioxide asphyxiation. Liver, heart, lung, spleen, and

-61-

kidney were collected from each animal. The median lobe of the liver was placed in neutral buffered formalin to preserve the sample for β -galactosidase immunohistochemistry. In addition, tissue from each organ was frozen to preserve it for hexon PCR analysis to determine vector content. A separate
5 sample of liver from each mouse was frozen to preserve it for a chemiluminescent β -galactosidase activity assay.

For β -galactosidase immunohistochemistry slices of liver, approximately 2-3 mm thick, were placed in 10% neutral buffered formalin. After fixation, these samples were embedded in paraffin, sectioned, and analyzed by
10 immunohistochemistry for β -galactosidase expression. A 1:1200 dilution was used of a rabbit anti- β -galactosidase antibody (ICN Pharmaceuticals, Inc.; Costa Mesa, CA) in conjunction with a Vectastain ABC kit (Vector Laboratories, Inc., Burlingame, CA) to visualize positive cells.

The chemiluminescent β -galactosidase activity assay was performed
15 using the Galacto-Light Plus™ chemiluminescent assay (Tropix, Inc., Foster City, CA) system. Tissue samples were collected in lysis matrix tubes containing two ceramic spheres (Bio101, Carlsbad, CA) and frozen on dry ice. The tissues were thawed and 500 μ l of lysis buffer from the Galacto-Light Plus kit was added to each tube. The tissue was homogenized for 30 seconds using a
20 FastPrep System (Bio101, Carlsbad, CA). Liver samples were homogenized for an additional 30 seconds. β -galactosidase activity was determined in the liver homogenates according to the manufacture's protocol.

For hexon PCR analysis DNA from tissues was isolated using the Qiagen Blood and Cell Culture DNA Midi or Mini Kits (Qiagen Inc., Chatsworth, CA).
25 Frozen tissues were partially thawed and minced using sterile disposable scalpels. Tissues were then lysed by incubation overnight at 55° C in Qiagen buffer G2 containing 0.2 mg/ml RNaseA and 0.1 mg/ml protease. Lysates were vortexed briefly and then applied to Qiagen-tip 100 or Qiagen-tip 25 columns. Columns were washed and DNAs were eluted as described in the manufacturer's
30 instructions. After precipitation, DNAs were dissolved in water and the concentrations were spectrophotometrically determined (A260 and A280) on a

-62-

DU-600 (Beckman Coulter, Inc.; Fullerton, CA) or a SPECTRAmax PLUS (Molecular Devices, Inc.; Sunnyvale, CA) spectrophotometer. 2.3.2.

PCR primers and a Taqman probe specific to adenovirus hexon sequences were designed using Primer Express software v. 1.0 (Applied Biosystems, Foster

5 City, CA). Primer and probe sequences were:

Hexon Forward primer: 5'-CTTCGATGATGCCGCGAGTG-3' (SEQ ID No. 38);

Hexon Reverse primer: 5'-GGGCTCAGGTACTCCGAGG-3' (SEQ ID No. 39); and

Hexon Probe: 5'-FAM-TTACATGCACATCTCGGGCCAGGAC-TAMRA-3' (SEQ ID No. 40).

10 Amplification was performed in a reaction volume of 50 μ l under the following conditions: 10 ng (tumor) or 1 μ g (liver and lung) of sample DNA, 1X Taqman Universal PCR Master Mix (Applied Biosystems), 600 nM forward primer, 900 nM reverse primer and 100 nM hexon probe. Thermal cycling conditions were: 2 minute incubation at 50° C, 10 minutes at 95° C, followed by
15 35 cycles of successive incubation at 95° C for 15 seconds and 60° C for 1 minute. Data was collected and analyzed using the 7700 Sequence Detection System software v. 1.6.3 (Applied Biosystems). Quantification of adenovirus copy number was performed using a standard curve that includes dilutions of adenovirus DNA from 1,500,000 copies to 15 copies in the appropriate
20 background of cellular genomic DNA. For analysis of tumor tissues, a standard curve in a background of 10 ng human DNA was generated. For analysis of mouse liver and lung tissues, a standard curve using the same adenovirus DNA dilutions in a background of 1 μ g CD-1 mouse genomic DNA was generated. Samples were amplified in triplicate, and the average number of total copies was
25 normalized to copies per cell based on the input DNA weight amount and a genome size of 6×10^9 bp.

The results of the β -galactosidase activity assay and adenoviral hexon DNA content for liver transduction by these vectors are shown in Figure 7A and 7B. The vector containing the KO1 or KO12 mutations alone showed, on
30 average, a slight increase in liver transduction compared to Av1nBg, which is consistent with several previous experiments. The vectors containing the PD1 mutation alone or combined with KO1 or KO12 showed a slight decrease in liver

-63-

transduction compared to Av1nBg, suggesting that integrins are involved to some extent in hepatic uptake of the adenoviral vectors.

The results of the immunohistochemical staining of liver sections for β -galactosidase were consistent with the activity assays (data not shown) and demonstrate that gene expression was localized specifically to hepatocytes. The vectors containing the KO1 or KO12 mutation alone showed a slight increase in liver transduction as revealed by a more intense and frequent immunohistochemical-staining pattern. The vectors containing the PD1 mutation, either alone or combined with KO1 or KO12, showed little difference in transduction compared to Av1nBg. These results demonstrate that ablating the viral interaction with CAR and/or integrins is not sufficient to fully detarget adenoviral vectors from the liver *in vivo*.

In summary, the fiber AB loop mutation contained in Av1nBgFKO1 or Av1nBgKO12 ablates interaction with human and mouse CAR *in vitro* and diminished transduction *in vitro*. *In vivo*, however, fiber AB loop mutations behaved unexpectedly, because such mutations were found to enhance adenoviral-mediated gene transfer to liver and results in increasing vector potency. The penton base, PD1 mutation that ablates interaction with the second receptor involved in adenoviral internalization had no effect *in vitro* and little to no effect *in vivo*. These studies indicated that other receptors are responsible for adenoviral gene transfer to the liver *in vivo*.

EXAMPLE 4

Description Of Adenoviral Vectors Containing A Fiber With Amino Acid Substitutions At The Heparin Sulfate Binding Domain In The Fiber Shaft

Vectors containing substitutions at all four of the amino acids in the four amino acid motif in the Ad5 fiber shaft (residues 91 to 94, KKTK; SEQ ID No. 1) were generated in order to ablate the potential interaction with HSP. The mutation is termed HSP because it potentially eliminates binding to heparan sulfate proteoglycans. Vectors containing the HSP mutation alone and combined with the KO1 mutation (fiber knob AB loop mutation that ablates CAR binding), the PD1 mutation (penton mutation that eliminates RGD/integrin interaction), and a triple knockout vector (HSP, KO1, PD1) were generated.

-64-

Generation of the HSP fiber mutation: The HSP mutation was incorporated into the fiber gene by using a PCR-based strategy of gene splicing by overlap extension (PCR SOEing). First, a segment of the Ad5 genome extending from within the E3 region into the 5' end of the fiber gene was

5 amplified by PCR using the plasmid pSQ1 (Figure 3B) as a template and two primers termed 5FF and 5HSPR. The DNA sequence of 5FF is as follows: 5' GAA CAG GAG GTG AGC TTA GA 3' (SEQ ID No. 5). This sequence corresponds to base pairs 25,199 - 25,218 of pSQ1. The DNA sequence of 5HSPR is as follows: 5' GGC TCC GGC TCC GAG AGG TGG GCT CAC AGT

10 GGT TAC ATT T 3' (SEQ ID No. 15). 5HSPR is a reverse primer for 5FF and corresponds to a region in the fiber shaft adjacent to the KKTK (SEQ ID No. 1) region. The primer contains a 5' extension that encodes a GAGA substitution for the native KKTK (encoded by SEQ ID No. 1) amino acid sequence. A second PCR using pSQ1 as a template amplified the region immediately 3' of the KKTK

15 (SEQ ID No. 1) site and extending past the MunI site located 40 base pairs 3' of the stop codon for the fiber gene. The two primers used for this reaction were 3HSPF and 3FR. The DNA sequence of 3HSPF is as follows: 5' GGA GCC GGA GCC TCA AAC ATA AAC CTG GAA AT 3' (SEQ ID No. 16). It contains a 5' extension that is complementary to the 5' extension of 5HSPR. The DNA

20 sequence of 3FR is as follows: 5' GTG GCA GGT TGA ATA CTA GG 3' (SEQ ID No. 8).

The two PCR products were joined by PCR SOEing using primers 5FF and 3FR. The resulting PCR product was digested with the restriction enzymes XbaI and MunI. The 2355 bp fragment was gel purified and ligated with the 6477 bp

25 XbaI to MunI fragment of the plasmid pFBshuttle(EcoRI) (Figure 8) to generate the plasmid pFBSEHSP. The plasmid pFBshuttle(EcoRI) was generated by digesting the plasmid pSQ1 with EcoRI, then gel purifying and self-ligating the 8.8 kb fragment containing the fiber gene. Next, the fiber gene containing the HSP mutation was transferred from pFBSEHSP into pSQ1 using a three-way

30 ligation. The 16,431 bp EcoRI to NdeI fragment of pSQ1, the 9043 bp NdeI to XbaI fragment of pSQ1, and the 7571 bp XbaI to EcoRI fragment of pFBSEHSP were isolated and ligated to generate pSQ1HSP (Figure 9).

-65-

To generate a recombinant adenoviral vector containing the HSP mutation in the fiber gene, pSQ1HSP was digested with ClaI and pAdmireRSVnBg (Figure 3A) was digested with Sall and PacI, then the two digested plasmids were co-transfected into 633 cells (von Seggern *et al.* (2000) *J Virology* 74:354-362).

- 5 Homologous recombination between the two plasmids generated a full-length adenoviral genome capable of replication in 633 cells, which inducibly express Ad5 E1A and constitutively express wild-type fiber protein. After propagation on 633 cells, the virus capsid contained wildtype and mutant fiber proteins. To obtain viral particles containing only the modified fiber with the HSP mutation,
- 10 the viral preparation was used to infect PerC6 cells, which do not express fiber. The resulting virus, termed Av1nBgFS*, was purified by standard CsCl centrifugation procedures.

Generation of vector containing the HSP and KO1 mutations

- To generate an adenoviral vector containing the HSP and KO1 mutations
- 15 in fiber, a PCR SOEing strategy identical to the one described above was used except that the plasmid pSQ1FKO1 was used as the template. The PCR SOEing product was digested with XbaI and MunI and ligated with the 6477 bp XbaI to MunI fragment of pFBshuttle(EcoRI) to generate pFBSEHSPKO1. The fiber gene containing the HSP and KO1 mutations was transferred from pFBSEHSPKO1 into
- 20 the pSQ1 backbone using a three-way ligation strategy identical to the one described above for the HSP mutation alone, to generate the plasmid pSQ1HSPKO1 (Figure 10). Recombinant adenoviral vector containing the HSP and KO1 mutations in the fiber gene was generated by co-transfecting
- 25 pSQ1HSPKO1 digested with ClaI and pAdmireRSVnBg digested with Sall and PacI into 633 cells. Adenovirus was propagated and purified as described above for the vector containing the HSP mutation alone. The resulting virus was termed Av1nBgFKO1S*.

-66-

Generation of vector containing the HSP and PD1 mutations

The following strategy was used to generate a recombinant adenoviral vector containing the fiber HSP mutation and the penton PD1 mutation. The plasmid pSQ1PD1 (Figure 4) was digested with the restriction enzymes Csp45I and SpeI and the 23,976 bp fragment was isolated and purified. In addition, the plasmid pSQ1HSP was also digested with Csp45I and SpeI and the 9090 bp fragment was isolated and purified and ligated to the 23,976 bp fragment to generate the plasmid pSQ1HSPPD1 (Figure 11), which contains the fiber HSP and penton PD1 mutations. An adenoviral vector was generated, propagated, and purified as described above. The resulting virus was termed Av1nBgS*PD1.

Generation of vector containing the HSP, KO1, and PD1 mutations

To generate an adenoviral vector containing the HSP, KO1, and PD1 mutations the following strategy was used. First, the plasmid pSQ1PD1 was digested with Csp45I and SpeI and the 23,976 bp fragment was isolated and purified. In addition, the plasmid pSQ1HSPKO1 was digested with Csp45I and SpeI and the 9090 bp fragment was isolated and purified. The two DNA fragments were ligated to form the plasmid pSQ1HSPKO1PD1 (Figure 12). Recombinant adenoviral vector was generated, propagated, and purified as described above. The resulting virus was termed Av1nBgFKO1S*PD1.

EXAMPLE 5***In Vitro* Evaluation Of Adenoviral Vectors Containing The HSP Fiber Mutation**

The transduction efficiencies of adenoviral vectors containing the HSP mutation in the fiber gene, either alone or combined with the KO1 and/or PD1 mutations, were evaluated on A549 and HeLa cells. The transduction efficiencies were compared to that of Av1nBg, an adenoviral vector containing wild type fiber and penton. The day prior to infection, cells were seeded into 24-well plates at a density of approximately 1×10^5 cells per well. Immediately prior to infection, the exact number of cells per well was determined by counting a representative well of cells. Each of the vectors, Av1nBg (see, Stevenson *et al.* (1997) *J. Virol.* 71:4782-4790), Av1nBgS*, Av1nBgFKO1S*, Av1nBgS*PD1, and Av1nBgFKO1S*PD1, were used to transduce A549 cells at each of the following particle per cell (PPC) ratios: 100, 500, 1000, 2500,

-67-

5000, 10,000. HeLa cells were transduced with each of the above vectors, as well as a vector containing the KO1 mutation alone (Av1nBgFKO1) and a vector containing the PD1 mutation alone (Av1nBgPD1) at 2000 PPC. The cell monolayers were stained with X-gal 24 hours after infection and the percentage of cells expressing β -galactosidase was determined by microscopic observation and counting of cells. Transductions were done in triplicate and three random fields in each well were counted, for a total of nine fields per vector.

The results (depicted in Figures 13A-13B) showed significantly reduced transduction efficiencies on A549 and HeLa cells using vectors containing the HSP mutation compared to Av1nBg. The vectors containing the HSP mutations, however, demonstrated a dose response on A549 cells, in that increasing PPC ratios yielded increasing transduction.

Competition experiments were done to determine which receptor molecular interactions are involved in transduction of A549 cells by the various vectors. Transductions were performed in the presence or absence of various competitors including Ad5 fiber knob, a 50 amino acid oligopeptide derived from Adenovirus serotype 2 penton base which spans the RGD tripeptide region, or heparin (Invitrogen Life Technologies, Gaithersburg, MD). Monolayers of A549 cells were cultured in Richters medium supplemented with 10% FBS and were transduced with Av1nBg, Av1nBgS*, Av1nBgFKO1S*, Av1nBgS*PD1, or Av1nBgFKO1S*PD1 in infection medium (IM, Richters medium plus 2% FBS). Different PPC ratios were used for the different vectors to achieve measurable transduction levels. The PPC ratios were as follows: Av1nBg: 500 PPC, Av1nBgS*: 10,000 PPC, Av1nBgFKO1S*: 20,000 PPC, Av1nBgS*PD1: 10,000 PPC, and Av1nBgFKO1S*PD1: 20,000 PPC. Fiber knob competition was performed by pre-incubating cells in IM containing 16 μ g/ml of fiber knob for 10 minutes at room temperature prior to infection with virus. Penton base peptide competition was performed by pre-incubating cells in IM containing 500nM peptide for 10 minutes at room temperature prior to infection with virus. Heparin competition was performed by pre-incubating each adenoviral vector in IM containing 3 mg/ml of heparin for 20 minutes at room temperature. In all cases, the competitor remained in the IM during the 1 hour infection when virus

-68-

- was rocked on the cell monolayers at 37° C in 5% CO₂. After infection, the monolayers were washed with PBS, 1 ml of complete medium was added per well and the cells were incubated for an additional 24 hours to allow for β -galactosidase expression. The cell monolayers were then fixed and stained with X-Gal. The percentage of cells transduced was determined by light microscopy as described above. Each condition was carried out in triplicate and three random fields per well were counted, for a total of nine fields per condition. The average percentage of transduction per high-power field was determined.
- 10 The results of the competition experiment (Figure 13C) showed that fiber knob inhibited transduction of cells by all vectors except for those that contained the KO1 mutation. The penton base peptide only inhibited transduction by Av1nBgFKO1S*. Heparin inhibited transduction by Av1nBgFKO1S* and Av1nBgFKO1S*PD1, but did not affect transduction by any of the other viruses
- 15 suggesting the presence of additional heparin binding sites on the adenoviral capsid but that the shaft contains the predominant site.

EXAMPLE 6

In Vivo Analysis Of Adenoviral Vectors Containing The HSP Mutation In Fiber

- The objective of this study was to evaluate the *in vivo* biodistribution of adenoviral vectors containing the HSP mutation and to determine whether this shaft modification influences adenoviral-mediated liver transduction. In addition, vectors containing the HSP mutation combined with KO1, or PD1, or a combination of all three mutations were evaluated as well as vectors containing the KO1 mutation alone and the PD1 mutation alone. A positive control cohort received Av1nBg and a negative control group received HBSS. Cohorts of five C57BL/6 mice received each vector via tail vein injection at a dose of 1×10^{13} particles per kg. The animals were sacrificed approximately 72 hours after vector administration by carbon dioxide asphyxiation. Liver, heart, lung, spleen, and kidney were collected from each animal. The median lobe of the liver was placed
- 20 in neutral buffered formalin to preserve the sample for β -galactosidase immunohistochemistry. In addition, tissue from each organ was frozen to preserve it for hexon real time PCR analysis to determine vector content. A
- 25
- 30

-69-

separate sample of liver from each mouse was frozen to preserve it for a chemiluminescent β -galactosidase activity assay. β -galactosidase immunohistochemistry, hexon real-time PCR and the chemiluminescent β -galactosidase activity assay were carried out as described in Example 3.

- 5 The results of the β -galactosidase activity assay (Figure 14A) and adenoviral hexon DNA content (Figure 14B) showed a dramatic reduction in liver transduction by vectors containing the HSP mutation. The vectors containing the HSP mutation alone resulted in reducing adenoviral-mediated liver gene expression by approximately 20-fold. When combined with the KO1 mutation
- 10 (HSP, KO1, PD1), yielded approximately a 1000-fold reduction in β -galactosidase activity in the liver compared to the control vector Av1nBg. The vector containing the KO1 mutation alone showed a slight increase, on average, in liver transduction compared to Av1nBg, which is consistent with several previous experiments. The vectors containing the PD1 mutation alone or combined with
- 15 KO1 showed a slight decrease in liver transduction compared to Av1nBg, although the decrease was not statistically significant. Analysis of hepatic adenoviral hexon DNA content (Figure 14B) confirmed these results.

- The results of the immunohistochemical staining of liver sections for β -galactosidase were consistent with the activity assays (data not shown) and
- 20 demonstrated that gene expression was localized specifically to hepatocytes. Vectors containing the HSP mutation, either alone or in combination with KO1 and/or PD1, showed a dramatic reduction in hepatocyte transduction. The vector containing the KO1 mutation alone showed a slight increase in liver transduction as revealed by a more intense and frequent immunohistochemical
- 25 staining pattern. The vectors containing the PD1 mutation, either alone or combined with KO1, showed little difference in transduction compared to Av1nBg.

EXAMPLE 7

- 30 Description of Adenoviral Vectors Containing the HSP Fiber Shaft Mutation with and without the KO1 Fiber Mutation and with and without a cRGD Targeting Ligand in the Fiber Knob HI Loop

-70-

Generation of vector containing the HSP fiber shaft mutation and a cRGD ligand in the HI loop: The following strategy was used to generate an adenoviral vector containing a fiber with the HSP shaft mutation and a cRGD ligand in the HI loop. The plasmid p5FloxHRFRGD was digested with the restriction enzymes BstXI
5 and KpnI and the 1157 bp fragment was isolated and purified. In addition, the fiber shuttle plasmid pFBSEHSP, described in Example 1 above, was digested with BstXI and KpnI and the 4549 bp and 3156 bp fragments were isolated and purified. The three fragments were ligated to generate the plasmid pFBSEHSPRGD, which encodes a fiber containing the HSP mutation and cRGD in
10 the HI loop. The fiber gene from this plasmid was transferred into the pSQ1 backbone as follows. The plasmid pFBSEHSPRGD was digested with EcoRI and XbaI and the 7601 bp fragment was isolated and purified. The plasmid pSQ1 (Figure 3B) was digested with the restriction enzymes EcoRI, NdeI, and XbaI and the 16,431 bp EcoRI to NdeI fragment and the 9043 bp NdeI to XbaI fragment
15 were isolated and purified. The three DNA fragments were ligated to generate the plasmid pSQ1HSPRGD (Figure 15A).

To generate a recombinant adenoviral vector containing the HSP mutation in the fiber gene along with a cRGD ligand in the HI loop, the plasmid pSQ1HSPRGD was digested with ClaI and co-transfected into 633 cells with
20 pAdmireRSVnBg which had been digested with SalI and PacI. After propagation on 633 cells, the virus capsid contained wildtype and mutant fiber proteins. To obtain viral particles containing only the modified fiber with the HSP mutation and a cRGD ligand, the viral preparation was used to infect PerC6 cells, which do not express fiber. The resulting virus, termed Av1nBgS*RGD, was purified
25 by standard CsCl centrifugation procedures.

Generation of vector containing the HSP fiber shaft mutation, the KO1 fiber knob mutation, and a cRGD ligand in the HI loop

The following strategy was used to generate an adenoviral vector containing a fiber with the HSP shaft mutation, the KO1 fiber knob mutation,
30 and a cRGD ligand in the HI loop. The plasmid p5FloxHRFRGD was digested with the restriction enzymes BstXI and KpnI and the 1157 bp fragment was isolated and purified. In addition, the fiber shuttle plasmid pFBSEHSPKO1,

-71-

described in Example 1 above, was digested with BstXI and KpnI and the 4549 bp and 3156 bp fragments were isolated and purified. The three fragments were ligated to generate the plasmid pFBSEHSPKO1RGD, which encodes a fiber containing the HSP mutation, the KO1 mutation, and cRGD in the HI loop. The fiber gene from this plasmid was transferred into the pSQ1 backbone as follows. The plasmid pFBSEHSPKO1RGD was digested with EcoRI and XbaI and the 7601 bp fragment was isolated and purified. The plasmid pSQ1 (Figure 3B) was digested with the restriction enzymes EcoRI, NdeI, and XbaI and the 16,431 bp EcoRI to NdeI fragment and the 9043 bp NdeI to XbaI fragment were isolated and purified. The three DNA fragments were ligated to generate the plasmid pSQ1HSPKO1RGD (Figure 15B).

To generate a recombinant adenoviral vector containing the HSP and KO1 mutations in the fiber gene along with a cRGD ligand in the HI loop, the plasmid pSQ1HSPKO1RGD was digested with ClaI and co-transfected into 633 cells with pAdmireRSVnBg which had been digested with SalI and PacI. After propagation on 633 cells, the virus capsid contained wildtype and mutant fiber proteins. To obtain viral particles containing only the modified fiber with the HSP and KO1 mutations and a cRGD ligand, the viral preparation was used to infect PerC6 cells, which do not express fiber. The resulting virus, termed Av1nBgFKO1S*RGD, was purified by standard CsCl centrifugation procedures.

EXAMPLE 8

***In Vitro* Evaluation of Adenoviral Vectors Containing the HSP Fiber Shaft Mutation with or without the Fiber Knob KO1 Mutation and with or without a cRGD Ligand in the HI Loop**

The transduction efficiencies of adenoviral vectors containing the HSP fiber shaft mutation with or without the fiber KO1 mutation and with or without the cRGD ligand in the HI loop were evaluated on A549 cells. The transduction efficiencies were compared to that of Av1nBg, an adenoviral vector containing wild type fiber. The day prior to infection, cells were seeded into 24-well plates at a density of approximately 1×10^5 cells per well. Immediately prior to infection, the exact number of cells per well was determined by counting a representative well of cells. Each of the vectors, Av1nBg, Av1nBgS*,

-72-

Av1nBgFKO1S*, Av1nBgS*RGD, and Av1nBgFKO1S*RGD, were used to transduce A549 cells at a particle to cell ratio of 6250. The cell monolayers were stained with X-gal 24 hours after infection and the percentage of cells expressing β -galactosidase was determined by microscopic observation and counting of cells. Transductions were done in triplicate and three random fields in each well were counted, for a total of nine fields per vector. The results (Figure 16) showed that the cRGD ligand dramatically increased the transduction efficiencies of vectors containing the HSP mutation alone or combined with the KO1 mutation. Av1nBgS* yielded approximately 22% positive cells, while Av1nBgS*RGD yielded approximately 95% positive cells. Similarly, Av1nBgFKO1S* yielded only 4% positive cells, while Av1nBgFKO1S*RGD yielded 85% positive cells. Therefore, the vector containing the shaft mutation is viable and can be retargeted with the addition of a ligand.

EXAMPLE 9

Construction Of Ad5 Vectors Containing The Ad35 Fiber And Derivatives Thereof

The KO1 and HSP mutations in the Ad5 fiber protein (5F), described above, were designed to ablate interactions that are responsible for the normal tropism of the Ad5 virus. An alternative strategy to detarget the virus is to replace the Ad5 fiber with a fiber from another serotype which does not bind CAR and which does not possess the heparin sulfate proteoglycan (HSP) binding domain (KKTK; SEQ ID No. 1) within the shaft. The fiber of adenovirus serotype 35 (35F) does not bind CAR and does not possess the HSP binding domain in its shaft. Replacement of the 5F with the 35F can detarget the liver and provide a suitable platform for retargeting the vector to the desired tissue.

Generation of an Ad5 based vector containing the Ad35 fiber: A PCR SOEing strategy was used to generate a vector based on the Ad5 serotype but containing the Ad35 fiber in place of the Ad5 fiber. First, PCR was used to amplify a region in the plasmid pSQ1 between the XbaI site at bp 25,309 and the start of the fiber gene. The primers used for this reaction were P-0005/U and P-0006/L. The DNA sequence of P-0005/U was as follows: 5' C TCT AGA AAT GGA CGG AAT TAT TAC AG 3' (SEQ ID No. 17). This sequence

-73-

corresponds to bp 25,308 through 25,334 of pSQ1. The DNA sequence of P-0006/L was as follows: 5' TCT TGG TCA TCT GCA ACA ACA TGA AGA TAG TG 3' (SEQ ID No. 18). It contains a 10 base pair 5' extension that is complementary to the start of the Ad35 fiber gene, while the remainder of the

5 primer anneals to the sequence immediately 5' of the ATG start codon of the fiber gene in pSQ1. A PCR product of the expected size, 583 bp, was obtained and the DNA was gel purified. A second PCR amplified the Ad35 fiber gene using DNA extracted from wildtype Ad35 virus as a template. The primers used for this reaction were P-0007/U and 35FMun. The DNA sequence of P-0007/U

10 was as follows: 5' GT TGT TGC AG ATG ACC AAG AGA GTC CGG CTC A 3' (SEQ ID No. 19). It contains a 10 base pair 5' extension that is homologous to the 10 bp immediately prior to the ATG start codon of the fiber gene in Ad5. The remainder of the primer anneals to the start of the Ad35 fiber gene. The DNA sequence of 35FMun was as follows: 5' AG CAA TTG AAA AAT AAA

15 CAC GTT GAA ACA TAA CAC AAA CGA TTC TTT A GTT GTC GTC TTC TGT AAT GTA AGA A 3' (SEQ ID No. 20). It contains a 46 base pair 5' extension that is complementary to the region of the Ad5 genome between the end of fiber and the MunI site 40 bp downstream of the fiber gene. In addition, the 5' extension encodes the last amino acid and stop codon of the Ad5 fiber gene.

20 This region was retained in the vector because it contains the polyadenylation site for the fiber gene. The remainder of the primer anneals to the 3' end of the Ad35 fiber gene, up to the next to last amino acid codon. A PCR product of the expected size, 1027 bp, was obtained and the DNA was gel purified. The two PCR products were mixed and joined together by PCR SOEing using primers

25 P-0005/U and P-0009. The DNA sequence of P-0009 was as follows: 5' AG CAA TTG AAA AAT AAA CAC GTT G 3' (SEQ ID No. 21). It corresponds to bp 27,648 through 27,669 of pSQ1 and overlaps the MunI site in that region. A PCR product of the expected size, 1590 bp, was obtained and gel purified. It was cloned into the plasmid pCR4blunt-TOPO (Invitrogen Corporation, Carlsbad

30 CA) using the Zero Blunt TOPO PCR Cloning Kit from Invitrogen. This intermediate cloning step simplified DNA sequencing of the PCR SOEing product. The resulting plasmid, termed pTOPOAd35F, was digested with XbaI and MunI

-74-

and the 1585 bp digestion product was gel purified and ligated with the 6477 bp fragment of pFBshuttle(EcoRI) digested with XbaI and MluI to generate the plasmid pFBshuttleAd35F. The Ad35 fiber gene was transferred from pFBshuttleAd35F into pSQ1 as follows. The plasmid pSQ1 was digested with EcoRI and the 24,213 bp fragment was gel purified. The plasmid pFBshuttleAd35F was linearized with EcoRI and ligated with the 24,213 bp fragment from pSQ1. Restriction diagnostics were performed to screen for constructs containing the Ad35 fiber gene inserted into the pSQ1 backbone in the correct orientation. The pSQ1 plasmid containing the Ad35 fiber gene in the proper orientation was termed pSQ1Ad35Fiber (Figure 17A). To generate adenoviral vector containing the Ad35 fiber, pSQ1Ad35Fiber was digested with ClaI and co-transfected into 633 cells with pAdmireRSVnBg which had been digested with SalI and PacI. After propagation on 633 cells, the resulting virus contained Ad5 fiber and Ad35 fibers on its capsid. The virus was amplified on PerC6 cells to generate virus containing only the Ad35 fiber on its capsid. The resulting virus preparation was termed Av1nBg35F.

Construction of adenoviral vectors containing chimeric fibers derived from Ad5 and Ad35: Two chimeric fiber constructs were prepared by PCR gene overlap extension using plasmids containing the full length Ad5 or Ad35 fiber cDNAs as templates. The Ad5 fiber tail and shaft regions (5TS; amino acids 1 to 403) were connected with the Ad35 fiber head region (35H; amino acids 137 to 323) to form the 5TS35H chimera, and the Ad35 fiber tail and shaft regions (35TS; amino acids 1 to 136) were connected with the Ad5 fiber head region (5H; amino acids 404 to 581) to form the 35TS5H chimera. The fusions were made at the conserved TLWT sequence at the fiber shaft-head junction.

For the construction of the 5TS35H chimera, the pFBshuttle(EcoRI) plasmid was used as the template with primers P1 and P2 to generate the 5' fragment. The 3' fragment was generated using the pFBshuttleAd35 plasmid as the template with the P3 and P4 primers. The sequence of each primer used in the construction of these chimeric fibers is listed in Table 2. Amplified PCR products of the expected size were obtained and were gel purified. A second PCR was carried out with the end primers P1 and P4 to join the two fragments

-75-

together. The DNA fragment generated in the second PCR was digested with Xba1 and Mun1 and was cloned directly into pFBshuttle(EcoR1) to create the fiber shuttle plasmid pFBshuttle5TS35H.

TABLE 2
5 Primers Used For The Exchange Of Fiber Shaft Regions Between Ad5 And Ad35 Fibers

Primer designation	Sequence	SEQ ID
P1	5'-GAACAGGAGGTGAGCTTAGA-3'	22
10 P2	5'-GTTAGGTGGAGGGTTTATTCCGGTCCAC AAAGTTAGCTTATC-3'	23
P3	5'-GATAAGCTAACTTTGTGGACCGGAATAAA CCCTCCACCTAAC-3'	24
P4	5'-GTGGCAGGTTGAATACTAGG-3	25
P5	5'-GTTAGGAGATGGAGCTGGTGTAGTCCATA AGGTGTTAATAC-3'	26
P6	5'-GTATTAACACCTTATGGACTACACCAGCT CCATCTCCTAAC-3'	27
15 P7	5'-TGCGCAAAAACAATCACCACGACAATCACAAT GTACATTGGAAGAAATCATACG-3'	28
P8	5'-ACATTGTGATTGTCGTGGTGATT GTTTTGCGCATATGCCATACAATTTGAATG-3'	29

For the construction of the 35TS5H chimera, the pFBshuttleAd35 plasmid was used as the template with the P1 and P5 primers to generate the 5' fragment. The 3' fragment was generated using the pFBshuttle(EcoR1) plasmid as the template with the P6 and P4 primers. Following the same procedure described above, the fiber shuttle plasmid pFBshuttle35TS5H was generated.

For the 35TS5H and 5TS35H chimeras, the fiber gene was transferred from the pFBshuttle(EcoRI) backbone into pSQ1 as described above for the vector containing the Ad35 fiber. The resulting plasmids were called pSQ135T5H (Figure 18A) and pSQ15T35H (Figure 18B). In addition, adenoviral vectors were generated using the co-transfection strategy described above.

Construction of Ad5 vectors containing the Ad35 fiber with a cRGD targeting peptide in the HI loop of the 35F fiber knob: To incorporate the cRGD

-76-

targeting peptide into the Ad35 fiber HI loop, the P7 and P8 oligonucleotide primers encoding the ten amino acid sequence HCDCRGDCFC (SEQ ID No. 30) were synthesized. The pFBshuttleAd35 plasmid containing the full length Ad35 fiber cDNA was used as the template in the PCR reaction with the P1 and P7
5 primer pair or with the P4 and P8 primer pair in order to generate the 5' and 3' PCR fragments. A second PCR was then carried out with the end primers P1 and P4 to join the two fragments together. The resulting PCR fragment was digested with Xba1 and Mun1 and was cloned into pFBshuttle(EcoR1) to create the fiber shuttle plasmid pFBshuttleAd35cRGD. The modified Ad35 fiber gene
10 was transferred into pSQ1 using the EcoRI cloning strategy described above to generate pSQ1Ad35FcRGD (Figure 17B). Adenoviral vector was generated using the co-transfection strategy described above.

EXAMPLE 10

15 *In Vitro* Evaluation Of Adenoviral Vectors Containing 35F And Derivatives Thereof

The transduction efficiencies of adenoviral vectors containing the 35F or derivatives thereof were evaluated on A549 cells. The transduction efficiencies were compared to that of Av1nBg, an adenoviral vector containing the 5F fiber. The day prior to infection, cells were seeded into 24-well plates at a density of
20 approximately 1×10^5 cells per well. Immediately prior to infection, the exact number of cells per well was determined by counting a representative well of cells. Each of the vectors, Av1nBg, Av1nBg35F, Av1nBg5T35H and Av1nBg35T5H were used to transduce A549 cells from 0 up to 1,000 particle per cell (PPC) ratios. The cell monolayers were stained with X-gal 24 hours after
25 infection and the percentage of cells expressing β -galactosidase was determined by microscopic observation and counting of cells. Transductions were done in triplicate and three random fields in each well were counted, for a total of nine fields per vector. The results (Figure 19) showed similar transduction efficiencies on A549 cells using the Av1nBg35F and Av1nBg5T35H vectors
30 compared to Av1nBg. The Av1nBg35T5H showed much lower transduction efficiencies on A549 cells compared to Av1nBg as a result of the Ad35 shaft domain. The Ad35 shaft domain does not contain a HSP binding motif and the

-77-

Av1nBg35T5H vector behaves similarly to the Av1nBgS* vector *in vitro* and *in vivo*. These studies also demonstrate that vectors containing fiber proteins without an HSP binding site are fully viable.

EXAMPLE 11

5 *in Vivo* Evaluation Of Adenoviral Vectors Containing 35F And Derivatives Thereof

The objective of this study was to evaluate the *in vivo* biodistribution of adenoviral vectors containing 35F fibers and derivatives thereof to determine whether vectors containing these fibers ablate liver transduction due to their shaft regions. A positive control cohort received Av1nBg and a negative control group received HBSS. Cohorts of five C57BL/6 mice received each vector via tail vein injection at a dose of 1×10^{13} particles per kg. The animals were sacrificed approximately 72 hours after vector administration by carbon dioxide asphyxiation. Liver, heart, lung, spleen, and kidney were collected from each animal. The median lobe of the liver was placed in neutral buffered formalin to preserve the sample for β -galactosidase immunohistochemistry. In addition, tissue from each organ was frozen to preserve it for hexon PCR analysis to determine vector content. A separate sample of liver from each mouse was frozen to preserve it for a chemiluminescent β -galactosidase activity assay. β -galactosidase immunohistochemistry, hexon real-time PCR and the chemiluminescent β -galactosidase activity assay were carried out as described in example 3.

The results of the β -galactosidase activity assay showed a dramatic reduction in liver transduction by vectors containing the Ad35 fiber or the 35T5H derivative (Figure 20) with an approximately 4- to 24-fold reduction in β -galactosidase activity in the liver compared to the control vector Av1nBg. These data demonstrate that shaft domains without HSP binding sites can effectively ablate hepatic *in vivo* gene transfer. In particular, HSP is the major entry mechanism for liver *in vivo*. CAR binding is a minor entry pathway.

-78-

EXAMPLE 12**Construction Of Ad5 Vectors Containing The Ad Serotype 41 Short Fiber And Derivatives Thereof**

The human adenovirus serotype 41 contains two different fibers on its capsid, encoded by two adjacent genes. One fiber has a molecular weight of 60kDa and is approximately 315A in length and is termed the long fiber. The other fiber has a molecular weight of 40kDa and is approximately 250+ in length and is termed the short fiber. The Ad41 short fiber does not bind CAR and does not possess the heparin binding domain (KKTK) in its shaft. Therefore, this fiber provides a useful platform for adenoviral vector targeting.

Construction of adenoviral vectors based on Ad5 but containing the Ad41 short fiber: A PCR SOEing strategy was used to generate a vector based on the Ad5 genome but containing the Ad41 short (Ad41s) fiber. First, PCR was used to amplify the region of pSQ1 between the XbaI site at bp 25,309 and the start of the fiber gene. The primer pair used for the PCR were P-0005/U and P-0010/L. The DNA sequence of P-0005/U was as follows: 5' C TCT AGA AAT GGA CGG AAT TAT TAC AG 3' (SEQ ID No. 17). The sequence corresponds to bp 25,308 through 25,334 of pSQ1 and overlaps the XbaI site in that region. The DNA sequence of P-0010/L was as follows: 5' TTC TTT TCA T CTG CAA CAA CAT GAA GAT AGT G 3' (SEQ ID No. 31). It contains a 5' extension corresponding to the first 10 bp of the Ad41s fiber gene. The remainder of the primer anneals to pSQ1 immediately 5' of the ATG start codon of the fiber gene. The PCR product was the expected size (583 bp). A second PCR was used to amplify the Ad41s fiber using the plasmid pDV60Ad41sF as a template. The primers used were P-0011/U and P-0012/L. The DNA sequence of P-0011/U was as follows: 5' GT TGT TGC AG ATG AAA AGA ACC AGA ATT GAA G 3' (SEQ ID No. 32). It contains a 10 bp 5' extension corresponding to the DNA sequence immediately 5' of the ATG start codon of the fiber gene in pSQ1. The remainder of the primer anneals to the beginning of the Ad41s fiber gene in pDV60Ad41sF. The DNA sequence of P-0012/L was as follows: 5' TG CAA TTG AAA AAT AAA CAC GTT GAA ACA TAA CAC AAA CGA TTC TTT ATT C TTC AGT TAT GTA GCA AAA TAC A 3' (SEQ ID No. 33). It contains a 51 bp

-79-

5' extension corresponding to the sequence in pSQ1 from the last codon of the fiber gene through the MunI site 40 bp downstream of the fiber gene. The remainder of the primer anneals to the 3' end of the Ad41s fiber gene in pDV60Ad41sF. The PCR product was the expected size (1219 bp). The two

5 PCR products were joined by PCR SOEing using primers P-0005/U and P-0009/L. The DNA sequence of P-0009/L was described above. The PCR SOEing reaction yielded the expected 1782 bp product. The product was cloned into pCR4blunt-TOPO to yield pCR4blunt-TOPOAd41sF. Next, pCR4blunt-TOPOAd41sF was digested with XbaI and MunI and the 1773 bp

10 fragment containing the Ad41s fiber gene was gel purified. This fragment was ligated with the 6477 bp XbaI to MunI fragment of pFBshuttle(EcoRI) to generate pFBshuttleAd41sF. The Ad41s fiber gene was transferred into the pSQ1 backbone as follows. First, pFBshuttleAd41sF was linearized using EcoRI and this fragment was ligated with the 24,213 bp EcoRI fragment of pSQ1 to

15 generate pSQ1Ad41sF (Figure 21A). Adenoviral vector containing the Ad41s fiber was generated using the co-transfection strategy described above.

Construction of Ad5 adenoviral vectors containing the Ad41 short fiber with a cRGD targeting ligand in the HI loop: A PCR SOEing strategy was used to generate a construct containing the Ad41s fiber with cRGD in the HI loop. The

20 plasmid pFBshuttleAd41sF was used as a template for the PCR amplifications. First, a 1782 bp fragment was amplified using primers 5FF and 41sRGDR. The primer 5FF was described above. It anneals to pFBshuttleAd41sF at the XbaI site upstream of the fiber gene. The DNA sequence of the primer 41sRGDR was as follows: 5' AGT ACA AAA ACA ATC ACC ACG ACA ATC ACA GTT TAT

25 CTC GTT GTA GAC GAC ACT GA 3' (SEQ ID No. 34). It contains a 30 bp 5' extension that encodes the cRGD targeting ligand. The remainder of the primer anneals to pFBshuttleAd41sF from bp 2878 through 2903. A second PCR amplified a 277bp region of pFBshuttleAd41sF using primers 3FR and 41sRGDF. The primer 3FR was described previously. It anneals to pFBshuttleAd41sF at the

30 MunI site downstream of the fiber gene. The DNA sequence of 41sRGDF was as follows: 5' TGT GAT TGT CGT GGT GAT TGT TTT TGT ACT AGT GGG TAT GCT TTT ACT TTT 3' (SEQ ID No. 35). It contains a 30 bp 5' extension that

-80-

encodes the cRGD targeting ligand and is complementary to the extension on 41sRGDR. The remainder of the primer anneals to pFBshuttleAd41sF from bp 2904 through 2924. The two PCR products were joined by PCR SOEing to generate a 2059 bp fragment using primers 5FF and 3FR. The product was
5 digested with XbaI and MluI and the 1803 bp DNA fragment was gel purified. The fragment was ligated with the 6477 bp fragment resulting from digestion of pFBshuttle(EcoRI) with XbaI and MluI. The resulting plasmid was termed pFBshuttleAd41sRGD. This plasmid was linearized by EcoRI digestion and ligated with the 24,213bp EcoRI fragment of pSQ1 to generate pSQ1Ad41sRGD
10 (Figure 21B).

EXAMPLE 13

***In Vivo* Evaluation Of Ad5 Vectors Containing The Ad41 Short Fiber And Derivatives Thereof**

This example evaluates the *in vivo* biodistribution of adenoviral vectors
15 containing 41sF fibers and derivatives thereof to determine whether vectors containing the these fibers ablate liver transduction due to modified shaft regions. A positive control cohort received Av3nBg (see, Gorziglia *et al.* (1996) *J. Virology* 70:4173-4178) or Ad5.βGal.ΔF/5F, and a negative control group received HBSS. Ad5.βGal.ΔF/5F is a derivative of the fiberless vector
20 Ad5.βgal.ΔF (ATCC accession number VR2636) modified to express AD5 fiber (see, *e.g.*, International PCT application No. WO0183729).

The Ad5.βGal.ΔF vector was pseudotyped with the Ad41sF fiber protein and injected *in vivo*. Cohorts of five C57BL/6 mice received each vector via tail vein injection at a dose of 1×10^{13} particles per kg. The animals were sacrificed
25 approximately 72 hours after vector administration by carbon dioxide asphyxiation. Liver, heart, lung, spleen, and kidney were collected from each animal. The median lobe of the liver was placed in neutral buffered formalin to preserve the sample for β-galactosidase immunohistochemistry. In addition, tissue from each organ was frozen to preserve it for hexon PCR analysis to
30 determine vector content. A separate sample of liver from each mouse was frozen to preserve it for a chemiluminescent β-galactosidase activity assay. β-galactosidase immunohistochemistry, hexon real-time PCR and the

-81-

chemiluminescent β -galactosidase activity assay was carried out as described in example 3.

The results of the hexon DNA analysis showed a dramatic reduction in liver transduction by vectors containing the Ad41sF fiber (Figure 22) with an
5 approximately a 5-fold reduction in liver adenoviral DNA content compared to either control vector.

In the above examples, several novel adenoviral vectors were generated containing various fiber modifications designed to ablate the normal tropism of the vector. See Table 3. Vectors were generated in which the heparan sulfate
10 binding domain in the fiber shaft was replaced by amino acid substitutions. This mutation, termed HSP, was also combined with the KO1 mutation (fiber knob AB loop mutation that ablates CAR binding), and the PD1 mutation (penton mutation that eliminates RGD/integrin interaction). In addition, a vector containing all three mutations (HSP, KO1, PD1) was generated. All vectors containing the HSP
15 mutation, either alone or combined with other capsid modifications, showed dramatically reduced transduction efficiencies on A549 and HeLa cells. Furthermore, the same vectors showed dramatically reduced transduction of the liver following systemic delivery to mice. As an alternative strategy to ablate the normal tropism of Ad5-based vectors, the Ad5 fiber was replaced by a fiber from
20 a different adenovirus serotype which does not bind CAR and does not contain the heparan binding domain in the shaft. Thus, vectors were generated containing the Ad35 fiber and the Ad41 short fiber. Versions of these two vectors containing a cRGD targeting ligand in the HI loop of the fiber were also produced. Additionally, vectors containing chimeric fibers were generated. A
25 vector containing the Ad35 fiber tail and shaft regions fused to the Ad5 fiber knob domain as well as a vector containing the Ad5 fiber tail and shaft fused to the Ad35 fiber knob domain were constructed. Vectors containing either the entire Ad35 or Ad41 short fiber showed a significant reduction in liver transduction following delivery to mice via the tail vein. The observation of
30 reduced liver transduction using vectors containing either an HSP mutation, the Ad35 fiber, or the Ad41 short fiber indicates the feasibility of detargeting adenoviral vectors *in vivo*. *In vitro* data with the Ad35 fiber or the Ad41 short

-82-

fiber with cRGD (see Example 14) indicate that the virus is completely viable, that is, it is not damaged by the absence of an HSP binding site and is retargetable. Taken together these data suggest that these vectors provide a suitable platform for retargeting strategies.

5

TABLE 3
Description Of Recombinant Adenoviral Vectors Used
To Demonstrate That Shaft Modifications Influence Tropism *In Vivo*
Vector

Vector	Description
Av1nBg	An E1 and E3-deleted adenoviral vector encoding a nuclear localizing β -galactosidase
Ad5 Fiber derivatives:	
Av1nBgFKO1	The same as Av1nBg but containing the KO1 AB loop mutation in the fiber gene
Av1nBgPD1	The same as Av1nBg but containing the penton PD1 mutation that deletes the integrin binding, RGD tripeptide
Av1nBgS*	The same as Av1nBg but containing the 4 amino acid substitution in the shaft referred to as S* that modifies the HSP binding motif
Av1nBgFKO1S*	The same as Av1nBg but containing the fiber KO1 and S* mutations combined
Av1nBgS*PD1	The same as Av1nBg but containing the fiber S* and penton PD1 mutations combined
Av1nBgFKO1S*PD1	The same as Av1nBg but containing the fiber KO1, S* and penton PD1 mutations combined
Ad35 fiber derivatives:	
Av1nBg35F	The same as Av1nBg but containing the full length Ad35 fiber cDNA
Av1nBg5T35H	The same as Av1nBg but containing the 5T35H chimeric fiber
Av1nBg35T5H	The same as Av1nBg but containing the 35T5H chimeric fiber
Av1nBg35FRGD	The same as Av1nBg but containing the full length Ad35 fiber cDNA with a cRGD ligand in the HI loop of the Ad35 fiber
Ad41sF fiber derivatives:	
Av1nBg41sF	The same as Av1nBg but containing the full length Ad41 short fiber cDNA

-83-

Vector	Description
Av1nBg41sFRGD	The same as Av1nBg but containing the full length Ad41 short fiber cDNA with a cRGD ligand in the HI loop of the Ad41 short fiber

EXAMPLE 14**5 *In Vitro* Evaluation Of Adenoviral Vectors Containing The Ad41sF With A cRGD Ligand In The HI Loop**

The transduction efficiencies of adenoviral vectors containing the Ad41sF fiber with the cRGD ligand in the HI loop were evaluated on A549 cells. The transduction efficiencies were compared to that of Av1nBg, an adenoviral vector containing wild type fiber or Av1nBgFKO1RGD, an adenoviral vector containing

10 the KO1 mutation in combination with the cRGD ligand in the HI loop. The day prior to infection, cells were seeded into 24-well plates at a density of approximately 1×10^5 cells per well. Immediately prior to infection, the exact number of cells per well was determined by counting a representative well of cells. Each of the vectors, Av1nBg, Av1nBgFKO1RGD, and Av1nBg41sFRGD

15 were used to transduce A549 cells at a particle to cell ratios of 0 up to 10,000. The cell monolayers were stained with X-gal 24 hours after infection and the percentage of cells expressing β -galactosidase was determined by microscopic observation and counting of cells. Transductions were done in triplicate and three random fields in each well were counted, for a total of nine fields per

20 vector. The results (Figure 23) show that the Av1nBg41sFRGD vector transduced cells to an equivalent level as Av1nBgFKO1RGD at all vector doses examined. Neither FKO1 or Ad41sF can bind CAR. The Ad41sF does not normally interact with CAR and additionally does not contain the HSP binding motif within the shaft domain. These data show that targeting peptides inserted

25 into the loop regions of the fiber knob of KO1 and Ad41sF allows for transduction of target cells via the targeted receptor. Surprisingly, HSP, not CAR and integrins, is the major entry route *in vivo* and ablation of HSP binding permits targeting of adenoviral vectors.

-84-

EXAMPLE 15**Effect of the shaft modification on the biodistribution of adenoviral vectors *in vivo***

The influence of fiber and penton modifications on the *in vivo*

- 5 biodistribution of adenoviral vectors containing fiber head, shaft and penton mutations was examined. Vectors containing the HSP mutation combined with KO1, or PD1, or a combination of all three mutations were evaluated as well as vectors containing the KO1 mutation alone and the PD1 mutation alone. The indicated adenoviral vectors were systemically administered to C57BL6 mice as
- 10 described above. A positive control cohort received Av1nBg and a negative control group received HBSS. Cohorts of five C57BL/6 mice received each vector via tail vein injection at a dose of 1×10^{13} particles per kg. The animals were sacrificed approximately 72 hours after vector administration by carbon dioxide asphyxiation. Liver, heart, lung, spleen, and kidney were collected from
- 15 each animal. Tissue from each organ was frozen to preserve it for real time PCR analysis to determine adenoviral hexon DNA content. A separate sample of liver from each mouse was frozen to preserve it for a chemiluminescent β -galactosidase activity assay. Hexon real-time PCR and the chemiluminescent β -galactosidase activity assay was carried out as described in Example 3.
- 20 The results derived from the liver are described in Example 6 (Figure 14A and B) and also shown in Figure 26 with results presented as percent control of Av1nBg. The effect of the S* shaft modification on the biodistribution of adenovirus to the other organs is shown in Figure 25. The average adenoviral DNA content was determined as adenoviral genomic copies per cell and
- 25 expressed as a percentage of the Av1nBg (+) control value. The average percent control value + standard deviation is shown (n=5 per group) for each tissue examined (Figure 25). Systemic delivery of Ad5 based vectors with wild-type fiber results in a preferential accumulation of vector DNA in the liver with 64 copies per cell with significantly less DNA found in the other organs
- 30 with 1.32 copies per cell found in lung, 2.18 copies per cell in spleen, 0.47 copies per cell found in heart, and 0.72 copies per cell in the kidney. All differences found with PD1, S*, KO1PD1, KO1S*, S*PD1, and KO1S*PD1 were

-85-

significantly different than the Av1nBg (+) control using a unpaired, t-test analysis, P value (0.024. When expressed as a percent of the Av1nBg control values, the influence of each mutation, individually or in combination, becomes apparent. The S* mutation dramatically reduced gene transfer to all four organs, 5 whereas, the KO1 mutation did not. Thus, the importance of the shaft for transduction *in vivo* extends to organs besides the liver. Finally, gene transfer to the lung, heart, and kidney was diminished with PD1 suggesting a role for integrin binding in vector entry in these organs.

EXAMPLE 16

10 Retargeting the S*, shaft modification and the 41sF fiber *in vivo*

Vectors containing the HSP mutation have been shown to effectively detarget adenoviral vectors *in vivo* (see examples 6 and 15). The objective of this study was to evaluate the ability to retarget vectors containing the S* modification or the Ad41sF to tumors *in vivo*. A cRGD peptide was genetically 15 incorporated into the fiber HI loop and evaluated *in vitro* (Examples 8 and 14). These same vectors were then evaluated *in vivo* in tumor-bearing mice. Athymic nu/nu female mice were injected with 8×10^6 A549 cells on the right hind flank. When tumors reached approximately 100mm³ in size, they were randomized into treatment groups. Cohorts of 6 mice received each vector via tail vein 20 injection at a dose of 1×10^{13} particles per kg. The animals were sacrificed approximately 72 hours after vector administration by carbon dioxide asphyxiation. Tumor, liver, heart, lung, spleen, and kidney were collected from each animal. Tissue from each organ was frozen to preserve it for real time PCR analysis to determine adenoviral hexon DNA content. Hexon real-time PCR was 25 carried out as described in example 3. A separate sample of liver from each mouse was frozen to preserve it for a chemiluminescent β -galactosidase activity assay. Hexon real-time PCR and the chemiluminescent β -galactosidase activity assay was carried out as described in example 3.

The adenoviral vector biodistribution to the liver and tumor for each 30 treatment group is shown in Figure 27. Vectors containing the S*, KO1S*, and 41sF fibers effectively detargeted the liver and tumor resulting in a significant reduction in the amount of adenoviral DNA found in each tissue in comparison to

-86-

the Av1nBg control. Vectors containing the cRGD targeting ligand restored transduction of the tumors to levels comparable to that achieved with the untargeted vector.

These data demonstrate successful liver detargeting accompanied with tumor retargeting. The extent of tumor retargeting is related to the affinity and type of ligand that is used. These data demonstrate the successful development of a targeted, systemically deliverable adenoviral vector that will target tumors *in vivo*.

EXAMPLE 17

10 Scale-Up Method For The Propagation Of Detargeted Adenoviral Vectors

The growth and propagation of doubly or triply ablated adenoviral vectors requires novel scale up technologies. These detargeted vectors require alternative cellular entry strategies to allow for the efficient growth and generation of high titer preparations. A strategy for vector growth that is generally applicable to all detargeted adenoviral vectors, that does not require the development of new cell lines, and that also can be used for generating targeted vectors is provided herein.

Three recombinant adenoviral vectors were prepared that contain single mutations in the fiber or penton or both mutations combined into one vector. These vectors are designated Av3nBgFKO1, Av1nBgPD1, and Av1nBgFKO1PD1, respectively. The construction of these vectors is described above and a general description of each vector can be found in Table 1 above.

Scale-up of detargeted adenoviral vectors: A polycation, specifically hexadimethrine bromide was obtained from Sigma Chemical Co (St. Louis, MO), Catalog No. 52495, and was maintained in the medium at 4 μ g/ml during the course of transfections and infections. To illustrate the effects of hexadimethrine bromide on the yield of detargeted adenoviral vectors the following experiment was carried out. Seven plates of AE1-2a adenoviral producer cells (Gorziglia *et al.* (1996) *J. Virology* 70:4173-4178) were transduced with 10 particles per cells of each of the indicated vectors (See Table 4). Each vector was incubated with medium (Richters with 2% HI-FBS) containing hexadimethrine bromide at 4 μ g/ml for 30 min at room temperature

-87-

prior to infection. The infection was carried out for 2 hrs. Complete medium containing hexadimethrine bromide at 4 $\mu\text{g/ml}$ was added to each plate. Final concentration of hexadimethrine bromide in all of these experiments was maintained at 4 $\mu\text{g/ml}$. The titers were determined spectrophotometrically using the conversion of 1OD at A260nm per 1×10^{12} particles (Mittereder *et al.* (1996) *J Virology* 70:7498-7509). The total particle yield was then normalized for the number of plates used for transduction.

The inclusion of hexadimethrine bromide in the medium during the course of infection allows for the efficient propagation of detargeted adenoviral vectors containing fiber and penton mutations either alone or in combination. The affect of hexadimethrine bromide on vector yields is shown in Table 4. A 35-fold improvement in the yield of Av3nBgFKO1 was found when hexadimethrine bromide was included in the culture medium and resulted in increasing the vector yield from 1.3×10^{10} up to 4.6×10^{11} vector particle per plate. Hexadimethrine bromide has a minimal effect on the yield of the Av1nBgPD1 adenoviral vector containing the penton, PD1 mutation with only a 1.2 fold improvement. The greatest effect using hexadimethrine bromide was found on the propagation of the doubly ablated adenoviral vector, Av1nBgFKO1PD1 with increases in vector yield from barely detectable levels up to 4.53×10^{10} vector particles per plate. These data demonstrate that use of nonspecific entry mechanisms allows for the efficient scale-up of detargeted adenoviral vectors.

TABLE 4
Efficient Scale-Up Of Detargeted Adenoviral Vectors Using hexadimethrine bromide

Vector	Vector Yield (particles/plate)		Fold Improvement
	(-) hexadimethrine bromide	(+) hexadimethrine bromide	
Av1nBg	3.89×10^{11}	5.72×10^{11}	1.47
Av3nBg	8.58×10^{10}	2.38×10^{11}	2.77
Av3nBgFKO1	1.30×10^{10}	4.60×10^{11}	35.4
Av1nBgPD1	1.95×10^{11}	2.40×10^{11}	1.23
Av1nBgFKO1PD1	TLTC*	4.53×10^{10}	†

-88-

*TLTC: Too low to count, a faint virus band was collected and the particle concentration was too dilute for titer determination.

† Significant improvement

The use of alternative polycations including protamine sulfate and poly-lysine as well as bifunctional proteins such as the anti-penton:TNF α fusion protein was investigated. Figure 24 show results that demonstrate all the reagents tested had some effect on enhancing transduction of the Av3nBgFKO1 vector. All of these compounds, when maintained in the medium during infection, enhanced transduction of the Av3nBgFKO1 detargeted adenoviral vector.

Bifunctional reagents: The use of bifunctional reagents for the propagation of detargeted adenoviral vectors was examined using the anti-penton:TNF α fusion protein. This particular reagent is a fusion protein between an antibody against Ad5 penton and the TNF α protein that is produced using stably transfected insect cells. This reagent will bind specifically to the adenoviral capsid via penton base and allow for binding to cell surface TNF receptors. The use of this reagent for the propagation of detargeted vectors is illustrated in Table 5 using Av3nBgFKO1 (also shown in Figure 24). Monolayers of S8 cells were infected with 10 or 100 particles per cell of Av3nBgFKO1 or a control vector in the presence or absence of 1 μ g/ml of the anti-penton:TNF α fusion protein. The monolayers were visually inspected over time for vector spread as indicated by the extent of cytopathic effect (CPE). The percentage of CPE at each time point is shown. The use of this bifunctional reagent clearly enhances the spread of the Av3nBgFKO1 vector throughout the monolayer.

TABLE 5
Efficient Scale-Up Of Detargeted Adenoviral
Vectors Using Bifunctional Reagents: Anti-Penton:TNF α

	10 ppc - anti-penton TNF	10 ppc + anti-penton TNF	100 ppc - anti-penton TNF	100 ppc + anti-penton TNF
	Percentage of CPE			
Ad5Luc1				
24 h	0%	0%	0%	0%

-89-

	10 ppc - anti-penton TNF	10 ppc + anti-penton TNF	100 ppc - anti-penton TNF	100 ppc + anti-penton TNF
	Percentage of CPE			
48 h	20-30%	20-30%	90-100%	90-100%
72 h	60-70%	80-90%	100%	100%
120 h	100%	100%	100%	100%
Av3nBgKO1 24hrs				
24 h	0%	0%	0%	0%
48 h	0%	10-20%	0%	90-100%
72 h	5%	60-70%	5%	100%
120 h	40-50%	100%	100%	100%

5

10

Since modifications will be apparent to those of skill in this art, it is intended that this invention be limited only by the scope of the appended claims.

-90-

WHAT IS CLAIMED IS:

1. A modified adenovirus capsid protein,
the unmodified capsid protein binds to heparin sulfate
proteoglycan (HSP); and
- 5 the capsid protein comprises a mutation, whereby binding to
heparin sulfate proteoglycan (HSP) is altered.
2. The modified protein of claim 1 that is a fiber protein
3. The capsid protein of claim 2, wherein the binding of the modified
fiber protein is eliminated or reduced compared to the unmodified protein.
- 10 4. The modified protein of claim 2, wherein the binding of the
modified fiber protein is eliminated or reduced compared to the unmodified
protein.
5. The modified protein of claim 3 that comprises an insertion,
deletion or replacement of amino acids.
- 15 6. The modified protein of claim 2, wherein the mutation alters the
motif that binds to HSP, whereby HSP interaction is altered.
7. The modified protein of claim 6, motif is BBXB or BBBXXB,
wherein the B is a basic amino acid and X is any amino acid.
8. The modified protein of claim 7, wherein the motif comprises the
20 consensus sequence KKTK.
9. The modified protein of claim 2, wherein the fiber is a modified
Ad5 or Ad2 fiber.
10. A modified protein of claim 2 that is a chimeric fiber protein,
comprising portions of fiber proteins from at least two different adenoviruses,
25 wherein:
a shaft or portion thereof is from a first adenovirus, whereby the resulting
fiber does not bind to HSP or binds to HSP with reduced affinity compared to an
unmodified fiber protein;
a shaft or portion thereof from the first adenovirus does not bind
30 to HSP or binds to HSP with reduced affinity compared to the second
adenovirus;
the second adenovirus binds to HSP; and

-91-

the portion comprises a sufficient portion to alter HSP binding of the resulting protein.

11. The modified protein of claim 10, wherein the binding to HSP of the modified fiber protein is eliminated or reduced compared to the unmodified
5 protein.

12. The modified protein of claim 10, wherein the remainder of the fiber protein is from the second adenovirus.

13. The modified protein of any of claims 2, 3, 10 and 11, further comprising one or more further modifications that reduce or eliminate interaction
10 of the resulting fiber with one or more cell surface proteins in addition to HSP.

14. The modified protein of claim 13, further comprising a ligand, whereby the resulting fiber binds to a receptor for the ligand.

15. The modified protein of claim 14, wherein the ligand is included in the knob region.

16. The modified protein of claim 14, wherein the ligand is inserted or it replaces a portion of the fiber, whereby the resulting fiber binds to a receptor for the ligand.

17. A modified protein of claim 11, wherein affinity for HSP is reduced at least by an amount selected from among reduced 5-fold, 10-fold and 100-
20 fold.

18. The modified protein of claim 11, wherein the first adenovirus is selected from the group consisting of subgroup B, D or F, and the second is of subgroup C.

19. The modified protein of claim 10, wherein the first adenovirus is
25 selected from the group consisting of Ad3, Ad35, Ad7, Ad11, Ad16, Ad21, Ad34, Ad40, Ad41 and Ad46.

20. The modified protein of claim 18, wherein the second adenovirus is Ad5 or Ad2.

21. The modified protein of claim 19, wherein the second adenovirus
30 is Ad5 or Ad2.

22. A modified protein of claim 1 selected from the group consisting of a fiber protein comprising:

-92-

the sequence of amino acids set forth in any of SEQ ID Nos. 52, 54, 56, 58, 62, 66, 70 and 72; or

a sequence of amino acids having 90% sequence identity with a sequence of amino acids set forth in any of SEQ ID Nos. 52, 54, 56, 58, 62, 66, 70 and 72; or

a sequence of amino acids encoded by a sequence of nucleotides that hybridizes under conditions of high stringency along at least 70% of its length to a sequence of nucleotides that encodes a sequence of amino acids set forth in any of SEQ ID Nos. 52, 54, 56, 58, 62, 66, 70 and 72.

- 10 23. A nucleic acid molecule encoding a modified protein of any of claims 1-12 and 14-22.
24. A nucleic acid molecule encoding a modified protein of claim 13.
25. The nucleic acid molecule of claim 23 that comprises a vector.
26. The nucleic acid molecule of claim 24 that comprises vector.
- 15 27. The nucleic acid molecule of claim 25 that is an adenovirus vector.
28. The nucleic acid molecule of claim 26 that is an adenovirus vector.
29. The vector of claim 27 that is an adenoviral vector from a subgroup B, C or D adenovirus.
30. The vector of claim 28 that is an adenoviral vector from a
- 20 subgroup B, C or D adenovirus.
31. A cell, comprising a nucleic acid molecule of claim 23.
32. A cell, comprising a nucleic acid molecule of claim 24.
33. The cell of claim 31 that is a eukaryotic cell.
34. The cell of claim 32 that is a eukaryotic cell.
- 25 35. A cell, comprising a nucleic acid molecule of claim 27, wherein: the cell is a eukaryotic cell; and the cell in a packaging cell.
36. A cell, comprising a nucleic acid molecule of claim 28, wherein: the cell is a eukaryotic cell; and
- 30 the cell in a packaging cell.

-93-

37. An adenoviral particle, comprising a modified protein of any of claims 1-12 and 14-22, whereby binding of the viral particle to HSP is altered compared to a particle that expresses an unmodified fiber.

38. An adenoviral particle, comprising a modified protein of claim 13,
5 whereby binding of the viral particle to HSP is altered compared to a particle that expresses an unmodified fiber.

39. An adenoviral particle of claim 37, wherein a native receptor for the fiber is coxsackie-adenovirus receptor (CAR).

40. The adenoviral particle of claim 39, further comprising a mutation
10 in the CAR-binding region of the capsid.

41. The adenoviral particle of claim 39, further comprising a mutation in the α_v integrin-binding region of the capsid, whereby binding to the integrin is eliminated or reduced.

42. The adenoviral particle of claim 40, further comprising a mutation
15 in the α_v integrin-binding region of the capsid, whereby binding to the integrin is eliminated or reduced

43. The adenoviral particle of claim 39, wherein the CAR-binding region of the capsid modified is on a fiber knob.

44. The adenoviral particle of claim 43, wherein the fiber knob
20 modification is in the AB loop or CD loop.

45. The adenoviral particle of claim 44, wherein the fiber knob modification is selected from the group consisting of KO1 and KO12.

46. The adenoviral particle of claim 39, wherein the adenovirus is a subgroup C, D or F adenovirus.

25 47. The adenoviral particle of claim 46, wherein the subgroup C virus is Ad2 or Ad5, the subgroup D virus is Ad46 and the subgroup F virus is Ad41.

48. The adenoviral vector of claim 27 that is an early generation adenoviral vector, a gutless adenoviral vector or a replication-conditional adenoviral vector.

30 49. The adenoviral vector of claim 28 that is an early generation adenoviral vector, a gutless adenoviral vector or a replication-conditional adenoviral vector.

-94-

50. The adenoviral vector of claim 48, wherein the replication-conditional adenoviral vector is an oncolytic adenoviral vector.

51. The adenoviral vector of claim 49, wherein the replication-conditional adenoviral vector is an oncolytic adenoviral vector.

5 52. The adenoviral vector of claim 27 that comprises heterologous nucleic acid.

53. The adenoviral vector of claim 28 that comprises heterologous nucleic acid.

10 54. The adenoviral vector of claim 52, wherein the heterologous nucleic acid encodes a polypeptide.

55. The adenoviral vector of claim 53, wherein the heterologous nucleic acid encodes a polypeptide.

56. The adenoviral vector of claim 52, wherein the heterologous nucleic acid comprises or encodes a regulatory nucleic acid.

15 57. The adenoviral vector of claim 53, wherein the heterologous nucleic acid comprises or encodes a regulatory nucleic acid.

58. The adenoviral vector of claim 52, wherein the heterologous nucleic acid comprises or encodes a promoter or RNA.

20 59. The adenoviral vector of claim 53, wherein the heterologous nucleic acid comprises or encodes a promoter or RNA.

60. The adenoviral vector of claim 59, wherein the promoter is a cell or tissue specific promoter.

61. The adenoviral vector of claim 59, wherein the promoter is operably linked to a gene of an adenovirus essential for replication.

25 62. The adenoviral vector of claim 60, wherein the tissue specific promoter is a tumor specific promoter.

63. The adenoviral vector of claim 58, wherein the polypeptide is a therapeutic polypeptide.

30 64. A method of expressing heterologous nucleic acid in a cell, comprising transducing the cell with an adenoviral vector of claim 57.

65. The method of claim 64, wherein:
the cell is a tumor cell;

-95-

the adenoviral vector is an oncolytic vector; and
the cell is killed .

66. The method of claim 64, wherein the cell is a mammalian cell.

67. The method of claim 64, wherein the cell is a primate cell.

5 68. The method of claim 67, wherein the cell is a human cell.

69. A method of reducing transduction of liver cells by an adenoviral particle, comprising reducing or eliminating binding of the particle to heparin sulfate proteoglycans (HSPs) on the liver cells.

10 70. A scale up method for the propagation of a detargeted adenoviral particle, comprising:

infecting a cell capable of replicating, maturing and packaging an adenoviral vector with a detargeted adenoviral vector in the presence of a reagent that results in entry of the adenoviral particle into the cell;

15 culturing the infected cell under conditions suitable for growth, spread and propagation of the adenoviral vector; and
recovering the resulting adenoviral particles.

71. The method of claim 70, wherein the reagent is a polycation.

20 72. The method of claim 71, wherein the polycation is selected from the group consisting of hexadimethrine bromide, polyethylenimine, protamine sulfate and poly-L-lysine.

73. The method of claim 70, wherein the reagent is a bifunctional protein that binds to the adenoviral particle and to a receptor on the cell.

74. The method of claim 73, wherein:
the bifunctional protein is selected from the group consisting of an
25 anti-fiber antibody ligand fusion, an anti-fiber-Fab-FGF conjugate, an anti-penton-antibody ligand fusion, an anti-hexon antibody ligand fusion and a polylysine-peptide fusion, wherein the ligand is a ligand that binds to the receptor.

30 75. The method of any one of claims 70-74, wherein the detargeted adenoviral particle expresses a modified capsid, whereby binding to at least one host cell receptor is reduced or eliminated compared with a wild-type adenovirus.

-96-

76. The method of claim 75, wherein the adenoviral particle is modified to eliminate or reduce binding with one host cell receptor.

77. The method of claim 75, wherein the adenoviral particle is modified to eliminate or reduce binding with two host cell receptors.

5 78. The method of claim 75, wherein the adenoviral particle is modified to eliminate or reduce binding with three host cell receptors.

79. The method of claim 75, wherein the particle is modified with one or more mutations selected from the group consisting of mutations that reduce or eliminate interactions with one or more of α_v integrins, coxsackie-adenovirus receptors (CAR), and heparin sulfate proteoglycans (HSP).
10

80. The method of claim 79, wherein the mutation is selected from the group consisting of PD1, KO1, KO12 and S*.

81. The modified protein of claim 2, wherein the mutation is in the shaft of a fiber.

15 82. A modified protein of claim 3, wherein affinity for HSP is reduced at least by an amount selected from among reduced 5-fold, 10-fold and 100-fold.

Figure 1




Figure 2




Figure 3A




Figure 3B




Figure 3C




Figure 4




Figure 5A




Figure 5B




Figure 6




Figure 7A




Figure 7B





Figure 8

Figure 9




Figure 10




Figure 11




Figure 12




Figure 13A




Figure 13B




Figure 13C




Figure 14A




Figure 14B




Figure 15A




Figure 15B





Figure 16

Figure 17A




Figure 17B




Figure 18A




Figure 18B




Figure 19




Figure 20




Figure 21A






Figure 21B

**Figure 22**





Figure 23

Figure 24






Figure 25

Figure 26





Figure 27



-1-

SEQUENCE LISTING

<110> The Scripps Research Institute
 Novartis AG
 Kaleko, Michael
 Nemerow, Glen R.
 Smith, Theodore
 Stevenson, Susan C.

<120> Fiber Shaft Modifications for Efficient Targeting

<130> 22908-1236PC

<140> Not yet assigned
 <141> Herewith

<150> 60/350,388
 <151> 2002-01-24

<150> 60/391,967
 <151> 2002-06-26

<160> 72

<170> PatentIn version 3.0

<210> 1
 <211> 4
 <212> PRT
 <213> adenovirus serotype 5

<400> 1
 Lys Lys Thr Lys
 1

<210> 2
 <211> 1746
 <212> DNA
 <213> adenovirus serotype 5

<400> 2
 atgaagcgcg caagaccgtc tgaagatacc ttcaaccccg tgtatccata tgacacggaa 60
 accggtcctc caactgtgcc ttttcttact cctccctttg tatcccccac tgggtttcaa 120
 gagagtcccc ctgggggtact ctctttgogc ctatccgaac ctctagttac ctccaatggc 180
 atgcttgcgc tcaaaatggg caacggcctc tctctggagc aggccggcaa ccttacctcc 240
 caaaatgtaa ccactgtgag cccacctctc aaaaaaacca agtcaaacat aaacctggaa 300
 atatctgcac ccctcacagt tacctcagaa gccctaactg tggctgccgc cgcacctcta 360
 atggtcgchg gcaacacact caccatgcaa tcacaggccc cgctaaccgt gcacgactcc 420
 aaacttagca ttgccaccca aggaccctc acagtgtcag aaggaaagct agccctgcaa 480
 acatcaggcc ccctcaccac caccgatagc agtaccctta ctatcactgc ctcaccctcc 540
 ctaactactg ccactggtag cttggggcatt gacttgaaag agcccattta tacacaaaat 600
 ggaaaactag gactaaagta cggggctcct ttgcatgtaa cagacgacct aaacactttg 660
 accgtagcaa ctgggtccagg tgtgactatt aataatactt ccttgcaaac taaagttact 720
 ggagccttgg gttttgattc acaaggcaat atgcaactta atgtagcagg aggactaagg 780
 attgattctc aaaacagacg ccttatactt gatgttagtt atccgtttga tgctcaaaac 840
 caactaaatc taagactagg acagggccct ctttttataa actcagccca caacttgat 900
 attaaactaca acaaaggcct ttacttgttt acagcttcaa acaattccaa aaagcttgag 960
 gttaacctaa gcactgccaa ggggttgatg tttgacgcta cagccatagc cattaatgca 1020
 ggagatgggc ttgaatttgg ttcacctaat gcaccaaaca caaatcccct caaaacaaaa 1080
 attggccatg gcctagaatt tgattcaaac aaggctatgg ttcctaaact aggaactggc 1140
 cttagttttg acagcacagg tgccattaca gtaggaaaca aaaataatga taagctaact 1200
 ttgtggacca caccagctcc agaggctaac tgtagactaa atgcagagaa agatgctaaa 1260

-2-

ctcacttttg	tcttaacaaa	atgtggcagt	caaatacttg	ctacagtttc	agttttggct	1320
gttaaaggca	gtttggctcc	aatatctgga	acagttcaaa	gtgctcatct	tattataaga	1380
tttgacgaaa	atggagtgct	actaaacaat	tccttcctgg	accagaata	ttggaacttt	1440
agaaatggag	atcttactga	aggcacagcc	tatacaaacg	ctgttggatt	tatgcctaac	1500
ctatcagctt	atccaaaatc	tcacggtaaa	actgccaaaa	gtaacattgt	cagtcaagtt	1560
tacttaaacy	gagacaaaac	taaacctgta	acactaacca	ttacactaaa	cggtagacag	1620
gaaacaggag	acacaactcc	aagtgcatac	tctatgtcat	tttcatggga	ctgggtctggc	1680
cacaactaca	ttaatgaaat	atttgccaca	tcctcttaca	ctttttcata	cattgcccac	1740
gaataa						1746

<210> 3
 <211> 1746
 <212> DNA
 <213> adenovirus serotype 5

<400> 3						
atgaagcgcg	caagaccgtc	tgaagatacc	ttcaaccccg	tgtatccata	tgacacggaa	60
accggtcctc	caactgtgcc	ttttcttact	cctccctttg	tatcccccaa	tgggtttcaa	120
gagagtcccc	ctgggggtact	ctctttgctc	ctatccgaac	ctctagttac	ctccaatggc	180
atgcttgctc	tcaaaatggg	caacggcctc	tctctggacg	aggccggcaa	ccttacctcc	240
caaaatgtaa	ccactgtgag	cccacctctc	aaaaaaacca	agtcaaacat	aaacctggaa	300
atatctgcac	ccctcacagt	tacctcagaa	gccctaactg	tggctgccgc	cgcacctcta	360
atggtcgctg	gcaacacact	caccatgcaa	tcacaggccc	cgctaaccgt	gcacgactcc	420
aaacttagca	ttgccaccca	aggacccctc	acagtgctcag	aaggaaagct	agccctgcaa	480
acatcaggcc	ccctcaccac	caccgatagc	agtaccctta	ctatcactgc	ctcaccctcc	540
ctaactactg	ccactggtag	cttgggcatt	gacttgaaaag	agccatttta	tacacaaaat	600
ggaaaactag	gactaaaagta	cggggctcct	ttgcatgtaa	cagacgacct	aaacactttg	660
accgtagcaa	ctgggtccagg	tgtgactatt	aataataactt	ccttgcaaac	taaagtactt	720
ggagccttgg	gttttgattc	acaaggcaat	atgcaactta	atgtagcagg	aggactaagg	780
attgattctc	aaaacagacg	ccttataactt	gatgttagtt	atccgtttga	tgctcaaaaac	840
caactaaatc	taagactagg	acagggccct	ctttttataa	actcagccca	caacttggat	900
attaactaca	acaaaggcct	ttactttgtt	acagcttcaa	acaattccaa	aaagcttgag	960
gttaacctaa	gcactgccaa	gggggttgatg	tttgacgcta	cagccatagc	cattaatgca	1020
ggagatgggc	ttgaatttgg	ttcacctaatt	gcaccaaaaca	caaattcccct	caaaacaaaa	1080
attggccatg	gcctagaatt	tgattcaaac	aaggctatgg	ttcctaaact	aggaactggc	1140
cttagttttg	acagcacagg	tgccattaca	gtaggaaaca	aaaataatga	taagctaact	1200
ttgtggacca	caccagctcc	atctcctaac	tgttcactaa	atggaggcgg	agatgctaaa	1260
ctcacttttg	tcttaacaaa	atgtggcagt	caaatacttg	ctacagtttc	agttttggct	1320
gttaaaggca	gtttggctcc	aatatctgga	acagttcaaa	gtgctcatct	tattataaga	1380
tttgacgaaa	atggagtgtc	actaaacaat	tccttcctgg	accagaata	ttggaacttt	1440
agaaatggag	atcttactga	aggcacagcc	tatacaaacg	ctgttggatt	tatgcctaac	1500
ctatcagctt	atccaaaatc	tcacggtaaa	actgccaaaa	gtaacattgt	cagtcaagtt	1560
tacttaaacy	gagacaaaac	taaacctgta	acactaacca	ttacactaaa	cggtagacag	1620
gaaacaggag	acacaactcc	aagtgcatac	tctatgtcat	tttcatggga	ctgggtctggc	1680
cacaactaca	ttaatgaaat	atttgccaca	tcctcttaca	ctttttcata	cattgcccac	1740
gaataa						1746

<210> 4
 <211> 1737
 <212> DNA
 <213> adenovirus serotype 5

<400> 4						
atgcggcgcg	cggcgatgta	tgaggaaaggt	cctcctccct	cctacgagag	tgtgggtgagc	60
gcggcgccag	tggcgggcggc	gctggggttct	cccttcgatg	ctcccctgga	cccgccgttt	120
gtgcctccgc	ggtagctgcg	gcctaccggg	gggagaaaca	gcatccgtta	ctctgagttg	180
gcacccctat	tcgacaccac	ccgtgtgtac	ctgggtggaca	acaagtcaac	ggatgtggca	240
tccttgaaat	accagaacga	ccacagcaac	tttctgacca	cggtcattca	aaacaatgac	300
tacagcccg	gggaggcaag	cacacagacc	atcaatcttg	acgaccggtc	gcactggggc	360
ggcgacctga	aaaccatcct	gcataccaac	atgccaaatg	tgaacgagtt	catgtttacc	420
aataagttta	aggcgcgggg	gatgggtgtcg	cgcttgcccta	ctaaggacaa	tcagggtggag	480

-3-

ctgaaatac	agtggtgga	gttcacgctg	cccgagggca	actactccga	gaccatgacc	540
atagacctta	tgaacaacgc	gatcgtggag	cactacttga	aagtgggcag	acagaacggg	600
gttctggaaa	gcgacatcgg	ggtaaagt	gacacccgca	acttcagact	ggggtttgac	660
cccgtcactg	gtcttgtcat	gcctggggta	tatacaaacg	aagccttcca	tccagacatc	720
atcttgctgc	caggatgcgg	ggtggacttc	acccacagcc	gcctgagcaa	cttggtgggc	780
atccgcaagc	ggcaaccctt	ccaggagggc	tttaggatca	cctacgatga	tctggagggt	840
ggtaacattc	ccgcactgtt	ggatgtggac	gcctaccagg	cgagcttgaa	agatgacacc	900
gaacagggcg	ggggtggcgc	agggcggcagc	aacagcagtg	gcagcggcgc	ggaagagaac	960
tccaacgcgg	cagccgcggc	aatgcagccg	gtggaggaca	tgaacgatag	ccgcggctac	1020
ccctacgacg	tgcccgaacta	cgcgggcacc	agcgccacac	gggctgagga	gaagcgcgct	1080
gaggccgaag	cagcggccga	agctgccgcc	cccgtgcgc	aacccgaggt	cgagaagcct	1140
cagaagaaac	cgggtgatcaa	acccctgaca	gaggacagca	agaaacgcag	ttacaaccta	1200
ataagcaatg	acagcacctt	caccagtagc	cgcagctggg	accttgcata	caactacggc	1260
gaccctcaga	ccggaatccg	ctcatggacc	ctgctttgca	ctcctgacgt	aacctgcggc	1320
tccgagcagg	tctactggtc	gttgccagac	atgatgcaag	accccgtagc	cttccgctcc	1380
acgcgccaga	tcagcaactt	tccggtgggtg	ggcgccgagc	tggtgcccgt	gcactccaag	1440
agcttctaca	acgaccaggc	cgtctactcc	caactcatcc	gccagtttac	ctctctgacc	1500
cacgtgttca	atcgctttcc	cgagaaccag	atcttggcgc	gcccgccagc	ccccaccatc	1560
accaccgtca	gtgaaaacgt	tcctgctctc	acagatcacg	ggacgctacc	gctgcgcaac	1620
agcatcggag	gagtcacgcg	agtgaccatt	actgacgcca	gacgccgcac	ctgccctac	1680
gtttacaagg	ccctgggcat	agtctcgccg	cgcgtcctat	cgagccgcac	tttttga	1737

<210> 5
 <211> 20
 <212> DNA
 <213> adenovirus serotype 5

<400> 5
 gaacaggagg tgagcttaga 20

<210> 6
 <211> 43
 <212> DNA
 <213> adenovirus serotype 5

<400> 6
 tccgcctcca tttagtgaac agttaggaga tggagctggg gtg 43

<210> 7
 <211> 44
 <212> DNA
 <213> adenovirus serotype 5

<400> 7
 tcactaaatg gaggcggaga tgctaaactc actttgggtct taac 44

<210> 8
 <211> 20
 <212> DNA
 <213> adenovirus serotype 5

<400> 8
 gtggcagggt gaatactagg 20

<210> 9
 <211> 8
 <212> PRT
 <213> adenovirus serotype 5

<400> 9
 His Ala Ile Arg Gly Asp Thr Phe

```

1          5
<210> 10
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> modified sequence for penton protein

<400> 10
Ser Arg Gly Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Gly Thr Ser
1          5          10          15

<210> 11
<211> 57
<212> DNA
<213> Artificial Sequence
<220>
<223> oligonucleotide for mutation generation

<400> 11
cgcggaagag aactccaacg cggcagccgc ggcaatgcag ccggtggagg acatgaa
57

<210> 12
<211> 59
<212> DNA
<213> Artificial Sequence
<220>
<223> oligonucleotide for mutation generation

<400> 12
tatcgttcat gtccctccacc ggctgcattg ccgcggctgc cgcgttggag ttctcttcc
59

<210> 13
<211> 75
<212> DNA
<213> Artificial Sequence
<220>
<223> oligonucleotide for mutation generation

<400> 13
cgatagccgc ggctaccctt acgacgtgcc cgactacgcg ggcaccagcg ccacacgggc
60
tgaggagaag cgcgc 75

<210> 14
<211> 73
<212> DNA
<213> Artificial Sequence
<220>
<223> oligonucleotide for mutation generation

<400> 14
tcagcgcgct tctcctcagc ccgtgtggcg ctggtgcccg cgtagtcggg cacgtcgtag
60
gggtagccgc ggc 73

<210> 15
<211> 40
<212> DNA
<213> Artificial Sequence
<220>
<223> oligonucleotide for mutation generation

```

-5-

<400> 15 ggctccggct ccgagagggtg ggctcacagt gggtacattt	40
<210> 16	
<211> 32	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> oligonucleotide for mutation generation	
<400> 16 ggagccggag cctcaaacaat aaacctggaa at	32
<210> 17	
<211> 27	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> amplification primer	
<400> 17 ctctagaaat ggacggaatt attacag	27
<210> 18	
<211> 32	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> amplification primer	
<400> 18 tcttggtcat ctgcaacaac atgaagatag tg	32
<210> 19	
<211> 32	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> amplification primer	
<400> 19 gttggtgcag atgaccaaga ggtccggct ca	32
<210> 20	
<211> 73	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> amplification primer	
<400> 20 agcaattgaa aaataaacac gttgaaacat aacacaaacg attctttagt tgtcgtcttc tgtaatgtaa gaa	60 73
<210> 21	
<211> 24	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> amplification primer	
<400> 21	

-6-

agcaattgaa aaataaacac gttg 24

<210> 22
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> amplification primer

<400> 22
gaacaggagg tgagcttaga 20

<210> 23
<211> 42
<212> DNA
<213> Artificial Sequence
<220>
<223> amplification primer

<400> 23
gttaggtgga ggggtttattc cgtccacaa agttagctta tc 42

<210> 24
<211> 42
<212> DNA
<213> Artificial Sequence
<220>
<223> amplification primer

<400> 24
gataagctaa ctttgtggac cggaataaac cctccaccta ac 42

<210> 25
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> amplification primer

<400> 25
gtggcaggtt gaatactagg 20

<210> 26
<211> 41
<212> DNA
<213> Artificial Sequence
<220>
<223> amplification primer

<400> 26
gttaggagat ggagctggtg tagtccataa ggtgttaata c 41

<210> 27
<211> 41
<212> DNA
<213> Artificial Sequence
<220>
<223> amplification primer

<400> 27
gtattaacac cttatggact acaccagctc catctcctaa c 41

-7-

<210> 28
 <211> 54
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> amplification primer

 <400> 28
 tgcgcaaaaa caatcaccac gacaatcaca atgtacattg gaagaaatca tacg 54

 <210> 29
 <211> 54
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> amplification primer

 <400> 29
 acattgtgat tgcgtggtg attgtttttg cgcataatgcc atacaatttg aatg 54

 <210> 30
 <211> 10
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> RGD targeting peptide

 <400> 30
 His Cys Asp Cys Arg Gly Asp Cys Phe Cys
 1 5 10

 <210> 31
 <211> 32
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> amplification primer

 <400> 31
 ttcttttcat ctgcaacaac atgaagatag tg 32

 <210> 32
 <211> 32
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> amplification primer

 <400> 32
 gttgttgcag atgaaaagaa ccagaattga ag 32

 <210> 33
 <211> 73
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> amplification primer

 <400> 33
 tgcaattgaa aaataaacac gttgaaacat aacacaaacg attcttttatt cttcagttat 60
 gtacaaaat aca 73

-8-

<210> 34
<211> 56
<212> DNA
<213> Artificial Sequence
<220>
<223> amplification primer

<400> 34
agtacaaaaa caatcaccac gacaatcaca gtttatctcg ttgtagacga cactga 56

<210> 35
<211> 51
<212> DNA
<213> Artificial Sequence
<220>
<223> amplification primer

<400> 35
tgtgattgtc gtggtgattg tttttgtact agtgggtatg cttttacttt t 51

<210> 36
<211> 4
<212> PRT
<213> Adenovirus type 5

<400> 36
Thr Leu Trp Thr
1

<210> 37
<211> 7
<212> PRT
<213> SV40

<400> 37
Pro Lys Lys Lys Arg Lys Val
1 5

<210> 38
<211> 19
<212> DNA
<213> Artificial Sequence
<220>
<223> amplification primer

<400> 38
cttcgatgat gccgcagtg 19

<210> 39
<211> 19
<212> DNA
<213> Artificial Sequence
<220>
<223> amplification primer

<400> 39
gggctcaggt actccgagg 19

<210> 40
<211> 25
<212> DNA

-9-

<213> Artificial Sequence
 <220>
 <223> amplification primer

<400> 40
 ttacatgcac atctcggggc aggac

25

<210> 41
 <211> 7607
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Plasmid GRE5-E1-SV40-Hygro

<400> 41
 tctagaagat ccgctgtaca ggatgttcta gctactttat tagatccgct gtacaggatg 60
 ttctagctac tttatttagat ccgctgtaca ggatgttcta gctactttat tagatccgct 120
 gtacaggatg ttctagctac tttatttagat ccgctgtacag gatgttctag ctactttatt 180
 agatcgatct cctggccggt cgggggtcaaa aaccagggtt ggctataaaa ggggggtgggg 240
 gcgcgttcgt cctcactctc ttccgcacgc ctgtctgcga gggccaggat cgatcctgag 300
 aacttcaggg tgagtttggg gacccttgat tgttctttct ttttcgctat tgtaaaattc 360
 atgttatatg gagggggcaa agttttcagg gtgtgttcta gaatgggaag atgtcccttg 420
 tatcaccatg gaccctcatg ataattttgt ttctttcact ttctactctg ttgacaacca 480
 ttgtctcctc ttatttttct ttcattttct gtaacttttt cgttaaactt tagcttgcat 540
 ttgtaacgaa ttttttaaatt cacttttgtt tatttgtcag attgtaagta ctttctctaa 600
 tcactttttt ttcaaggcaa tcagggtata ttatatgtta cttcagcaca gtttttagaga 660
 acaattgtta taattaaatg ataaggtaga atattttctgc atataaattc tggctggcgt 720
 ggaaatatct ttattggtag aaacaactac atcctgggtca tcacccctgcc tttctcttta 780
 tggttacaat gatatacact gtttgagatg aggataaaat actctgagtc caaaccgggc 840
 cctctgcta accatgttca tgcttcttc ttttctctac agctcctggg caacgtgctg 900
 gttattgtgc tgtctcatca ttttgcaaaa gaattagatc taagcttctg cagctcgagg 960
 actcggctga ctgaaaatga gacatattat ctgccacgga ggtgttatta ccgaagaaat 1020
 ggccgccagt cttttggacc agctgatcga agagggtactg gctgataatc ttccacctcc 1080
 tagccatttt gaaccaccta ccttcacga actgtatgat ttagacgtga cggcccccga 1140
 agatcccaac gaggaggcgg tttcgcagat ttttcccgac tctgtaatgt tggcgggtgca 1200
 ggaagggatt gacttactca cttttccgcc ggcgcgccgt tctccggagc cgcctcacct 1260
 ttcccggcag cccgagcagc cggagcagag agccttgggg ccggtttcta tgccaaacct 1320
 tgtaccggag gtgatcgatc ttacctgcca cgaggctggc tttccacca gtgacgacga 1380
 ggtgaagag ggtgaggagt ttgtgttaga ttgtgtgag caccocgggc acggttgag 1440
 gtcttgtcat tatcaccgga ggaatacggg ggaccagat attatgtgtt cgctttgcta 1500
 tatgaggacc tgtggcatgt ttgtctacag taagtgaaaa ttatgggcag tgggtgatag 1560
 agtgggtggg ttgggtgtgg aatttttttt ttaattttta cagttttgtg gtttaaagaa 1620
 ttttgtattg tgattttttt aaaaggctct gtgtctgaac ctgagcctga gcccgagcca 1680
 gaaccggagc ctgcaagacc taccgcctgt cctaaaatgg cgcttgctat cctgagacgc 1740
 ccgacatcac ctgtgtctag agaatgcaat agtagtacgg atagctgtga ctccggctct 1800
 tctaacacac ctccctgagat acaccgggtg gtcccgctgt gccccattaa accagttgcc 1860
 gtgagagtgt gtgggcgtcg ccaggctgtg gaatgtatcg aggacttgct taacgagcct 1920
 gggcaacctt tggacttgag ctgtaaaacgc cccaggccat aagggtgtaa cctgtgattg 1980
 cgtgtgtggg taacgccttt gtttgcgtgaa tgagttgatg taagtttaat aaagggtgag 2040
 ataattgtta acttgcattg cgtgttaaat ggggcggggc ttaaagggtg tataatgcgc 2100
 cgtgggctaa tcttgggttac atctgacctc atggaggctt gggagtgttt ggaagatttt 2160
 tctgctgtgc gtaacttgct ggaacagagc tctaacagta cctcttggtt ttggaggttt 2220
 ctgtggggct catcccaggc aaagttagtc tgcagaatta aggaggatta caagtgggaa 2280
 tttgaagagc ttttgaatc ctgtggtgag ctgtttgatt ctttgaatct gggtcaccag 2340
 gcgcctttcc aagagaaggt catcaagact ttggattttt ccacaccggg gcgcgctgcg 2400
 gctgctgttg cttttttgag ttttataaag gataaatgga gcgaagaaac ccatctgagc 2460
 ggggggtacc tgctggattt tctggccatg catctgtgga gagcggttgt gagacacaag 2520
 aatcgccctg tactgttgct ttccgtccgc ccggcgataa taccgacgga ggagcagcag 2580
 cagcagcagg aggaagccag gcggcgccgg caggagcaga gcccatggaa cccgagagcc 2640
 ggccctggacc ctccgggaatg aatgttgtac aggtggctga actgtatcca gaactgagac 2700

gcattttgac	aattacagag	gatgggcagg	ggctaaaggg	ggtaaagagg	gagcgggggg	2760
cttgtaggac	tacagaggag	gctaggaatc	tagcttttag	cttaatgacc	agacaccgctc	2820
ctgagtgat	tacttttcaa	cagatcaagg	ataattgccc	taatgagctt	gatctgctgg	2880
cgcagaagta	ttccatagag	cagctgacca	cttactggct	gcagccaggg	gatgattttg	2940
aggaggctat	tagggatat	gcaaagggtg	cacttaggcc	agattgcaag	tacaagatca	3000
gcaaacttgt	aaatatcagg	aattgttgct	acatttctgg	gaacggggcc	gagggtggaga	3060
tagatacga	ggataggggtg	gcctttagat	gtagcatgat	aaatatgtgg	ccgggggtgc	3120
ttggcatgga	cggggtgggtt	attatgaatg	taagggtttac	tggccccaat	tttagcggta	3180
cggttttcc	ggccaataacc	aaccttatcc	tacacggtgt	aagcttctat	gggtttaaca	3240
atacctgtgt	ggaagcctgg	accgatgtaa	gggttcgggg	ctgtgccttt	tactgctgct	3300
ggaagggggg	ggtgtgtcgc	cccaaaagca	gggcttcaat	taagaaatgc	ctctttgaaa	3360
ggtgtaccct	gggtatcctg	tctgagggtg	actccagggt	gcgccacaat	gtggcctccg	3420
actgtgggtg	cttcagctga	gtgaaaagcg	tggctgtgat	taagcataac	atgggtatgtg	3480
gcaactgcga	ggacagggcc	tctcagatgc	tgacctgtct	ggacggcaac	tgtcacctgc	3540
tgaagaccat	tcacgtagcc	agccactctc	gcaaggcctg	gccagtgttt	gagcataaca	3600
tactgacccg	ctgttccttg	catttgggta	acaggagggg	ggtgttccca	ccttaccat	3660
gcaatttgag	tcacactaag	atattgcttg	agcccagagag	catgtccaag	gtgaacctga	3720
acggggtgtt	tgacatgacc	atgaagatct	ggaagggtgt	gaggtacgat	gagacccgca	3780
ccagggtgcag	accctgcgag	tgtggcggtg	aacatattag	gaaccagcct	gtgatgctgg	3840
atgtgaccga	ggagctgagg	cccgatcact	tgggtgctggc	ctgcacccgc	gctgagtttg	3900
gctctagcga	tgaagataca	gattgaggtg	ctgaaatgtg	tgggcgtggc	ttaagggtgg	3960
gaaagaatat	ataagggtggg	ggtcttatgt	agttttgtat	ctgttttgca	gcagcccgccg	4020
ccgccatgag	caccaactcg	tttgatggaa	gcattgtgag	ctcatatttg	acaacgcgca	4080
tgcccccctg	ggccgggggtg	cgtcagaatg	tgatgggctc	cagcattgat	ggtcgccccg	4140
tcctgcccgc	aaactctact	accttgacct	acgagaccgt	gtctggaacg	ccgttggaga	4200
ctgcagcttc	cgccgcgctc	tcagccgctg	cagccaccgc	ccgcgggatt	gtcagctgact	4260
ttgctttcct	gagcccgctt	gcaagcagtg	cagcttcccg	ttcatccgcc	cgcatgaca	4320
agttgacggc	tcttttgcca	caattggatt	ctttgaccgc	ggaacttaat	gtcgtttctc	4380
agcagctgtt	ggatctgcgc	cagcaggttt	ctgccctgaa	ggcttccctc	cctcccaatg	4440
cggtttaaaa	cataaataaa	aaaccagact	ctgtttggat	ttggatcaag	caagtgtcct	4500
gctgtctcag	ctgactgctt	aagtgcgaag	ccgaattgga	tccaattcgg	atcgatctta	4560
ttaaagcaga	acttgtttat	tgacgcttat	aatgggtaca	aataaagcaa	tagcatcaca	4620
aatttcacaa	ataaagcatt	tttttcaactg	cattctagtt	gtggtttgct	caaactcatc	4680
aatgtatctt	atcatgtctg	gtcagactcta	gactcttccg	cttccctcgt	cactgactcg	4740
ctgcgctcgg	tcggttcggct	gcggcgagcg	gtatcagctc	actcaaaggc	ggtaatacgg	4800
ttatccacag	aatcagggtg	taacgcaggg	aagaacatgt	gagcaaaaagg	ccagcaaaag	4860
gccaggaacc	gtaaaaaggc	cgcggttgctg	gcgtttttcc	ataggctccg	ccccctgac	4920
gagcatcaca	aaaatcgacg	ctcaagtcag	aggtggcgaa	acccgacagg	actataaaga	4980
taccaggcgt	ttccccctgg	aagctccctc	gtgcgctctc	ctgttccgac	cctgccgctt	5040
accggatacc	tgctccgctt	tctcccttcg	ggaagcgtgg	cgctttctca	tagctcacgc	5100
tgtaggtatc	tcagttcggt	gtaggtcggt	cgctccaagc	tgggctgtgt	gcacgaaccc	5160
ccggttcagc	ccgaccgctg	cgccttatcc	ggtaactatc	gtcttgagtc	caacccggta	5220
agacacgact	tatcgccact	ggcagcagcc	actggtaaca	ggattagcag	agcgagggtat	5280
gtaggcgggtg	ctacagagtt	cttgaagtg	tggcctaact	acggctacac	tagaaggaca	5340
gtatttggtg	tctgcgctct	gctgaagcca	gttaccttcg	gaaaaagagt	tggtagctct	5400
tgatccggca	aacaaaccac	cgtgggtagc	ggtgggtttt	ttgtttgcaa	gcagcagatt	5460
acgcgcagaa	aaaaaggatc	tcaagaagat	cctttgatct	tttctacggg	gtctgacgct	5520
cagtggaaac	aaaactcacg	ttaaggggatt	ttggtcatga	gattatcaaa	aaggatcttc	5580
acctagatcc	ttttaaatga	aaaatgaagt	tttaaatcaa	tctaaagtat	atatgagtaa	5640
acttggtctg	acagttacca	atgcttaatc	agtgcggcac	ctatctcagc	gatctgtcta	5700
tttcggtcat	ccatagttgc	ctgactcccc	gtcgtgtaga	taactacgat	acgggagggc	5760
ttaccatctg	gccccagtg	tgcaatgata	ccgcgagacc	cacgctcacc	ggctccagat	5820
ttatcagcaa	taaaccagcc	agccggaagg	gccgagcgca	gaagtgggtc	tgcaacttta	5880
tcgcctcca	tccagcttat	taattgttgc	cggaagcta	gagtaagtag	ttcgcgagtt	5940
aatagtttgc	gcaacgttgt	tgccattgct	acaggcatcg	tgggtgcacg	ctcgctggtt	6000
ggtatggctt	cattcagctc	cggttcccaa	cgatcaaggc	gagttacatg	atcccccatg	6060
ttgtgcaaaa	aagcggttag	ctccttcggg	cctccgatcg	ttgtcagaag	taagttggcc	6120
gcagtgttat	cactcatggg	tatggcagca	ctgcataaatt	ctcttactgt	catgccatcc	6180
gtaagatgct	tttctgtgac	tggtgagtab	tcaaccaagt	cattctgaga	atagtgatg	6240
cggcgaccga	gttgctcttg	ccggcgctca	atacgggata	ataccgcgcc	acatagcaga	6300
actttaaaaag	tgctcatcat	tggaaaacgt	tcttcggggc	gaaaactctc	aaggatctta	6360

-11-

```

ccgctgttga gatccagttc gatgtaaccc actcgtgcac ccaactgatc ttcagcatct 6420
tttactttca ccagcgtttc tgggtgagca aaaacaggaa ggcaaaatgc cgcaaaaaag 6480
ggaataaggg cgacacggaa atgttgaata ctcatactct tcctttttca atattattga 6540
agcatttatc agggttattg tctcatgagc ggatacatat ttgaatgtat ttagaaaaat 6600
aaacaaatag ggggtccgcg cacatttccc cgaaaagtgc cacctgacgt ctaagaaacc 6660
attattatca tgacattaac ctataaaaaat aggcgtatca cgaggcccct ttcgtctcgc 6720
gcgtttcggg gatgacgggtg aaaacctctg acacatgcag ctcccggaga cggtcacagc 6780
ttgtctgtaa gcggatgccg ggagcagaca agcccgtcag ggcgcgtcag cgggtgttgg 6840
cgggtgtcgg ggctggctta actatgcggc atcagagcag attgtactga gagtgcacca 6900
tatgcggtgt gaaataaccgc acagatgcgt aaggagaaaa taccgcatca ggaaattgta 6960
agcgttaata ttttgttaaa attcgcgtta aatttttgtt aaatcagctc attttttaac 7020
caataggccg aaatcggcaa aatcccttat aaatcaaaag aatagaccga gatagggttg 7080
agtgtgttcc cagtttggaa caagagtcca acgtggactc acctatcacc ctaatcaagt 7140
ggcgcaaaaa ccgtctatca gggcgatggc ccactacgtg aacctcacc cccccgattt 7200
tttttggggg cgaggtgccg taaagcacta aatcggaacc ctaaaaggag ccccgattt 7260
agagcttgac ggggaaagcc ggcgaaacgt gcgagaaagg aagggaagaa agcgaaagga 7320
gcggcgctta gggcgctggc aagtgtagcg gtcacgctgc gcgtaaccac cacaccgcc 7380
gcgcttaatg cgcgcttaca gggcgctcc cattcgccat ttagccagc tggcgaaagg gggatgtgct 7440
gaagggcgat cgggtcgggc ctcttcgcta ttacgccagc tggcgaaagg gggatgtgct 7500
gcaaggcgat taagtgggtt aacgccaggg ttttcccagt cacgacgttg taaaacgacg 7560
gccagtgaat tgtaatacga ctactatag ggcaatttaa ttcgggg 7607

```

<210> 42

<211> 11600

<212> DNA

<213> Artificial Sequence

<220>

<223> Plasmid MMTV-E2a-SV40-Neo

<400> 42

```

gaattccgca ttgcagagat attgtatttta agtgcctagc tcgatacaat aaacgccatt 60
tgaccattca ccacattggg gtgcacctcc aagcttgggc agaaatgggt gaactcccg 120
gagtgtccta cacctagggg agaagcagcc aaggggttgt ttcccaccaa ggacgaccgc 180
tctgcgcaca aacggatgag cccatcagac aaagacatat tcattctctg ctgcaaaactt 240
ggcatagctc tgctttgcct ggggctattg tagctcttct cggttcgtgc tcgcagggct 300
ctcacccctg actcttttaa tagctcttct gtgcaagatt acaatctaaa caattcggag 360
aactcgacct tcctcctgag gcaaggacca cagccaactt cctcttaca ggcgcacga 420
ttttgtcctt cagaaataga aataagaatg cttgtctaaa attatatttt taccaataag 480
accaatccaa taggtagatt attagttact atgtaaagaa atgaatcatt atcttttagt 540
actattttta ctcaaattca gaagttagaa atgggaatag aaaatagaaa gagacgctca 600
acctcaattg aagaacagggt gcaaggacta ttgaccacag gcctagaagt aaaaaaggga 660
aaaaagagtg tttttgtcaa aataggagac aggtggtggc aaccagggac ttatagggga 720
ccttacatct acagaccaac agatgcccc cttaccatata caggaagata tgacttaaat 780
tgggataggg ggggttacagt caatggctat aaagtgttat atagatccct cccttttctg 840
gaaagactcg ccagagctag acctccttgg tgtatgttgt ctcaagaaga aaagacgac 900
atgaaacaac aggtacatga ttatatttat cttagaacag gaatgcactt ttgggggaaag 960
attttccata ccaaggaggg gacagtggct ggactaatag aacattattc tgcaaaaact 1020
catggcatga gttattatga atagccttta ttggcccaac cttgcggttc ccagggttta 1080
agtaagtttt tggttacaaa ctgttcttaa aacgaggatg tgagacaagt ggtttcctga 1140
cttggttttg tatcaaagggt tctgatctga gctctgagtg ttctattttc ctatgttctt 1200
ttggaattta tccaaatctt atgtaaatgc ttatgtaaac caagatataa aagagtgtc 1260
attttttgag taaacttgca acagtcctaa cattcacctc ttgtgtgttt gtgtctgttc 1320
gccatcccg ctcgcgtcgt cacttatcct tcactttcca gagggtccc cgcagacc 1380
cggcgaccct caggtcggcc gactgcgcca gctggcgccc gaacaggga cctcgataa 1440
gtgacccttg tctctatttc tactatttgg tggttgtctt gtattgtctc tttcttgtct 1500
ggctatcatc acaagagcgg aacggactca ccatagggac caagctagcg cttctcgtcg 1560
cgtccaagac cctcaaagat ttttggcact tcgttgagcg aggcgatata aggtatgaca 1620
gcgccttgcc gcaaggccag ctgcttgtcc gctcggctgc ggttggcacg gcagatagg 1680
ggtatcttgc agttttggaa aaagatgtga taggtggcaa gcacctctgg cacggcaaat 1740
acggggtaga agttgaggcg cgggttgggc tcgcatgtgc cgttttcttg gcgtttgggg 1800

```

-12-

ggtaacgcgcg	gtgagaatag	gtggcggttcg	taggcaaggc	tgacatccgc	tatggcgagg	1860
ggcacatcgc	tgcgctcttg	caacgcgtcg	cagataatgg	cgcactggcg	ctgcagatgc	1920
ttcaacagca	cgtcgtctcc	cacatctagg	tagtcgccat	gcctttcgtc	ccccgcgcg	1980
acttgttcct	cgtttgctc	tgcgttgtcc	tggctcttgc	ttttatcctc	tggtgggtact	2040
gagcggtcct	cgtcgtcttc	gcttacaaaa	cctgggtcct	gctcgataat	cacttcctcc	2100
tcctcaagcg	ggggtgcctc	gacggggaag	gtggtaggcg	cgttggcggc	atcggtggag	2160
gcggtgggtg	cgaactcaga	gggggcgggt	aggctgtcct	tcttctcgac	tgactccatg	2220
atctttttct	gcctatagga	gaaggaaatg	gccagtcggg	aagaggagca	gcgcgaaacc	2280
acccccgagc	gcggacgcgg	tgcggcgcga	cgcccccaa	ccatggagga	cggtgcgtcc	2340
ccgtccccgt	cgccgcgcgc	tccccgggcg	cccccaaaaa	agcggtatgag	gcggcggtatc	2400
gagtcggagg	acgaggaaga	ctcatcacaa	gacgcgctgg	tgccgcgcac	accagccccg	2460
cggtccatcga	cctcggcgcc	ggatttggcc	attgcgccca	agaagaaaaa	gaagcgccct	2520
tctcccaagc	ccgagcgccc	gccatcacca	gaggtaatcg	tggaacagca	ggaagaaaga	2580
gaagatgtgg	cgctacaaat	ggtgggtttc	agcaaccac	cggtgctaata	caagcatggc	2640
aaaggaggta	agcgcacagt	gcggcggtcg	aatgaagacg	acccagtggc	gcgtgggtatg	2700
cggacgcaag	aggaagagga	agagcccagc	gaagcggaaa	gtgaaattac	ggtgatgaac	2760
ccgctgagtg	tgccgatcgt	gtctgcgtgg	gagaaggcca	tggaaggctgc	gcgcgcgctg	2820
atggacaagt	accacgtgga	taacgatcta	aaggcgaaact	tcaaactact	gcctgacca	2880
gtggaagctc	tgccggccgt	atgcaagacc	tggtgaacg	aggagcaccg	cggtgtgcag	2940
ctgaccttca	ccagcaacaa	gacctttgtg	acgatgatgg	ggcgattcct	gcaggcggtac	3000
ctgcagtcgt	ttgcagaggt	gacctacaag	catcacgagc	ccacgggctg	cgctgtgtgg	3060
ctgcaccgct	gcgtgagat	cgaaggcgag	cttaagtgtc	tacacggaag	cattatgata	3120
aataaggagc	acgtgattga	aatggatgtg	acgagcgaaa	acgggcagcg	cgcgctgaag	3180
gagcagctca	gcaaggccaa	gatcgtgaag	aaccgggtggg	gccgaaatgt	ggtgcagatc	3240
tccaacaccg	acgcaagggtg	ctgcgtgcac	gacgcggcct	gtccggccaa	tcagttttcc	3300
ggcaagtctt	gcggcatggt	cttctctgaa	ggcgcaaagg	ctcaggtggc	ttttaagcag	3360
atcaaggctt	ttatgcaggc	gctgtatcct	aacgcccaga	ccgggcacgg	tcaccttttg	3420
atgccactac	ggtgcgagtg	caactcaaag	cctgggcacg	cgcccttttt	gggaaggcag	3480
ctaccaaagt	tgactccgtt	cgccctgagc	aacgcggagg	acctggacgc	ggatctgatc	3540
tccgacaaga	gcgtgctggc	cagcgtgcac	caccggcgcc	tgatagtgtt	ccagtgtgc	3600
aacctgtgtg	atcgcaactc	gcgcgcgcag	ggcgagggcc	ccaactgcga	cttcaagata	3660
tcggcgcccc	acctgctaaa	cgcttgggtg	atggtgcgca	gcctgtggag	tgaaaacttc	3720
accgagctgc	cgcggtgggt	tgtgcctgag	tttaagtggg	gcactaaaca	ccagtatcgc	3780
aacgtgtccc	tgccagtggc	gcatagcgat	gcgcggcaga	acccctttga	tttttaaaccg	3840
gcgcagaccg	caagggtggg	ggtaaaataa	caccgagag	tgtacaaata	aaagcatttg	3900
cctttattga	aagtgtctct	agtacattat	ttttacatgt	ttttcaagt	acaaaaagaa	3960
gtggcgctcc	taatctgcgc	actgtggctg	cggaagtagg	gcgagtggcg	ctccagggaag	4020
ctgtagagct	gttccctggt	gcgacgcagg	gtgggctgta	cctggggact	gttgagcatg	4080
gagttgggta	ccccggtaat	aaggttcacg	gtggggttgt	gatccatggg	agtttggggc	4140
cagttggcaa	aggcgtggag	aaacatgcag	cagaatagtc	cacaggcggc	cgagttgggc	4200
ccctgtacgc	tttgggtgga	cctttccagc	gttatacagc	ggtcggggga	agaagcaatg	4260
gcgctacggc	gcaggagtga	ctcgtactca	aactggtaaa	cctgcttgag	tcgctggtca	4320
gaaaagccaa	agggtctaaa	gaggtagcat	gtttttgagt	gcgggttcca	ggcaaaggcc	4380
atccagtgtg	cgccccagtg	ctcgcgacgc	gccgtattga	ctatggcgca	ggcgagcttg	4440
tgtggagaaa	caaagcctgg	aaagcgcttg	tcatagggtg	ccaaaaaata	tggtccacaa	4500
ccaagatctt	tgacaatggc	tttcagttcc	tgctcactgg	agcccatggc	ggcagctgtt	4560
gttgatgttg	cttgcttctt	tatgttgtgg	cgttgccggc	cgagaagggc	gtgcgcagggt	4620
acacggtttc	gatgacgcgc	cgggtgcggcc	ggtgcacacg	gaccacgtca	aagacttcaa	4680
acaaaacata	aagaagggtg	ggctcgtcca	tggtatccat	atatagggcc	cgggttataa	4740
ttacctcagg	tcgacctoga	gggatccttg	tgaaggaacc	ttacttctgt	ggtgtgacat	4800
aattggacaa	actacctaca	gagatttaaa	gctctaagggt	aaatataaaa	tttttaagt	4860
tataatgtgt	taaactactg	attctaattg	tttgtgtatt	ttagattcca	acctatggaa	4920
ctgatgaatg	ggagcagtg	tggaaatgcct	ttaatgagga	aaacctgttt	tgctcagaag	4980
aaatgccatc	tagtgatgat	gaggctactg	ctgactctca	acattctact	cctccaaaaa	5040
agaagagaaa	ggtagaagac	cccaaggact	ttccttcaga	attgctaagt	tttttgagtc	5100
atgctgtgtt	tagtaataga	actcttgctt	gctttgctat	ttacaccaca	aaggaaaaag	5160
ctgcactgct	atacaagaaa	attatggaaa	aatattctgt	aacctttata	agtaggcata	5220
acagttataa	tcataacata	ctgttttttc	ttactccaca	caggcataga	gtgtctgcta	5280
ttaataacta	tgctcaaaaa	ttgtgtacct	ttagcttttt	aatttgtaaa	gggggttaata	5340
aggaatattt	gatgtatagt	gccttgacta	gagatcataa	tcagccatac	cacatttgta	5400
gaggtttttac	ttgcttttaa	aaacctccca	cacctccccc	tgaacctgaa	acataaaatg	5460

-13-

aatgcaattg	ttgttggttaa	cttgttttatt	gcagcttata	atgggttacaa	ataaagcaat	5520
agcatcacaa	atttcacaaa	ttaaagcattt	ttttcactgc	attctagtgtg	tggtttgtcc	5580
aaactcatca	atgtatctta	tcattgtctgg	atccggctgt	ggaatgtgtg	tcagttaggg	5640
tgtggaaagt	ccccaggctc	cccagcaggc	agaagtatgc	aaagcatgca	tctcaattag	5700
tcagcaacca	gggtgtggaaa	gtccccaggc	tccccagcag	gcagaagtat	gcaaagcatg	5760
catctcaatt	agtcagcaac	catagtcccg	cccctaactc	cgcccatccc	gcccctaact	5820
ccgcccagtt	ccgcccattc	tccgccccat	ggctgactaa	ttttttttat	ttatgcagag	5880
gccgaggccg	cctcggcctc	tgagctattc	cagaagtatg	gaggaggcctt	ttttggaggc	5940
ctaggctttt	gcaaaaagct	tcacgctgcc	gcaagcactc	agggcgcaag	ggctgctaaa	6000
ggaagcggaa	cacgtagaaa	gccagtccgc	agaaacgggtg	ctgacccccg	atgaatgtca	6060
gctactgggc	tatctggaca	agggaaaacg	caagcgcaaa	gagaaagcag	gtagcttgca	6120
gtgggcttac	atggcgatag	ctagactggg	cgggttttatg	gacagcaagc	gaaccggaat	6180
tgccagctgg	ggcgccctct	ggtaagggtt	ggaagccctg	caaagtaaac	tggatggcctt	6240
tcttgccgcc	aaggatctga	tggcgagggg	gatcaagatc	tgatcaagag	acaggatgag	6300
gatcggttctg	catgattgaa	caagatggat	tgacgcagag	ttctccggcc	gcttgggtgg	6360
agaggctatt	cggctatgac	tgggcacaac	agacaaatcgg	ctgctctgat	gccgccgtgt	6420
tccggctgtc	agcgcagggg	cgccccggtc	tttttgtcaa	gaccgacctg	tccggtgcc	6480
tgaatgaact	gcaggacgag	gcagcgcggc	tatcgtggct	ggccacgacg	ggcgttcctt	6540
gcgcagctgt	gctcgacgtt	gtcactgaag	cggaagggga	ctggctgcta	ttgggcgaag	6600
tgccggggca	ggatctcctg	tcattctcacc	ttgctcctgc	cgagaaagta	tccatcatgg	6660
ctgatgcaat	gcggcggtgtg	catacgcttg	atccggctac	ctgccccattc	gaccaccaag	6720
cgaacatctg	catcgagcga	gcacgtactc	ggatgggaagc	cggtcttgct	gatcaggatg	6780
atctggacga	agagcatcag	gggtcgcgc	cagccgaact	gttcgccagg	ctcaaggcgc	6840
gcatgcccga	cggcgaggat	ctcgtcgtga	cccatggcga	tgcctgcttg	ccgaatatca	6900
tggtggaaaa	tggccgcttt	tctggattca	tcgactgtgg	ccggctgggt	gtggcggacc	6960
gctatcagga	catagcgttg	gctaccctgt	atattgtcga	agagcttggc	ggcgaatggg	7020
ctgaccgctt	cctcgtgctt	tacggtatcg	ccgctcccg	ttcgcagcgc	atcgcttct	7080
atcgcttct	tgacgagttc	ttctgagcgg	gactctgggg	ttcgaaatga	ccgaccaagc	7140
gacgcccac	ctgccatcac	gagatttctga	ttccaccgcc	gccttctatg	aaaggttggg	7200
cttcggaatc	gttttccggg	acgccggctg	gatgatcttc	cagcgcgggg	atctcatgct	7260
ggagtctctc	gcccaccccg	ggctcgatcc	cctcgcgagt	tgggtcagct	gctgcctgag	7320
gctggacgac	ctcgcggagt	tctaccggca	gtgcaaatcc	gtcggcatcc	aggaaaccag	7380
cagcggctat	ccgcgcaccc	atgccccga	actgcaggag	tggggaggca	cgatggccgc	7440
tttgggtccg	gatctttgtg	aaggaaacct	acttctgtgg	tgtgacataa	ttggacaaac	7500
tacctacaga	gatttaaagc	tctaaggtaa	atataaaatt	tttaagtgt	taatgtgtta	7560
aactactgat	tctaattggt	tgtgtatttt	agattccaac	ctatggaact	gatgaatggg	7620
agcagtgggtg	gaatgccttt	aatgaggaaa	acctgttttg	ctcagaagaa	atgccatcta	7680
gtgatgatga	ggctactgct	gactctcaac	attctactcc	tccaaaaaag	aagagaaagg	7740
tagaagaccc	caaggacttt	ccttcagaat	tgctaagttt	tttgagtcat	gctgtgttta	7800
gtaatagaac	tcttgcttgc	tttgctattt	acaccacaaa	ggaaaaagct	gcactgctat	7860
acaagaaaa	tatggaaaaa	tattctgtaa	cctttataag	taggcataac	agttataatc	7920
ataacatact	gttttttctt	actccacaca	ggcatagagt	gtctgctatt	aataactatg	7980
ctcaaaaatt	gtgtaccttt	agctttttta	tttgtaaagg	ggtaataaag	gaatatttga	8040
tgtatagtgc	cttgactaga	gatcataatc	agccatacca	catttgtaga	ggttttactt	8100
gctttaaaaa	acctcccaca	cctccccctg	aacctgaaac	ataaaatgaa	tgcaattggt	8160
gttggttaact	tgttttattgc	agcttataat	ggttacaaat	aaagcaatag	catcacaaat	8220
ttcacaaata	aagcattttt	ttcactgcat	tctagtgtgtg	gtttgtccaa	actcatcaat	8280
gtatcttatac	atgtctggat	ccccaggaag	ctcctctgtg	tcctcataaa	ccctaaccctc	8340
ctctacttga	gaggacattc	caatcatagg	ctgcccattc	acctctgtg	tcctcctggt	8400
aattagggtca	cttaacaaaa	aggaaattgg	gtagggtttt	ttcacagacc	gctttctaa	8460
ggtaattttta	aaatatctgg	gaagtccctt	ccactgctgt	gttcagaaag	tgttggtaaa	8520
cagcccacaa	atgtcaacag	cagaaacata	caagctgtca	gctttgcaca	agggcccaac	8580
accctgctca	tcaagaagca	ctgtgggttg	tgtgttagta	atgtgcaaaa	caggaggcac	8640
attttcccca	cctgtgtagg	ttccaaaata	cttagtgttt	tcattttttac	ttggatcagg	8700
aaccagcac	tccactggat	aagcattatc	cttatccaaa	acagccttgt	ggtcagtgtt	8760
catctgctga	ctgtcaactg	tagcattttt	tgggggttaca	gtttgagcag	gatatttggg	8820
cctgtagttt	gctaacacac	cctgcagctc	caaaggttcc	ccaccaacag	caaaaaaatg	8880
aaaatttgag	ccttgaatgg	gttttccag	accattttca	tgagtttttt	gtgtccctga	8940
atgcaagtgt	aacatagcag	ttaccccaat	aacctcagtt	ttaacagtaa	cagcttccca	9000
catcaaaaata	tttccacagg	ttaagtcctc	atttaaatta	ggcaaaggaa	ttcttgaaga	9060
cgaaagggcc	tcgtgatacg	cctattttta	taggttaattg	tcatgataat	aatggtttct	9120

-14-

tagacgtcag	gtggcacttt	tcggggaaat	gtgcgcggaa	cccctatttg	tttatttttc	9180
taaatacatt	caaatatgta	tccgctcatg	agacaataac	cctgataaat	gcttcaataa	9240
tattgaaaaa	ggaagagtat	gagtattcaa	catttcctgt	tcgcccttat	tccctttttt	9300
gcggcatttt	gccttcctgt	ttttgctcac	ccagaaacgc	tggtgaaagt	aaaagatgct	9360
gaagatcagt	tggtgacacg	agtgggttac	atcgaactgg	atctcaacag	cggtaaagatc	9420
cttgagagtt	ttcgccccga	agaacgtttt	ccaatgatga	gcacttttaa	agttctgcta	9480
tgtggcgagg	tattatcccc	tggtgacgcc	gggcaagagc	aactcggctg	ccgcatacac	9540
tattctcaga	atgacttggt	tgagtactca	ccagtcacag	aaaagcatct	tacggatggc	9600
atgacagtaa	gagaattatg	cagtgcctgcc	ataaccatga	gtgataaacac	tgcgggccaac	9660
ttactttctga	caacgatcgg	aggaccgaag	gagctaaccg	cttttttgca	caacatgggg	9720
gatcatgtaa	ctcgccctga	tcgttgggaa	ccggagctga	atgaagccat	accaaacgac	9780
gagcgtgaca	ccacgatgcc	tgacgaatg	gcaacaacgt	tgcgcaaaact	attaactggc	9840
gaactactta	ctctagcttc	ccggcaacaa	ttaatagact	ggatggaggc	ggataaagtt	9900
gcaggaccac	ttctgcgctc	ggcccttcgg	gctggctggg	ttattgctga	taaactctgga	9960
gccggtgagc	gtgggtctcg	cggtatcatt	gcagcactgg	ggccagatgg	taagccctcc	10020
cgtatcgtag	ttatctacac	gacggggagt	caggcaacta	tggtgaaacg	aaatagacag	10080
atcgctgaga	taggtgcctc	actgattaag	cattggtaac	tgtcagacca	agtttactca	10140
tatatacttt	agattgattt	aaaacttcat	ttttaattta	aaaggatcta	ggtgaagatc	10200
ctttttgata	atctcatgac	caaaatccct	taacgtgagt	tttcggtcca	ctgagcgtca	10260
gaccccgtag	aaaagatcaa	aggatcttct	tgagatcctt	tttttctgcg	cgtaatctgc	10320
tgcttgcaaa	caaaaaaacc	accgctacca	gcggtgggtt	gtttgcccga	tcaagagcta	10380
ccaactcttt	ttccgaaggt	aactggcttc	agcagagcgc	agataccaaa	tactgtcctt	10440
ctagtgtagc	cgtagttagg	ccaccacttc	aagaactctg	tagcaccgcc	tacatacctc	10500
gctctgctaa	tcctgttacc	agtggctgct	ggcagtggcg	ataagtcgtg	tcttaccggg	10560
ttggactcaa	gacgatagtt	accggataag	gcgcagcggg	cggtctgaac	gggggggttcg	10620
tgacacacagc	ccagcttgga	gcgaacgacc	tacaccgaac	tgagatacct	acagcgtgag	10680
ctatgagaaa	gcgccacgct	tcccgaaggg	agaaaggcgg	acaggatatcc	ggtaagcggc	10740
aggggtcgaa	caggagagcg	cacgagggag	cttccagggg	gaaacgcctg	gtatctttat	10800
agtcctgtcg	ggtttcgcca	cctctgactt	gagcgtcgat	ttttgtgatg	ctcgtcaggg	10860
ggggcgagcc	tatggaaaaa	cgccagcaac	gcggcctttt	tacggttcct	ggccttttgc	10920
tggtcctttt	ctcacatggt	ctttcctgcg	ttatcccctg	attctgtgga	taaccgtatt	10980
accgcctttg	agtgaactga	taccgctcgc	cgacccgaa	cgaccgagcg	cagcgagtca	11040
gtgacgaggg	aagcggaaga	gcgcctgatg	cggtattttc	tccttacgca	tctgtgcggg	11100
atttcacacc	gcataatggt	cactctcagt	acaatctgct	ctgatgccgc	atagttaagc	11160
cagtatctgc	tccctgcttg	tgtgttggag	gtcgtgagt	agtgcgcgag	caaaatttaa	11220
gctacaacaa	ggcaaggctt	gaccgacaa	tgcatgaaga	atctgcttag	ggttaggcgt	11280
tttgcgctgc	ttcgcgatgt	acgggccaaga	tatacgcgta	tctgagggga	ctaggggtgtg	11340
tttagggtaa	aagcgggggt	tcgggtgtac	gcgggttagga	gtcccctcag	gatatagtag	11400
tttcgctttt	gcataaggag	ggggaaatgt	agtcttatgc	aatacacttg	tagtcttgca	11460
acatggtaac	gatgagttag	caacatgcct	tacaaggaga	gaaaaagcac	cgtgcatgcc	11520
gattgggtgga	agtaagggtg	tacgatcgtg	ccttattagg	aaggcaacag	acgggtctga	11580
catggattgg	acgaaccact					11600

<210> 43
 <211> 35211
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Plasmid Av1nBg

<400> 43						
catcatcaat	aatatacctt	atthttggatt	gaagccaata	tgataatgag	gggggtggagt	60
ttgtgacgtg	gcgcggggcg	tgggaacggg	gcgggtgacg	tagtagtgtg	gcggaagtgt	120
gatgttgcaa	gtgtggcgga	acacatgtaa	gcgacggatg	tgccaaaagt	gacgtttttg	180
gtgtgcgcg	gtgtacacag	gaagtacaaa	ttttcgcgcg	gttttagggc	gatgttgtag	240
taaattttgg	cgtaaccgag	taagatttgg	ccattttcgc	gggaaaactg	aataagagga	300
agtgaatct	gaataatttt	gtgttactca	tagcgcgtaa	tatttgtcta	gggccgcggg	360
gactttgacc	gtttacgtgg	agactcgccc	aggtgttttt	ctcaggtgtt	ttccgcgttc	420
cgggtcaaag	ttggcggttt	attattatag	tcagtacgta	ccagtgcact	ggcctaggaa	480
gcttggtacc	ggtgaattcg	ctagcgttcg	cgccccgatg	tacggggccag	atatacgcgt	540

atctgagggg actaggggtgt gtttagggcga aaagcggggc ttcgggtgta cgcgggttagg 600
agtccccctca ggatatagta gtttcgcttt tgcataggga gggggaaatg tagtcttatg 660
caatactctt gtagtcttgc aacatggtaa cgatgagtta gcaacatgcc ttacaaggag 720
agaaaaagca ccgtgcatgc cgattgggtg aagtaagggtg gtacgatcgt gccttattag 780
gaaggcaaca gacgggtctg acatggattg gacgaaccac tgaattccgc attgcagaga 840
tattgtatctt aagtgcctag ctcgatacaa taaacgccat ttgaccattc accacattgg 900
tgtgcacctc cggccctggc cactctcttc cgcacgcgtg tctgcggggg ccagctgttg 960
ggctcgcggg tgaggacaaa ctcttcggcg tctttccagt actcttggat cggaaacccg 1020
tcggctcccg aacggtaact cgcgcgcgag ggacctgagc gagtccgcat cgaccggatc 1080
ggaaaacctc tcgagaaagg cgtgtaacca gtcacagtcg ctctagaact agtggatccc 1140
ccgggctgca ggaattcgat ctatagggat aaaggtccaa aaaagaagag aaaggtagaa 1200
gaccccaagg actttccttc agaattgcta aaaccctggc gttaccaaac ttaatcgctt ggcgctcgtt 1260
ttacaacgtc gtgactggga taatagcgaa gaggcccgca ccgatcgccc ttcccaacag 1380
ccccctttcg ccagctggcg atggcgcttt gcctgggttc cggcaccaga agcgggtgccg 1440
ttgcgagcgc tgaatggcga tcttcctgag gccgatactg tcgtcgtccc ctcaaactgg 1500
gaaagctggc gttacgatgc gccatctac accaactgaa cctatcccat tacgggtcaat 1560
cagatgcacg ttcccacgga gaatccgacg ccagacgcga ggttggtact cgctcacatt taatgttgat 1620
ccgcccgtttg tacaggaagg ctgggtcggg tacggccagg acagtcggtt gccgtctgaa 1740
gaaagctggc gcaacggggc acgcgcggga gataatgtgg gatgagcgg ggtgctgcgt 1800
catctgtggg gcgcatcttt ggaagatcag accgactaca ccaatcagcg atttccatgt tgccactcgc 1920
tttgacctga tttcagccg agtcttctta tggcagggtg aaacgcaggt ttcagatgtg cggcgagttg 1980
cgtgactacc tacgggtaac aattatcgat gagcgtgggt gttatgccga cgccagcgcc 2040
accgcgcttc tcggcggtga cccgaaactg tggagcgccg aaatcccga tctctatcgt 2160
ctacgtctga aactgcacac cgccgacggc acgctgattg aagcagaagc ctgcatgtc 2220
gcggtgggtg aggtgcggat tgaaaatggg ctgctgctgc tgaacggcaa gccgttgctg 2280
gggtttccgcg ttaacgtca cagcatcat gctgatgaag ctgtgcgacc gctacggcct 2340
attcgaggcg aggatgtgc accatccgct gtggtacacg ccacggcatg atcgtctgac 2400
acgatgggtc accatccgct atattgaaac cgaacgcgta acgcgaatgg tgcagcgca 2460
gatgaagcca cggtggctac cggcgatgag gctctgggtc gaatcaggcc acggcgctaa 2520
cgctggctac cggccaccga ctgtgcccga atacgcccac cgtttacagg gctggtcggc 2580
cccttcccgg tctttgcca agcgctttcg atatgatgaa aacggcaacc cgtggtcggc 2640
cgcccgctga agcgctttcg cgctgattaa atacgccgaa cgatcgccag ttctgtatga 2700
aaatactggc agcgctttcg cgctgattaa atacgccgaa cgatcgccag ttctgtatga 2760
gtggatcagt cgctgattaa atacgccgaa cgatcgccag ttctgtatga 2820
gattttggcg atacgccgaa cgatcgccag ttctgtatga 2880
cgcacggcgc aaacatcga agtatccga gctggatggg cactcgcact 2940
ttatccgggc aaacatcga agtatccga gctggatggg cactcgcact 3000
ctcctgcact ggaatgggtgg cacaaggtaa acagtgtgatt agtgcctctg 3060
gatgtcgctc cacaaggtaa acagtgtgatt agtgcctctg 3120
gccgggcaac tctggctcac agtacgcgta agtacgcgta 3180
gccgggcaca tcagcgctg gcagcagtgg agtacgcgta 3240
cccgcgcgt ccacgcccag cccgcatctg gcagcagtgg 3300
ctgggtaata agcgttggca atttaaccgc cccgcatctg 3360
ggcgataaaa aacaactgct gacgcccgtg cccgcatctg 3420
aacgacattg gcgtaagtga agcgaccgc cccgcatctg 3480
aaggcgcgcg gccattacca gaccgctcac gattgatggg 3540
gctgatcgcg tgcgtattac gattgatggg gcatccggcg 3600
atcagccgga aaacctaccg gctcggtatg cttgtgacctg 3660
gaagtggcga gggtaaaact gctcggtatg cttgtgacctg 3720
gtagcagagc gttttgacctg gctcggtatg cttgtgacctg 3780
actgcccgtc aaaacgggtc gctcggtatg cttgtgacctg 3840
ttcccgagcg acttccagtt caacatcagc cgcggaagaa 3900
tggcgcgcg agccatcgcc atctgctgca cgcggaagaa 3960
agccatcgcc atctgctgca cgcggaagaa 4020
agccatcgcc atctgctgca cgcggaagaa 4080
agccatcgcc atctgctgca cgcggaagaa 4140
agccatcgcc atctgctgca cgcggaagaa 4200

-16-

atgggggattg	gtggcgacga	ctcctggagc	cgtcagtat	cgccggaatt	tcagctgagc	4260
gccggtcgct	accattacca	gttgggtctgg	tgtcaaaaat	aataatctcg	aatcaagctt	4320
atcgataccg	togaaacttg	tttattgcag	cttataatgg	ttacaaataa	agcaatagca	4380
tcacaaat	cacaaataaa	gcattttttt	cactgcattc	tagttgtggg	ttgtccaaac	4440
tcataaatgt	atcttatcat	gtctggatcc	gacctcggt	ctggaaggtg	ctgaggtacg	4500
atgagacccg	caccaggtgc	agaccctgcg	agtgtggcgg	tacacatatt	aggaaccagc	4560
ctgtgatgct	ggatgtgacc	gaggagctga	ggcccgatca	cttgggtgctg	gcctgcaccc	4620
gcgctgagtt	tggctctagc	gatgaagata	cagattgagg	tactgaaatg	tggtggcgctg	4680
gcttaagggg	gggaaagaat	atataagggtg	gggggtcttat	gtagttttgt	atctgttttg	4740
cagcagccgc	cgccgccatg	agcaccaact	cgtttgatgg	aagcattgtg	agctcatatt	4800
tgacaacgcg	catgccccca	tgggcccgggg	tgcgtcagaa	tgtgatgggc	tccagcattg	4860
atgggtcgccc	cgtcctgccc	gcaaaactcta	ctaccttgac	ctacgagacc	gtgtctggaa	4920
cgccgttgga	gactgcagcc	tccgcccgcg	cttcagccgc	tgacagccacc	gcccgcggga	4980
ttgtgactga	ctttgctttc	ctgagcccg	ttgcaagcag	tgacgcttcc	cgttcatccg	5040
cccgcgatga	caagttgacg	gctcttttgg	cacaattgga	ttctttgacc	cggaactta	5100
atgtcgtttc	tcagcagctg	ttggatctgc	gccagcaggt	ttctgccctg	aaggcttcct	5160
cccctcccaa	tgcggtttaa	aacataaata	aaaaaccaga	ctctgtttgg	atttggatca	5220
agcaagtgtc	ttgtctctt	tatttagggg	ttttcgcg	gcggtaggcc	cggaaccagc	5280
ggctcgcgtc	gttgaggggc	ctgtgtattt	tttccaggac	gtggtaaagg	tgactctgga	5340
tgttcagata	catgggcata	agcccgctct	tggggtggag	gtagcaccac	tgacagactt	5400
catgctgcgg	gggtggtgtg	tagatgatcc	agtcgtagca	ggagcgctgg	gcgtggtgcc	5460
taaaaatgtc	tttcagtagc	aagctgattg	ccaggggcag	gcccttgggtg	taagtgttta	5520
caaagcgggt	aagctgggat	gggtgcatac	gtggggatat	gagatgcac	ttggactgta	5580
tttttaggtt	ggctatgttc	ccagccatat	ccctccgggg	attcatgttg	tgagaacca	5640
ccagcacagt	gtatccgggtg	cacttgggaa	atttgtcatg	tagcttagaa	ggaaatgctg	5700
ggaagaactt	ggagacgccc	ttgtgacctc	caagattttc	catgcattcg	tccataatga	5760
tggcaatggg	cccacggggc	gcggcctggg	cgaagatatt	tctgggatca	ctaactgcat	5820
agttgtgttc	aggatgagat	cgctcataggc	cattttttaca	aagcgcgggc	ggaggggtgcc	5880
agactgcggg	ataatggttc	catccggccc	aggggcgtag	ttaccctcac	agatttgcac	5940
ttcccacgct	ttgagttcag	atggggggat	catgtctacc	tgccggggcga	tgaagaaaac	6000
ggtttccggg	gtagggggaga	tcagctggga	agaaagcagg	ttcctgagca	gctgcgactt	6060
accgcagccg	gtgggcccgt	aaatcacacc	tattaccggg	tgcaactggg	agttaagaga	6120
gctgcagctg	ccgtcatccc	tgagcagggg	ggccacttcg	tttagcatgt	ccctgactcg	6180
catgttttcc	ctgaccaa	ccgccagaag	gcgctcgccg	cccagcgata	gcagttcttg	6240
caaggaagca	aagtttttca	acgggtttgag	accgtccgcc	gtaggcatgc	ttttgagcgt	6300
ttgaccaagc	agttccaggg	gggtcccacag	ctcggtcacc	tgctctacgg	catctcgatc	6360
cagcatatct	cctcgtttcg	cggggttgggg	cggtcttcgc	tgtacggcag	tagtcggtgc	6420
tcgtccagac	gggcccagggt	catgtctttc	cacgggcgca	gggtcctcgt	cagcgtagtc	6480
tgggtcacgg	tgaaggggtg	cgctccgggc	tcgcgcgtgg	ccagggtgcg	cttgaggctg	6540
gtcctgctgg	tgctgaagcg	ctgcccgtct	tgcgcctgcg	cgctcgccag	gtagcatttg	6600
accatggtgt	catagtccag	cccctccgcg	gcgtggccct	tggcgcgcag	cttgcccttg	6660
gaggaggcgc	cgcacgaggg	gcagtgcaga	cttttgaggg	cgtagagctt	gggcgcgaga	6720
aataccgatt	ccggggagta	ggcatccgcg	ccgcaggccc	cgcagacggt	ctcgcatctc	6780
acgagccagg	tgagctctgg	ccgttcgggg	tcaaaaacca	ggtttcccc	atgctttttg	6840
atgcgtttct	tacctctggt	ttccatgagc	cggtgtccac	gctcggtgac	gaaaaggctg	6900
tcggtgtccc	cgtatacaga	cttgagaggc	ctgtcctcga	gcggtgttcc	gcggtcctcc	6960
tcgtatagaa	actcggacca	ctctgagaca	aaggctcgcg	tccaggccag	cacgaaggag	7020
gctaagtggg	aggggtagcg	gtcgttgtcc	actagggggg	ccactcgctc	cagggtgtga	7080
agacacatgt	cgccctcttc	ggcatcaagg	aaggtgattg	gtttgtaggt	gtaggccacg	7140
tgaccgggtg	ttcctgaagg	ggggctataa	aggggggtgg	gggcgcgttc	gtcctcactc	7200
tcttcgcgat	cgctgtctgc	gagggccagc	tgttgggggtg	agtactccct	ctgaaaagcg	7260
ggcatgactt	ctgcgctaag	attgtcagtt	tccaaaaacg	aggaggattt	gatattcacc	7320
tggcccgcgg	tgatgccttt	gaggggtggc	gcataccatct	ggtcagaaaa	gacaatcttt	7380
ttgttgtcaa	gcttgggtggc	aaacgaccgc	tagagggcgt	tggaacgcaa	cttggcgatg	7440
gagcgcaggg	tttgggtttt	gtcgcgatcg	gcgcgctcct	tggccgcgat	gtttagctgc	7500
acgtattcgc	gcgcaacgca	ccgccattcg	ggaaagacgg	tgggtgcgctc	gtcgggaccc	7560
aggtgcacgc	gccaaaccgcg	gttgtgcagg	gtgacaagggt	caacgcgtgtg	ggctacctct	7620
ccgcgtaggg	gctcgttggt	ccagcagagg	cggccgcctc	tgcgcgagca	gaatggcggt	7680
aggggggtcta	gctcgcgtctc	gtccggggggg	tctcgcgtcca	cggtaaagac	cccgggcagc	7740
aggcgcgcgt	cgaagtagtc	tatcttgcac	ccttgcaagt	ctagcgcctg	ctgccatgcg	7800
cgggcggcaa	gcgcgcgctc	gtatgggttg	agtgggggac	cccatggcat	gggggtgggtg	7860

-17-

agcgcggagg	cgtacatgcc	gcaaagtgtcg	taaacgtaga	ggggctctct	gagtattcca	7920
agatatgtag	ggtagcatct	tccaccgcgg	atgctggcgc	gcacgtaatc	gtatagttcg	7980
tgcgagggag	cgaggaggtc	gggaccgagg	ttgctacggg	cgggctgctc	tgctcggaag	8040
actatctgcc	tgaagatggc	atgtgagttg	gatgatatgg	ttggacgctg	gaagacgttg	8100
aagctggcgt	ctgtgagacc	taccgcgtca	cgcacgaagg	aggcgttaga	gtcgcgcagc	8160
ttgttgacca	gctcggcggg	gacctgcacg	tctagggcgc	agtagtccag	ggtttccttg	8220
atgatgtcat	acttatcctg	tccctttttt	ttccacagct	cgcgggtgag	gacaaaactct	8280
tcgcgggtctt	tccagtactc	ttggatcgga	aaccgcgcgg	cctccgaacg	gtaagagcct	8340
agcatgtaga	actggttgac	ggcctggtag	gcgcagcatc	ccttttctac	gggtagcgcg	8400
tatgcctgcg	cggccttccg	gagcgaggtg	tggtgagcgc	caaagggtgc	cctgaccatg	8460
actttgaggt	actggtatth	gaagtacgtg	tcgtcgcac	cgcctgtctc	ccagagcaaa	8520
aagtcctgtc	gctttttgga	acgcggattt	ggcagggcga	agggtgacatc	gttgaagatg	8580
atctttcccg	cgcgagggat	aaagtgtcgt	gtgatgcgga	agggtcccgc	cacctcgga	8640
cggttggttaa	ttacctgggc	ggcgagcacg	atctcgtcaa	agcgttgat	gttgtggccc	8700
acaatgtaaa	gttccaagaa	gcgcgggatg	cccttgatgg	aaggcaatth	tttaagttcc	8760
tcgtaggtga	gctcttcagg	ggagctgagc	ccgtgtctctg	aaagggccca	gtctgcaaga	8820
tgaggggttg	aagcgacgaa	tgagctccac	aggctcacgg	ccattagcat	ttgcagggtg	8880
tcgcgaaaagg	tcctaaactg	gcgacctatg	gcatcttttt	ctgggggtgat	gcagtagaag	8940
gtaagcgggt	cttgttccca	gcgggtcccat	ccaaggttcg	cggctaggtc	tcgcgcggca	9000
gtcactagag	gctcatctcc	gccgaacttc	atgaccagca	tgaagggcac	gagctgcttc	9060
ccaaaggccc	ccatccaagt	ataggtctct	acatcgtagg	tgacaaagag	acgctcgggtg	9120
cgaggatgcg	agccgatcgg	gaagaactgg	atctcccgc	accaattgga	ggagtggcta	9180
ttgatgtggt	gaaagtagaa	gtccctgcga	cgggcccgaac	actcgtgctg	gcttttgtaa	9240
aaacgtgctc	agtactggca	gcgggtgcacg	ggctgtacat	cctgcacgag	gttgacctga	9300
cgaccgcgca	caaggaagca	gagtggaat	ttgagcccct	cgcctggcgg	gtttggctgg	9360
tggtcttcta	cttcggctgc	ttgtccttga	ccgtctggct	gctcgagggg	agttacgggtg	9420
gatcggaacca	ccacgcgcgg	cgagcccaaa	gtccagatgt	ccgcgcgcgg	cggtcggagc	9480
ttgatgacaa	catcgcgag	atgggagctg	tccatggtct	ggagctccc	cggtcgcagg	9540
tcaggcggga	gctcctgcag	gtttacctcg	catagacggg	tcagggcgcg	ggctagatcc	9600
aggtgatacc	taatttccag	gggctgggtg	gtggcggcgt	cgatggcttg	caagaggccg	9660
catccccgcg	gcgcgactac	ggtaccgcgc	ggcgggcggg	gggcccgcgg	gggtccttg	9720
gatgatgcat	ctaaaagcgg	tgacgcgggc	gagccccggg	aggtaggggg	ggctccggac	9780
ccgcggggag	agggggcagg	ggcacgtcgg	cgcgcgcgc	gggcaggagc	tggtgctgcg	9840
cgcgtagggt	gctggcgaa	gcgacgacgc	ggcggttgat	ctcctgaatc	tggcgcctct	9900
gcgtgaagac	gacgggccc	gtgagcttga	gcctgaaaga	gagttcgaca	gaatcaattt	9960
cggtgtcggt	gacggcggcc	tggcgcaaaa	tctcctgcac	gtctcctgag	ttgtcttgat	10020
aggcgatctc	ggccatgaac	tgctcgatct	cttctcctg	gagatctccg	cgctccggctc	10080
gctccacggg	ggcggcgagg	tcgttgga	tgccggccat	gagctgcgag	aaggcggtga	10140
ggcctccctc	gttccagacg	cggctgtaga	ccacgcccc	ttcggcatcg	cgggcgcgca	10200
tgaccacctg	cgcgagattg	agctccacgt	gcggggcgaa	gacggcgtag	tttcgcaggc	10260
gctgaaagag	gtagttgagg	gtgggtggcgg	tgtgttctgc	cacgaagaag	tacataaccc	10320
agcgtcgcaa	cgtggattcg	ttgatatacc	ccaaggcctc	aaggcgctcc	atggcctcgt	10380
agaagtccac	ggcgaagtgg	aaaaactggg	agttgcgcgc	cgacacgggt	aactcctcct	10440
ccagaagacg	gatgagctcg	gcgacagtgt	cgcgcacctc	gcgctcaaag	gctacagggg	10500
cctcttcttc	ttcttcaatc	tcctcttcca	taagggcctc	cccttctctc	tcctctggcg	10560
gcgggtggggg	agggggggaca	cggcggcgac	gacggcgcac	cgggaggcgg	tcgacaaagc	10620
gctcgatcat	ctccccgcgg	cgacggcgca	tggtctcggt	gacggcgcg	ccgttctcgc	10680
ggggggcgag	ttggaagacg	ccgcccgtca	tgtcccgggt	atgggttggc	ggggggctgc	10740
catgcggcag	ggatacggcg	ctaacgatgc	atctcaacaa	ttgttggtga	ggtagctccg	10800
cgccgagggg	cctgagcgag	tccgcatcga	ccggatcgga	aaacctctcg	agaaaggcgt	10860
ctaaccagtc	acagtcgcaa	ggtaggctga	gcaccgtggc	gggcggcagc	gggcggcggt	10920
cgggggttggt	tctggcggag	gtgctgctga	tgatgtaatt	aaagtaggcg	gtcttgagac	10980
ggcggatggg	cgacagaagc	accatgtcct	tggttcgggc	ctgctgaatg	cgcaggcggt	11040
cggccatgcc	ccaggcttcg	ttttgacatc	ggcgcaggtc	tttgtagtag	tccttgatga	11100
gcctttctac	cggcacttct	tcttctcctt	cctcttgctc	tgcatctctt	gcacttatcg	11160
ctgcggcggc	ggcggagttt	ggcggtaggt	ggcgccctct	tcctcccatg	cgtgtgaccc	11220
cgaagcccct	catcggtga	agcagggcta	agtcggcgac	aacgcgctcg	gctaataatg	11280
cctgctgcac	ctgcgtgagg	gtagactgga	agtcctcat	gtccacaaag	cgggtggatg	11340
cgcgcgtggt	gatgggtgaa	gtgcagttgg	ccataacgga	ccagttaacg	gtctgggtgac	11400
ccggctgcga	gagctcgggtg	tacctgagac	gcgagtaagc	cctcgagtca	aatacgtagt	11460
cgttgcaagt	ccgcaccagg	tactggtatc	ccacaaaaaa	gtgcggcggc	gggtggcggt	11520

agagggggcca	gcgtaggggtg	gccgggggctc	cggggggagag	atcttccaac	ataaggcgat	11580
gatatccgta	gatgtacctg	gacatccagg	tgatgccggc	ggcgggtggg	gaggcgcgcg	11640
gaaagtcgcg	gacgcgggtt	cagatgttgc	gcagcggcaa	aaagtgtctc	atggtcggga	11700
cgctctggcc	ggtcaggcgc	gcgcaatcgt	tgacgctcta	gaccgtgcaa	aaggagagcc	11760
tgtaagcggg	cactcttccg	tggctctggg	gataaattcg	caagggtatc	atggcggacg	11820
accgggggtt	gagccccgta	tccggcccg	cgccgtgatc	catgcgggta	ccgcccgcgt	11880
gtcgaaccca	ggtgtgcgac	gtcagacaac	gggggagtg	tccttttggc	ttccttccag	11940
gcgcggcgcc	tgctgcgcta	gcttttttgg	ccactggccg	cgcgagcggt	aagcggttag	12000
gctggaaagc	gaaagcatta	agtggctcgc	tccctgtagc	cggagggtta	ttttccaagg	12060
gttgagtcgc	gggacccccg	gttcgagctc	cggaccggcc	ggactgcggc	gaacgggggt	12120
ttgcctcccc	gtcatgcaag	acccccgctt	caaatttcct	cggaaacagg	gacgagcccc	12180
ttttttgctt	ttcccagatg	catccgggtg	tgccggcagat	gcgccccctc	cctcagcagc	12240
ggcaagagca	agagcagcgg	cagacatgca	gggcaccctc	ccctcctcct	accgcgtcag	12300
gaggggagac	atccgcgggt	gacgcggcag	cagatggtga	ttacgaaccc	ccgcggcgcc	12360
gggcccggca	ctacctggac	ttggaggagg	gcgaggccct	ggcgcggtta	ggagcgccct	12420
ctcctgagcg	gtaccaaggg	gtgcagctga	agcgtgatac	gcgtgaggcg	tacgtgccgc	12480
ggcagaacct	gtttcgcgac	cgcgaggagg	aggagcccca	ggagatgcgg	gatcgaaagt	12540
tccacgcagg	gcgcgagctg	cggcatggcc	tgaatcgcca	gcgggtgctg	cgcgaggagg	12600
actttgagcc	cgacgcgcga	accgggatta	gtcccgcgcg	cgcacacgtg	gcggcccgccg	12660
acctggtaac	cgcatacgag	cagacgggtga	accaggagat	taactttcaa	aaaagcttta	12720
acaaccacgt	gcgtacgctt	gtggcgcgcg	aggaggtggc	tataggactg	atgcactctgt	12780
gggactttgt	aagcgcgctg	gagcaaaaacc	caaatagcaa	gccgctcatg	gcgcagctgt	12840
tccttatagt	gcagcacagc	agggacaacg	aggcattcag	ggatgcgctg	ctaaacatag	12900
tagagcccga	gggcccgtgg	ctgctcgatt	tgataaacat	cctgcagagc	atagtggtgc	12960
aggagcgcag	cttgagcctg	gctgacaagg	tggccgccat	caactattcc	atgcttagcc	13020
tgggcaagtt	ttacgcccgc	aagatatacc	atacccttta	cgttcccata	gacaaggagg	13080
taaagatcga	ggggttctac	atgcgcagtg	cgctgaaggt	gcttaccttg	agcgacgacc	13140
tgggcgttta	tcgcaacgag	cgcattccaca	aggccgtgag	cgtgagccgg	cgccgcgagc	13200
tcagcgaccg	cgagctgatg	cacagcctgc	aaagggccct	ggctggcgacg	ggcagcgccg	13260
atagagaggc	cgagtcctac	tttgacgcgg	gcgctgacct	gcgctggggc	ccaagccgac	13320
gcgcctctga	ggcagctggg	gccggacctg	ggctggcggt	ggcaccgcgc	cgcgctggca	13380
acgtcggcgg	cgtggaggaa	tatgacgagg	acgatgagta	cgagccagag	gacggcgagt	13440
actaagcggg	gatgtttctg	atcagatgat	gcaagacgca	acggaccggg	cggtgcgggg	13500
ggcgctgcag	agccagccgt	ccggccctta	ctccacggag	gactggcgcc	aggatcatgga	13560
ccgcatcatg	tcgctgactg	cgcgcaatcc	tgacgcgttc	cggcagcagc	cgcaaggccaa	13620
ccggctctcc	gcaattctgg	aagcgggtgg	cccgccgcgc	gcaaacccca	cgcacgagaa	13680
ggtgctggcg	atcgtaaacg	cgctggccga	aaacaggggc	atccggcccg	acgaggcccg	13740
cctggtctac	gacgcgctgc	ttcagcgctg	ggctcggttac	aacagcgcca	acgtgcagac	13800
caacctggac	cggtcggtgg	gggatgtgcg	cgaggccgtg	gcgcagcggtg	agcgcgcgca	13860
gcagcagggc	aacctgggct	ccatggttgc	actaaagcc	ttcctgagta	cacagcccgc	13920
caacgtgcgc	cggggacagg	aggactacac	caactttgtg	agcgcaactgc	ggctaattgg	13980
gactgagaca	ccgcaaagtg	agggtgtacca	gtctggggcca	gactattttt	tccagaccag	14040
tagacaaggc	ctgcagaccg	taaacctgag	ccaggctttc	aaaaacttgc	aggggctgtg	14100
gggggtgccc	gctcccacag	gcgaccgcgc	gaccgtgtct	agcttgctga	cgcccaactc	14160
gcgcctgttg	ctgctgctaa	tagcgccctt	cacggacagt	ggcagcggtg	cccgggacac	14220
atacctaggt	cacttgctga	cactgtaccg	cgaggccata	ggtcaggcgc	atgtggacga	14280
gcatactttc	caggagatta	caagtgtcag	ccgcgcgctg	gggcaggagg	acacgggcag	14340
cctggaggca	accctaaact	acctgctgac	caaccggcgg	cagaagatcc	cctcgttgca	14400
cagtttaaac	agcgaggagg	agcgcatttt	gcgctacgtg	cagcagagcg	tgagccttaa	14460
cctgatgcgc	gacggggtaa	cgcccagcgt	ggcgctggac	atgaccgcgc	gcaacatgga	14520
accgggcatg	tatgcctcaa	accggccggt	tatcaaccgc	ctaattggact	acttgcatcg	14580
cgcgcccgcc	gtgaaccccc	agtatttcac	caatgccatc	ttgaacccgc	actggctacc	14640
gccccctggg	ttctacaccg	ggggatttga	ggtgcccag	ggtaacgatg	gattcctctg	14700
ggagcacata	gacgacagcg	tgttttcccc	gcaaccgcag	accctgctag	agttgcaaca	14760
gcgcgagcag	gcagaggcgg	cgctgcgaaa	ggaaagcttc	cgcaggccaa	gcagcttgct	14820
cgatctaggc	gctgcggccc	cgcggtcaga	tgctagtagc	ccattttcaa	gcttgatagg	14880
gtctcttacc	agcactcgca	ccaccgcgcc	gcgcctgctg	ggcgaggagg	agtaccta	14940
caactcgctg	ctgcagccgc	agcgcgaaaa	aaacctgcct	ccggcaattc	ccaaccaagg	15000
gatatagagc	ctagtggaga	agatgagtag	atggaagacg	tacgcgcagg	agcacaggga	15060
cgtgccaggc	ccgcgcccgc	ccaccgcgtg	tcaaaggcac	gaccgtcagc	ggggctcggg	15120
gtgggaggac	gatgactcgg	cagacgacag	cagcgtcctg	gatttgggag	ggagtggcaa	15180

cccgtttgcg	caccttcgcc	ccaggctggg	gagaatgttt	taaaaaaaaa	aaagcatgat	15240
gcaaaataaaa	aaactcacca	aggccatggc	accgagcgtt	ggtttttcttg	tattcccctt	15300
agtatgcggc	gcgcggcgat	gtatgaggaa	ggtcctcctc	cctcctacga	gagtgtgggt	15360
agcgcggcgc	cagtggcggc	ggcgctgggt	tctcccttcg	atgctcccct	ggacccgcgc	15420
tttgtgcctc	cgcggtacct	ggggcctacc	ggggggagaa	acagcatccg	ttactctgag	15480
ttggcaccoc	tattcgacac	cacccgtgtg	tacctggtgg	acaacaagtc	aacggatgtg	15540
gcatccctga	actaccagaa	cgaccacagc	aactttctga	ccacggtcat	tcaaaacaat	15600
gactacagcc	cgggggaggg	aagcacacag	accatcaatc	ttgacgaccg	gtcgcactgg	15660
ggcggcgacc	tgaaaacccat	cctgcatacc	aacatgccaa	atgtgaacga	gttcatgttt	15720
accaataagt	ttaaggcgcg	ggtgatgggt	tcgcgcttgc	ctactaagga	caatcagggt	15780
gagctgaaat	acgagtgggt	ggagtccacg	ctgcccaggg	gcaactactc	cgagaccatg	15840
accatagacc	ttatgaacaa	cgcgatcgtg	gagcactact	tgaaagtggg	cagacagaac	15900
gggggttctg	aaagcgacat	cggggtaaag	tttgacaccc	gcaacttcag	actgggggtt	15960
gaccccgctc	ctggtcttgt	catgcctggg	gtatatacaa	acgaagcctt	ccatccagac	16020
atcatttttg	tgccaggatg	cggggtggac	ttcacccaca	gccgcctgag	caacttggtg	16080
ggcatccgca	agcgggaacc	cttccaggag	ggcttttagga	tcacctacga	tgatctggag	16140
ggtggttaaca	ttcccgcact	gttggatgtg	gacgcctacc	aggcgagcct	gaaagatgac	16200
accgaacagg	gcgggggtgg	cgcaaggcgg	agcaacagca	gtggcagcgg	cgcggaagag	16260
aactccaacg	cggcagccgc	ggcaatgcag	ccggtggagg	acatgaacga	tcatgccatt	16320
cgcgcgacac	cctttgcccac	acgggctgag	gagaagcgcg	ctgaggccga	agcagcggcc	16380
gaagctgccc	cccccgctgc	gcaacccgag	gtcgagaagc	ctcagaagaa	accggtgatc	16440
aaacccctga	cagaggacag	caagaaaacg	agttacaacc	taataagcaa	tgacgacacc	16500
ttcacccagt	accgcagctg	gtaccttgca	tacaactacg	gcgaccctca	gaccggaatc	16560
cgctcatgga	ccctgctttg	cactcctgac	gtaacctgcg	gctcggagca	ggtctactgg	16620
tcggttgccag	acatgatgca	agaccccggt	accttccgct	ccacgcgcga	gatcagcaac	16680
tttcgggtgg	tgggcgccga	gctgttgccc	gtgcactcca	agagcttcta	caacgaccag	16740
gccgtctact	cccaactcat	ccgccaagtt	actctctga	cccacgtgtt	caatcgcttt	16800
cccgagaacc	agattttggc	gcgcccgcga	gccccacca	tcaccaccgt	cagtgaanaac	16860
gttccctgctc	tcacagatca	cgggacgcta	ccgctgcgca	acagcatcgg	aggagtccag	16920
cgagtgaacca	ttactgacgc	cagacgcgcg	acctgcccct	acgtttacaa	ggccctgggc	16980
atagtctcgc	cgcgctcct	atcgagccgc	actttttgag	caagcatgtc	catccttata	17040
tcgcccagca	ataacacagg	ctggggcctg	cgcttcccaa	gcaagatgtt	tgggcgggcc	17100
aagaagcgct	ccgaccaaca	cccagtgcgc	gtgcgcgggc	actaccgcgc	gccctggggc	17160
gcgcacaaac	gcggccgcac	tgggcgccac	accgtcgatg	acgccatcga	cgcggtgggt	17220
gaggaggcgc	gcaactacac	gcccacgcgc	ccaccagtgt	ccacagtgga	cgcgccattt	17280
cagaccgtgg	tgcgcgagc	ccggcgctat	gctaaaatga	agagacggcg	gaggcgcgta	17340
gcacgtcgcc	accgccgcgc	accgggcact	gccgcccac	gcgcggcggc	ggccctgctt	17400
aaccgcgcac	gtcgacccgg	ccgacggggc	gccatgcggg	ccgctcgaag	gctggccgcg	17460
ggtattgtca	ctgtgcccc	caggtccagg	gcacgagcgg	ccgcccgcagc	agccgcggcc	17520
attatgtcta	tgactcaggg	tcgcaggggc	aacgtgtatt	gggtgcgcga	ctcggttagc	17580
ggcctgcgcg	tgcccgtgcg	cacccgcccc	ccgcgcaact	agattgcaag	aaaaaactac	17640
ttagactcgt	actgttgtat	gtatccagcg	gcggcgccgc	gcaacgaagc	tatgtccaag	17700
cgcaaaatca	aagaagagat	gctccagggt	atcgcgccgc	agatctatgg	ccccccgaag	17760
aaggaagagc	aggattacaa	gccccgaaag	ctaaagcggg	tcaaaaagaa	aaagaaagat	17820
gatgatgatg	aacttgacga	cgagggtgaa	ctgctgcacg	ctaccgcgcc	caggcgacgg	17880
gtacagtggg	aagggtcgacg	cgtaaaacgt	gttttgcgac	ccggcaccac	cgtagtcttt	17940
acgcccgggtg	agcgctccac	ccgcacctac	aagcgcgtgt	atgatgaggt	gtacggcgac	18000
gaggacctgc	ttgagcaggg	caacgagcgc	ctcggggagt	ttgcctacgg	aaagcggcac	18060
aaggacatgc	tggcggttgc	gctggacgag	ggcaacccaa	cacctagcct	aaagcccgtg	18120
acactgcagc	aggtgctgcc	cgcgcttgca	ccgtccgaag	aaaagcgcg	cctaaagcgc	18180
gagtctgggtg	acttggcacc	caccgtgcag	ctgatgggtac	ccaagcgcca	gcgactggaa	18240
gatgtcttgg	aaaaaatgac	cgtggaacct	gggctggagc	ccgaggtccg	cgtgcggcca	18300
atcaagcagg	tggcgccggg	actgggcgtg	gcagaccgtg	acgttcagat	accactacc	18360
agtagcaccg	gtattgccac	cgccacagag	ggcatggaga	cacaaacgtc	cccggttgcc	18420
tcagcggtgg	cggatgccgc	ggtgcaggcg	gtcgctgcgg	ccgcgtccaa	gacctctacg	18480
gaggtgcaaa	cggacccgtg	gatgtttcgc	gtttcagccc	cccgcgcccc	gcgcggttcg	18540
aggaagtacg	gcgcgccgac	cgcgctactg	cccgaatatg	ccctacatcc	ttccattgcg	18600
cctacccccg	gctattcgtg	ctacacctac	cgccccagaa	gacgagcaac	tacccgcgcg	18660
cgaaccacca	ctggaacccg	ccgcccgcgt	cgccgtcgcc	agccccgtgt	ggccccgatt	18720
tccgtgcgca	gggtggctcg	cgaaggaggc	aggaccctgg	tgctgccaac	agcgcgctac	18780
cacccagca	tcgtttaaaa	gccggtcttt	gtgggtcttg	cagatatggc	cctcacctgc	18840

cgccctccgtt tcccgggtgcc gggattccga ggaagaatgc accgtaggag gggcatggcc 18900
ggccacgggcc tgacggggcgg gcgcaccacc ggccggcgccg cgcgctcgac 18960
cgctcgcatgc gcgggcggtat cctgccccctc cttattccac tgatcgccgc ggcgattggc 19020
gccgtgccccg gaattgcatc cgtggcccttg caggcgcgaga gacactgatt aaaaacaagt 19080
tgcattgtgga aaaatcaaaa taaaaagtct ggactctcac gctcgcttgg tccgtgaact 19140
atcttgtaga atggaagaca tcaactttgc gtctctggcc ccgcgacacg gctcgcgccc 19200
gttcattggga aactggcaag atatcggcac cagcaatatg agcgggtggcg ccttcagctg 19260
gggctcgctg tggagcgcca ttaaaaattt cgggtccacc gttaagaact atggcagcaa 19320
ggcctgggaac agcagcacag gccagatgct tggcctctgg gagggataag ttgaaagagc aaaatttcca 19380
acaaaagggtg gtagatggcc acagtaagct tgatccccgc cctcccgtag aggagcctcc 19500
ggcagtgcaa aataagatta ctccagaggg gcgtggcgaa aagcgtccgc gccccgacag 19560
accggccgtg ctggtgacgc aaatagacga gcctccctcg tacgaggagg cactaaagca 19620
ggaagaaact accacccgctc ccacgcgcgc catggctacc cagagggagc gccagcacac 19680
aggcctgccc accacccgctc cctccccgcgc cgacaccag cagaaacctg tgctgccagg 19740
accgtaacg cttggtttaa cccgtcctag ccgcgcgtcc ctgcgccgcg ccgccagcgg 19800
cccgaaccgc ttgcgggccc tagccagtggt tgaagcgccg acgatgcttc tgaatagcta acgtgtcgta 19920
tccgcgatcg gtgcaatccc atgtcgccgc cagaggagct ccgcagtggt ctggtgcagt ttgcccgcgc 20040
gggtctggggg gtatgctgctc ttcgatgatg gagccccggg gtttagaaac cccacggtgg 20100
tgtgtgtcat tggctacccc gagccccggg gtttagaaac cccacggtgg 20160
ctttccaaga cggagtacct tgaataacaa gacgctgggg caccctagct 20220
caggacgcct tgaataacaa gacgctgggg caccctagct 20280
tacttcagcc cccagcggtt aggcgcgggtt caccctagct 20340
acagaccgtt cccagcggtt aggcgcgggtt caccctagct 20400
tactcgtaca ttgacatccc ggcgctgctg gacaggggccc ctacttttaa 20460
tccacgtact acaacgcctt aaacctagaa gaagaggacg atgacaacga 20520
ggcactgcct ctcttgaaat aaaaactcac gtatttgggc aggcgcctta 20580
gctgctactg ctgagcagca tcaaataggt tcaaatagga gaatctcagt ggtacgaaac 20640
gacgagcaag ctgagcagca tcaaataggt tcaaatagga gaatctcagt ggtacgaaac 20700
aatattacaa agggaggtat aaacctgaac ggagagtcct caaatgaaaa 20760
aaaacatttc aacctgaacc ggagagtcct caaatgaaaa 20820
catgcagctg ggagagtcct caaatgaaaa 20880
gcaaaaccca aagtggaaat ggtattgtac cactattaag taattacatt 20940
ctagaaagtc aagtggaagt cttacatgcc ccaacaggcc taattacatt 21000
gataacttga cttacatgcc ccaacaggcc taattacatt 21060
actcatattt cttacatgcc ccaacaggcc taattacatt 21120
caatctatgc ccaacaggcc taattacatt 21180
tattacaaca gcacgggtaa tgaaaatca tgaatacaga gactcttacc 21240
gttgtagatt tgcaagacag ttctatgtgg tggaactgaa aaggtataaac 21300
gggtgatagaa ccaggctact tgaatacaga gactcttacc 21360
gttagaatta tgaatacaga gactcttacc 21420
ggaggtgtga aagatgctac aagatgctac aagatgctac 21480
ggatgggaaa aaatcaatct aaatgccaac gctaaagtac 21540
tttgccatgg tgcccagcaa acgactacat gaacaagcga 21600
gcgctgtatt acgactacat gaacaagcga 21660
ccaaacacct agcactacat gaacaagcga 21720
attaaccttg gagcacgctg gtcccttgac ctaccgctca 21780
caccgcaatg ctggcctgcg ctaccgctca 21840
ttccacatcc aggtgcctca gaagtctctt cttcaggaag 21900
tcatacacct acgagtggaa taaggggtga cggagccagc 21960
ggaaatgacc ccatggccca agtcccttaa ccaacgctg 22020
accttcttcc ccaacgctg ccaacgctg 22080
accaacgacc ccaacgctg ccaacgctg 22140
gccaacgcta cgcgccttaa gactatctc catatccatc 22200
tgggccttca cgcgccttaa gactatctc catatccatc 22260
tattacacct actctggctc tttgactct aattaagcgc 22320
tttaagaagg tggcatttac cttgactct aattaagcgc 22380
cttaccacca acgagtttga tgaccaaaaga ctgtatctcc 22440
cagtgtaaca tgaccaaaaga ctgtatctcc 22500
taccagggct tgagccgtca caactctgga ggcattctac 22560
ttccagccca tgagccgtca caactctgga ggcattctac 22620
ggcatcctac tgagccgtca caactctgga ggcattctac 22680

-21-

gaaggacagg	cctacccctgc	taacttcccc	tatccgctta	taggcaagac	cgcagttgac	22560
agcattatccc	agaaaaagtt	tcttttgcgat	cgcacccttt	ggcgcacatccc	attctccagtt	22620
aactttatgt	ccatgggcgc	actcacagac	ctggggccaaa	accttctcta	cgccaaactcc	22680
gcccacgcgc	tagacatgac	ttttgaggtg	gatcccatgg	acgagccccc	ccttcttttat	22740
gtttttgtttg	aagtctttga	cgtgggtccgt	gtgcaccggc	cgcaccgcgg	cgatcatcgaa	22800
accgtgtacc	tgcgcacgcc	cttctcggcc	ggcaacgcga	caacataaag	aagcaagcaa	22860
catcaacaac	agctgcgcgc	atggggctcca	gtgagcagga	actgaaagcc	attgtcaaag	22920
atcttgggtg	tggggccatat	tttttgggca	cctatgacaa	gcgctttcca	ggctttgttt	22980
ctccacacaa	gctgcgcctgc	gccatagtc	atacggccgg	tgcgcgagact	gggggagctac	23040
actggatggc	ctttgcctgg	aaccgcgact	caaaaacatg	ctacctcttt	gagccctttg	23100
gctttttctga	ccagcgactc	aagcaggttt	accagtttga	gtacgagtc	ctcctgcgcgc	23160
gtagcggccat	tgcttcttcc	cccgaccgt	gtataacgct	ggaaaagtcc	acccaaagcc	23220
tacagggggcc	caactgggccc	gctgtggac	tattctgctg	catgtttctc	cacgcctttg	23280
ccaactggcc	ccaaactccc	atggatcaca	accccaccat	gaaccttatt	accgggggtac	23340
ccaactccat	gctcaacagt	ccccaggtac	agccccccct	gcgtcgcaac	caggaacagc	23400
tctacagctt	cctggagcgc	cactcgcctt	acttccgcag	ccacagtgcg	cagattagga	23460
gcgcacattc	tttttgtcac	ttgaaaaaca	tgtaaaaata	atgtactaga	gacactttca	23520
ataaaggcaa	atgcttttat	ttgtacactc	tgggtgatt	atttaccccc	acccttgccg	23580
tctgcgcctg	ttaaaaatca	aaggggttct	gccgcgcate	gctatgcgcc	actggcaggg	23640
acacgttgcg	atactggtgt	ttagtgtctc	acttaaaactc	aggcacaacc	atccgcggga	23700
gctcggtgaa	gttttctactc	cacaggtctc	gcaccatcac	caacgcgttt	agcaggtcgg	23760
gcgccgatata	cttgaagtcg	cagttggggc	ctccgccttg	cgcgcgcgag	ttgcgatata	23820
caggggttgca	gcactggaac	actatcagcg	ccgggtggtg	cacgctggcc	agcacgctct	23880
tgtcggagat	cagatccgcg	tccaggtcct	ccgcgttgct	cagggcggaac	ggagtcaact	23940
ttggtagctg	ccttcccaaa	aagggcgcg	ggccaggctt	tgagtgcac	tgcaccgta	24000
gtggcatcaa	aaggtgaccg	tgcccggtct	ggcgcttagg	atacagcgcc	tgcataaaag	24060
ccttgatctg	cttaaaagcc	acctgagcct	ttgcgccttc	agagaagaac	atgccgcaag	24120
acttgccgga	aaactgattg	gccggacagg	ccgcgtcgtg	cacgcagcac	cttgcgctcg	24180
tggtggagat	ctgcaccaca	tttcggcccc	accggttctt	cacgatcttg	gccttgctag	24240
actgctcctt	cagcgcgcgc	tgccggtttt	cgtcgtcac	atccatttca	atcacgtgct	24300
ccttatttat	cataatgctt	ccgtgtagac	acttaagctc	gccttcgatc	tcagcgcagc	24360
ggtgcagcca	caacgcgcag	cccgtgggct	cgtgatgctt	gtaggtcacc	tctgcaaacg	24420
actgcaggta	cgcttcgagg	aatcgcccca	tcatcgtcac	aaaggtcttg	ttgctgggtga	24480
aggtcagctg	caaccgcgcg	tgctcctcgt	tcagccagg	cttgcatagc	gccgcagag	24540
cttccacttg	gtcaggcagt	agtttgaagt	tcgcctttag	atcggtatcc	acgtgggtact	24600
tgtccatcag	cgcgcgcgca	gcctccatgc	ccttctccca	cgcagacacg	atcggcacac	24660
tcagcgggtt	catcacccgta	atttcaacttt	ccgcttcgct	gggctcttcc	tcttctctct	24720
gcgtccgcat	accacgcgcc	actgggtcgt	cttcattcag	ccgcgcgact	gtgcgcttac	24780
ctcctttgccc	atgcttgatt	agcaccgggtg	ggttgctgaa	acccaccatt	tgtagcgcca	24840
catcttctct	ttcttctctg	ctgtccacga	ttacctctgg	tgatggcggg	cgctcgggct	24900
tgggagaagg	gcgcttcttt	ttcttcttgg	gcgcaatggc	caaatccgcc	gccgaggtcg	24960
atggccgcgg	gctgggtgtg	cgcggcacca	gcgcgtcttg	tgatgagtt	tctcgtcct	25020
cggactcgat	acgccgcctc	atccgctttt	ttggggggcgc	ccggggaggc	ggcggcgagc	25080
gggacgggga	cgacacgtcc	tccatgggtg	ggggacgtcg	cgccgcacccg	cgtccgcgct	25140
cgggggtggg	ttcgcgctgc	tcctcttccc	gactggccat	ttccttctcc	tataggcaga	25200
aaaagatcat	ggagttagtc	gagaagaagg	acagcctaac	cgccccctct	gagttcgcca	25260
ccaaccgctc	caccgatgcc	gccaacgcgc	ctaccacctt	ccccgtcgag	gcacccccgc	25320
ttgaggagga	ggaagtgatt	atcgagcagg	acccaggttt	tgtaagcgaa	gacgacgagg	25380
accgctcagt	accaacagag	gataaaaaagc	aagaccagga	caacgcagag	gcaaacgagg	25440
aacaagtccg	gcgggggggac	gaaaggcatg	gcgactacct	agatgtggga	gacgacgtgc	25500
tggtgaagca	tctgcagcgc	cagtgcgcca	ttatctgcga	cgcgttgcaa	gagcgcagcg	25560
atgtgcccc	cgccatagcg	gatgtcagcc	ttgcctacga	acgccacct	ttctcaccgc	25620
gcgtaccccc	caaacgcga	gaaaacggca	cgtcgagcc	caaccgcgc	ctcaactct	25680
accccgattt	tgccgtgcca	gaggtgcttg	ccacctatca	catctttttc	caaaactgca	25740
agataccctt	atcctgcccgt	gccaaccgca	gccgagcgga	caagcagctg	gccttgccggc	25800
agggcgctgt	catacctgat	atcgccctgc	tcaacgaagt	gccccaaatc	tttgagggtc	25860
ttggacgcga	cgagaagcgc	gcgggcaaacg	ctctgcaaca	ggaaaacagc	gaaaatgaaa	25920
gtcactctgg	agtggtgggtg	gaactcgagg	gtgacaacgc	gcgcctagcc	gtactaaaac	25980
gcagcatcga	ggtcacccac	tttgccctacc	cggcaacttaa	cctaccccc	aaggtcatga	26040
gcacagtcac	gagtgagctg	atcgtgcgcc	gtgcgcagcc	cctggagagg	gatgcaaatt	26100
tgcaagaaca	aacagaggag	ggcctacccg	cagttggcga	cgagcagcta	gcgcgctggc	26160

-22-

ttcaaacgcg	cgagcctgcc	gacttggagg	agcgacgcaa	actaatgatg	gccgcagtg	26220
tcgttaccgt	ggagcttgag	tgcatgcagc	ggttctttgc	tgacccggag	atgcagcgca	26280
agctagagga	aacattgcac	tacacctttc	gacagggcta	cgtacgccag	gcctgcaaga	26340
tctccaacgt	ggagctctgc	aacctgggtc	cctaccttgg	aattttgcac	gaaaaccgcc	26400
ttgggcaaaa	cgtgcttcat	tccacgctca	agggcgaggc	gcgcccgcag	tacgtccgcg	26460
actgcgttta	cttattttcta	tgctacacct	ggcagacggc	catgggctgt	tggcagcagt	26520
gcttggagga	gtgcaacctc	aaggagctgc	agaaactgct	aaagcaaaac	ttgaaggacc	26580
tatggacggc	cttcaacgag	cgctccgtgg	ccgcgcacct	ggcggacatc	attttccccg	26640
aacgcctgct	taaaacctg	caacagggtc	tgccagactt	caccagtcaa	agcatggtgc	26700
agaactttag	gaactttatc	ctagagcgct	caggaatctt	gcccgcacc	tgctgtgcac	26760
ttcctagcga	ctttgtgccc	attaagtacc	gcgaatgccc	tccgcgcgtt	tgggggccact	26820
gctaccttct	gcagctagcc	aactaccttg	cctaccactc	tgacataatg	gaagacgtga	26880
gcggtgacgg	tctactggag	tgctactgtc	gctgcaacct	atgcaccccc	caccgctccc	26940
tggtttgcaa	ttcgcagctg	cttaacgaaa	gtcaaattat	cggtagcttt	gagctgcagg	27000
gtccctcgcc	tgacgaaaag	tccgcggctc	cggggttgaa	actcactccg	gggctgtgga	27060
cgtcggctta	ccttcgcaaa	tttgtacctg	aggactacca	cgcccacgag	attaggttct	27120
acgaagacca	atcccccccc	ccaaatgcgg	agcttaccgc	ctgcgtcatt	acccagggcc	27180
acattcttgg	ccaattgcaa	gccatcaaca	aagcccgcga	agagtttctg	ctacgaaagg	27240
gacggggggg	ttacttggac	ccccagtcog	gcgaggagct	caacccaatc	ccccgcgcc	27300
cgcagcccta	tcagcagcag	ccgcggggcc	ttgcttcccc	ggatggcacc	caaaaagaag	27360
ctgcagctgc	cgccgccacc	cacggacgag	gaggaatact	gggacagtca	ggcagaggag	27420
gttttggacg	aggaggagga	ggacatgatg	gaagctggg	agagcctaga	cgagggaagt	27480
tccgaggtcg	aagaggtgtc	agacgaaaca	ccgtcacctc	cggctcgatt	cccctcgccg	27540
gcgccccaga	aatcggaac	cggttccagc	atggctacaa	cctccgctcc	tcaggcgccg	27600
ccggcactgc	ccgttcgccc	acccaaccgt	agatgggaca	ccactggaac	cagggccggt	27660
aagtccaagc	agccgccgcc	gttagcccaa	gagcaacaac	agcgccaagg	ctaccgctca	27720
tggcgcgggg	acaagaacgc	catagttgct	tgcttgcaag	actgtggggg	caacatctcc	27780
ttcgcccgcc	gctttcttct	ctaccatcac	ggcgtggcct	tcccccgtaa	catcctgcat	27840
tactaccgtc	atctctacag	cccatactgc	accggcgcca	gcggcgagcg	cagcaacagc	27900
agcggccaca	cagaagcaaa	ggcgaccgga	tagcaagact	ctgacaaagc	ccaagaaatc	27960
cacagcgggc	gcagcagcag	gaggaggagc	gctgcgtctg	gcgcccacac	aaccggtatc	28020
gaccgcgag	cttagaaaca	ggatttttcc	cactctgtat	gctatatatt	aacagagcag	28080
gggccaagaa	caagagctga	aaataaaaaa	caggctctctg	cgatccctca	cccgagctg	28140
cctgtatcac	aaaagcgaag	atcagcttcg	gcgcacgctg	gaagacgcgg	aggctctctt	28200
cagtaaatac	tgcgcgctga	ctcttaagga	ctagtttcgc	gccctttctc	aaatttaagc	28260
gcgaaaacta	cgtcatctcc	agcggccaca	ccggcgccca	gcacctgtcg	tcagcgccat	28320
tatgagcaag	gaaattcccc	cgccctacat	gtggagttac	cagccacaaa	tgggacttgc	28380
ggctggagct	gcccagact	actcaaccgc	aataaactac	atgagcgccg	gacccacat	28440
gatatcccg	gtcaacggaa	tccgcgccca	ccgaaaccga	attctcttgg	aacaggcgcc	28500
tattaccacc	acacctcgta	ataaccttaa	tccccgtagt	tggcccgtg	ccctggtgta	28560
ccaggaaagt	cccgctccca	ccactgtgtg	acttcccaga	gacgcccagg	ccgaagttca	28620
gatgactaac	tcagggcgcg	agcttgccgg	cggctttcgt	cacaggggtg	ggtcgcccg	28680
gcagggtata	actcacctga	caatcagagg	gcgagggtatt	cagctcaacg	acgagtcggt	28740
gagctcctcg	cttgggtctcc	gtccggacgg	gacatttcag	atcggcggcg	ccggccgctc	28800
ttcattcacg	cctcgtcagg	caatcctaac	tctgcagacc	tcgtcctctg	agccgcgctc	28860
tggaggcatt	ggaactctgc	aatttattga	ggagtttgtg	ccatcggtct	actttaaccc	28920
cttctcgga	cctcccgcc	actatccgga	tcaatttatt	cctaactttg	acgcggtaaa	28980
ggactcgccg	gacggctacg	actgaatgtt	aagtggagag	gcagagcaac	tgccgctgaa	29040
acacctgggt	cactgtcgcc	gccacaagtg	ctttgcccgc	gactccggtg	agttttgcta	29100
ctttgaattg	ccgaggatc	atatcgaggg	ccggcgccac	ggcgtccggc	ttaccgcca	29160
gggagagctt	gcccgtagcc	tgattcgga	gtttaccag	cgccccctgc	tagttgagcg	29220
ggacagggga	ccctgtgttc	tactgtgat	ttgcaactgt	cctaaccctg	gattacatca	29280
agatctttgt	tgccatctct	gtgctgagta	taataaatac	agaaattaaa	atatactggg	29340
gctcctatcg	ccatcctgta	aacggccacc	tcttcacccc	cccaaggcaaa	ccaaggcgaa	29400
ccttacctg	tacttttaac	atctctccct	ctgtgattta	caacagtttc	aaccagacg	29460
gagtgagct	acgagagaa	ctctccgagc	tcagctactc	catcagaaaa	aaccaccacc	29520
tccttacctg	ccgggaacgt	acgagtgctg	caccggccgc	tgcaaccacac	ctaccgctg	29580
accgtaaac	agactttttc	cggacagacc	tcaataactc	tgtttaccag	aacaggaggt	29640
gagcttagaa	aaccttagg	gtattaggcc	aaaggcgag	ctactgtggg	gtttatgaac	29700
aattcaagca	actctacggg	ctattctaat	tcagggtttct	ctagaaatgg	acggaattat	29760
tacagagcag	cgccctgctag	aaagacgcag	ggcagcgccc	gagcaacagc	gcatgaatca	29820

-23-

agagctccaa gacatgggta acttgcacca gtgcaaaagg ggtatctttt gtctggtaaa 29880
 gcaggccaaa gtcacctacg acagtaatac caccggacac cgccttagct acaagttgcc 29940
 aaccaagcgt cagaaattgg tggatcatgg gggagaaaag cccattacca taactcagca 30000
 ctcggtagaa accgaaggct gcattcactc accttgtcaa ggacctgagg atctctgcac 30060
 ccttattaag accctgtgcg gtctcaaaga tcttattccc tttactaat aaaaaaaat 30120
 aataaagcat cacttactta aaatcagtta gcaaatctct gtccagttta ttcagcagca 30180
 cctccttgcc ctctcccag ctctgggtatt gcagcttctc cctggctgca aactttctcc 30240
 acaatctaaa tgggaatgtca gtttctctct gtctctgtcc atccgcaccc actatcttca 30300
 tgttggtgca gatgaagcgc gcaagaccgt ctgaagatac cttcaacccc gtgtatccat 30360
 atgacacgga aaccggctct ccaactgtgc cttttcttac tctcctctt gtatccccc 30420
 atggggttca agagagtcct cctgggggtac tctctttgcg cctatccgaa cctctagtta 30480
 cctccaattg catgcttgcg ctcaaaatgg gcaacggcct ctctctggac gaggccggca 30540
 acccttacct ccaaaatgta accactgtga gccacactct caaaaaaac aagtcaaac 30600
 taaacctgga aatatctgca cccctcacag ttacctcaga agcctaact gtggctgccc 30660
 ccgcacctct aatgggtcgg ggcaacacac taccatgca atcacaggcc ccgctaaccg 30720
 tgcacgactc caaacttagc attgccaccc aaggaccctt cacagtgtca gaaggaaagc 30780
 tagccctgca aacatcaggc cccctcacca ccaccgtag cagtacctt actatcactg 30840
 cctcaccccc tctaactact gccactggta gcttgggcat tgacttgaag gagccattt 30900
 atacacaaaa tggaaaacta ggactaaagt acgggggtcc tttgcatgta acagacgacc 30960
 taaacacttt gaccgtagca actgggtccag gtgtgactat taataatact tccttgcaaa 31020
 ctaaagttag tggagccttg ggttttgatt cacaaggcaa tatgcaactt aatgtagcag 31080
 gaggactaag gattgattct caaacagac gccctatact tgatgttagt tatccgtttg 31140
 atgctcaaaa ccaactaaat ctaagactag gacagggccc tctttttata aactcagccc 31200
 acaacttgga tattaactac aacaaaggcc tttacttgtt tacagcttca aacaattcca 31260
 aaaagcttga ggttaacctc agcactgcca aggggttgat gtttgacgct acagccatag 31320
 ccattaatgc agggatggg cttgaatttg gttcacctaa tgcaccaaac acaaatcccc 31380
 tcaaaacaaa aattggccat ggccatagaat ttgattcaaa caaggctatg gttcctaaac 31440
 taggaactgg ccttagtttt gacagcacag gtgccattac agtaggaaac aaaaataatg 31500
 ataagctaac tttgtggacc acaccagctc catctcctaa ctgtagacta aatgcagaga 31560
 aagatgctaa actcactttg gtcttaacaa aatgtggcag tcaaatactt gctacagttt 31620
 cagttttggc tgttaaaggc agtttggctc caatatctgg aacagttcaa agtgctcatc 31680
 ttattataag atttgacgaa aatggagtgc tactaaacaa ttccttctctg gaccagaat 31740
 attggaactt tagaaatgga gatcttactg aaggcacagc ctatacaaac gctgttggat 31800
 ttatgcctaa cctatcagct tatccaaaaa ctcacggtaa aactgcaaaa agtaacattg 31860
 tcagtcaagt ttacttaaac ggagacaaaa aacactaacc attacactaa 31920
 acggtacaca ggaaacagga gacacaactc caagtgcata ctctatgtca ttttcatggg 31980
 actggctctg ccacaactac ataatgaaa tatttgccac atcctcttac actttttcat 32040
 acattgcccc agaataaaga atcgtttctg ttatgtttca acgtgtttat ttttcaattg 32100
 cagaaaaatt caagtcaatt ttcatctagt agtatagccc caccaccaca tagcttatac 32160
 agatcacctg accttaattc aactcacaga accctagtat tcaacctgcc acctccctcc 32220
 caacacacag agtacacagt cctttctccc cggctggcct taaaaagcat catatcatgg 32280
 gtaacagaca tattcttagg tgttatattc cacacggttt cctgtcgagc caaacgctca 32340
 tcagtcatat taataaactc cccgggcagc tcacttaagt tcatgtcgct gtccagctgc 32400
 tgagccacag gctgctgtcc aacttgcggg gcttaaacgg gcggcgaagg agaagtcac 32460
 gcctacatgg gggtagagtc ataactcgtg atcaggatag ggcggtggg ctgcagcagc 32520
 gcgcgaataa actgctgccc ccgccgctcc gtctgcagg aatacaacat ggcagtggtc 32580
 tcctcagcga tgattcgac cgcccgcagc ataaggcgcc ttgtcctccg ggcacagcag 32640
 cgcacctga tctcacttaa atcagcacag taactgcagc acagcaccac aatattgttc 32700
 aaaaatccac agtgcaggc gctgtatcca aagctcatgg cggggaccac agaaccacg 32760
 tggccatcat accacaagcg caggtagatt aagtggcgac ccctcataaa cagctggac 32820
 ataaacatta cctcttttgg catgttgtaa ttcaccacct cccggtacca tataaacctc 32880
 tgattaaact tggcgccatc caccaccatc cttaaaccagc tggccaaaac ctgcccgcg 32940
 gctataacac gcaggaacc gggactggaa caatgacagt ggagagccca ggactcgtaa 33000
 ccatggatca tcatgtcgt catgatatca atgttggcac aacacaggca cacgtgcata 33060
 cacttctca ggattacaag ctctcccgc gttagaacca tatcccagg aacaacccat 33120
 tcctgaatca gcgtaaatcc cacactgcag ggaagacctc gcacgtaact cacgttgtgc 33180
 attgtcaaa tggtacattc gggcagcagc gtagtatcct ccagtatggg agcgcggtt 33240
 tctgtctcaa aaggaggtag acgatcccta ctgtacggag tgcgcccaga caaccgagat 33300
 cgtgttggtc gtagtgtcat gccaaatgga acgcccggac tagtcatatt tcctgaagca 33360
 aaaccaggtg cggcggtgac aaacagatct gcgtctccgg tctcgccgct tagatcgctc 33420
 tgtgtagtag ttgtagtata tccactctct caaagcatcc aggcgcccc tggcttcggg 33480

-24-

```

ttctatgtaa actccttcat gcgcgcgtgc cctgataaca tccaccaccg cagaataagc 33540
cacacccagc caacctacac attcggtctg cgagtcacac acgggaggag cgggaagagc 33600
tggaagaacc atgttttttt ttttattcca aaagattatc caaaacctca aaatgaagat 33660
ctattaagtg aacgcgctcc cctccggtgg cgtggtcaaa ctctacagcc aaagaacaga 33720
taatggcatt tgtaagatgt tgcacaatgg cttccaaaag gcaaaccggc ctcacgtcca 33780
agtggacgta aaggctaacc ccttcagggt gaatctcttc tataaacatt ccagcacctt 33840
caaccatgcc caaataattc tcatctcgcc accttctcaa tatatctcta agcaaatccc 33900
gaatattaag tccggccatt gtaaaaatct gctccagagc gccctccacc ttcagcctca 33960
agcagcgaat catgattgca aaaattcagg ttcctcacag acctgtataa gattcaaaaag 34020
cggaacatta acaaaaatac cgcatccc ctagtccctt ccaggggcca gctgaacata 34080
atcgtagcag tctgcacgga ccagcgcgcc cacttccccg ccaggaacct tgacaaaaga 34140
acccacactg attatgacac gcatactcgg agctatgcta accagcgtag ccccgatgta 34200
agctttgttg catgggcggc gatataaaat gcaagggtgt gctcaaaaaa tcaggcaaaag 34260
cctcgcgcaa aaaagaaagc acatcgtagt ttctctcaaa catgtctgag ggtttctgca 34320
ccggaaccac cacagaaaaa gacaccattt ttaaaccatta gaagcctgtc ttacaacagg 34440
taaacacaaa ataaaataac aaaaaaacat taagacggac taccggccatg ccggcggtgac cgtaaaaaaa 34500
aaaaacaacc cttataagca taagacggac gcaccaccga cagctcctcg gtcattgtccg gattcataat 34560
ctggtcaccg tgattaaaaa gcaccaccga caggttgatt catcggtcag tgctaaaaag cgaccgaaat 34620
gtaagactcg gtaaacacat cgcaggcgta gagacaacat aaacacctga tacagccccc ataggaggta 34680
agcccggggg aatacatacc aaaaacacat aacacacctg acagcgcttc caacagcgga gccataacag 34800
taacaaaatt aataggagag aaaaacacat agaacaacat acagcgcttc caactcgaca cggcaccagc 34860
aaatagcacc ctcccgtccc gaaacacctt aaaggggcaa gtgcagagcg cgcacgcgga agtatatata ggactaaaaa 34920
tcagccttac cagtaaaaaa acagtgtaaa cacaaaaaac acccagaaaa ccgcacgcga acctacgccc 34980
tcaatcagtc gggttaaagtc gcaaaaaaac ctcaaacttc cacttccgtt ttcccacgtt 35040
atgacgtaac gcaaaaaaac ccacaacttc acaatcccc aacacataca gttactccgc 35100
agaaacgaaa ccaattttaat taagaaaact acgccccgc ccacgtcaca aactccaccc 35160
acgtcaccgc ccccggtccc caatccaaaa taaggatat tattgatgat g 35211
cctcattatc atattgggctt

```

<210> 44

<211> 33622

<212> DNA

<213> Artificial Sequence

<220>

<223> Plasmid Av3nBg

<400> 44

```

catcatcaat aatatacctt attttggatt gaagccaata tgataatgag ggggtggagt 60
ttgtgacgtg gcgcggggcg tgggaacggg gcgggtgacg tagtagtggt gcggaagtgt 120
gatgttgcaa gtgtggcgga acacatgtaa gcgacggatg tggcaaaagt gacgtttttg 180
gtgtgcgcgg gtgtacacag gaagtgacaa ttttcgcgcg gttttaggcg gatgttgtag 240
taaatttggg cgtaaccgag taagatttgg ccattttcgc gggaaaactg aataagagga 300
agtgaatatc gaataatttt gtgttactca tagcgcgtaa tatttgtcta gggccgcggg 360
gactttgacc gtttacgttg agactcgccc agggcgaaaag cggggccttc gttgtacgcg 480
acgcgtatct gaggggacta ggggtgtgtt agcttttgca tagggagggg gaaatgtagt 540
gttaggagtc cctcaggat atagtagttt cgcttttgca taggttagcaa catgccttac 600
cttatgcaat actcttgtag tcttgcaaca tggtaacgat aggttggtac gatcgtgcct 660
aaggagagaa aaagcaccgt gcatgccgat tgggtggaag aaggttggtac ttccgcattg 720
tattaggaag gcaacagacg ggtctgacat ggattggacg aaccactgaa ccatcacca 780
cagatattat gtatttaagt ccctagctcg atacaataaa cgccatttga ccggggccag 840
cattgggtgtg cacctccggc cctggccact ctcttccgca tcgctgtctg tccagtactc ttggatcgga 900
ctgttgggct cgcggttgag gacaaaactc tcgcggtctt gccagggag ctgagcgagt cgcgtcctc agaactagt 1020
aac>cgtcgg cctccgaacg gtactccgac gaaaggcgtg taaccagtca gtccaaaaaa gaagagaaag 1080
cggatcgga gctgcaggaa ttcatctag atggataaag ttttgagtga ttcactggcc 1140
gatccccggg gctgcaggaa tccctcagaa ttgctaagtt cccaacttaa tcgccttgca 1200
gtagaagacc ccaaggactt ctgggaaaac cctggcgtaa cccgcaccga tcgcccttcc 1260
gtcgttttac aacgtcgtga ctggcgtaat agcgaagagg ggtttccggc accagaagcg 1320
gcacatcccc ctttcgccag tggcgaaatg cgctttgcct

```


gtgccggaaa	gctggctgga	gtgcgatctt	cctgaggccg	atactgtcgt	cgccccctca	1380
aactggcaga	tgcacggtta	cgatgcgccc	atctacacca	acgtaacccta	tcccattacg	1440
gtcaatccgc	cgtttggtcc	cacggagaat	ccgacggggt	gttactcgct	cacatttaat	1500
gttgatgaaa	gctggctaca	ggaaggccag	acgcgaatta	tttttgatgg	cgtaactcgc	1560
gcgtttcatc	tgtgggtgcaa	cgggcgctgg	gtcgggttacg	gccaggacag	tcgtttgccg	1620
tctgaatttg	acctgagcgc	atttttacgc	gccggagaaa	accgcctcgc	ggtgatggtg	1680
ctgcgttgga	gtgacggcag	ttatctggaa	gatcaggata	tgtggcggat	gagcggcatt	1740
ttccgtgacg	tctcgttgct	gcataaaccg	actacacaaa	tcagcgattt	ccatggtgcc	1800
actcgcttta	atgatgattt	cagccgcgct	gtactggagg	ctgaagtcca	gatgtgcggc	1860
gagttgcgtg	actacctacg	ggtaacagtt	tctttatggc	agggtgaaac	gcaggctgcc	1920
agcggcaccg	cgcttttcgg	cggtgaaatt	atcgatgagc	gtggtggtta	tgccgatcgc	1980
gtcacactac	gtctgaacgt	cgaaaaccgc	aaactgtgga	gcgccgaaat	cccgaatctc	2040
tatcgtgcgg	tgggtgaact	gcacaccgcc	gacggcacgc	tgattgaagc	agaagcctgc	2100
gatgtcggtt	tccgcgaggt	gcggattgaa	aatggtctgc	tgctgctgaa	cggaagccgc	2160
ttgtcgattc	gaggcggtta	ccgtcacgag	catcatcctc	tgcatggtca	ggtcatggat	2220
gagcagacga	tgggtgcagga	tatcctgctg	atgaagcaga	acaactttaa	cgccgtgcgc	2280
tgttcgcat	atccgaacca	tccgctgtgg	tacacgctgt	gcgaccgcta	cgccctgtat	2340
gtggtggatg	aagccaatat	tgaaccacac	ggcatggtgc	caatgaatcg	tctgaccgat	2400
gatccgcgct	ggctaccggc	gatgagcgaa	cgctaacgcg	gaatgggtgca	gcgcgatcgt	2460
aatcaccoga	gtgtgatcat	ctgggtcgctg	gggaatgaat	caggccacgg	cgctaatac	2520
gacgcgctgt	atcgctggat	caaactctgtc	gaccttccc	gcccgggtgca	gtatgaaggc	2580
ggcggagccg	acaccacggc	caccgatatt	atttgcccga	tgtagcgcgc	cgtagatgaa	2640
gaccagccct	tcccggctgt	gccgaaatgg	tccatcaaaa	aatggctttc	gctacctgga	2700
gagacgcgcc	cgctgatcct	ttgcgaatac	gccacgcgca	tgggtaacag	tcttggegg	2760
ttcgctaaat	actggcaggc	gtttcgctcag	tatccccggt	tacaggcgcg	cttcgtctgg	2820
gactgggtgg	atcagtcgct	gattaaatat	gatgaaaacg	gcaaccctg	gtcggcttac	2880
ggcgggtgatt	ttggcgatac	cccgaacgat	cgccagttct	gtatgaacgg	tctggtcttt	2940
gccgaccgca	cgccgcatac	gaagcaaaaac	accagcgaat	accagcagca	gtttttccag	3000
ttccgtttat	ccgggcaaac	catcgaagtg	gatggtaaagc	acctgttccg	tcatagcgat	3060
aacgagctcc	tgcactggat	ggtggcgctg	ttgattgaac	cgctggcaag	cggtgaagtg	3120
cctctggatg	tccgtccaca	aggtaaacag	tgctgagtc	tgccctgaact	accgcagccg	3180
gagagcgccg	ggcaactctg	gctcacagta	cgctagtgc	aaccgaacgc	gaccgcatgg	3240
tcagaagccg	ggcacatcag	cgctggcag	cagtggcgctc	tggcggaaaa	cctcagtgtg	3300
acgctccccg	cgcgctccca	cgccatcccc	catctgacca	ccagcgaaat	ggatttttgc	3360
atcgagctgg	gtaataagcg	ttggcaattt	aaccgccagt	caggctttct	ttcacagatg	3420
tggattggcg	ataaaaaaca	actgctgacg	ccgctgcgcg	atcagttcac	ccgtgcaccg	3480
ctggataacg	acattggcgt	aagtgaagcg	acccgcattg	accctaacgc	ctgggtcgaa	3540
cgctggaaagg	cgccggggcca	ttaccaggcc	gaagcagcgt	tgttgacgtg	cacggcagat	3600
acacttgctg	atgcggtgct	gattacgacc	gctcacgcgt	ggcagcatca	ggggaaaacc	3660
ttattttatca	gccggaaaac	ctaccggatt	gatggtagtg	gtcaaattggc	gattaccggt	3720
gatgttgaag	tggcgagcga	tacaccgcgt	cgccgcgga	ttggcctgaa	ctgccagctg	3780
gcgcaggtag	cagagcgggt	aaactggctc	ggattagggc	cgcaagaaaa	ctatcccagc	3840
cgcttactg	ccgcctgttt	tgaccgctgg	gatctgccat	tgtcagacat	gtataccccg	3900
tacgtcttcc	cgagcgaaaa	cggtctgcgc	tgccggacgc	gcgaattgaa	ttatggccca	3960
caccagtggc	gcggcgactt	ccagttcaac	atcagccgct	acagtcaaca	gcaactgatg	4020
gaaaccagcc	atcgccatct	gctgcacgcg	gaagaaggca	catggctgaa	tatcgacggt	4080
ttccatatgg	ggattgggtg	cgacgactcc	tggagcccg	cagtatcggc	ggaatttcag	4140
ctgagcgccg	gtcgctacca	ttaccagttg	gtctggtgtc	aaaaataata	atctcgaatc	4200
aagcttatcg	ataccgtcga	aacttggtta	ttgcagctta	taatggttac	aaataaagca	4260
atagcatcac	aaatttcaca	aataaagcat	ttttttact	gcattctagt	tgtggtttgt	4320
ccaaactcat	caatgtatct	tatcatgtct	ggatccgacc	tcggatctgg	aagggtgctga	4380
ggtacgatga	gacccgcacc	aggtgcagac	cctgcgagtg	tggcggtaaa	catattagga	4440
accagcctgt	gatgctggat	gtgaccgagg	agctgaggcc	cgatcacttg	gtgctggcct	4500
gcacccgcgc	tgagtttggc	tctagcgatg	aagatacaga	ttgaggtact	gaaatgtgtg	4560
ggcgtggcct	aaggggtgga	aagaatatat	aagtggggg	tcttatgtag	ttttgtatct	4620
gttttgcagc	agccgcggcc	gccatgagca	ccaactcggt	tgatggaagc	attgtgagct	4680
catatttgac	aacgcgcag	cccccatggg	ccgggggtgc	tcagaatgtg	atgggctcca	4740
gcattgatgg	tgcggccgtc	ctgcccgcga	actctactac	cttgacctac	gagaccgtgt	4800
ctggaacgcc	gttggagact	gcagcctcgc	ccgcgcttc	agccgctgca	gccaccgcc	4860
gcgggattgt	gactgacttt	gctttcctga	cgccgcttgc	aagcagtgca	gcttcccggt	4920
catccgcccg	cgatgacaag	ttgacggctc	ttttggcaca	attggattct	ttgaccggg	4980

-26-

aacttaatgt	cgtttctcag	cagctgttgg	atctgcgcca	gcaggtttct	gccctgaagg	5040
cttcctcccc	tcccaatgcg	gtttaaaaca	taaataaaaa	accagactct	gtttggattt	5100
ggatcaagca	agtgtcttgc	tgtctttatt	taggggtttt	gcgcgcgcgc	tagggccggg	5160
accagcggtc	tcggtcggtg	agggctcctgt	gtattttttc	caggacgtgg	taaaggtgac	5220
tctggatgtt	cagatacatg	ggcataagcc	cgtctctggg	gtggaggtag	caccactgca	5280
gagcttcatg	ctgcgggggtg	gtgttgtaga	tgatccagtc	gtagcaggag	cgctgggcgt	5340
ggtgcctaaa	aatgtctttc	agtagcaagc	tgattgccag	gggcaggccc	ttggtgtaag	5400
tgtttacaaa	gcggttaagc	tgggatgggt	gcatacgtgg	ggatatgaga	tgcatcttgg	5460
actgtatttt	taggttggct	atgttcccag	ccatatccct	ccggggattc	atgttggtgca	5520
gaaccaccag	cacagtgtat	ccgggtgact	tgggaaattt	gtcatgtagc	ttagaaggaa	5580
atgcgtggaa	gaacttggag	acgcccttgt	gacctccaag	attttccatg	cattcgtcca	5640
taatgatggc	aatgggcccc	cgggcggcgg	cctgggcgaa	gatatttctg	ggatcactaa	5700
cgtcatagtt	gtgttccagg	atgagatcgt	catagcccat	ttttacaaag	cgcgggcgga	5760
gggtgccaga	ctgcggtata	atggttccat	ccggcccagg	ggcgtagtta	ccctcacaga	5820
tttgcatttc	ccacgctttg	agttcagatg	gggggatcat	gtctacctgc	ggggcgatga	5880
agaaaacggt	ttccggggta	ggggagatca	gctgggaaga	aagcaggttc	ctgagcagct	5940
gcgacttacc	gcagccgggtg	ggcccgtaaa	tcacacctat	taccggctgc	aactggtagt	6000
taagagagct	gcagctgcgc	tcacccctga	gcaggggggc	cacttcgtta	agcatgtccc	6060
tgactcgcat	gttttccctg	accaaaccog	ccagaaggcg	ctcgccgccc	agcगतagca	6120
gttcttgcaa	ggaagcaaag	tttttcaacg	gttttgagacc	gtccgcccga	ggcatgcttt	6180
tgagcgtttg	accaagcagt	tccaggcggt	cccacagctc	ggtcacctgc	tctacggcat	6240
ctcgatccag	catatctcct	cgtttcgcgg	gttggggcgg	ctttcgctgt	acggcagtag	6300
tcggtgctcg	tccagacggg	ccagggtcat	gtctttccac	gggcgcaggg	tcctcgctcag	6360
cgtagtctgg	gtcacgggtga	aggggtgcgc	tccgggctgc	gcgctggcca	gggtgcgctt	6420
gaggctggtc	ctgctgggtgc	tgaagcgctg	cgggtcttcg	ccctgcgcgt	cggccaggta	6480
gcatttgacc	atgggtgtcat	agtccagccc	ctccgcggcg	tggcccttgg	cgcgagctt	6540
gcccttggag	gaggcgccgc	acgaggggca	gtgcagactt	ttgagggcgt	agagcttggg	6600
gcgagagaaat	accgattccg	gggagtaggc	atccgcgcgc	caggcccccgc	agacgggtctc	6660
gcattccacg	agccagggtga	gctctggccg	ttcgggggtca	aaaaccagggt	ttcccccatg	6720
ctttttgatg	cgtttcttac	ctctgggtttc	catgagccgg	tgtccacgct	cggtgacgaa	6780
aaggctgtcc	gtgtccccgt	atacagactt	gagaggcctg	tcctcgagcg	gtgttccgcg	6840
gtcctcctcg	tatagaaact	cggaccactc	tgagacaaag	gctcgcgctc	aggccagcac	6900
gaaggaggct	aagtgggagg	ggtagcgggtc	gttgtccact	aggggggtcca	ctcgctccag	6960
gggtgtgaaga	cacatgtcgc	cctcttcggc	atcaagggaag	gtgattgggt	tgtagggtga	7020
ggccacgtga	ccgggtgttc	ctgaaggggg	gctataaaag	gggggtggggg	cgcgttcgctc	7080
ctcactctct	tccgcactgc	tgctctgcgag	ggccagctgt	tggggtagt	actccctctg	7140
aaaagcgggc	atgacttctg	cgctaagatt	gtcagtttcc	aaaaacgagg	aggatttgat	7200
attcacctgg	cccgcgggtga	tgcctttgag	gggtggccgca	tccatctggt	cagaaaagac	7260
aatctttttg	ttgtcaagct	tgggtggcaaa	cgaccgcgtag	agggcggttg	acagcaactt	7320
ggcgatggag	cgcagggttt	ggtttttgtc	cgatcggcg	cgctccttgg	ccgcgattgt	7380
tagctgcacg	tattcgcgcg	caacgcaccg	ccattcggga	aagacggtgg	tgcgctcgctc	7440
gggcaccagg	tgcacgcgcc	aaccgcgggt	gtgcagggtg	acaagggtcaa	cgctgggtggc	7500
tacctctccg	cgtaggcgct	cgttgggtcca	gcagaggcgg	ccgcccttgc	gcgagcagaa	7560
tggcggtagg	gggtctagct	gcgtctcgtc	cgggggggtct	gcgtccacgg	taaagacccc	7620
gggcagcagg	cgcgcgtcga	agtagtctat	cttgcatcct	tgcaagtcta	gcgcctgctg	7680
ccatgcgcgg	gcggcaagcg	cgcgctcgta	tgggttgagt	gggggacccc	atggcatggg	7740
gtgggtgagc	gcggaggcgt	acatgccgca	aatgtcgtaa	acgtagaggg	gctctctgag	7800
tattccaaga	tatgtagggt	agcatcttcc	accgcggatg	ctggcgcgca	cgtaatcgta	7860
tagttcgtgc	gagggagctga	ggaggtcggg	accgaggttg	ctacgggcgg	gctgctctgc	7920
tcggaagact	atctgcctga	agatggcatg	tgagttggat	gatattggtg	gacgtcgga	7980
gacgttgaag	ctggcgctcg	tgagacctac	cgcgtcacgc	acgaaggagg	cgtaggagtc	8040
gcgcagcttg	ttgaccagct	cggcggtgac	ctgcacgtct	agggcgcgagt	agtccagggt	8100
ttccttgatg	atgtcatact	tatcctgtcc	cttttttttc	cacagctcgc	ggttgaggac	8160
aaactcttcg	cggctcttcc	agtactcttg	gatcggaaac	ccgtcggcct	ccgaacggta	8220
agagcctagc	atgtagaact	ggttgacggc	ctggtaggcg	cagcatccct	tttctacggg	8280
tagcgcgtat	gcctgcgcgg	ccttcgggag	cgaggtgtgg	gtgagcgcaa	aggtgtccct	8340
gaccatgact	ttgaggtact	ggtatttgaa	gtcagtgctg	tcgcatccgc	cctgctccca	8400
gagcaaaaaag	tccgtgcgct	ttttggaacg	cggatttggc	agggcggaagg	tgacatcggt	8460
gaagagtatc	tttcccgcgc	gaggcataaa	gttgcggtg	atgcggaagg	gtcccggcac	8520
ctcggaacgg	ttgttaatta	cctgggcggc	gagcacgac	tcgtcaaagc	cggttgatgt	8580
gtggccccaca	atgtaaagtt	ccaagaagcg	cgggatgccc	ttgatggaag	gcaatttttt	8640

aagttcctcg taggtgagct cttcagggga gctgagcccg tgctctgaaa gggcccagtc 8700
tgcaagatga ggggttggaa cgacgaatga gctccacagg tcacggggcca ttagcatttg 8760
caggtggctcg cgaaagggtcc taaactggcg acctatggcc attttttctg ggggtgatgca 8820
gtagaaggta agcgggtctt gtcccagcg gtcccatcca aggttcgcbg ctaggctctcg 8880
cgcggcagtc actagaggct catctccgcc gaacttcatg accagcatga agggcacgag 8940
ctgcttccca aaggccccc tccaagtata ggtctctaca tcgtagggtga caaagagacg 9000
ctcgggtgca ggatgcbgagc cgatcgggaa gaactggatc tcccgcacc aattggaggga 9060
gtggctattg atgtggtgaa agtagaagtc cctgcbgagc gccgaacact cgtgctggct 9120
tttgtaaaaa cgtgcbgagc actggcagcg gtgcbgaggc tgtacatcct gcacgaggtt 9180
gacctgacga ccgcbgacaa ggaagcagag tgggaatttg agccctcgc ctggcgggtt 9240
tggctgggtg tcttctactt cggctgcttg tcttgaccg tctggctgct cgaggggaggt 9300
tacgggtggat cggaccacca cgcgcagatg ggagctgtcc atggtctgga gctcccgcgg 9360
tcggagcttg atgacaacat cctgcagggt tactcgcag agacgggtca gggcgcgggc 9420
cgtcagggtca ggcgggagct tttccagggg ctgggtgggt gggcgctcga tggcttgcaa 9540
tagatccagg ccccgcbgag gatgcatcta aaagcgggtg cgcggcgag ccccgaggg tagggggggc 9600
gagggcgcag gatgcatcta aaagcgggtg cgcggcgag ccccgaggg tagggggggc 9660
gtccttggat tccggacccg ccgggagagc gggcagggc acgtcgcgc ggcgcgcgg 9720
tgctgcbgag gtagggtgct gggcgaacgc acgacgcgc ggttgatctc ctgaatctgg 9780
cgcctctgca tgaagacgac gggcccggtg agcttgagcc tgaaagagag ttcgacagaa 9840
tcaatttcgg tgcgttgac ggcggcctgg cgcaaatct cctgcacgct tcctgagttg 9900
tcttgatagg cgatctcgcc ggcgaggtcg tggaaatgc gggccatgag ctgcbgagaag 10020
ccggctcgct ccacgggtgg cccagcgcgg ctgtagacca cgcccccttc ggcctcgcgg 10080
gcgcbgcatg ccacctgcgc gagattgagc tccacgtgcc gggcgaagac ggcgtagttt 10140
cgcaggcgt gaaagaggta ggtgaggggt gtggcggtgt gttctgccac gaagaagtac 10200
ataacccagc gtcgcaacgt ggattcgttg gaagtggaaa aactgggagt tgcgcgcga caggttaac 10320
gcctcgtaga agtccacggc gagctcggcg acagtgctgc gcacctcgcg ctcaaaggct 10380
tctcctcca gaagacggat ttcaatctcc tcttccataa gggcctcccc ttcttcttct 10440
acaggggcct tctggcgggc gggggacagc cggcgacgac ggcgcaccgg gaggcggctc 10500
tctggcgggc acaaagcgt ccgcbgctc cccgcgcga cggcgcatgg tctcggtagc ggcgcggccg 10560
ttctcgcggg ggcgcagttg gaagacgcgc cccgtcatgt cccgggttatg ggttggcggg 10620
gggctgccat gcggcagggg tacggcgcta acgatgcac tcaacaattg ttgttaggt 10680
actcgcgcgc cgagggacct gagcaggtcc gcatcgacc gatcggaata cctctcgaga 10740
aaggcgtcta accagtcaca gtcgcaagg aggtcgagca ccgtggcggg cggcagcggg 10800
cggcggtcgg ggttggttct ggcggaggtg ctgctgatga tgtaattaaa gtaggcggct 10860
ttgagacggc ggatggctga cagaagcacc atgtccttg gtccggcctg ctgaatgcgc 10920
aggcggtcgg ccatgcccc cacttcttct tctccttct cgtagttggc gccctcttc tcccatgct 10980
tgcctgagcc tttctaccgg ggagttggc agggctaggt cggcgacaac gcgctcggct 11040
tctatcgct cggcgcgcc agcctcat gctgacagc catccatgtc cacaagcgg 11100
gtgacccga aatattggc cctggttgat ggtgtaagt cagttggcca taacggacca gttaacggct 11160
aatattggc cctggttgat ggtgtaagt cagttggcca taacggacca gttaacggct 11220
tggtgacccg gctgcbgag ctcgggtgtac ctgagacgc agtaagccct cgagtcgaat 11280
acgtagtcgt tgcaagtcgg caccaggtac tggatatcca ccaaaaagt ggcggcgcc 11340
tggcggtaga ggggcccagc taggggtggc ggggctccgg gggcgagatc ttccaacata 11400
aggcgatgat atccgtagat gtacctggac ggggctccgg atccaggtga tgcggcgcc 11460
gcgcgcggaa agtcgcggac gcggttccag atgttgcgca gcggcaaaaa gtgctccatg 11520
gtcgggacgc tctggcggc caggcgcgc caatcggtga cgtctagac cgtgcaaaa 11580
gagagcctgt aagcgggcac tcttccgtgg tctggtggat aaattcgcaa gggatatcat 11640
gcggacgacc ggggttcgag ccccgatatc ggcgcgtccg cgtgatccat ggcggttacc 11700
cccgcgtgtc gaacccaggt gtgcbgagc agacaacggg ggagtgctcc ttttggcttc 11760
cttccaggcg cggcggtgc tgcgctagc ttttggcca ctggcgcgc ctgtagccgg agggttattt 11820
cggttaggc ggaagcgaa agcattaaat ggcctcgtcc ctgtagccgg accggccgga ctgcbgcaa 11880
tccaagggtt gaggcgcgg acccccgggt cgagctcgcg attcctccgg aaacagggac 11940
cgggggtttg cctcccgcgc atgcaagacc ccggtgctgc ggcagatgcg ccccccctct 12000
gagccctttt tttgcttttc aagagcaaga ggcagcgag acactcccc tccctctacc 12060
gcgtcaggag gggcgacatc cgcggttgac ggcgcagcag atggtgatta cgaaccccc 12120
cggcgccggg cccggcacta cctggacttg gaggagggcg agggcctggc gcggctagga 12240

gcgcccctctc ctgagcggta cccaaggggtg cagctgaagc gtgatacgcg tgaggcggtac 12360
 gtgccgcggc agaacctgtt tgcgcaccgc gagggagagg agccccagga gatgcgggat 12420
 cgaaagttcc acgcagggcg cgagctgcgg catggcctga atcgcgagcg gttgctgcgc 12480
 gaggaggact ttgagcccga cgcgcgaacc gggattagtc ccgcgcgcgc acacgtggcg 12540
 gccgccgacc tggtaacgcg atacgagcag acggtgaacc aggagattaa ctttcaaaaa 12600
 agctttaaca accacgtgcg tacgcttggt gcgcgcgagg aggtggctat aggactgatg 12660
 catctgtggg actttgtaag cgcgctggag caaaacccaa atagcaagcc gctcatggcg 12720
 cagctgttcc ttatagtgcg gcacagcagg gacaacgagg cattcagggg tgcgctgcta 12780
 aacatagtag agcccagggg ccgctggctg ctcgatttga taaacatcct gcagagcata 12840
 gtggtgcagg agcgcagctt gagcctggct gacaaggtgg ccgccatcaa ctattccatg 12900
 cttagcctgg gcaagtttta cgcccgaag atataccata ccccttacgt tcccatagac 12960
 aaggaggtaa agatcgaggg gttctacatg cgcattggcg tgaaggtgct taccttgagc 13020
 gacgacctgg gcgtttatcg caacgagcgc atccacaagg ccgtgagcgt gagccggcgg 13080
 cgcgagctca gcgaccgca gctgatgcac agcctgcaaa gggccctggc tggcacggcg 13140
 agcggcgata gagaggcga gtcctacttt gcgcggggcg ggacctggcg ctgggccccca 13200
 agccgacgcg ccctggaggc agctggggcc ggaggaatat gacgaggacg atgagtacga acccgcgcg 13260
 gctggcaacg tcggcgggcg gtttctgatc agatgatgca agacgcaacg gccagaggag 13320
 ggcgagtact aagcgggtgat gcttctgatc cacttaactc cagcgacgac tggcgccagg 13380
 tgccggcgcg gctgcagagc cagccgtccg ctgactgcgc gcaatcctga cgcgttccgg cagcagccgc 13500
 tcatggaccg catcatgtcg attctggaag cggtggtccc ggcgcgcgca aacccccacg 13560
 aggccaaacc gcttccgca gtaaacgcgc tggccgaaaa cagggccatc cggcccgcag 13620
 acgagaaggt gctggcgatc gcgctgcttc agcgcgtggc tgcgtacaac agcggcaacg 13680
 agccggcctt ggtctacgac ctggtggggg atgtgcgcga ggccgtggcg cagcgtgagc 13740
 tgcagaccaa cctggaccgg ctgggctcca tgggtgact aaacgccttc ctgagtacac 13800
 gcgcgcagca gcagggcaac ggacaggagg actacaccaa ctttgtgagc gactgcggcg 13860
 agcccgccaa cgtgccgcgg caaagtggag tgtaccagtc ggccagagac tattttttcc 13920
 taatggtgac tgagacaccg aacagcgtaa accgcgcgac cgtgtctagc aacttgcagg 13980
 agaccagtag acaaggcctg cccacaggcg ctgctaatag tgtaccgcga ggccataggt agcgtgtccc 14040
 ggctgtgggg cctgttgctg ttgctgacac gagattacaa gtgtcagccg tggtgaccaa 14100
 ccaactcgcg cctgttgctg ctttaactacc gaggaggagc gcatthttgcg ccagcgtggc 14160
 gggacacata cctaggtcac ttgctgacac cttaaactacc ggggtaacgc ccagcgtggc 14220
 tggacgagca tactttccag cttaaactacc ggggtaacgc ccagcgtggc 14280
 cgggcagcct ggaggcaacc ttaaacagc gatgcgcgac gggcatgtat gggcgtttat 14340
 cgcttgacag ttttaaacag gatgcgcgac gggcatgtat gggcgtttat 14400
 gccttaacct acatggaacc tgcatcgcg gcctcaaacc gggcgtttat 14460
 acatggaacc tgcatcgcg gcctcaaacc gggcgtttat 14520
 tgcatcgcg gcctcaaacc gggcgtttat 14580
 ggctaccgcg cctctggttt cgacatagac gaggcgggcg gctggacatg 14640
 tccctctggg cgacatagac gaggcgggcg gctggacatg 14700
 tgcaacagcg cgagcaggca tctaggcgct tcttaccagc cctgctgggc 14760
 gcttgtccga tcttaccagc cctgctgggc 14820
 tgatagggct cctcgctgctg cagcgcgagc gtggacaaga 14880
 acctaaacaa ctcgctgctg gtggacaaga 14940
 acaacgggat agagagccta gccaggcccc gactcggcag 15000
 acaggacagt gccaggcccc gactcggcag 15060
 gtctggtgtg gtttgccgac cttcgcccc ctcaccaagg 15120
 gtggcaacct aaataaaaaa ctcaccaagg 15180
 gcatgatgca atgcccgcg cgccgatgta 15240
 tccccctagt atgcccgcg cgccgatgta 15300
 tgtggtgagc gcggcgccag tggcgggcg gctgggttct 15360
 cccgcggtt gtgcccgcg ggtacctgcg gcttaccggg 15420
 ctctgagttg gcacccctat tgcacaccac ccgtgtgtac 15480
 ggtgtggga tccctgaact accagaacga ccacagcaac 15540
 aaacaatgac tacagcccgg gggaggcaag cacacagacc 15600
 gactggggg gcgacactga aaaccatcct gcataccaac 15660
 catgtttacc aataagttta aggcgcgggt gatggtgtcg 15720
 tcaggtggag ctgaaatacg agtgggtgga gttcacgctg 15780
 gaccatgacc atagacctta tgaacaacgc gatcgtggag 15840
 acagaacggg gttctggaaa gcgacatcgg ggtaaagttt 15900
 ggggtttgac cccgtcactg gtcttgtcat gctggggta 15960
 tccagacatc attttgctgc caggatgcgg ggtggacttc acccacagcc

cttggtgggc atccgcaagc ggcaaccctt ccaggagggc tttaggatca cctacgatga 16020
tctggagggg ggtaacattc ccgcaactgt ggatgtggac gcctaccagg cgagcttgaa 16080
agatgacacc gaacagggcg ggggtggcgc agggcgagc aacagcagtg gcagcggcgc 16140
ggaagagaa tccaacgcgg cagccgcggc aatgcagccg gtggaggaca tgaacgatca 16200
tgccattcgc ggcgacacct ttgccacacg ggctgaggag aagcgcgctg aggcggaagc 16260
agcggccgaa ggtgccgccc ccgctgcgca acccgaggtc gagaagcctc agaagaaacc 16320
ggtgatcaaa cccctgacag aggacagcaa gaaacgcagt tacaacctaa taagcaatga 16380
cagcaccttc acccagtagc gcagctggta ccttgcatat aactacggcg accctcagac 16440
cggaatccgc tcatggaccc tgctttgcac tccctgacgt acctgcggtc cggagcaggt 16500
ctactggctg ttgccagaca tgatgcaaga ccccgtagac ttccgctcca cgcgccagat 16560
cagcaacttt ccggtgggtg gcgcccagct gttgcccgtg cactccaaga gcttctacaa 16620
cgaccaggcc gtctactccc aactcatccg ccgcccagcc ctgcccgaaca gcatcggagg 16680
tgaaaacggt cctgctctca cagatcacgg gacgtaccc tgcccctacg tttacaaggc 16740
agtccagcga gtgaccatta ctgacgccag acgcccagcc ttttgagcaa gcatgtccat 16800
cctgggcata gtctcgccgc gcgtcctatc gagccgcaact tttccaagca agatgtttgg 16860
ccttatatcg cccagcaata acacaggtcg gggcctgcgc ttcccaagca accggtcgcc 16920
cggggccaag aagcgtccg accaaccacc ggcgcactgg gcgcaccacc ccatcgacgc 17040
ctggggcgcg cacaacgcg gccgcactgg cgcgaccacc cagtggtcca cagtggacgc 17100
ggtgggtggg gaggcgcgca actacacgcc cagccgcca gcgctatgct gacggcggag 17160
ggccattcag accgtgggtg gcggagcccg cggcactgcc gcccacgcg cggcggcgcc 17220
gcgcgtagca cgtcgccacc gcgcggccg gcacggccg atgcccggcg ctgaaaggct 17280
cctgcttaac cgcgcacgtc tgccccccag gtccaggcga cgagcggccg ccgcagcagc 17340
ggccgcgggt agtgctatga ctccagggtcg caggggcaac gtgtattggg tgccgcgactc 17400
cgccggccatt ctgcccgtgc ccgtgcccac tccgcccccg cgcaactaga ttgcaagaaa 17460
ggttagcggc gactcgtact gttgtatgta ccaggtcatc ccgcccccg gcggcgcgca acgaagctat 17520
aaactactta aaatcaaaag aagagatgct ccaggtcatc ccgcccccg gcggcgcgca tctatggccc 17580
gtccaagcgc gaagagcagg attacaagcc cggaaagcta aagcgggtca aaaagaaaaa 17640
cccgaagaag gatgatgaac ttgacgacga ggtggaactg ctgcacgcta ccgcgcccag 17700
gaaagatgat cagtggaaaag gtgcagcgtt aaacgtggt ctcgacccg gcaccaccgt 17760
gcgacgggta agtcgtgagc gctccacccg caactacaag cgcgtgtatg atgaggtgta 17820
agtccttacg cccggtgagc agcaggccaa cgagcgctc ggggagtttg cctacggaaa 17880
cgccgacgag gacatgctgg cggttgccgt ggacgagggc gcttgacccg tccgaagaaa agcgcggcct 17940
gcggcataag gacatgctgg cggttgccgt ggacgagggc gcttgacccg atggtaccca agcgcggcct 18000
gcccgttaaca ctgcagcagg tgctgcccgc tggcaccac cgtgcagctg ctggagcccc aggtccgctg 18060
aaagcgcgag tctggtgact tggcaccac aaatgaccgt cgccgggact gggcgtgcag accgtggacg 18120
actggaagat gtcttggaag aatgaccgt cgccgggact gggcgtgcag accgtggacg 18180
gcggccaatc aagcaggtgg agcaccagta ttgccaccgc cagagagggc gtaggagacac aaacgtcccc 18240
cactaccagt gcggtggcgg atgcccgggt gacagagggc gtaggagacac aaacgtcccc 18300
ggttgccctc gtgcaaacgg acccgtggat gtttcgctt gctactgccc caactaccgc cgtccaagac 18360
ctctacggag aagtagcggc ccgccagcgc atcgtggcta cccctaccgc cgtcgccagc cgtcgccagc 18420
cggttcgagg acccccggct gaacccgcgg tggctcgcg agggagcagg accctggtgc tgccaacagc 18480
cattgcccct ccccccggct gaacccgcgg tggctcgcg agggagcagg accctggtgc tgccaacagc 18540
ccgacgccga accaccactg tggtcgcgaa tttaaaagcc cgggtgccgg cggtgcccgt ctagctgggg 18600
cccgatattc gtgcccaggg tggctcgcg agggagcagg accctggtgc tgccaacagc 18660
gcgctaccac cccagcatcg tttaaaagcc cgggtgccgg cggtgcccgt ctagctgggg 18720
cacctgccgc ctccgtttcc cggtgcccgt cggtgcccgt ctagctgggg 18780
catggccggc cagcgctga cggtatcct ttgcatccgt ggccttgcag ggcggcgcg 18840
gtcgacccgt gtgcaaacgg acccgtggat gtttcgctt gctactgccc caactaccgc cgtcgccagc 18900
gattggcgcc gtgcaaacgg acccgtggat gtttcgctt gctactgccc caactaccgc cgtcgccagc 18960
aacaagttgc atgtggaaaa atcaaaataa aaagtctgga ggccttgcag ggcggcgcg 19020
tgtaactatt ttgtagaatg gaagacatca actttgcgtc tctggccccg ctctcacgct 19080
cgcccccgtt catgggaaac tggcaagata tccggcaccag caatatgagc ggtggcgctt 19140
tcagctgggg ctgctgtggt agcagagggc agatgctgag cctctggcat tagcgggggt 19200
gcgcaaggc ctggaacagc gatggcctgg cctctggcat tagcgggggt 19260
atccaaca aaaggtggta aagattaaca gtaagcttga tccccgccct tcccgcgccc 19320
ccaaccaggc agcctccacc ggcggtggag acagtgcttc cagagggggc tggcgaaaag cgtccgcgcc 19380
agcctccacc ggcggtggag agaaactctg gtgacgagcc tccctcgtag gaggaggcac 19440
ccgacaggga cctgcccacc acccgtccca tcgcccggc ggctaccgga gtgctggggc 19500
taaagcaagg cgtaacgctg gacctgcctc cccccgcga ccccagcag aaacctgtgc 19560
agcacacacc

-30-

tgccaggccc	gaccgcccgtt	gttgtaaccc	gtcctagccg	cgcgtccctg	cgccgcgcgcg	19680
ccagcgggtcc	gcgatcgttg	cggccccgtag	ccagtggcaa	ctggcaaagc	acactgaaca	19740
gcacgtggg	tctgggggtg	caatccctga	agcgcgcgacg	atgcttctga	atagctaaccg	19800
tgctgatatgt	gtgtcatgta	tgcgtccatg	tgcgcgcag	aggagctgct	gagccgcgcg	19860
gcgcgcgctt	tccaagatgg	ctaccccttc	gatgatgccg	cagtggctctt	acatgcacat	19920
ctcggggccag	gacgcctcgg	agtacctgag	ccccgggctg	gtgcagtttg	cccgcgcac	19980
cgagacgtac	ttcagcctga	ataacaagtt	tagaaacccc	acgggtggcgc	ctacgcacga	20040
cgtgaccaca	gaccggtccc	agcgtttgac	gctgcggttc	atccctgtgg	accgtgagga	20100
tactgcgtac	tcgtacaagg	cgcggttcac	cctagctgtg	ggtgataacc	gtgtgctgga	20160
catggcttcc	acgtactttg	acatccgcgg	cgtgctggac	aggggccccta	cttttaagcc	20220
ctactctggc	actgcctaca	acgcccctggc	tcccaagggt	gccccaaatc	cttgcgatg	20280
ggatgaagct	gctactgctc	ttgaaataaa	cctagaagaa	gaggacgatg	acaacgaaga	20340
cgaagtagac	gagcaagctg	agcagcaaaa	aactcacgta	tttgggcagg	cgccttattc	20400
tggatataaat	attacaaagg	aggggtattca	aatagggtgtc	gaaggctcaa	cacctaaata	20460
tgccgataaaa	acattttcaac	ctgaacctca	aataggagaa	tctcagtggt	acgaaactga	20520
aattaatcat	gcagctggga	gagtccttaa	aaagactacc	ccaatgaaac	catgttacgg	20580
ttcatatgca	aaaccacaaa	atgaaaatgg	agggcaaggc	attcttgtaa	agcaacaaaa	20640
tggaaagcta	gaaagtcaag	tggaaatgca	atttttctca	actactgagg	cgaccgcagg	20700
caatggtgat	aacttgactc	ctaaagtggg	attgtacagt	gaagatgtag	atatagaaac	20760
cccagacact	catatttctt	acatgcccac	tattaaggaa	ggtaactcac	gagaactaat	20820
gggccaacaa	tctatgccc	acaggcctaa	ttacattgct	tttagggaca	attttattgg	20880
tctaattgtat	tacaacagca	cgggtaatat	gggtgttctg	gcggggccaag	catcgcagt	20940
gaatgctggt	gtagatttgc	aagacagaaa	cacagagctt	tcataaccagc	ttttgcttga	21000
ttccattggg	gatagaacca	gggtacttttc	tatgtggaat	caggctgttg	acagctatga	21060
tccagatggt	agaattattg	aaaatcatgg	aactgaagat	gaacttccaa	attactgctt	21120
tccactggga	gggtgtgatta	atacagagac	tcttaccaag	gtaaaaccta	aaacaggtca	21180
ggaaaatgga	tgggaaaaaag	atgctacaga	attttcagat	aaaaatgaaa	taagagtggg	21240
aaataatttt	gccatggaaa	tcaatctaaa	tgccaaacctg	tggagaaaatt	tcctgtactc	21300
caacatagcg	ctgtatttgc	ccgacaagct	aaagtacagt	ccttccaacg	taaaaatttc	21360
tgataaccca	aacacctacg	actacatgaa	caagcgagtg	gtggctcccg	ggttagtggg	21420
ctgctacatt	aaccttggag	cacgctgggtc	ccttgactat	atggacaacg	tcaaccctatt	21480
taaccaccac	cgcaatgctg	gcctgcgcta	cgctccaatg	ttgctgggca	atggctcgcta	21540
tgtgcccttc	cacatccagg	tgccctcagaa	gttctttgcc	attaaaaacc	tccttctcct	21600
gccgggctca	tacacctacg	agtggaaactt	caggaaggat	gttaacatgg	ttctgcagag	21660
ctccctagga	aatgacctaa	gggttgacgg	agccagcatt	aagtttgata	gcatttgcct	21720
ttacgccacc	ttcttcccca	tggcccaaaa	caccgcctcc	acgcttgagg	ccatgcttag	21780
aaacgacacc	aacgaccagt	cctttaacga	ctatctctcc	gccgccaaaca	tgctctaccc	21840
tatacccgcc	aacgctacca	acgtgcccac	atccatcccc	tcccgcact	gggcggcttt	21900
ccgcggctgg	gccttcacgc	gccttaagac	taaggaaacc	ccatcactgg	gctcgggcta	21960
cgacccttat	tacacctact	ctggctctat	accctaccta	gatggaaacct	tttacctcaa	22020
ccacaccttt	aagaagggtg	ccattacctt	tgactcttct	gtcagctggc	ctggcaatga	22080
cgcttgccag	acccccaacg	agtttgaaat	taagcgctca	ggtgacgggg	aggggttaaaa	22140
cattggctac	tgtaacatga	ccaaagactg	gttcttggtg	caaagtctag	ctaactacaa	22200
tagaaacttc	cagggcttct	atatcccaga	gagctacaag	gaccgcatgt	actccttctt	22260
acagggtggc	cagcccattga	gccgtcaggt	ggtggatgat	actaaataca	aggactacca	22320
catgcgcgaa	atcctacacc	aacacaacaa	ctctggattt	gttggctacc	ttgccccac	22380
agttgacagc	attaccacga	aaaagtcttct	cttcccctat	ccgcttatag	gcaagaccgc	22440
ctccagtaac	tttatgtcca	tgggcgcact	ttgcgatcgc	accctttggc	gcatcccat	22500
caactccgcc	cacgcgctag	acatgacttt	cacagacctg	ggccaaaacc	ttctctacgc	22560
tctttatggt	ttggttgaag	tctttgacgt	tgaggtggat	cccatggacg	agccaccct	22620
catcgaaacc	gtgtacctgc	gcacgcctt	ggtcccggtg	caccggcgcg	accgcggcgt	22680
caagcaacat	caacaacagc	tgccgccatg	ggctccagtg	aacgccacaa	cataaagaag	22740
gtcaaagatc	ttggttgtgg	gccatatttt	ttgggcacct	agcaggaact	gaaagccatt	22800
tttggttctc	cacacaagct	cgctgcgcgc	atagctcaata	atgacaagcg	ctttccaggc	22860
ggcgtacact	ggatggcctt	tgccctggaac	ccgcactcaa	cggccggctcg	cgagactggg	22920
ccctttgggt	tttctgacca	gcgactcaag	caggtttacc	aaacatgcta	cctctttgag	22980
ctgcgcgcta	gcgccattgc	ttcttcccc	gaccgctgta	agtttgagta	cgagtcactc	23040
caaagcgtac	aggggcccac	ctcggccgcg	tgtggactat	taacgctgga	aaagtccacc	23100
gcctttgcca	actggcccca	aactccccatg	gatcacaacc	tctgtgcat	gtttctccac	23160
ggggtaccca	actccatgct	caacagtcctc	caggtacagc	ccaccatgaa	ccttattacc	23220
				ccaccctgcg	tcgcaaccag	23280

-31-

gaacagctct	acagcttcct	ggagcgccac	tcgccctact	tccgcagcca	cagtgcgcag	23340
attaggagcg	ccacttcctt	ttgtcacttg	aaaaacatgt	aaaaataatg	tactagagac	23400
actttcaata	aaggcaaatg	cttttatttg	tacactctcg	ggtgattatt	tacccccacc	23460
cttgccgtct	gcgcggtttg	gggagggcgg	ggcgacgggg	acgggggacga	cacgtcctcc	23520
atgggtgggg	gacgtcgcg	cgacccgcgt	ccgcgctcgg	gggtgggttc	gcgctgctcc	23580
tcttcccgac	tggccatttc	cttctcctat	aggcagaaaa	agatcatgga	gtcagtcgag	23640
aagaaggaca	gcctaaccgc	cccctctgag	ttcgccacca	ccgcctccac	cgatgccgcc	23700
aacgcgccta	ccaccttccc	cgctcgaggca	cccccgcttg	aggaggagga	agtgattatc	23760
gagcaggacc	caggttttgt	aagcgaagac	gacgaggacc	gctcagtacc	aacagaggat	23820
aaaaagcaag	accaggacaa	cgcagaggca	aacgaggaa	aagtgcggcg	gggggacgaa	23880
aggcatggcg	actacctaga	tgtgggagac	gacgtgctgt	tgaagcatct	gcagcgccag	23940
tgcgccatta	tctgcgacgc	gttgcaagag	cgacgcgatg	tgccccctcg	catagcggat	24000
gtcagccttg	cctacgaacg	ccacctattc	tcaccgcgcg	taccccccaa	acgccaagaa	24060
aacggcacat	gcgagcccaa	cccgcgcctc	aacttctacc	ccgtatttgc	cggtgccagag	24120
gtgcttgcca	cctatcacat	ctttttccaa	aactgcaaga	tacccctatc	ctgccgtgcc	24180
aaccgcagcc	gagcggacaa	gcagctggcc	ttgcggcagg	gcgctgtcat	acctgatata	24240
gcctcgctca	acgaagtgcc	aaaaatcttt	gagggctctg	gacgcgacga	gaagcgcgcg	24300
gcaaacgctc	tgcaacagga	aaacagcgaa	aatgaaagt	actctggagt	gttgggtgga	24360
ctcgagggtg	acaacgcgcg	cctagccgta	ctaaaacgca	gcatcgaggt	caccactttt	24420
gcctaccggg	cacttaacct	accccccaag	gtcatgagca	cagtcatgag	tgagctgata	24480
gtgcgccttg	cgacgcccct	ggagagggat	gcaaatttgc	aagaacaaac	agaggagggg	24540
ctaccgcgag	ttggcgacga	gcagctagcg	cgctggcttc	aaacgcgcga	gcctgccgac	24600
ttggaggagc	gacgcaaaat	aatgatggcc	gcagtgctcg	ttaccgtgga	gcttgagtgc	24660
atgcagcggg	tctttgctga	cccggagatg	cagcgcaagc	tagaggaaaac	attgcaactac	24720
acctttcgac	agggctacgt	acgcccaggcc	tgcaagatct	ccaacgtgga	gctctgcaac	24780
ctggctctcct	accttggaa	tttgacgaa	aaccgccttg	ggcaaaaacgt	gcttcatttc	24840
acgctcaagg	gcgagggcgc	ccgcgactac	ctccgcgact	gcgtttactt	atttctatgc	24900
tacacctggc	agacggccat	gggcgttttg	cagcagtgct	tgaggaggatg	caacctcaag	24960
gagctgcaga	aactgtataa	gcaaaacttg	aaggacctat	ggacggccct	caacgagcgc	25020
tccgtggccg	cgacactggc	ggacatcatt	ttccccgaac	gcctgcttaa	aacctgcaa	25080
cagggctctg	cagactctac	cagtcaaagc	atgttgacga	actttaggaa	ctttatccta	25140
gagcgctcag	gaatcttgcc	cgccacctgc	tgtgcacttc	ctagcgactt	tgtgcccatt	25200
aagtaccgcg	aatgccctcc	gccgcttttg	ggccactgct	accttctgca	gtagcccaac	25260
taccttgcc	accactctga	cataatggaa	gacgtgagcg	gtgacggctc	actggagtgt	25320
cactgtcgct	gcaacctatg	caccccgac	cgctccctgg	tttgcaattc	gcagctgctt	25380
aacgaagaatc	aaattatcgg	tacctttgag	ctgcagggtc	cctcgccctga	cgaaaagtcc	25440
gcggctccgg	ggttgaaaact	cactccgggg	ctgtggacgt	cggcttacct	tcgcaaat	25500
gtacctgagg	actaccacgc	ccacgagatt	aggttctacg	aagaccaatc	ccgcccgcga	25560
aatgcggagc	ttaccgcctg	cgctcat	caggggccaca	ttcttgccca	attgcaagcc	25620
atcaacaaa	cccgcgaaga	gtttctgcta	cgaaagggac	gggggggttta	cttggaacccc	25680
cagtcggcg	aggagctcaa	cccaatcccc	ccgcccgcgc	agccctatca	gcagcagccg	25740
cgggcccttg	cttcccagga	tggcacccaa	aaagaagctg	cagctgccgc	cgccacccac	25800
ggacgaggag	gaatactggg	acagtacggc	agaggaggtt	ttggacgagg	aggaggagga	25860
catgatggaa	gactgggaga	gcctagacga	ggaagcttcc	gaggtcgaag	aggtgtcaga	25920
cgaaacaccg	tcaccctcgg	tcgcattccc	ctcgccggcg	ccccagaaat	cggaaccggg	25980
ttccagcatg	gctacaacct	ccgctcctca	ggcgccggcg	gcactgcccg	ttcgccgacc	26040
caaccgtaga	tgggacacca	ctggaaccag	ggccggtaag	tccaagcagc	cgccgcctgt	26100
agcccaagag	caacaacagc	gccaaggcta	ccgctcatgg	cgccggcaca	agaacgccat	26160
agttgcttgc	ttgcaagact	gtgggggcaa	catctccttc	gcccgcgcgt	ttcttctcta	26220
ccatcacggc	gtggccttcc	ccgtaacat	cctgcattac	taccgtcatc	tctacagccc	26280
atactgcacc	ggcggcagcg	gcagcggcag	caacagcagc	ggccacacag	aagcaaaggc	26340
gaccggatag	caagactctg	acaaaagccca	agaaatccac	agcggcggca	gcagcaggag	26400
gaggagcgct	gcgtctggcg	cccaacgaac	ccgtatcgac	ccgcgagctt	agaaacagga	26460
tttttccac	tctgtatgct	atatttcaac	agagcagggg	ccaagaacaa	gagctgaaaa	26520
taaaaaacag	gtctctgcga	tccctcacc	gcagctgcct	gtatcaciaa	agcgaagatc	26580
agcttcggcg	cacgctggaa	gacgcggagg	ctctcttcag	taaatactgc	gcgctgactc	26640
ttaaggacta	gtttcgcgcc	ctttctcaaa	tttaagcgcg	aaaactacgt	catctccagc	26700
ggccacaccc	ggcgccagca	cctgtcgtca	gcgccttat	gagcaaggaa	attcccacgc	26760
ctacatgtg	gagttaccag	ccacaaatgg	cacttgccgc	tggagctgcc	caagactact	26820
caacccgaat	aaactacatg	agcgcgggac	cccacatgat	atcccgggtc	aacggaatcc	26880
gcgcccaccg	aaaccgaatt	ctcttggaac	aggcggtat	taccaccaca	cctcgtaata	26940

accttaatcc	cogtagttgg	cccgtgccc	tggtgtacca	ggaaagtccc	gctcccacca	27000
ctgtgggtact	tcccagagac	gcccaggccg	aagttcagat	gactaactca	ggggcgagc	27060
ttgcggggcgg	ctttcgtcac	aggggtgagg	cgcccgggca	gggtataact	cacctgacaa	27120
tcagaggggag	aggtattcag	ctcaacgacg	agtcgggtgag	ctcctcgctt	ggtctccgtc	27180
cggacggggac	atctcagatc	ggcgggcgccg	gccgtccttc	attcacgcct	cgtcaggcaa	27240
tcctaactct	gcagacctcg	tccctcgagc	cgcgctctgg	aggcattgga	actctgcaat	27300
ttattgagga	gtttgtgcca	tcgggtctact	ttaaccctt	ctcgggacct	cccggccact	27360
atccggatca	atcttattcct	aactttgacg	cggtaaagga	ctcggcgagc	ggctacgact	27420
gaatgttaag	tggagaggca	gagcaactgc	gcctgaaaca	cctgggtccac	tgtcgccgcc	27480
acaagtgtct	tgcccgcgac	tccgggtgagt	tttgctactt	tgaattgccc	gaggatcata	27540
tcagagggccc	ggcgacacgc	gtccggctta	ccgcccaggg	agagcttgcc	cgtagcctga	27600
ttcgggagtt	taccacgcgc	cccctgctag	ttgagcggga	caggggagcc	tgtgttctca	27660
ctgtgatttg	caactgtcct	aaccttggat	tacatcaaga	tctttgttgc	catctctgtg	27720
ctgagtataa	taaatacaga	aattaaaata	tactggggct	cctatcgcca	tcctgtaaac	27780
gccaccgtct	tcaccgcgcc	aagcaaacca	aggcgaaact	tacctggtac	ttttaacatc	27840
tctccctctg	tgatttacaa	cagtttcaac	ccagacggag	tgagtctacg	agagaacctc	27900
tccgagctca	gctactccat	cagaaaaaac	accaccttcc	ttacctgccg	ggaacgtacg	27960
agtgcgtcac	cggccgctgc	accacacctt	ccgcctgacc	gtaaaccaga	ctttttccgg	28020
acagacctca	ataactctgt	ttaccagaac	aggaggtgag	cttagaaaac	ccttagggta	28080
ttaggccaaa	ggcgacagcta	ctgtgggggt	tatgaacaat	tcaagcaact	ctacgggcta	28140
ttctaattca	ggtttctcta	gaaatggacg	gaattattac	agagcagcgc	ctgctagaaa	28200
gacgcagggc	agcgggccgag	caacagcgca	tgaatcaaga	gctccaagac	atggttaact	28260
tgcaccagtg	caaaaaggggt	atcttttctg	tggtaaaagca	ggccaaagtc	acctacgaca	28320
gtaataccac	cggacaccgc	cttagctaca	agttgccaac	caagcgtcag	aaattgggtg	28380
tcattggtggg	agaaaagccc	attaccataa	ctcagcactc	ggtagaaacc	gaaggctgca	28440
ttcactcacc	ttgtcaagga	cctgaggatc	tctgcaccct	tattaagacc	ctgtgcggtc	28500
tcaaagatct	tattcccttt	aactaataaa	aaaaaataat	aaagcatcac	ttacttaaaa	28560
tcagttagca	aattttctgtc	cagtttatte	agcagcacct	ccttgccctc	ctcccagctc	28620
tggtattgca	gcttctctct	ggctgcaaac	tttctccaca	atctaaatgg	aatgtcagtt	28680
tctctctgtt	cctgtccatc	cgcacccact	atcttcatgt	tgttgagat	gaagcgcgca	28740
agaccgtctg	aagatacctt	caaccccggt	tatccatatg	acacggaaac	cggctctcca	28800
actgtgcctt	ttcttactcc	tccctttgta	tcccccattg	ggtttcaaga	gagtccccct	28860
ggggtactct	ctttgcgctt	atccgaacct	ctagttacct	ccaatggcat	gcttgcgctc	28920
aaaatgggca	acggcctctc	tctggacgag	gcccggcaacc	ttacctccca	aaatgtaacc	28980
actgtgagcc	cacctctcaa	aaaaaccaag	tcaaacataa	acctggaat	atctgcaccc	29040
ctcacagtta	cctcagaagc	cctaactgtg	gctgcgcgcg	caactcta	ggcgcggggc	29100
aacacactca	ccatgcaatc	acaggccccg	ctaaccgtgc	acgactccaa	acttagcatt	29160
gccacccaag	gacccctcac	agtgtcagaa	ggaaagctag	ccctgcaaac	atcaggcccc	29220
ctcaccacca	ccgatagcag	tacccttact	atcactgcct	cacccccctc	aactactgcc	29280
actggtagct	tgggcattga	cttgaaagag	cccatttata	cacaaaatgg	aaaactagga	29340
ctaaagtacg	gggctccttt	gcatgtaaca	gacagcttaa	acactttgac	cgtagcaact	29400
ggtccagggtg	tgactattaa	taataacttc	ttgcaaaacta	aagttactgg	agccttgggt	29460
tttgattcac	aaggcaatat	gcaacttaat	gtagcaggag	gactaaggat	tgattctcaa	29520
aacagacgcc	ttatacttga	tggtagttat	ccgtttgatg	ctcaaaacca	actaaatcta	29580
agactaggac	agggccctct	ttttataaac	tcagcccaca	acttggtat	taactacaac	29640
aaaggccctt	acttgtttac	agcttcaaac	aattccaaaa	agcttgaggt	taacctaagc	29700
actgccaagg	ggttgatgtt	tgacgctaca	gccatagcca	ttaatgcagg	agatgggctt	29760
gaatttggtt	cacctaatgc	accaaacaca	aatccctca	aaacaaaaat	tggccatggc	29820
ctagaatttg	attcaaacaa	ggctatgggt	cctaaactag	gaactggcct	tagttttgac	29880
agcacagggtg	ccattacagt	aggaacaaaa	aataatgata	agctaaactt	gtggaccaca	29940
ccagctccat	ctcctaactg	tagactaaat	gcagagaaag	atgctaaact	cactttgggtc	30000
ttacaacaaat	gtggcagtc	aatacttgct	acagtttcag	ttttgggtgt	taaaggcagt	30060
ttggctccaa	tatctggaac	agttcaaaag	gctcatctta	ttataagatt	tgacgaaaaa	30120
ggagtgtctac	taaacaattc	cttccctggac	ccagaattat	ggaacttttag	aaatggagat	30180
cttactgaag	gcacagccta	tacaaaagct	gttgatttta	tgccctaacct	atcagcttat	30240
ccaaaatctc	acgggtaaaa	tgccaaaagt	aacattgtca	gtcaagttta	cttaaacgga	30300
gacaaaacta	aacctgtaac	actaaccatt	acactaaacg	gtacacagga	aacaggagac	30360
acaactccaa	gtgcatactc	tatgtcattt	tcatgggact	ggtctggcca	caactacatt	30420
aatgaaatat	ttgccacatc	ctcttacact	ttttcataca	ttgcccaga	ataaagaatc	30480
gtttggtgta	tgtttcaacg	tgtttatatt	tcaattgcag	aaaatttcaa	gtcatttttc	30540
attcagtagt	atagccccac	caccacatag	cttatacaga	tcaccgtacc	ttaatcaaac	30600

-33-

tcacagaacc	ctagtattca	acctgccacc	tccctcccaa	cacacagagt	acacagtcct	30660
ttctccccgg	ctggccttaa	aaagcatcat	atcatgggta	acagacatat	tcttaggtgt	30720
tatattccac	acgggtttcct	gtcagaccaa	acgtcatca	gtgatattaa	taaaactccc	30780
gggcagctca	cttaagttca	tgctcgctgtc	cagctgctga	gccacaggct	gctgtccaac	30840
ttgcggttgc	ttaacgggcg	gcgaaggaga	agtccacgcc	tacatggggg	tagagtcata	30900
atcgtgcatc	aggatagggc	ggtggtgctg	cagcagcgcg	cgaataaaact	gctgccgcgc	30960
ccgctccgctc	ctgcaggaat	acaacatggc	agtggctctcc	tcagcgatga	ttcgcaccgc	31020
ccgcagcata	aggcgcttgc	tcctccgggc	acagcagcgc	accctgatct	cacttaaatc	31080
agcacagtaa	ctgcagcaca	gcaccacaat	attgttcaaa	atcccacagt	gcaaggcgct	31140
gtatccaaag	ctcatggcgg	ggaccacaga	acccacgtgg	ccatcatacc	acaagcgag	31200
gtagattaag	tggcgacccc	tcataaacac	gctggacata	aacattacct	cttttggcat	31260
ggtgtaattc	accacctccc	ggtaccatat	aaacctctga	ttaaacatgg	cgccatccac	31320
caccatccta	aaccagctgg	ccaaaacctg	cccgcggct	atacactgca	gggaaccggg	31380
actggaacaa	tgacagtgga	gagcccagga	ctcgtaacca	tggatcatca	tgctcgctcat	31440
gatatcaatg	ttggcacaac	acaggcacac	gtgcatacac	ttcctcagga	ttacaagctc	31500
ctcccgctt	agaaccatat	cccagggaac	aacccattcc	tgaatcagcg	taaatcccac	31560
actgcaggga	agacctcgca	cgtaactcac	ggtgtgcatt	gtcaaagtgt	tacattcggg	31620
cagcagcgga	tgatcctcca	gtatggtagc	gtgggtttct	gtctcaaaag	gaggtagacg	31680
atccctactg	tacggagtgc	gccgagacaa	ccgagatcgt	ggtggctcgt	gtgtcatgcc	31740
aaatggaacg	ccggacgtag	tcataatttc	tgaagcaaaa	ccaggtgcgg	gcgtgacaaa	31800
cagatctgcg	tctccggtct	cgccgcttag	atcgtctgt	gtagtagttg	tagtatatcc	31860
actctctcaa	agcatccagg	cgccccctgg	cttcgggttc	tatgtaaact	ccttcattgcg	31920
ccgctgcctc	gataacatcc	accacgcgag	aataagccac	accagccaa	cctacacatt	31980
cggttctgcga	gtcacacacg	ggaggagcgg	gaagagctgg	aagaaccatg	tttttttttt	32040
tattccaaaa	gattatccaa	aacctcaaaa	tgaagatcta	ttaagtgaac	gcgctccccct	32100
ccggtggcgt	ggtcaaaactc	tacagccaaa	gaacagataa	tggcatttgt	aagatggtgc	32160
acaatggctt	ccaaaaggca	aacggccctc	acgtccaagt	ggacgtaaag	gctaaaccct	32220
tcagggtgaa	tctcctctat	aaacattcca	gcaccttcaa	ccatgcccaa	ataattctca	32280
tctcgccacc	ttctcaatat	atctctaagc	aaatccccga	tattaagtcc	ggccattgta	32340
aaaatctgct	ccagagcgcc	ctccaccttc	agcctcaagc	agcgaatcat	gattgcaaaa	32400
attcagggtt	ctcacagacc	tgtataagat	tcaaaagcgg	aacattaaca	aaaataaccgc	32460
gatcccgtag	gtcccttcgc	agggccagct	gaacataatc	gtgcaggctc	gcacggacca	32520
gcgcggccac	ttccccgcca	ggaaccttga	caaaagaacc	cacactgatt	atgacacgca	32580
tactcggagc	tatgctaacc	agcgtagccc	cgatgtaagc	tttgttgcat	gggcggcgat	32640
ataaaatgca	aggtgctgct	caaaaaatca	ggcaaagcct	cgcgcaaaaa	agaaagcaca	32700
tcgtagtcat	gctcatgcag	ataaaggcag	gtaagctccg	gaaccaccac	agaaaaagac	32760
accatttttc	tctcaaacat	gtctgcgggt	ttctgcataa	acacaaaata	aaataacaaa	32820
aaaacattta	aacattagaa	gcctgtctta	caacaggaaa	aacaaccctt	ataagcataa	32880
gacggactac	ggccatgccc	gcgtgaccgt	aaaaaaaactg	gtcaccgtga	ttaaaaagca	32940
ccaccgacag	ctcctcggtc	atgtccggag	tcataatgta	agactcggta	aacacatcag	33000
ggtgattcat	cggtcagtgc	taaaaagcga	ccgaaatagc	ccgggggaat	acatacccg	33060
aggcgtagag	acaacattac	agcccccata	ggaggtataa	caaaattaat	aggagagaaa	33120
aacacataaa	cacctgaaaa	accctcctgc	ctaggcaaaa	tagcaccctc	ccgctccaga	33180
acaacataca	gcgcttcaca	gcggcagcct	aacagtcagc	cttaccagta	aaaaagaaaa	33240
cctattaaaa	aaacaccact	cgacacggca	ccagctcaat	cagtcacagt	gtaaaaaagg	33300
gccaagtgca	gagcgagtat	atataggact	aaaaaatgac	gtaacgggta	aagtccacaa	33360
aaaacaccca	gaaaaccgca	cgcgaacctc	cgcccagaaa	cgaaagccaa	aaaaccacaa	33420
acttcctcaa	atcgctcactt	ccgttttccc	acgttacgta	acttcccatt	ttaagaaaac	33480
tacaattccc	aacacataca	agttactccg	ccctaaaacc	tacgtcaccc	gccccgttcc	33540
cacgccccgc	gccagtcac	aaactccacc	ccctcattat	catattggct	tcaatccaaa	33600
ataaggtata	ttattgatga	tg				33622

<210> 45

<211> 1746

<212> DNA

<213> Artificial Sequence

<220>

<223> 5F KO1

<400> 45

-34-

```

atgaagcgcg caagaccgtc tgaagatacc ttcaaccccg tgtatccata tgacacggaa 60
accggctcctc caactgtgcc ttttcttact cctccctttg tatcccccaa tgggtttcaa 120
gagagtcctcc ctgggggtact ctctttgcgc ctatccgaac ctctagttac ctccaatggc 180
atgcttgcgcg tcaaaatggg caacggcctc tctctggacg aggcgggcaa ccttacctcc 240
caaaatgtaa ccactgtgag cccacctctc aaaaaaacca agtcaaacat aaacctggaa 300
atatctgcac ccctcacagt tacctcagaa gccctaactg tggctgccgc cgcacctcta 360
atggtcgcgcg gcaacacact caccatgcaa tcacaggccc cgctaaccgt gcacgactcc 420
aaacttagca ttgccaccca aggaccctc acagtgtcag aaggaaagct agccctgcaa 480
acatcaggcc ccctcaccac caccgatagc agtaccctta ctatcactgc ctaccccct 540
ctaactactg ccactggtag cttgggcatt gacttgaaag agcccattta tacacaaaat 600
ggaaaactag gactaaagta cggggctcct ttgcatgtaa cagacgacct aaacactttg 660
accgtagcaa ctggtccagg tgtgactatt aataatactt ccttgcaaac taaagtact 720
ggagccttgg gttttgattc acaaggcaat atgcaactta atgtagcagg aggactaagg 780
attgattctc aaaacagacg ccttatactt gatgttagtt atccgtttga tgctcaaac 840
caactaaatc taagactagg acagggccct ctttttataa actcagccca caacttggat 900
attaactaca acaaaggcct ttacttgttt acagcttcaa acaattccaa aaagcttgag 960
gttaacctaa gcaactgccaa ggggttgatg tttgacgcta cagccatagc cattaatgca 1020
ggagatgggc ttgaatttgg ttcacctaat gcaccaaaca caaatcccct caaaacaaaa 1080
attggccatg gcctagaatt tgattcaaac aaggctatgg ttcctaaact aggaactggc 1140
cttagttttg acagcacagg tgccattaca gtaggaaaca aaaataatga taagctaact 1200
ttgtggacca caccagctcc agaggctaac tgtagactaa atgcagagaa agatgctaaa 1260
ctcacttttg tcttaacaaa atgtggcagt caaatacttg ctacagtttc agttttggct 1320
gttaaaggca gtttggctcc aatatctgga acagttcaca gtgctcatct tattataaga 1380
tttgacgaaa atggagtgt actaaacaat tccttctgga acccagaata ttggaacttt 1440
agaaatggag atcttactga aggcacagcc tatacaaacg ctgttggatt tatgcctaac 1500
ctatcagctt atccaaaatc tcacggtaaa actgccaaaa gtaacattgt cagtcaagtt 1560
tacttaaacg gagacaaaac taaacctgta acactaacca ttacactaaa cggtagacag 1620
gaaacaggag acacaactcc aagtgcatac tctatgtcat tttcatggga ctggtctggc 1680
cacaactaca ttaatgaaat atttgccaca tcctcttaca ctttttcata cattgcccac 1740
gaataa

```

<210> 46

<211> 581

<212> PRT

<213> Artificial Sequence

<220>

<223> 5F K01

<400> 46

```

Met Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn Pro Val Tyr Pro
1      5      10
Tyr Asp Thr Glu Thr Gly Pro Pro Thr Val Pro Phe Leu Thr Pro Pro
20     25     30
Phe Val Ser Pro Asn Gly Phe Gln Glu Ser Pro Pro Gly Val Leu Ser
35     40     45
Leu Arg Leu Ser Glu Pro Leu Val Thr Ser Asn Gly Met Leu Ala Leu
50     55     60
Lys Met Gly Asn Gly Leu Ser Leu Asp Glu Ala Gly Asn Leu Thr Ser
65     70     75
Gln Asn Val Thr Thr Val Ser Pro Pro Leu Lys Lys Thr Lys Ser Asn
85     90     95
Ile Asn Leu Glu Ile Ser Ala Pro Leu Thr Val Thr Ser Glu Ala Leu
100    105    110
Thr Val Ala Ala Ala Pro Leu Met Val Ala Gly Asn Thr Leu Thr
115    120    125
Met Gln Ser Gln Ala Pro Leu Thr Val His Asp Ser Lys Leu Ser Ile
130    135    140
Ala Thr Gln Gly Pro Leu Thr Val Ser Glu Gly Lys Leu Ala Leu Gln
145    150    155
Thr Ser Gly Pro Leu Thr Thr Thr Asp Ser Ser Thr Leu Thr Ile Thr
160

```

-35-

				165					170				175		
Ala	Ser	Pro	Pro	Leu	Thr	Thr	Ala	Thr	Gly	Ser	Leu	Gly	Ile	Asp	Leu
			180					185					190		
Lys	Glu	Pro	Ile	Tyr	Thr	Gln	Asn	Gly	Lys	Leu	Gly	Leu	Lys	Tyr	Gly
		195					200					205			
Ala	Pro	Leu	His	Val	Thr	Asp	Asp	Leu	Asn	Thr	Leu	Thr	Val	Ala	Thr
	210					215					220				
Gly	Pro	Gly	Val	Thr	Ile	Asn	Asn	Thr	Ser	Leu	Gln	Thr	Lys	Val	Thr
225				230						235					240
Gly	Ala	Leu	Gly	Phe	Asp	Ser	Gln	Gly	Asn	Met	Gln	Leu	Asn	Val	Ala
				245					250					255	
Gly	Gly	Leu	Arg	Ile	Asp	Ser	Gln	Asn	Arg	Arg	Leu	Ile	Leu	Asp	Val
			260					265					270		
Ser	Tyr	Pro	Phe	Asp	Ala	Gln	Asn	Gln	Leu	Asn	Leu	Arg	Leu	Gly	Gln
		275					280					285			
Gly	Pro	Leu	Phe	Ile	Asn	Ser	Ala	His	Asn	Leu	Asp	Ile	Asn	Tyr	Asn
	290				295						300				
Lys	Gly	Leu	Tyr	Leu	Phe	Thr	Ala	Ser	Asn	Asn	Ser	Lys	Lys	Leu	Glu
305				310						315					320
Val	Asn	Leu	Ser	Thr	Ala	Lys	Gly	Leu	Met	Phe	Asp	Ala	Thr	Ala	Ile
				325					330					335	
Ala	Ile	Asn	Ala	Gly	Asp	Gly	Leu	Glu	Phe	Gly	Ser	Pro	Asn	Ala	Pro
			340					345					350		
Asn	Thr	Asn	Pro	Leu	Lys	Thr	Lys	Ile	Gly	His	Gly	Leu	Glu	Phe	Asp
		355					360					365			
Ser	Asn	Lys	Ala	Met	Val	Pro	Lys	Leu	Gly	Thr	Gly	Leu	Ser	Phe	Asp
	370					375					380				
Ser	Thr	Gly	Ala	Ile	Thr	Val	Gly	Asn	Lys	Asn	Asn	Asp	Lys	Leu	Thr
385				390					395						400
Leu	Trp	Thr	Thr	Pro	Ala	Pro	Glu	Ala	Asn	Cys	Arg	Leu	Asn	Ala	Glu
				405					410					415	
Lys	Asp	Ala	Lys	Leu	Thr	Leu	Val	Leu	Thr	Lys	Cys	Gly	Ser	Gln	Ile
			420					425					430		
Leu	Ala	Thr	Val	Ser	Val	Leu	Ala	Val	Lys	Gly	Ser	Leu	Ala	Pro	Ile
	435						440					445			
Ser	Gly	Thr	Val	Gln	Ser	Ala	His	Leu	Ile	Ile	Arg	Phe	Asp	Glu	Asn
	450					455					460				
Gly	Val	Leu	Leu	Asn	Asn	Ser	Phe	Leu	Asp	Pro	Glu	Tyr	Trp	Asn	Phe
465				470						475					480
Arg	Asn	Gly	Asp	Leu	Thr	Glu	Gly	Thr	Ala	Tyr	Thr	Asn	Ala	Val	Gly
				485					490					495	
Phe	Met	Pro	Asn	Leu	Ser	Ala	Tyr	Pro	Lys	Ser	His	Gly	Lys	Thr	Ala
		500						505					510		
Lys	Ser	Asn	Ile	Val	Ser	Gln	Val								

```
<210> 47
<211> 1776
<212> DNA
<213> Artificial Sequence

<220>
```

-36-

<223> 5F KO1RGD

<400> 47

```

atgaagcgcg caagaccgtc tgaagatacc ttcaaccccg tgtatccata tgacacggaa 60
accggtcctc caactgtgcc ttttcttact cctccctttg tatcccccac tgggtttcaa 120
gagagtcccc ctgggggtact ctctttgcgc ctatccgaac ctctagttac ctccaatggc 180
atgcttgccg tcaaaatggg caacggcctc tctctggacg aggcgggcaa ccttacctcc 240
caaaatgtaa ccactgtgag cccacctctc aaaaaaacca agtcaaacad aaacctggaa 300
atatctgcac ccctcacagt tacctcagaa gccctaactg tggctgcccgc cgcacctcta 360
atggctgcgg gcaacacact caccatgcaa tcacaggccc cgctaaccgt gcacgactcc 420
aaacttagca ttgccaccca aggacccctc acagtgtcag aaggaaagct agccctgcaa 480
acatcaggcc ccctcaccac caccgatagc agtaccctta ctatcactgc ctcacccctc 540
ctaactactg ccactggtag cttgggcatt gacttgaaag agccatttta tacacaaaat 600
ggaaaactag gactaaagta cggggctcct ttgcatgtaa cagacgacct aaacactttg 660
accgtagcaa ctgggtccagg tgtgactatt aataatactt ccttgcaaac taaagttact 720
ggagccttgg gttttgattc acaaggcaat atgcaactta atgtagcagg aggactaagg 780
attgattctc aaaacagacg ccttatactt gatgttagtt atccgtttga tgctcaaac 840
caactaaatc taagactagg acagggccct ctttttataa actcagccca caacttggat 900
attaactaca acaaaggcct ttacttgttt acagcttcaa acaattccaa aaagcttgag 960
gttaacctaa gcactgcca ggggttgatg tttgacgcta cagccatagc cattaatgca 1020
ggagatgggc ttgaatttgg ttcacctaat gcaccaaa caaatcccct caaaacaaaa 1080
attggccatg gcctagaatt tgattcaaac aaggctatgg ttcctaaact aggaactggc 1140
cttagttttg acagcacagg tgccattaca gtaggaaaca aaaataatga taagctaact 1200
ttgtggacca caccagctcc atctcctaac tgtagactaa atgcagagaa agatgctaaa 1260
ctcacttttg tcttaacaaa atgtggcagt caaatacttg ctacagtttc agttttggct 1320
gttaaaggca gtttggctcc aatatctgga acagttcaaa gtgctcatct tattataaga 1380
tttgacgaaa atggagtgc actaaacaat tccttcctgg acccagaata ttggaacttt 1440
agaaatggag atcttactga aggcacagcc tatacaaacg ctgttggatt tatgcctaac 1500
ctatcagctt atccaaaatc tcacggtaaa actgccaaa gtaacattgt cagtcaagtt 1560
tacttaaacg gagacaaaac taaacctgta acactaacca ttactactaa cggtacacag 1620
gaaacaggtg atcattgtga ttgtcgtggg gattgttttt gtacaactcc aagtgcatat 1680
tctatgtcat tttcatggga ctggtctggc cacaactaca ttaatgaaat atttgccaca 1740
tcctcttaca ctttttcata cattgcccac gaataa 1776

```

<210> 48

<211> 591

<212> PRT

<213> Artificial Sequence

<220>

<223> 5F KO1RGD

<400> 48

```

Met Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn Pro Val Tyr Pro
1      5      10
Tyr Asp Thr Glu Thr Gly Pro Pro Thr Val Pro Phe Leu Thr Pro Pro
20     25     30
Phe Val Ser Pro Asn Gly Phe Gln Glu Ser Pro Pro Gly Val Leu Ser
35     40     45
Leu Arg Leu Ser Glu Pro Leu Val Thr Ser Asn Gly Met Leu Ala Leu
50     55     60
Lys Met Gly Asn Gly Leu Ser Leu Asp Glu Ala Gly Asn Leu Thr Ser
65     70     75
Gln Asn Val Thr Thr Val Ser Pro Pro Leu Lys Lys Thr Lys Ser Asn
85     90     95
Ile Asn Leu Glu Ile Ser Ala Pro Leu Thr Val Thr Ser Glu Ala Leu
100    105    110
Thr Val Ala Ala Ala Ala Pro Leu Met Val Ala Gly Asn Thr Leu Thr
115    120    125
Met Gln Ser Gln Ala Pro Leu Thr Val His Asp Ser Lys Leu Ser Ile
130    135    140

```

-37-

Ala	Thr	Gln	Gly	Pro	Leu	Thr	Val	Ser	Glu	Gly	Lys	Leu	Ala	Leu	Gln
145					150					155					160
Thr	Ser	Gly	Pro	Leu	Thr	Thr	Thr	Asp	Ser	Ser	Thr	Leu	Thr	Ile	Thr
				165					170					175	
Ala	Ser	Pro	Pro	Leu	Thr	Thr	Ala	Thr	Gly	Ser	Leu	Gly	Ile	Asp	Leu
			180					185					190		
Lys	Glu	Pro	Ile	Tyr	Thr	Gln	Asn	Gly	Lys	Leu	Gly	Leu	Lys	Tyr	Gly
		195					200					205			
Ala	Pro	Leu	His	Val	Thr	Asp	Asp	Leu	Asn	Thr	Leu	Thr	Val	Ala	Thr
	210					215					220				
Gly	Pro	Gly	Val	Thr	Ile	Asn	Asn	Thr	Ser	Leu	Gln	Thr	Lys	Val	Thr
225					230					235					240
Gly	Ala	Leu	Gly	Phe	Asp	Ser	Gln	Gly	Asn	Met	Gln	Leu	Asn	Val	Ala
				245					250					255	
Gly	Gly	Leu	Arg	Ile	Asp	Ser	Gln	Asn	Arg	Arg	Leu	Ile	Leu	Asp	Val
			260					265					270		
Ser	Tyr	Pro	Phe	Asp	Ala	Gln	Asn	Gln	Leu	Asn	Leu	Arg	Leu	Gly	Gln
		275					280					285			
Gly	Pro	Leu	Phe	Ile	Asn	Ser	Ala	His	Asn	Leu	Asp	Ile	Asn	Tyr	Asn
	290				295						300				
Lys	Gly	Leu	Tyr	Leu	Phe	Thr	Ala	Ser	Asn	Asn	Ser	Lys	Lys	Leu	Glu
305					310					315					320
Val	Asn	Leu	Ser	Thr	Ala	Lys	Gly	Leu	Met	Phe	Asp	Ala	Thr	Ala	Ile
				325					330					335	
Ala	Ile	Asn	Ala	Gly	Asp	Gly	Leu	Glu	Phe	Gly	Ser	Pro	Asn	Ala	Pro
			340					345					350		
Asn	Thr	Asn	Pro	Leu	Lys	Thr	Lys	Ile	Gly	His	Gly	Leu	Glu	Phe	Asp
		355					360					365			
Ser	Asn	Lys	Ala	Met	Val	Pro	Lys	Leu	Gly	Thr	Gly	Leu	Ser	Phe	Asp
	370					375					380				
Ser	Thr	Gly	Ala	Ile	Thr	Val	Gly	Asn	Lys	Asn	Asn	Asp	Lys	Leu	Thr
385					390					395					400
Leu	Trp	Thr	Thr	Pro	Ala	Pro	Glu	Ala	Asn	Cys	Arg	Leu	Asn	Ala	Glu
				405					410					415	
Lys	Asp	Ala	Lys	Leu	Thr	Leu	Val	Leu	Thr	Lys	Cys	Gly	Ser	Gln	Ile
			420					425					430		
Leu	Ala	Thr	Val	Ser	Val	Leu	Ala	Val	Lys	Gly	Ser	Leu	Ala	Pro	Ile
		435					440					445			
Ser	Gly	Thr	Val	Gln	Ser	Ala	His	Leu	Ile	Ile	Arg	Phe	Asp	Glu	Asn
		450				455					460				
Gly	Val	Leu	Leu	Asn	Asn	Ser	Phe	Leu	Asp	Pro	Glu	Tyr	Trp	Asn	Phe
465				470						475					480
Arg	Asn	Gly	Asp	Leu	Thr	Glu	Gly	Thr	Ala	Tyr	Thr	Asn	Ala	Val	Gly
				485					490					495	
Phe	Met	Pro	Asn	Leu	Ser	Ala	Tyr	Pro	Lys	Ser	His	Gly	Lys	Thr	Ala
			500					505					510		
Lys	Ser	Asn	Ile	Val	Ser	Gln	Val	Tyr	Leu	Asn	Gly	Asp	Lys	Thr	Lys
		515					520					525			
Pro	Val	Thr	Leu	Thr	Ile	Thr	Leu	Asn	Gly	Thr	Gln	Glu	Thr	Gly	Asp
		530				535					540				
His	Cys	Asp	Cys	Arg	Gly	Asp	Cys	Phe	Cys	Thr	Thr	Pro	Ser	Ala	Tyr
545					550					555					560
Ser	Met	Ser	Phe	Ser	Trp	Asp	Trp	Ser	Gly	His	Asn	Tyr	Ile	Asn	Glu
				565					570					575	
Ile	Phe	Ala	Thr	Ser	Ser	Tyr	Thr	Phe	Ser	Tyr	Ile	Ala	Gln	Glu	
			580					585					590		

<210> 49

<211> 1746

<212> DNA

-38-

<213> Artificial Sequence

<220>

<223> 5F KO12

<400> 49

```

atgaagcgcg caagaccgtc tgaagatacc ttcaaccccg tgtatccata tgacacggaa 60
accggtcctc caactgtgcc ttttcttact cctccctttg tatcccccac tgggtttcaa 120
gagagtcccc ctgggggtact ctctttgctc ctatccgaac ctctagttag ctccaatggc 180
atgcttgctc tcaaaatggg caacggcctc tctctggacg aggccggcaa ccttacctcc 240
caaaatgtaa ccactgtgag cccacctctc aaaaaaacca agtcaaacat aaacctggaa 300
atatctgcac ccctcacagt tacctcagaa gccctaactg tggctgccgc cgcacctcta 360
atggctcgcg gcaacacact caccatgcaa tcacaggccc cgctaaccgt gcacgactcc 420
aaacttagca ttgccacca aggaccctc acagtgtcag aaggaaagct agccctgcaa 480
acatcaggcc ccctcaccac caccgatagc agtaccctta ctatcactgc ctcacccctc 540
ctaactactg ccactggtag cttggggcatt gacttgaaag agcccattta tacacaaaat 600
ggaaaactag gactaaagta cggggctcct ttgcatgtaa cagacgacct aaacactttg 660
accgtagcaa ctggtccagg tgtgactatt aataatactt ccttgcaaac taaagttact 720
ggagccttgg gttttgattc acaaggcaat atgcaactta atgtagcagg aggactaagg 780
attgattctc aaaacagacg ccttatactt gatgttagtt atccgtttga tgctcaaaac 840
caactaaatc taagactagg acagggcctt ctttttataa actcagccca caacttggat 900
attaactaca acaaaggcct ttacttgttt acagcttcaa acaattccaa aaagcttgag 960
gttaacctaa gcactgcca ggggttgatg ttgacgcta cagccatagc cattaatgca 1020
ggagatgggc ttgaatttgg ttcacctaat gcaccaaaca caaatcccct caaaacaaaa 1080
attggccatg gcctagaatt tgattcaaac aaggctatgg ttctaaact aggaactggc 1140
cttagttttg acagcacagg tgccattaca gtaggaaaca aaaataatga taagctaact 1200
ttgtggacca caccagctcc atctcctaac tgttactaa atggaggcgg agatgctaaa 1260
ctcacttttg tcttaacaaa atgtggcagt caaatacttg ctacagtttc agttttggct 1320
gttaaaggca gtttggctcc aatatctgga acagttcaaa gtgctcatct tattataaga 1380
tttgacgaaa atggagtgt actaaacaat tccttctctg acccagaata ttggaacttt 1440
agaaatggag atcttactga aggcacagcc tatacaaacg ctgttggatt tatgcctaat 1500
ctatcagctt atccaaaatc tcacggtaaa actgccaaaa gtaacattgt cagtcaagtt 1560
tacttaaacy gagacaaaac taaacctgta acactaacca ttacactaaa cggtagacacag 1620
gaaacaggag acacaactcc aagtgcatac tctatgtcat tttcatggga ctggtctggc 1680
cacaactaca ttaatgaaat atttgccaca tcctcttaca ctttttcata cattgcccac 1740
gaataa

```

<210> 50

<211> 581

<212> PRT

<213> Artificial Sequence

<220>

<223> 5F KO12

<400> 50

```

Met Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn Pro Val Tyr Pro
1      5      10      15
Tyr Asp Thr Glu Thr Gly Pro Pro Thr Val Pro Phe Leu Thr Pro Pro
20      25      30
Phe Val Ser Pro Asn Gly Phe Gln Glu Ser Pro Pro Gly Val Leu Ser
35      40      45
Leu Arg Leu Ser Glu Pro Leu Val Thr Ser Asn Gly Met Leu Ala Leu
50      55      60
Lys Met Gly Asn Gly Leu Ser Leu Asp Glu Ala Gly Asn Leu Thr Ser
65      70      75      80
Gln Asn Val Thr Thr Val Ser Pro Pro Leu Lys Lys Thr Lys Ser Asn
85      90      95
Ile Asn Leu Glu Ile Ser Ala Pro Leu Thr Val Thr Ser Glu Ala Leu
100     105     110
Thr Val Ala Ala Ala Ala Pro Leu Met Val Ala Gly Asn Thr Leu Thr

```


-40-

<210> 51
 <211> 1746
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> 5F S*

<400> 51
 atgaagcgcg caagaccgtc tgaagatacc ttcaaccccg tgtatccata tgacacggaa 60
 accggtcctc caactgtgcc ttttcttact cctccctttg tatcccccaa tggggtttcaa 120
 gagagtcccc ctgggggtact ctcttttgcg ctatccgaac ctctagttac ctccaatggc 180
 atgcttgcg tcaaaatggg caacggcctc tctctggacg aggccggcaa ccttacctcc 240
 caaaatgtaa ccactgtgag cccacctctc ggagccggag cctcaaacat aaacctggaa 300
 atatctgcac ccctcacagt tacctcagaa gccctaactg tggctgcccgc cgcacctcta 360
 atggctcgcg gcaacacact caccatgcaa tcacaggccc cgctaaccgt gcacgactcc 420
 aaacttagca ttgccaccca aggaccctc acagtgtcag aaggaaagct agccctgcaa 480
 acatcaggcc ccctcaccac caccgatagc agtaccctta ctatcactgc ctcacccctc 540
 ctaactactg ccactggtag cttgggcatt gacttgaaag agcccattta tacacaaaat 600
 ggaaaactag gactaaagta cggggctcct ttgcatgtaa cagacgacct aaacactttg 660
 accgtagcaa ctggtccagg tgtgactatt aataatactt ccttgcaaac taaagttact 720
 ggagccttgg gttttgattc acaaggcaat atgcaactta atgtagcagg aggactaagg 780
 attgattctc aaaacagacg ccttatactt gatgttagtt atccgtttga tgctcaaac 840
 caactaaatc taagactagg acagggccct ctttttataa actcagccca caacttggat 900
 attaactaca acaaaggcct ttacttgttt acagcttcaa acaattccaa aaagcttgag 960
 gttaacctaa gcaactgccaa ggggttgatg tttgacgcta cagccatagc cattaatgca 1020
 ggagatgggc ttgaatttgg ttcacctaat gcaccaaaca caaatcccct caaaacaaaa 1080
 attggccatg gcctagaatt tgattcaaac aaggctatgg ttcctaaact aggaactggc 1140
 cttagttttg acagcacagg tgccattaca gtaggaaaca aaaataatga taagctaact 1200
 ttgtggacca caccagctcc atctcctaac tgtagactaa atgcagagaa agatgctaaa 1260
 ctcacttttg tcttaacaaa atgtggcagt caaatacttg ctacagtttc agttttggct 1320
 gttaaaggca gtttggctcc aatatctgga acagttcaaa gtgctcatct tattataaga 1380
 tttgacgaaa atggagtgt actaaacaat tccttcctgg acccagaata ttggaacttt 1440
 agaaatggag atcttactga aggcacagcc tatacaaacg ctggttgatt tatgcctaac 1500
 ctatcagctt atccaaaatc tcacggtaaa actgccaaaa gtaacattgt cagtcaagtt 1560
 tacttaaacg gagacaaaac taaacctgta acactaacca ttacactaaa cgggtacacag 1620
 gaaacaggag acacaactcc aagtgcatac tctatgtcat tttcatggga ctggtctggc 1680
 cacaactaca ttaatgaaat atttgccaca tcctcttaca ctttttcata cattgccccaa 1740
 gaataa 1746

<210> 52
 <211> 581
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> 5F S*

<400> 52
 Met Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn Pro Val Tyr Pro
 1 5 10 15
 Tyr Asp Thr Glu Thr Gly Pro Pro Thr Val Pro Phe Leu Thr Pro Pro
 20 25 30
 Phe Val Ser Pro Asn Gly Phe Gln Glu Ser Pro Pro Gly Val Leu Ser
 35 40 45
 Leu Arg Leu Ser Glu Pro Leu Val Thr Ser Asn Gly Met Leu Ala Leu
 50 55 60
 Lys Met Gly Asn Gly Leu Ser Leu Asp Glu Ala Gly Asn Leu Thr Ser
 65 70 75 80
 Gln Asn Val Thr Thr Val Ser Pro Pro Leu Gly Ala Gly Ala Ser Asn
 85 90 95

-41-

Ile Asn Leu Glu Ile Ser Ala Pro Leu Thr Val Thr Ser Glu Ala Leu
 100 105 110
 Thr Val Ala Ala Ala Pro Leu Met Val Ala Gly Asn Thr Leu Thr
 115 120 125
 Met Gln Ser Gln Ala Pro Leu Thr Val His Asp Ser Lys Leu Ser Ile
 130 135 140
 Ala Thr Gln Gly Pro Leu Thr Val Ser Glu Gly Lys Leu Ala Leu Gln
 145 150 155 160
 Thr Ser Gly Pro Leu Thr Thr Thr Asp Ser Ser Thr Leu Thr Ile Thr
 165 170 175
 Ala Ser Pro Pro Leu Thr Thr Ala Thr Gly Ser Leu Gly Ile Asp Leu
 180 185 190
 Lys Glu Pro Ile Tyr Thr Gln Asn Gly Lys Leu Gly Leu Lys Tyr Gly
 195 200 205
 Ala Pro Leu His Val Thr Asp Asp Leu Asn Thr Leu Thr Val Ala Thr
 210 215 220
 Gly Pro Gly Val Thr Ile Asn Asn Thr Ser Leu Gln Thr Lys Val Thr
 225 230 235 240
 Gly Ala Leu Gly Phe Asp Ser Gln Gly Asn Met Gln Leu Asn Val Ala
 245 250 255
 Gly Gly Leu Arg Ile Asp Ser Gln Asn Arg Arg Leu Ile Leu Asp Val
 260 265 270
 Ser Tyr Pro Phe Asp Ala Gln Asn Gln Leu Asn Leu Arg Leu Gly Gln
 275 280 285
 Gly Pro Leu Phe Ile Asn Ser Ala His Asn Leu Asp Ile Asn Tyr Asn
 290 295 300
 Lys Gly Leu Tyr Leu Phe Thr Ala Ser Asn Asn Ser Lys Lys Leu Glu
 305 310 315 320
 Val Asn Leu Ser Thr Ala Lys Gly Leu Met Phe Asp Ala Thr Ala Ile
 325 330 335
 Ala Ile Asn Ala Gly Asp Gly Leu Glu Phe Gly Ser Pro Asn Ala Pro
 340 345 350
 Asn Thr Asn Pro Leu Lys Thr Lys Ile Gly His Gly Leu Glu Phe Asp
 355 360 365
 Ser Asn Lys Ala Met Val Pro Lys Leu Gly Thr Gly Leu Ser Phe Asp
 370 375 380
 Ser Thr Gly Ala Ile Thr Val Gly Asn Lys Asn Asn Asp Lys Leu Thr
 385 390 395 400
 Leu Trp Thr Thr Pro Ala Pro Ser Pro Asn Cys Arg Leu Asn Ala Glu
 405 410 415
 Lys Asp Ala Lys Leu Thr Leu Val Leu Thr Lys Cys Gly Ser Gln Ile
 420 425 430
 Leu Ala Thr Val Ser Val Leu Ala Val Lys Gly Ser Leu Ala Pro Ile
 435 440 445
 Ser Gly Thr Val Gln Ser Ala His Leu Ile Ile Arg Phe Asp Glu Asn
 450 455 460
 Gly Val Leu Leu Asn Asn Ser Phe Leu Asp Pro Glu Tyr Trp Asn Phe
 465 470 475 480
 Arg Asn Gly Asp Leu Thr Glu Gly Thr Ala Tyr Thr Asn Ala Val Gly
 485 490 495
 Phe Met Pro Asn Leu Ser Ala Tyr Pro Lys Ser His Gly Lys Thr Ala
 500 505 510
 Lys Ser Asn Ile Val Ser Gln Val Tyr Leu Asn Gly Asp Lys Thr Lys
 515 520 525
 Pro Val Thr Leu Thr Ile Thr Leu Asn Gly Thr Gln Glu Thr Gly Asp
 530 535 540
 Thr Thr Pro Ser Ala Tyr Ser Met Ser Phe Ser Trp Asp Trp Ser Gly
 545 550 555 560
 His Asn Tyr Ile Asn Glu Ile Phe Ala Thr Ser Ser Tyr Thr Phe Ser
 565 570 575
 Tyr Ile Ala Gln Glu

-42-

580

<210> 53
 <211> 1776
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> 5F S*RGD

<400> 53
 atgaagcgcg caagaccgtc tgaagatacc ttcaaccccg tgtatccata tgacacggaa 60
 accggtcctc caactgtgcc ttttcttact cctccctttg tatcccccac tgggtttcaa 120
 gagagtcccc ctgggttact ctctttgcgc ctatccgaac ctctagttac ctccaatggc 180
 atgcttgccg tcaaaatggg caacggcctc tctctggacg aggccggcaa ccttacctcc 240
 caaaatgtaa ccactgtgag cccacctctc ggagccggag cctcaaacad aaacctggaa 300
 atatctgcac ccctcacagt tacctcagaa gccctaactg tggctgccgc cgcacctcta 360
 atggtcgcgg gcaacacact caccatgcaa tcacaggccc cgctaaccgt gcacgactcc 420
 aaacttagca ttgccacca aggaccctc acagtgtcag aaggaaagct agccctgcaa 480
 acatcaggcc ccctcaccac caccgatagc agtaccctta ctatcactgc ctcacccctc 540
 ctaactactg ccactggtag cttgggcatt gacttgaaag agcccattta tacacaaaat 600
 ggaaaactag gactaaagta cggggctcct ttgcatgtaa cagacgacct aaacactttg 660
 accgtagcaa ctgggtccagg tgtgactatt aataatactt ccttgcaaac taaagttact 720
 ggagccttgg gttttgattc acaaggcaat atgcaactta atgtagcagg aggactaagg 780
 attgattctc aaaacagacg ccttatactt gatgttagtt atccgtttga tgctcaaac 840
 caactaaatc taagactagg acagggccct ctttttataa actcagccca caacttggat 900
 attaaactaca acaaaggcct ttacttggtt acagcttcaa acaattccaa aaagcttgag 960
 gttaacctaa gcactgccaa ggggttgatg tttgacgcta cagccatagc cattaatgca 1020
 ggagatgggc ttgaatttgg ttcacctaat gcaccaaaca caaatcccct caaaacaaaa 1080
 attggccatg gcctagaatt tgattcaaac aaggctatgg ttcctaaact aggaactggc 1140
 cttagttttg acagcacagg tgccattaca gtaggaaaca aaaataatga taagctaact 1200
 ttgtggacca caccagctcc atctcctaac tgtagactaa atgcagagaa agatgctaaa 1260
 ctacttttgg tcttaacaaa atgtggcagt caaatacttg ctacagtttc agttttggct 1320
 gttaaaggca gtttggctcc aatatctgga acagttcaaa gtgctcatct tattataaga 1380
 tttgacgaaa atggagtgtc actaaacaat tccttcctgg acccagaata ttggaacttt 1440
 agaaatggag atcttactga aggcacagcc tatacaaacg ctgttggatt tatgcctaac 1500
 ctatcagctt atccaaaatc tcacggtaaa actgccaaaa gtaacattgt cagtcaagtt 1560
 tacttaaacg gagacaaaac taaacctgta acactaacca ttactactaa cggtagacag 1620
 gaaacaggtg atcattgtga ttgtcgtggt gattgttttt gtacaactcc aagtgcatac 1680
 tctatgtcat tttcatggga ctggtctggc cacaactaca ttaatgaaat atttgccaca 1740
 tctcttaca ctttttcata cattgcccaa gaataa 1776

<210> 54
 <211> 591
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> 5F S*RGD

<400> 54
 Met Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn Pro Val Tyr Pro
 1 5 10 15
 Tyr Asp Thr Glu Thr Gly Pro Pro Thr Val Pro Phe Leu Thr Pro Pro
 20 25 30
 Phe Val Ser Pro Asn Gly Phe Gln Glu Ser Pro Pro Gly Val Leu Ser
 35 40 45
 Leu Arg Leu Ser Glu Pro Leu Val Thr Ser Asn Gly Met Leu Ala Leu
 50 55 60
 Lys Met Gly Asn Gly Leu Ser Leu Asp Glu Ala Gly Asn Leu Thr Ser

-44-

Ser Met Ser Phe Ser Trp Asp Trp Ser Gly His Asn Tyr Ile Asn Glu
 565 570 575
 Ile Phe Ala Thr Ser Ser Tyr Thr Phe Ser Tyr Ile Ala Gln Glu
 580 585 590

<210> 55
 <211> 1746
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> 5F KO1S*

<400> 55
 atgaagcgcg caagaccgtc tgaagatacc ttcaaccccg tgtatccata tgacacggaa 60
 accggtccctc caactgtgcc ttttcttact cctccctttg tatcccccac tgggtttcaa 120
 gagagtcctc ctgggggtact ctctttgcgc ctatccgaac ctctagttac ctccaatggc 180
 atgcttgccg tcaaaatggg caacggcctc tctctggacg aggccggcga ccttacctcc 240
 caaaatgtaa ccactgtgag cccacctctc ggagccggag cctcaaacat aaacctggaa 300
 atatctgcac ccctcacagt tacctcagaa gccctaactg tggctgcccgc cgcacctcta 360
 atggtcgcgg gcaacacact caccatgcaa tcacaggccc cgctaaccgt gcacgactcc 420
 aaacttagca ttgccaccca aggaccctc acagtgtcag aaggaaagct agccctgcaa 480
 acatcaggcc ccctcaccac caccgatagc agtaccctta ctatcactgc ctcacccctc 540
 ctaactactg ccactggtag cttgggcatt gacttgaaag agccattta tacacaaaat 600
 ggaaaactag gactaaagta cggggctcct ttgcatgtaa cagacgacct aaacactttg 660
 accgtagcaa ctgggtccagg tgtgactatt aataatactt ccttgcaaac taaagttact 720
 ggagccttgg gttttgattc acaaggcaat atgcaactta atgtagcagg aggactaagg 780
 attgattctc aaaacagacg ccttatactt gatgttagtt atccgtttga tgctcaaaac 840
 caactaaatc taagactagg acagggccct ctttttataa actcagccca caacttggat 900
 attaactaca acaaaggcct ttacttgttt acagcttcaa acaattccaa aaagcttgag 960
 gttaacctaa gcaactgcaa ggggttgatg tttgacgcta cagccatagc cattaatgca 1020
 ggagatgggc ttgaatttgg ttcacctaata gcaccaaaca caaatcccct caaaacaaaa 1080
 attggccatg gcctagaatt tgattcaaac aaggctatgg ttcctaaact aggaactggc 1140
 cttagttttg acagcacagg tgccattaca gtaggaaaca aaaataatga taagctaact 1200
 ttgtggacca caccagctcc agaggctaac tgtagactaa atgcagagaa agatgctaaa 1260
 ctacttttgg tcttaacaaa atgtggcagt caaatacttg ctacagtttc agttttggct 1320
 gttaaaggca gtttggctcc aatatctgga acagttcaaa gtgctcatct tattataaga 1380
 tttgacgaaa atggagtgtc actaaacaat tccttcctgg acccagaata ttggaacttt 1440
 agaaatggag atcttactga aggcacagcc tatacaaacy ctggttgatt tatgcctaac 1500
 ctatcagctt atccaaaatc tcacggtaaa actgccaaaa gtaacattgt cagtcaagtt 1560
 tacttaaacg gagacaaaac taaacctgta acactaacca ttactactaa cgttacacag 1620
 gaaacaggag acacaactcc aagtgcatac tctatgtcat tttcatggga ctggtctggc 1680
 cacaactaca ttaatgaaat atttgccaca tcctcttaca ctttttcata cattgcccaa 1740
 gaataa 1746

<210> 56
 <211> 581
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> 5F KO1S*

<400> 56
 Met Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn Pro Val Tyr Pro
 1 5 10 15
 Tyr Asp Thr Glu Thr Gly Pro Pro Thr Val Pro Phe Leu Thr Pro Pro
 20 25 30
 Phe Val Ser Pro Asn Gly Phe Gln Glu Ser Pro Pro Gly Val Leu Ser
 35 40 45

-45-

Leu Arg Leu Ser Glu Pro Leu Val Thr Ser Asn Gly Met Leu Ala Leu
 50 55 60
 Lys Met Gly Asn Gly Leu Ser Leu Asp Glu Ala Gly Asn Leu Thr Ser
 65 70 75 80
 Gln Asn Val Thr Thr Val Ser Pro Pro Leu Gly Ala Gly Ala Ser Asn
 85 90 95
 Ile Asn Leu Glu Ile Ser Ala Pro Leu Thr Val Thr Ser Glu Ala Leu
 100 105 110
 Thr Val Ala Ala Ala Ala Pro Leu Met Val Ala Gly Asn Thr Leu Thr
 115 120 125
 Met Gln Ser Gln Ala Pro Leu Thr Val His Asp Ser Lys Leu Ser Ile
 130 135 140
 Ala Thr Gln Gly Pro Leu Thr Val Ser Glu Gly Lys Leu Ala Leu Gln
 145 150 155 160
 Thr Ser Gly Pro Leu Thr Thr Thr Asp Ser Ser Thr Leu Thr Ile Thr
 165 170 175
 Ala Ser Pro Pro Leu Thr Thr Ala Thr Gly Ser Leu Gly Ile Asp Leu
 180 185 190
 Lys Glu Pro Ile Tyr Thr Gln Asn Gly Lys Leu Gly Leu Lys Tyr Gly
 195 200 205
 Ala Pro Leu His Val Thr Asp Asp Leu Asn Thr Leu Thr Val Ala Thr
 210 215 220
 Gly Pro Gly Val Thr Ile Asn Asn Thr Ser Leu Gln Thr Lys Val Thr
 225 230 235 240
 Gly Ala Leu Gly Phe Asp Ser Gln Gly Asn Met Gln Leu Asn Val Ala
 245 250 255
 Gly Gly Leu Arg Ile Asp Ser Gln Asn Arg Arg Leu Ile Leu Asp Val
 260 265 270
 Ser Tyr Pro Phe Asp Ala Gln Asn Gln Leu Asn Leu Arg Leu Gly Gln
 275 280 285
 Gly Pro Leu Phe Ile Asn Ser Ala His Asn Leu Asp Ile Asn Tyr Asn
 290 295 300
 Lys Gly Leu Tyr Leu Phe Thr Ala Ser Asn Asn Ser Lys Lys Leu Glu
 305 310 315 320
 Val Asn Leu Ser Thr Ala Lys Gly Leu Met Phe Asp Ala Thr Ala Ile
 325 330 335
 Ala Ile Asn Ala Gly Asp Gly Leu Glu Phe Gly Ser Pro Asn Ala Pro
 340 345 350
 Asn Thr Asn Pro Leu Lys Thr Lys Ile Gly His Gly Leu Glu Phe Asp
 355 360 365
 Ser Asn Lys Ala Met Val Pro Lys Leu Gly Thr Gly Leu Ser Phe Asp
 370 375 380
 Ser Thr Gly Ala Ile Thr Val Gly Asn Lys Asn Asn Asp Lys Leu Thr
 385 390 395 400
 Leu Trp Thr Thr Pro Ala Pro Glu Ala Asn Cys Arg Leu Asn Ala Glu
 405 410 415
 Lys Asp Ala Lys Leu Thr Leu Val Leu Thr Lys Cys Gly Ser Gln Ile
 420 425 430
 Leu Ala Thr Val Ser Val Leu Ala Val Lys Gly Ser Leu Ala Pro Ile
 435 440 445
 Ser Gly Thr Val Gln Ser Ala His Leu Ile Ile Arg Phe Asp Glu Asn
 450 455 460
 Gly Val Leu Leu Asn Asn Ser Phe Leu Asp Pro Glu Tyr Trp Asn Phe
 465 470 475 480
 Arg Asn Gly Asp Leu Thr Glu Gly Thr Ala Tyr Thr Asn Ala Val Gly
 485 490 495
 Phe Met Pro Asn Leu Ser Ala Tyr Pro Lys Ser His Gly Lys Thr Ala
 500 505 510
 Lys Ser Asn Ile Val Ser Gln Val Tyr Leu Asn Gly Asp Lys Thr Lys
 515 520 525
 Pro Val Thr Leu Thr Ile Thr Leu Asn Gly Thr Gln Glu Thr Gly Asp

-46-

530		535		540
Thr Thr Pro Ser Ala Tyr Ser Met Ser Phe Ser Trp Asp Trp Ser Gly				
545		550		555
His Asn Tyr Ile Asn Glu Ile Phe Ala Thr Ser Ser Tyr Thr Phe Ser				
	565		570	575
Tyr Ile Ala Gln Glu				
580				

<210> 57
 <211> 1776
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> 5F KO1S*RGD

<400> 57
 atgaagcgcg caagaccgtc tgaagatacc ttcaaccccc tgtatccata tgacacggaa 60
 accggtcctc caactgtgccc ttttcttact cctccctttg tatcccccac tgggtttcaa 120
 gagagtcccc ctgggggtact ctcttttgccg ctatccgaac ctctagttac ctccaatggc 180
 atgcttgccg tcaaaatggg caacggcctc tctctggacg aggcgggcaa ccttacctcc 240
 caaaatgtaa ccaactgtgag cccacctctc ggagccggag cctcaaaccat aaacctggaa 300
 atatctgcac ccctcacagt tacctcagaa gccctaactg tggctgccgc cgcacctcta 360
 atggctcgccg gcaacacact caccatgcaa tcacaggccc cgctaaccgt gcacgactcc 420
 aaacttagca ttgccaccca aggaccctc acagtgtcag aaggaaagct agccctgcaa 480
 acatcaggcc ccctcaccac caccgatagc agtacccctta ctatcactgc ctaccccct 540
 ctaactactg ccactggtag cttgggcatt gacttgaaag agccatttta tacacaaaat 600
 ggaaaactag gactaaagta cggggctcct ttgcatgtaa cagacgacct aaacactttg 660
 accgtagcaa ctggtccagg tgtgactatt aataatactt ccttgcaaac taaagttact 720
 ggagccttgg gttttgattc acaaggcaat atgcaactta atgtagcagg aggactaagg 780
 attgattctc aaaacagacg ccttatactt gatgttagtt atccgtttga tgctcaaaac 840
 caactaaatc taagactagg acagggccct ctttttataa actcagccca caacttggat 900
 attaactaca acaaaggcct ttacttgttt acagcttcaa acaattccaa aaagcttgag 960
 gttaacctaa gcaactgcaa ggggttgatg tttgacgcta cagccatagc cattaatgca 1020
 ggagatgggc ttgaatttgg ttcacctaatt gcaccaaaca caaatcccct caaaacaaaa 1080
 attggccatg gcctagaatt tgattcaaac aaggctatgg ttcctaaact aggaactggc 1140
 cttagttttg acagcacagg tgccattaca gtaggaaaca aaaataatga taagctaact 1200
 ttgtggacca caccagctcc agaggctaac ttagactaa atgcagagaa agatgctaaa 1260
 ctcaatttgg tcttaacaaa atgtggcagt caaataactg ctacagtttc agttttggct 1320
 gttaaaggca gtttggctcc aatatctgga acagttcaaa gtgctcatct tattataaga 1380
 tttgacgaaa atggagtgct actaaacaat tccttcctgg acccagaata ttggaacttt 1440
 agaaatggag atcttactga aggcacagcc tatacaaacg ctggttgatt tatgcctaac 1500
 ctatcagctt atccaaaatc tcacggtaaa actgccaaaa gtaacattgt cagtcaagtt 1560
 tacttaaacg gagacaaaac taaacctgta acactaacca ttactactaa cggtacacag 1620
 gaaacaggtg atcattgtga ttgtcgtggt gattgttttt gtacaactcc aagtgcatac 1680
 tctatgtcat tttcatggga ctggtctggc cacaactaca ttaatgaaat atttgccaca 1740
 tcctcttaca ctttttcata cattgcccac gaataa 1776

<210> 58
 <211> 591
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> 5F KO1S*RGD

<400> 58
 Met Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn Pro Val Tyr Pro
 1 5 10 15
 Tyr Asp Thr Glu Thr Gly Pro Pro Thr Val Pro Phe Leu Thr Pro Pro

-48-

Lys Ser Asn Ile Val Ser Gln Val Tyr Leu Asn Gly Asp Lys Thr Lys
 515 520 525
 Pro Val Thr Leu Thr Ile Thr Leu Asn Gly Thr Gln Glu Thr Gly Asp
 530 535 540
 His Cys Asp Cys Arg Gly Asp Cys Phe Cys Thr Thr Pro Ser Ala Tyr
 545 550 555 560
 Ser Met Ser Phe Ser Trp Asp Trp Ser Gly His Asn Tyr Ile Asn Glu
 565 570 575
 Ile Phe Ala Thr Ser Ser Tyr Thr Phe Ser Tyr Ile Ala Gln Glu
 580 585 590

<210> 59
 <211> 972
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> 35F

<400> 59
 atgaccaaga gagtccggct cagtgactcc ttcaaccctg tctacccta tgaagatgaa 60
 agcacctccc aacacccctt tataaaccca gggtttattt ccccaaattg cttcacacaa 120
 agcccagacg gagttcttac tttaaaatgt ttaacccac taacaaccac aggcggatct 180
 ctacagctaa aagtgggagg gggacttaca gtggatgaca ctgatggtac cttacaagaa 240
 aacatacgtg ctacagcacc cattactaaa aataatcact ctgtagaact atccattgga 300
 aatggattag aaactcaaaa caataaacta tgtgccaaat tgggaaatgg gttaaaaattt 360
 aacaacggtg acatttgtat aaaggatagt attaacacct tatggactgg aataaaccct 420
 ccacctaact gtcaaatgtt ggaaaacact aatacaaatg atggcaaat tacttttagta 480
 ttagtaaaaa atggagggtt tgtaaatggc tacgtgtctc tagttggtgt atcagacact 540
 gtgaacacaa tgttcacaca aaagacagca aacatccaat taagattata ttttgactct 600
 tctggaaatc tattaactga ggaatcagac ttaaaaattc cacttaaaaa taaatcttct 660
 acagcgacca gtgaaactgt agccagcagc aaagccttta tgccaagtac tacagcttat 720
 cccttcaaca ccactactag ggatagttaa aactacattc atggaatatg ttactacatg 780
 actagttatg atagaagtct atttcccttg aacatttcta taatgctaaa cagccgtatg 840
 atttcttcca atgttgcccta tgccatacaa tttgaatgga atctaaatgc aagtgaatct 900
 ccagaaagca acatagctac gctgaccaca tccccctttt tcttttctta cattacagaa 960
 gacgacgaat aa 972

<210> 60
 <211> 323
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> 35F

<400> 60
 Met Thr Lys Arg Val Arg Leu Ser Asp Ser Phe Asn Pro Val Tyr Pro
 1 5 10 15
 Tyr Glu Asp Glu Ser Thr Ser Gln His Pro Phe Ile Asn Pro Gly Phe
 20 25 30
 Ile Ser Pro Asn Gly Phe Thr Gln Ser Pro Asp Gly Val Leu Thr Leu
 35 40 45
 Lys Cys Leu Thr Pro Leu Thr Thr Gly Gly Ser Leu Gln Leu Lys
 50 55 60
 Val Gly Gly Gly Leu Thr Val Asp Asp Thr Asp Gly Thr Leu Gln Glu
 65 70 75 80
 Asn Ile Arg Ala Thr Ala Pro Ile Thr Lys Asn Asn His Ser Val Glu
 85 90 95
 Leu Ser Ile Gly Asn Gly Leu Glu Thr Gln Asn Asn Lys Leu Cys Ala

-49-

Lys	Leu	Gly	100	Asn	Gly	Leu	Lys	Phe	105	Asn	Asn	Gly	Asp	Ile	110	Cys	Ile	Lys
		115						120						125				
Asp	Ser	Ile	Asn	Thr	Leu	Trp	Thr	Gly	Ile	Asn	Pro	Pro	Pro	Pro	Asn	Cys		
		130				135							140					
Gln	Ile	Val	Glu	Asn	Thr	Asn	Thr	Asn	Asp	Gly	Lys	Leu	Thr	Leu	Val			
145					150					155					160			
Leu	Val	Lys	Asn	Gly	Gly	Leu	Val	Asn	Gly	Tyr	Val	Ser	Leu	Val	Gly			
			165						170						175			
Val	Ser	Asp	Thr	Val	Asn	Gln	Met	Phe	Thr	Gln	Lys	Thr	Ala	Asn	Ile			
			180					185						190				
Gln	Leu	Arg	Leu	Tyr	Phe	Asp	Ser	Ser	Gly	Asn	Leu	Leu	Thr	Glu	Glu			
		195					200						205					
Ser	Asp	Leu	Lys	Ile	Pro	Leu	Lys	Asn	Lys	Ser	Ser	Thr	Ala	Thr	Ser			
		210				215						220						
Glu	Thr	Val	Ala	Ser	Ser	Lys	Ala	Phe	Met	Pro	Ser	Thr	Thr	Ala	Tyr			
225					230					235					240			
Pro	Phe	Asn	Thr	Thr	Thr	Arg	Asp	Ser	Glu	Asn	Tyr	Ile	His	Gly	Ile			
			245						250					255				
Cys	Tyr	Tyr	Met	Thr	Ser	Tyr	Asp	Arg	Ser	Leu	Phe	Pro	Leu	Asn	Ile			
		260						265					270					
Ser	Ile	Met	Leu	Asn	Ser	Arg	Met	Ile	Ser	Ser	Asn	Val	Ala	Tyr	Ala			
		275					280					285						
Ile	Gln	Phe	Glu	Trp	Asn	Leu	Asn	Ala	Ser	Glu	Ser	Pro	Glu	Ser	Asn			
		290				295					300							
Ile	Ala	Thr	Leu	Thr	Thr	Ser	Pro	Phe	Phe	Phe	Ser	Tyr	Ile	Thr	Glu			
305					310					315					320			
Asp	Asp	Glu																

<210> 61
 <211> 1002
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> 35F RGD

<400> 61
 atgaccaaga gagtccggct cagtgactcc ttcaaccctg tctacccta tgaagatgaa 60
 agcacctccc aacacccctt tataaaccce gggtttattt ccccaaattg cttcacacaa 120
 agcccagacg gagttcttac tttaaaatgt ttaacccac taacaaccac aggcggatct 180
 ctacagctaa aagtgggagg gggacttaca gtggatgaca ctgatggtag cttacaagaa 240
 aacatacgtg ctacagcacc cattactaaa aataatcact ctgtagaact atccattgga 300
 aatggattag aaactcaaaa caataaacta tgtgccaaat tgggaaatgg gttaaaattt 360
 aacaacggtg acatttgtat aaaggatagt attaacacct tatggactgg aataaaccct 420
 ccacctaact gtcaaattgt ggaaaacact aatacaaact atggcaaact tacttttagta 480
 ttagtaaaaa atggaggggt tgtaaatggc tacgtgtctc tagttgggtg atcagacact 540
 gtgaacaaaa tgttcacaca aaagacagca aacatccaat taagattata ttttgactct 600
 tctggaaatc tattaactga ggaatcagac ttaaaaattc cacttaaaaa taaatcttct 660
 acagcgacca gtgaaactgt agccagcagc aaagccttta tgccaagtac tacagcttat 720
 cccttcaaca ccactactag ggatagtga aactacattc atggaatatg ttactacatg 780
 actagttatg atagaagtct atttcccttg aacatttcta taatgctaaa cagccgtatg 840
 atttcttcca atgtacattg tgattgtcgt ggtgattgtt tttgcgcata tgccatacaa 900
 tttgaatgga atctaaatgc aagtgaatct ccagaaagca acatagctac gctgaccaca 960
 tccccctttt tcttttctta cattacagaa gacgacgaat aa 1002

<210> 62
 <211> 333
 <212> PRT

<220>

<223> 35F RGD

<400> 62

Met 1	Thr	Lys	Arg	Val 5	Arg	Leu	Ser	Asp	Ser 10	Phe	Asn	Pro	Val	Tyr 15	Pro
Tyr	Glu	Asp	Glu 20	Ser	Thr	Ser	Gln	His 25	Pro	Phe	Ile	Asn 30	Pro	Gly	Phe
Ile	Ser	Pro 35	Asn	Gly	Phe	Thr	Gln 40	Ser	Pro	Asp	Gly	Val 45	Leu	Thr	Leu
Lys	Cys 50	Leu	Thr	Pro	Leu	Thr 55	Thr	Thr	Gly	Gly	Ser 60	Leu	Gln	Leu	Lys
Val 65	Gly	Gly	Gly	Leu 70	Thr	Val	Asp	Asp	Thr	Asp 75	Gly	Thr	Leu	Gln	Glu 80
Asn	Ile	Arg	Ala 85	Thr	Ala	Pro	Ile	Thr	Lys 90	Asn	Asn	His	Ser	Val 95	Glu
Leu	Ser	Ile	Gly 100	Asn	Gly	Leu	Glu	Thr 105	Gln	Asn	Asn	Lys	Leu	Cys	Ala
Lys	Leu	Gly 115	Asn	Gly	Leu	Lys	Phe 120	Asn	Asn	Gly	Asp	Ile 125	Cys	Ile	Lys
Asp	Ser 130	Ile	Asn	Thr	Leu	Trp 135	Thr	Gly	Ile	Asn	Pro 140	Pro	Pro	Asn	Cys
Gln 145	Ile	Val	Glu	Asn 150	Thr	Asn	Thr	Asn	Asp	Gly 155	Lys	Leu	Thr	Leu	Val 160
Leu	Val	Lys	Asn 165	Gly	Gly	Leu	Val	Asn	Gly 170	Tyr	Val	Ser	Leu	Val 175	Gly
Val	Ser	Asp	Thr 180	Val	Asn	Gln	Met	Phe 185	Thr	Gln	Lys	Thr	Ala 190	Asn	Ile
Gln	Leu	Arg 195	Leu	Tyr	Phe	Asp	Ser 200	Ser	Gly	Asn	Leu 205	Leu	Thr	Glu	Glu
Ser	Asp 210	Leu	Lys	Ile	Pro	Leu 215	Lys	Asn	Lys	Ser	Ser 220	Thr	Ala	Thr	Ser
Glu 225	Thr	Val	Ala	Ser 230	Ser	Lys	Ala	Phe	Met 235	Pro	Ser	Thr	Thr	Ala	Tyr 240
Pro	Phe	Asn	Thr 245	Thr	Thr	Arg	Asp	Ser	Glu 250	Asn	Tyr	Ile	His	Gly 255	Ile
Cys	Tyr	Tyr	Met 260	Thr	Ser	Tyr	Asp	Arg 265	Ser	Leu	Phe	Pro	Leu 270	Asn	Ile
Ser	Ile	Met 275	Leu	Asn	Ser	Arg	Met 280	Ile	Ser	Ser	Asn	Val 285	His	Cys	Asp
Cys	Arg 290	Gly	Asp	Cys	Phe	Cys 295	Ala	Tyr	Ala	Ile	Gln 300	Phe	Glu	Trp	Asn
Leu 305	Asn	Ala	Ser	Glu 310	Ser	Pro	Glu	Ser	Asn	Ile 315	Ala	Thr	Leu	Thr	Thr 320
Ser	Pro	Phe	Phe 325	Phe	Ser	Tyr	Ile	Thr	Glu 330	Asp	Asp	Glu			

<210> 63

<211> 1164

<212> DNA

<213> Artificial Sequence

<220>

<223> 41SF

<400> 63

atgaaaaagaa ccagaattga agacgacttc aaccccgctc acccctatga cacctttctca 60
actcccagca tcccctatgt agctccgccc ttcgtttctt ctgacgggtt acaggaaaaa 120

-51-

```

ccccaggag ttttagcact caagtacact gaccccata ctaccaatgc taagcatgag 180
cttactttta aacttgaag caacataact ttagaaaatg gggtactttc ggccacagtt 240
cccactgttt ctctccctc tacaaacagt aacaactccc tgggttttagc cacatccgct 300
cccatagctg tatcagctaa ctctctcaca ttggccaccg ccgcaccact gacagtaagc 360
aacaaccagc ttagtattaa cgcgggcgaga ggttttagtta taactaaciaa tgccttaaca 420
gttaatccta ccggagcgct aggttttcaat aacacaggag ctttacaatt aaatgctgca 480
ggaggaatga gagtggacgg tgccaactta attcttcag tagcatatcc ctttgaagca 540
atcaaccagc taacactgag attagaaaac ggttagaag taaccagcgg aggaaagcct 600
aacgttaagt tgggatcagg cctccaattt gacagtaacg gacgcattgc tattagtaat 660
agcaaccgaa ctggaagtgt accatccctc actaccattt ggtctatctc gcctacgcct 720
aactgctcca tttatgaaac ccaagatgca aacctatttc tttgtctaac taaaaacgga 780
gctcacgtat taggtactat aacaatcaaa ggtcttaaa gagcactgag ggaaatgcac 840
gataacgctc tatcttttaa acttcccttt gacaatcagg gaaatttact taactgtgcc 900
ttggaatcat ccacctggcg ttaccaggaa accaacgcag tggcctctaa tgccttaaca 960
tttatgccca acagtacagt gtatccacga aacaaaaccg ctcacccggg caacatgctc 1020
atccaaatct cgcctaacat caccttcagt gtcgtctaca acgagataaa cagtgggtat 1080
gcttttactt ttaaattggtc agccgaaccg ggaaaacctt ttcacccacc taccgctgta 1140
ttttgctaca taactgaaga ataa

```

<210> 64

<211> 387

<212> PRT

<213> Artificial Sequence

<220>

<223> 41sF

<400> 64

```

Met Lys Arg Thr Arg Ile Glu Asp Asp Phe Asn Pro Val Tyr Pro Tyr
1      5      10      15
Asp Thr Phe Ser Thr Pro Ser Ile Pro Tyr Val Ala Pro Pro Phe Val
20     25     30
Ser Ser Asp Gly Leu Gln Glu Lys Pro Pro Gly Val Leu Ala Leu Lys
35     40     45
Tyr Thr Asp Pro Ile Thr Thr Asn Ala Lys His Glu Leu Thr Leu Lys
50     55     60
Leu Gly Ser Asn Ile Thr Leu Glu Asn Gly Leu Leu Ser Ala Thr Val
65     70     75     80
Pro Thr Val Ser Pro Pro Leu Thr Asn Ser Asn Asn Ser Leu Gly Leu
85     90     95
Ala Thr Ser Ala Pro Ile Ala Val Ser Ala Asn Ser Leu Thr Leu Ala
100    105    110
Thr Ala Ala Pro Leu Thr Val Ser Asn Asn Gln Leu Ser Ile Asn Ala
115    120    125
Gly Arg Gly Leu Val Ile Thr Asn Asn Ala Leu Thr Val Asn Pro Thr
130    135    140
Gly Ala Leu Gly Phe Asn Asn Thr Gly Ala Leu Gln Leu Asn Ala Ala
145    150    155    160
Gly Gly Met Arg Val Asp Gly Ala Asn Leu Ile Leu His Val Ala Tyr
165    170    175
Pro Phe Glu Ala Ile Asn Gln Leu Thr Leu Arg Leu Glu Asn Gly Leu
180    185    190
Glu Val Thr Ser Gly Gly Lys Leu Asn Val Lys Leu Gly Ser Gly Leu
195    200    205
Gln Phe Asp Ser Asn Gly Arg Ile Ala Ile Ser Asn Ser Asn Arg Thr
210    215    220
Arg Ser Val Pro Ser Leu Thr Thr Ile Trp Ser Ile Ser Pro Thr Pro
225    230    235    240
Asn Cys Ser Ile Tyr Glu Thr Gln Asp Ala Asn Leu Phe Leu Cys Leu
245    250    255
Thr Lys Asn Gly Ala His Val Leu Gly Thr Ile Thr Ile Lys Gly Leu

```

-52-

	260		265		270
Lys Gly Ala	Leu Arg Glu Met His	Asp Asn Ala	Leu Ser Leu Lys Leu		
	275	280	285		
Pro Phe Asp	Asn Gln Gly Asn Leu	Leu Asn Cys Ala	Leu Glu Ser Ser		
	290	295	300		
Thr Trp Arg	Tyr Gln Glu Thr Asn	Ala Val Ala	Ser Asn Ala Leu Thr		
305	310	315	320		
Phe Met Pro	Asn Ser Thr Val Tyr	Pro Arg Asn	Lys Thr Ala His Pro		
	325	330	335		
Gly Asn Met	Leu Ile Gln Ile Ser	Pro Asn Ile	Thr Phe Ser Val Val		
	340	345	350		
Tyr Asn Glu	Ile Asn Ser Gly Tyr	Ala Phe Thr	Phe Lys Trp Ser Ala		
	355	360	365		
Glu Pro Gly	Lys Pro Phe His	Pro Pro Thr Ala	Val Phe Cys Tyr Ile		
	370	375	380		
Thr Glu Glu					
385					

<210> 65
 <211> 1194
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> 41sF RGD

<400> 65
 atgaaaagaa ccagaattga agacgacttc aaccccgctc acccctatga caccttctca 60
 actcccagca tcccctatgt agctccgccc ttcgtttctt ctgacggggt acaggaaaaa 120
 cccccaggag ttttagcact caagtacact gaccccatc ctaccaatgc taagcatgag 180
 cttactttta aacttggaag caacataact ttagaaaatg gggtactttc ggccacagtt 240
 cccactgttt ctcctcccct tacaacagc aacaactccc tgggttttagc cacatccgct 300
 cccatagctg tatcagctaa ctctctcaca ttggccaccg ccgcaccact gacagtaagc 360
 aacaaccagc ttagtattaa cgcgggcaga gggttagtta taactaacia tgccttaaca 420
 gttaatccta ccggaagcgt aggtttcaat aacacaggag ctttacaatt aaatgctgca 480
 ggaggaatga gaggggacgg tgccaactta attcttcatg tagcatatcc ctttgaagca 540
 atcaaccagc taacactgcg attagaaaac ggggttagaag taaccagcgg aggaaagctt 600
 aacgttaagt tgggatcagg cctccaattt gacagtaacg gacgcattgc tattagtaat 660
 agcaaccgaa ctggaagtgt accatccctc actaccattt ggtctatctc gcctacgcct 720
 aactgctcca tttatgaaac ccaagatgca aacctatttc tttgtctaac taaaaacgga 780
 gctcacgtat taggtactat aacaatcaaa ggtcttaaag gagcactgcg ggaaatgcac 840
 gataacgctc tatcttttaa acttcccttt gacaatcagg gaaatttact taactgtgcc 900
 ttggaatcat ccacctggcg ttaccaggaa accaacgcag tggcctctaa tgccttaaca 960
 tttatgcccc acagtacagt gtatccacga aacaaaaccg ctcacccggg caacatgctc 1020
 atccaaatct cgctaacat caccttcagt gtcgtctaca acgagataaa ctgtgattgt 1080
 cgtgggtgatt gtttttgtac tagtgggtat gcttttactt ttaaattggtc agccgaaccg 1140
 ggaaaacctt ttcacccacc taccgctgta ttttgctaca taactgaaga ataa 1194

<210> 66
 <211> 397
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> 41sF RGD

<400> 66
 Met Lys Arg Thr Arg Ile Glu Asp Asp Phe Asn Pro Val Tyr Pro Tyr
 1 5 10 15
 Asp Thr Phe Ser Thr Pro Ser Ile Pro Tyr Val Ala Pro Pro Phe Val

-53-

			20					25					30				
Ser	Ser	Asp	Gly	Leu	Gln	Glu	Lys	Pro	Pro	Gly	Val	Leu	Ala	Leu	Lys		
		35					40					45					
Tyr	Thr	Asp	Pro	Ile	Thr	Thr	Asn	Ala	Lys	His	Glu	Leu	Thr	Leu	Lys		
	50					55					60						
Leu	Gly	Ser	Asn	Ile	Thr	Leu	Glu	Asn	Gly	Leu	Leu	Ser	Ala	Thr	Val		
65				70					75						80		
Pro	Thr	Val	Ser	Pro	Leu	Thr	Asn	Ser	Asn	Asn	Ser	Leu	Gly	Leu			
			85					90					95				
Ala	Thr	Ser	Ala	Pro	Ile	Ala	Val	Ser	Ala	Asn	Ser	Leu	Thr	Leu	Ala		
			100					105					110				
Thr	Ala	Ala	Pro	Leu	Thr	Val	Ser	Asn	Asn	Gln	Leu	Ser	Ile	Asn	Ala		
		115					120					125					
Gly	Arg	Gly	Leu	Val	Ile	Thr	Asn	Asn	Ala	Leu	Thr	Val	Asn	Pro	Thr		
	130					135					140						
Gly	Ala	Leu	Gly	Phe	Asn	Asn	Thr	Gly	Ala	Leu	Gln	Leu	Asn	Ala	Ala		
145				150					155						160		
Gly	Gly	Met	Arg	Val	Asp	Gly	Ala	Asn	Leu	Ile	Leu	His	Val	Ala	Tyr		
			165					170					175				
Pro	Phe	Glu	Ala	Ile	Asn	Gln	Leu	Thr	Leu	Arg	Leu	Glu	Asn	Gly	Leu		
		180						185					190				
Glu	Val	Thr	Ser	Gly	Gly	Lys	Leu	Asn	Val	Lys	Leu	Gly	Ser	Gly	Leu		
		195					200					205					
Gln	Phe	Asp	Ser	Asn	Gly	Arg	Ile	Ala	Ile	Ser	Asn	Ser	Asn	Arg	Thr		
	210				215						220						
Arg	Ser	Val	Pro	Ser	Leu	Thr	Thr	Ile	Trp	Ser	Ile	Ser	Pro	Thr	Pro		
225				230					235						240		
Asn	Cys	Ser	Ile	Tyr	Glu	Thr	Gln	Asp	Ala	Asn	Leu	Phe	Leu	Cys	Leu		
			245					250					255				
Thr	Lys	Asn	Gly	Ala	His	Val	Leu	Gly	Thr	Ile	Thr	Ile	Lys	Gly	Leu		
			260					265					270				
Lys	Gly	Ala	Leu	Arg	Glu	Met	His	Asp	Asn	Ala	Leu	Ser	Leu	Lys	Leu		
		275				280						285					
Pro	Phe	Asp	Asn	Gln	Gly	Asn	Leu	Leu	Asn	Cys	Ala	Leu	Glu	Ser	Ser		
	290				295						300						
Thr	Trp	Arg	Tyr	Gln	Glu	Thr	Asn	Ala	Val	Ala	Ser	Asn	Ala	Leu	Thr		
305				310						315					320		
Phe	Met	Pro	Asn	Ser	Thr	Val	Tyr	Pro	Arg	Asn	Lys	Thr	Ala	His	Pro		
			325					330					335				
Gly	Asn	Met	Leu	Ile	Gln	Ile	Ser	Pro	Asn	Ile	Thr	Phe	Ser	Val	Val		
			340					345									

```
<210> 67
<211> 1737
<212> DNA
<213> Artificial Sequence
```

<220>
<223> Ad5 PD1 penton

```
<400> 67
atgcggcgcg cggcgatgta tgaggaaggt cctcctccct cctacgagag tgtggtgagc 60
gcggcgccag tggcggcggc gctgggttct cccttcgatg ctcccctgga cccgccgttt 120
gtgcctccgc ggtacctgcg gcctaccggg gggagaaaca gcatccgtta ctctgagttg 180
```

-54-

```

gcacccctat tgcacaccac ccgtgtgtac ctggtggaca acaagtcaac ggatgtggca 240
tccctgaact accagaacga ccacagcaac tttctgacca cggtcattca aaacaatgac 300
tacagcccg ggaggcaag cacacagacc atcaatcttg acgaccggtc gcactggggc 360
ggcgacctga aaaccatcct gcataccaac atgccaaatg tgaacgagtt catgtttacc 420
aataagttta aggcgcgggt gatggtgtcg cgcttgcccta ctaaggacaa tcaggtggag 480
ctgaaatacg agtgggtgga gttcacgctg cccgagggca actactccga gaccatgacc 540
atagacctta tgaacaacgc gatcgtggag cactacttga aagtgggcag acagaacggg 600
gttctggaaa gcgacatcgg ggtaaagttt gacacccgca acttcagact ggggtttgac 660
cccgctactg gtcttgatcat gcctggggta tatacaaacg aagccttcca tccagacatc 720
attttgctgc caggatgcgg ggtggacttc acccacagcc gcctgagcaa cttgttgggc 780
atccgcaagc ggcaaccctt ccaggagggc tttaggatca cctacgatga tctggagggt 840
ggtaacattc ccgactgtt ggatgtggac gcctaccagg cgagcttgaa agatgacacc 900
gaacagggcg ggggtggcgc aggcggcagc aacagcagtg gcagcggcgc ggaagagaac 960
tccaacgcgg cagccgcggc aatgcagccg gtggaggaca tgaacgatag ccgcggctac 1020
ccctacgacg tgcccgacta cgcgggcacc agcggccacac gggctgagga gaagcgcgct 1080
gaggccgaag cagcggccga agctgcccgc cccgctgcgc aaccgcaggt cgagaagcct 1140
cagaagaac cggtgatcaa acccctgaca gaggacagca agaaacgcag ttacaaccta 1200
ataagcaatg acagacctt caccagtag cgactctggt accttgcata caactacggc 1260
gaccctcaga ccggaatccg ctcatggacc ctgctttgca ctctgacgt aacctgcggc 1320
tcggagcagg tctactggtc gttgccagac atgatgcaag accccgtgac cttccgctcc 1380
acgcgccaga tcagcaactt tccgggtggtg ggcgcgcgagc tgttgcccgt gcactccaag 1440
acgttctaca acgaccaggc cgtctactcc cagactctcc caactctgac ctctctgacc 1500
cagctgttca atcgctttcc cgagaaccag attttggcgc gcccgcgcagc cccaccatc 1560
accaccgtca gtgaaaacgt tcctgctctc acagatcacg ggacgctacc gctgcgcaac 1620
agcatcggag gagtccagcg agtgaccatt actgacgcca gacgccgcac ctgcccctac 1680
gtttacaagg ccctgggcat agtctcgccg cgcgtctat cgagccgcac tttttga 1737

```

<210> 68

<211> 578

<212> PRT

<213> Artificial Sequence

<220>

<223> Ad5 PD1 penton

<400> 68

```

Met Arg Arg Ala Ala Met Tyr Glu Glu Gly Pro Pro Pro Ser Tyr Glu
1          5          10          15
Ser Val Val Ser Ala Ala Pro Val Ala Ala Ala Leu Gly Ser Pro Phe
20          25          30
Asp Ala Pro Leu Asp Pro Pro Phe Val Pro Pro Arg Tyr Leu Arg Pro
35          40          45
Thr Gly Gly Arg Asn Ser Ile Arg Tyr Ser Glu Leu Ala Pro Leu Phe
50          55          60
Asp Thr Thr Arg Val Tyr Leu Val Asp Asn Lys Ser Thr Asp Val Ala
65          70          75          80
Ser Leu Asn Tyr Gln Asn Asp His Ser Asn Phe Leu Thr Thr Val Ile
85          90          95
Gln Asn Asn Asp Tyr Ser Pro Gly Glu Ala Ser Thr Gln Thr Ile Asn
100         105         110
Leu Asp Asp Arg Ser His Trp Gly Gly Asp Leu Lys Thr Ile Leu His
115         120         125
Thr Asn Met Pro Asn Val Asn Glu Phe Met Phe Thr Asn Lys Phe Lys
130         135         140
Ala Arg Val Met Val Ser Arg Leu Pro Thr Lys Asp Asn Gln Val Glu
145         150         155         160
Leu Lys Tyr Glu Trp Val Glu Phe Thr Leu Pro Glu Gly Asn Tyr Ser
165         170         175
Glu Thr Met Thr Ile Asp Leu Met Asn Asn Ala Ile Val Glu His Tyr
180         185         190
Leu Lys Val Gly Arg Gln Asn Gly Val Leu Glu Ser Asp Ile Gly Val

```

Lys	Phe	Asp	Thr	Arg	Asn	Phe	Arg	Leu	Gly	Phe	Asp	Pro	Val	Thr	Gly	
	210					215					220					
Leu	Val	Met	Pro	Gly	Val	Tyr	Thr	Asn	Glu	Ala	Phe	His	Pro	Asp	Ile	
225					230					235					240	
Ile	Leu	Leu	Pro	Gly	Cys	Gly	Val	Asp	Phe	Thr	His	Ser	Arg	Leu	Ser	
				245					250					255		
Asn	Leu	Leu	Gly	Ile	Arg	Lys	Arg	Gln	Pro	Phe	Gln	Glu	Gly	Phe	Arg	
			260					265					270			
Ile	Thr	Tyr	Asp	Asp	Leu	Glu	Gly	Gly	Asn	Ile	Pro	Ala	Leu	Leu	Asp	
		275					280					285				
Val	Asp	Ala	Tyr	Gln	Ala	Ser	Leu	Lys	Asp	Asp	Thr	Glu	Gln	Gly	Gly	
	290					295					300					
Gly	Gly	Ala	Gly	Gly	Ser	Asn	Ser	Ser	Gly	Ser	Gly	Ala	Glu	Glu	Asn	
305					310						315				320	
Ser	Asn	Ala	Ala	Ala	Ala	Ala	Met	Gln	Pro	Val	Glu	Asp	Met	Asn	Asp	
				325					330					335		
Ser	Arg	Gly	Tyr	Pro	Tyr	Asp	Val	Pro	Asp	Tyr	Ala	Gly	Thr	Ser	Ala	
			340					345					350			
Thr	Arg	Ala	Glu	Glu	Lys	Arg	Ala	Glu	Ala	Glu	Ala	Ala	Ala	Glu	Ala	
		355					360					365				
Ala	Ala	Pro	Ala	Ala	Gln	Pro	Glu	Val	Glu	Lys	Pro	Gln	Lys	Lys	Pro	
	370					375					380					
Val	Ile	Lys	Pro	Leu	Thr	Glu	Asp	Ser	Lys	Lys	Arg	Ser	Tyr	Asn	Leu	
385					390						395				400	
Ile	Ser	Asn	Asp	Ser	Thr	Phe	Thr	Gln	Tyr	Arg	Ser	Trp	Tyr	Leu	Ala	
				405					410					415		
Tyr	Asn	Tyr	Gly	Asp	Pro	Gln	Thr	Gly	Ile	Arg	Ser	Trp	Thr	Leu	Leu	
			420					425					430			
Cys	Thr	Pro	Asp	Val	Thr	Cys	Gly	Ser	Glu	Gln	Val	Tyr	Trp	Ser	Leu	
		435					440					445				
Pro	Asp	Met	Met	Gln	Asp	Pro	Val	Thr	Phe	Arg	Ser	Thr	Arg	Gln	Ile	
	450					455					460					
Ser	Asn	Phe	Pro	Val	Val	Gly	Ala	Glu	Leu	Leu	Pro	Val	His	Ser	Lys	
465					470					475					480	
Ser	Phe	Tyr	Asn	Asp	Gln	Ala	Val	Tyr	Ser	Gln	Leu	Ile	Arg	Gln	Phe	
				485					490					495		
Thr	Ser	Leu	Thr	His	Val	Phe	Asn	Arg	Phe	Pro	Glu	Asn	Gln	Ile	Leu	
			500					505					510			
Ala	Arg	Pro	Pro	Ala	Pro	Thr	Ile	Thr	Thr	Val	Ser	Glu	Asn	Val	Pro	
		515					520					525				
Ala	Leu	Thr	Asp	His	Gly	Thr	Leu	Pro	Leu	Arg	Asn	Ser	Ile	Gly	Gly	
	530					535										

<400> 69
atgaagcgcg caagaccgtc tgaagatacc.ttcaaccccg tgtatccata tgacacggaa 60

-56-

```

accggtcctc caactgtgcc ttttcttact cctccctttg tatcccccac tgggtttcaa 120
gagagtcctc ctgggggtact ctcttttgcc ctatccgaac ctctagttac ctccaatggc 180
atgcttgccg tcaaaatggg caacggcctc tctctggacg aggcgggcaa ccttacctcc 240
caaaatgtaa ccactgtgag cccacctctc aaaaaaacca agtcaaacad aaacctggaa 300
atatctgcac ccctcacagt tacctcagaa gccctaactg tggctgccgc cgcacctcta 360
atggctgcgg gcaacacact caccatgcaa tcacaggccc cgctaaccgt gcacgactcc 420
aaacttagca ttgccaccca aggacccctc acagtgtcag aaggaaagct agccctgcaa 480
acatcaggcc ccctcaccac caccgatagc agtaccctta ctactactgc ctcacccctc 540
ctaactactg ccactggtag cttggggcatt gacttgaaaag agccatttta tacacaaaat 600
ggaaaactag gactaaagta cggggctcct ttgcatgtaa cagacgacct aaacactttg 660
accgtagcaa ctgggtccagg tgtgactatt aataatactt ccttgcaaac taaagttact 720
ggagccttgg gttttgattc acaaggcaat atgcaactta atgtagcagg aggactaagg 780
attgattctc aaaacagacg ccttatactt gatgttagtt atccgtttga tgctcaaac 840
caactaaatc taagactagg acagggccct ctttttataa actcagccca caacttggat 900
attaactaca acaaaggcct ttacttgttt acagcttcaa acaattccaa aaagcttgag 960
gttaacctaa gcaactgcaa ggggttgatg tttgacgcta cagccatagc cattaatgca 1020
ggagatgggc ttgaatttgg ttcacctaat gcaccaaaca caaatcccct caaaacaaaa 1080
attggccatg gctagaatt tgattcaaac aaggctatgg ttcctaaact aggaactggc 1140
cttagttttg acagcacagg tgccattaca gtaggaaaca aaaataatga taagctaact 1200
ttgtggaccg gaataaaccc tccacctaac tgtcaaatg tggaaaacac taatacaaat 1260
gatggcaaac ttactttagt attagtaaaa aatggaggggc ttgttaatgg ctacgtgtct 1320
ctagtgggtg tatcagacac tgtgaaccaa atgttcacac aaaagacagc aaacatccaa 1380
ttaagattat attttgactc ttctggaaat ctattaactg aggaatcaga cttaaaaatt 1440
ccacttaaaa ataaatcttc tacagcgacc agtgaaactg tagccagcag caaagccttt 1500
atgccaagta ctacagctta tcccttcaac accactacta gggatagtga aaactacatt 1560
catggaatat gttactacat gactagttat gatagaagtc tatttccctt gaacattttc 1620
ataatgctaa acagccgtat gatttcttcc aatgttgctt atgccatata atttgaatgg 1680
aatctaaatg caagtgaatc tccagaaagc aacatagcta cgctgaccac atcccccttt 1740
ttcttttctt acattacaga agacgacgaa taa 1773

```

<210> 70

<211> 590

<212> PRT

<213> Artificial Sequence

<220>

<223> STS35H

<400> 70

```

Met Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn Pro Val Tyr Pro
1           5           10           15
Tyr Asp Thr Glu Thr Gly Pro Pro Thr Val Pro Phe Leu Thr Pro Pro
20           25           30
Phe Val Ser Pro Asn Gly Phe Gln Glu Ser Pro Pro Gly Val Leu Ser
35           40           45
Leu Arg Leu Ser Glu Pro Leu Val Thr Ser Asn Gly Met Leu Ala Leu
50           55           60
Lys Met Gly Asn Gly Leu Ser Leu Asp Glu Ala Gly Asn Leu Thr Ser
65           70           75           80
Gln Asn Val Thr Thr Val Ser Pro Pro Leu Lys Lys Thr Lys Ser Asn
85           90           95
Ile Asn Leu Glu Ile Ser Ala Pro Leu Thr Val Thr Ser Glu Ala Leu
100          105          110
Thr Val Ala Ala Ala Pro Leu Met Val Ala Gly Asn Thr Leu Thr
115          120          125
Met Gln Ser Gln Ala Pro Leu Thr Val His Asp Ser Lys Leu Ser Ile
130          135          140
Ala Thr Gln Gly Pro Leu Thr Val Ser Glu Gly Lys Leu Ala Leu Gln
145          150          155          160
Thr Ser Gly Pro Leu Thr Thr Thr Asp Ser Ser Thr Leu Thr Ile Thr
165          170          175

```


-57-

Ala	Ser	Pro	Pro	Leu	Thr	Thr	Ala	Thr	Gly	Ser	Leu	Gly	Ile	Asp	Leu
			180					185					190		
Lys	Glu	Pro	Ile	Tyr	Thr	Gln	Asn	Gly	Lys	Leu	Gly	Leu	Lys	Tyr	Gly
		195					200					205			
Ala	Pro	Leu	His	Val	Thr	Asp	Asp	Leu	Asn	Thr	Leu	Thr	Val	Ala	Thr
		210				215					220				
Gly	Pro	Gly	Val	Thr	Ile	Asn	Asn	Thr	Ser	Leu	Gln	Thr	Lys	Val	Thr
225					230					235					240
Gly	Ala	Leu	Gly	Phe	Asp	Ser	Gln	Gly	Asn	Met	Gln	Leu	Asn	Val	Ala
			245						250					255	
Gly	Gly	Leu	Arg	Ile	Asp	Ser	Gln	Asn	Arg	Arg	Leu	Ile	Leu	Asp	Val
			260					265					270		
Ser	Tyr	Pro	Phe	Asp	Ala	Gln	Asn	Gln	Leu	Asn	Leu	Arg	Leu	Gly	Gln
		275					280					285			
Gly	Pro	Leu	Phe	Ile	Asn	Ser	Ala	His	Asn	Leu	Asp	Ile	Asn	Tyr	Asn
		290				295					300				
Lys	Gly	Leu	Tyr	Leu	Phe	Thr	Ala	Ser	Asn	Asn	Ser	Lys	Lys	Leu	Glu
305					310					315					320
Val	Asn	Leu	Ser	Thr	Ala	Lys	Gly	Leu	Met	Phe	Asp	Ala	Thr	Ala	Ile
				325					330					335	
Ala	Ile	Asn	Ala	Gly	Asp	Gly	Leu	Glu	Phe	Gly	Ser	Pro	Asn	Ala	Pro
		340						345					350		
Asn	Thr	Asn	Pro	Leu	Lys	Thr	Lys	Ile	Gly	His	Gly	Leu	Glu	Phe	Asp
		355					360					365			
Ser	Asn	Lys	Ala	Met	Val	Pro	Lys	Leu	Gly	Thr	Gly	Leu	Ser	Phe	Asp
		370				375					380				
Ser	Thr	Gly	Ala	Ile	Thr	Val	Gly	Asn	Lys	Asn	Asn	Asp	Lys	Leu	Thr
385					390					395					400
Leu	Trp	Thr	Gly	Ile	Asn	Pro	Pro	Pro	Asn	Cys	Gln	Ile	Val	Glu	Asn
			405						410					415	
Thr	Asn	Thr	Asn	Asp	Gly	Lys	Leu	Thr	Leu	Val	Leu	Val	Lys	Asn	Gly
			420					425					430		
Gly	Leu	Val	Asn	Gly	Tyr	Val	Ser	Leu	Val	Gly	Val	Ser	Asp	Thr	Val
		435					440				445				
Asn	Gln	Met	Phe	Thr	Gln	Lys	Thr	Ala	Asn	Ile	Gln	Leu	Arg	Leu	Tyr
		450				455					460				
Phe	Asp	Ser	Ser	Gly	Asn	Leu	Leu	Thr	Glu	Glu	Ser	Asp	Leu	Lys	Ile
465					470				475					480	
Pro	Leu	Lys	Asn	Lys	Ser	Ser	Thr	Ala	Thr	Ser	Glu	Thr	Val	Ala	Ser
			485						490					495	
Ser	Lys	Ala	Phe	Met	Pro	Ser	Thr	Thr	Ala	Tyr	Pro	Phe	Asn	Thr	Thr
		500						505					510		
Thr	Arg	Asp	Ser	Glu	Asn	Tyr	Ile	His	Gly	Ile	Cys	Tyr	Tyr	Met	Thr
		515					520					525			
Ser	Tyr	Asp	Arg	Ser	Leu	Phe	Pro	Leu	Asn	Ile	Ser	Ile	Met	Leu	Asn
		530				535					540				
Ser	Arg	Met	Ile	Ser	Ser	Asn	Val	Ala	Tyr	Ala	Ile	Gln	Phe	Glu	Trp
545					550				555					560	
Asn	Leu	Asn	Ala	Ser	Glu	Ser	Pro	Glu	Ser	Asn	Ile	Ala	Thr	Leu	Thr
			565					570						575	
Thr	Ser	Pro	Phe	Phe	Phe	Ser	Tyr	Ile	Thr	Glu	Asp	Asp	Glu		
			580					585					590		

<210> 71

<211> 945

<212> DNA

<213> Artificial Sequence

<220>

<223> 35TS5H

-58-

<400> 71

```

atgaccaaga gagtccggct cagtgactcc ttcaaccctg tctaccacct tgaagatgaa 60
agcaccctccc aacacccctt tataaaccca gggtttattt ccccaaatgg cttcacacaa 120
agcccagacg gagttcttac tttaaaatgt ttaacccac taacaaccac aggcggatct 180
ctacagctaa aagtgggagg gggacttaca gtggatgaca ctgatggtac cttacaagaa 240
aacatacgtg ctacagcacc cattactaaa aataatcact ctgtagaact atccattgga 300
aatggattag aaactcaaaa caataaacta tgtgccaaat tgggaaatgg gttaaaattt 360
aacaacgggtg acatttgtat aaaggatagt attaacacct tatggactac accagctcca 420
tctcctaact gtagactaaa tgcagagaaa gatgctaaac tcactttggt cttaacaaaa 480
tgtggcagtc aaatacttgc tacagtttca gttttggctg ttaaaggcag tttggctcca 540
atatctggaa cagttcaaaag tgctcatctt attataagat ttgacgaaaa tggagtgtga 600
ctaaacaatt ccttcctgga cccagaatat tggaaacttta gaaatggaga tcttactgaa 660
ggcacagcct atacaaacgc tggtggattt atgcctaacc tatcagctta tccaaaatct 720
cacggtaaaa ctgccaaaag taacattgtc agtcaagttt acttaaacgg agacaaaact 780
aaacctgtaa cactaaccat tacactaaac ggtacacagg aaacaggaga cacaactcca 840
agtgcatact ctatgtcatt ttcattgggac tgggtctggcc acaactacat taatgaaata 900
tttggccacat cctcttacac tttttcatac attgccccaa aataa 945

```

<210> 72

<211> 314

<212> PRT

<213> Artificial Sequence

<220>

<223> 35TS5H

<400> 72

```

Met Thr Lys Arg Val Arg Leu Ser Asp Ser Phe Asn Pro Val Tyr Pro
 1          5          10          15
Tyr Glu Asp Glu Ser Thr Ser Gln His Pro Phe Ile Asn Pro Gly Phe
          20          25          30
Ile Ser Pro Asn Gly Phe Thr Gln Ser Pro Asp Gly Val Leu Thr Leu
          35          40          45
Lys Cys Leu Thr Pro Leu Thr Thr Thr Gly Gly Ser Leu Gln Leu Lys
          50          55          60
Val Gly Gly Gly Leu Thr Val Asp Asp Thr Asp Gly Thr Leu Gln Glu
65          70          75          80
Asn Ile Arg Ala Thr Ala Pro Ile Thr Lys Asn Asn His Ser Val Glu
          85          90          95
Leu Ser Ile Gly Asn Gly Leu Glu Thr Gln Asn Asn Lys Leu Cys Ala
          100          105          110
Lys Leu Gly Asn Gly Leu Lys Phe Asn Asn Gly Asp Ile Cys Ile Lys
          115          120          125
Asp Ser Ile Asn Thr Leu Trp Thr Thr Pro Ala Pro Ser Pro Asn Cys
130          135          140
Arg Leu Asn Ala Glu Lys Asp Ala Lys Leu Thr Leu Val Leu Thr Lys
145          150          155          160
Cys Gly Ser Gln Ile Leu Ala Thr Val Ser Val Leu Ala Val Lys Gly
          165          170          175
Ser Leu Ala Pro Ile Ser Gly Thr Val Gln Ser Ala His Leu Ile Ile
          180          185          190
Arg Phe Asp Glu Asn Gly Val Leu Leu Asn Asn Ser Phe Leu Asp Pro
          195          200          205
Glu Tyr Trp Asn Phe Arg Asn Gly Asp Leu Thr Glu Gly Thr Ala Tyr
210          215          220
Thr Asn Ala Val Gly Phe Met Pro Asn Leu Ser Ala Tyr Pro Lys Ser
225          230          235          240
His Gly Lys Thr Ala Lys Ser Asn Ile Val Ser Gln Val Tyr Leu Asn
          245          250          255
Gly Asp Lys Thr Lys Pro Val Thr Leu Thr Ile Thr Leu Asn Gly Thr
260          265          270

```

-59-

Gln Glu Thr Gly Asp Thr Thr Pro Ser Ala Tyr Ser Met Ser Phe Ser
275 280 285
Trp Asp Trp Ser Gly His Asn Tyr Ile Asn Glu Ile Phe Ala Thr Ser
290 295 300
Ser Tyr Thr Phe Ser Tyr Ile Ala Gln Glu
305 310